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ABSTRACT 
Peritoneal membrane (PM) failure in patients with end stage renal disease submitted to peritoneal 
dialysis (PD) cannot be predicted and does not occur in every patient in the same sequence and to the 
same extent. Moreover, long-term PD leads to morphological and functional alterations in the PM, 
reducing the lifespan of this dialysis up to five years, and forcing the replacement of PD by other renal 
replacement therapies. This represents a lower quality of life for the patients and extra cost of tens of 
million euros per year for the Portuguese National Health System.  
Peritoneal dialysis effluent (PDE) represents an underestimated biochemical window into the 
peritoneum and a useful reservoir of potential clinical biomarkers. Therefore, this work aims to develop 
longitudinal studies to unravel the evolution of the peptidome and proteome of the PDE with time, to 
identify specific molecular changes that can be particularly interesting for the understanding and early 
detection of long-term PM alterations. To achieve this goal, mass spectrometry (MS)-based methods are 
needed to improve PDE proteome and peptidome analysis and to overcome some drawbacks that can 
arise from such a complex biological sample that can hamper the proteome and peptidome coverage.  
For this reason, this thesis is focused also in the use of sample treatments and methodologies to 
reduce PDE sample complexity prior to MS analysis. Therefore, different methods of sample treatment 
were assessed with success as proteomics tools for getting insight into the PDE proteome and peptidome. 
Furthermore, this research constitutes the first proteome and peptidome-based longitudinal study of PD 
patient. In addition, the results represent the highest proteome and peptidome coverage ever achieved 
for this complex sample. Hence, this knowledge could be useful for the proteomic and clinical PD-
devoted research community. 
Keywords: Peritoneal dialysis effluent, Sample preparation, Mass spectrometry, Proteome 
analysis, Peptidome analysis, Longitudinal studies 
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RESUMO 
A falha da membrana peritoneal (MP) em pacientes submetidos a diálise peritoneal (DP), não é 
um fenómeno possível de predizer, não ocorrendo de forma uniforme em todos os pacientes. A DP 
prolongada no tempo induz alterações morfológicas e funcionais na MP, o que reduz o tempo útil de 
tratamento a um máximo de 5 anos. Após este período, o paciente é forçosamente transferido para outro 
tipo de terapia de substituição renal, perdendo qualidade de vida e aumentando os custos de tratamento 
em dezenas de milhões de euros para o Serviço Nacional Saúde.  
O efluente de diálise peritoneal (EDP), quando não menosprezado, representa um reservoir de 
potenciais biomarcadores que poderá ser útil para entender a bioquímica do peritoneu. Assim, este 
trabalho pretende efetuar um estudo temporal de modo a avaliar o conteúdo peptidómico e proteómico 
do EDP. A identificação de proteínas e péptidos indicadores de alterações da MP é particularmente 
interessante para compreender os mecanismos de alterações da MP ao longo do tratamento. No entanto, 
é necessário desenvolver métodos que melhorem e permitam ultrapassar algumas das dificuldades que 
advém da complexidade biológica deste tipo de amostra e que impedem a análise apropriada destas. 
Por as razões acima mencionadas, esta tese é focada também na investigação e aplicação de 
metodologias para o tratamento de amostra de forma a reduzir previamente a complexidade das amostras 
de EDP antes da análise por espectrometria de massa. Diferentes metodologias foram testadas e 
permitiram com sucesso a análise proteómica e peptidómica das amostras de EDP. A investigação 
desenvolvida representa o primeiro estudo longitudinal neste tipo de amostra em pacientes de DP e com 
o maior número de proteínas e péptidos alguma vez identificados. Este conhecimento poderá ser útil 
para a comunidade proteómica e médica que desenvolvem investigação nesta área. 
Palavras-chave: Efluente de diálise peritoneal, Preparação de amostra, Espectrometria de massa, 
Análise proteómica, Análise peptidómica, Estudo Longitudinal. 
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1-A general revision of chronic kidney disease and renal replacement therapies 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders affecting kidney 
structure and function [1]. Currently, the international guidelines define CKD as decreased kidney 
function shown by a glomerular filtration rate (GFR) of less than 60 mL/min per 1.73 m2, or markers of 
kidney damage (albuminuria), or both, of at least 3 months duration, regardless of the underlying cause 
[2]. Given the important of the GFR in the pathophysiology of the complications, the disease is classified 
into five stages based on GFR: Stage 1 (> than 90 mL/min per 1.73 m2); Stage 2 (60–89 mL/min per 
1.73 m2); Stage 3 (30–59 mL/min per 1.73 m2); Stage 4 (15–29 mL/min per 1.73 m2) and stage 5 (< than 
15 mL/min per 1.73 m2) (Figure 1). Also, albuminuria stages should be taken into account for prognosis, 
since increased albuminuria is correlated with mortality and kidney outcomes [1]. 
 
Figure 1 – Prognosis of CKD based on GFR and albuminuria stages. Image adapted from Levey and Coresh, 2012 [1].  
Additionally, CKD is a leading cause of end stage renal disease (ESRD) and cardiovascular 
morbidity and mortality worldwide, resulting in a growing social and economic burden [3]. ESRD is the 
irreversible loss of kidney function, which is fatal if not treated with renal replacement therapies (RRT) 
or renal transplantation [4].Thus, kidney failure is defined as a GFR of less than 15 mL/min per 1.73 
m², or the need for treatment with dialysis or transplantation [5]. However, for patients with ESRD 
unable to receive a kidney transplant, replacement of kidney function with dialysis is necessary to extend 
life, hemodialysis (HD) and peritoneal dialysis (PD) being the two major forms of therapy.  
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HD involves the passage of blood via an extracorporeal circuit whereby removal of small 
solutes, toxins, and water is achieved across a synthetic, semipermeable dialysis membrane [6].Given 
the technical differences between dialysis and ultrafiltration, patients can undergo solute clearance, 
volume removal, or both simultaneously [7]. In PD, the dialysis membrane is the highly vascularized 
internal lining of the peritoneal cavity. Intraperitoneal installation of hypertonic high glucose PD 
solution creates a transmembrane osmotic and diffusive gradient that facilitates water removal 
(ultrafiltration), convection and diffusion of uremic toxins [6]. Each year over 100.000 Americans and 
similar number of Europeans move from advanced non-dialysis-dependent CKD to RRT, these patients 
usually have an GFR <25 mL/min 1.73 m2 at the time of the transition. From these patients, <5% undergo 
kidney transplantation and the majority move on to renal replacement therapy (RRT) [5] 
Nowadays, the number of people worldwide suffering from chronic kidney diseases and 
requiring dialysis treatment is rising at a constant rate of around 6% annually, with more than 3.4 M 
patients expected in 2018 and approximately 4.9 M by 2025 [8]. Likewise, as the global burden of CKD 
continues to increase, so does the need for a cost-effective RRT [9]. To-date there is a focus of interest 
in peritoneal dialysis (PD), as it provides a better quality of life and autonomy for the patients than other 
renal replacement therapies (RRT) such as hemodialysis and represents a cost-effective RRT. Despite 
these benefits, the utilization of PD has not always increased [9],[10]. In the last decade, approximately 
196,000 end stage renal disease (ESRD) patients were performing PD worldwide, representing 11% of 
the dialysis population [11].  
Therefore, to move the PD therapy forward some strategies need to be implemented to facilitate 
PD utilization, such as, policies and incentives to favour this therapy, appropriate training for 
nephrologists to increase the use of the therapy and to decrease the rates of technique failure. In addition, 
the PD community should undertake clinically meaningful studies with a strong focus on technique 
survival [9] [10]. 
2-Peritoneal Dialysis: a peritoneal membrane-based treatment technique 
Peritoneal dialysis (PD) is a life-sustaining therapy that involves solute and fluid exchange, 
mainly between peritoneal capillary blood and dialysis solution in the peritoneal cavity [12]. This 
therapy is based on using the peritoneum, defined as the serosal membrane that covers the peritoneal 
cavity, because it is a semipermeable membrane through which ultrafiltration and diffusion of 
circulating compounds occur[10],[11],[13].  
The peritoneum is composed of two principal parts, (i) the parietal peritoneum, which covers 
the inner surface of the abdominal and pelvic walls including the diaphragm, and (ii) the visceral 
peritoneum, which covers visceral organs, forms the visceral mesentery that connects loops of bowel, 
and reflects over and covers the inner surface of the abdominal wall. In the physiological state, the 
peritoneal cavity retains 50–100 mL of peritoneal fluid. This space can be enlarged by the instillation of 
fluid, normal-sized adults can tolerate 2 or more liters of fluid without discomfort [5][13][14]. In PD 
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patients, the compact zone of the visceral peritoneum is ~20 µm thicker and the parietal peritoneum can 
be thickened up to 500 µm in long-term PD patients when compared with 50 µm of a normal parietal 
peritoneum [15]. 
The PD efficiency is dependent of important anatomic components of the PM, such as, the 
mesothelium, the insterstitium, the microcirculation and the visceral lymphatics. The mesothelial cell 
monolayer, mesothelium, lines the peritoneal cavity [14]. These cells secrete lubricants, anticoagulants 
and surface-lowering substances for the peritoneum, minimizing the friction between intra-abdominal 
organs, caused by intestinal peristalsis or respiratory movement [16]. In the steady state, mesothelial 
cells produce 5-100 mL of peritoneal fluid containing complement factors, immunoglobulins, defensins, 
and immune cells such as macrophages, lymphocytes, eosinophils, and mast cells that exert anti-
infection actions and regulate the inflammatory response [17].  
The homogenous basement membrane underling the mesothelial cells (MC), is between 25 and 
40 mm thick, and is believed to be composed of type IV collagen, proteoglycogens, and glycoproteins 
[14]. Below the mesothelium is the submesothelial compact zone. It contains the interstitium, which is 
the supporting structure of the peritoneum and is primarily composed of a mucopolysaccharide matrix, 
contains bundles of collagen fibers, blood vessels, the lymphatics, occasional macrophages, 
glycosaminoglycans, and fibroblasts. There are aqueous and lipophilic phases. The aqueous phase 
mediates transport of water, electrolytes, protein, nutrients, and hormones [6][14].  
The blood supply to the visceral and parietal peritoneum (that constitute 60% and 40% of the 
total surface area of peritoneum, respectively) arises from 2 sources: (1) the celiac and mesenteric 
arteries, with venous drainage via the portal vein; and (2) the circumflex, iliac, lumbar, intercostal, and 
epigastric arteries draining directly into the systemic circulation, bypassing the hepatic portal system. 
The number of perfused capillaries determines the functional area for the exchange between blood and 
dialysate. The solute exchange occurs according to the three pore model (TMP) (described below in 
section 2.1), in which ultra-small pores (aquaporin (AQP)-1) mediate water flux along osmotic 
gradients, small pores (40-60 Å) transport readily dialyzable molecules (sodium and urea) and large 
pores (100-200 Å) are responsible for movement of macrolecules (β-2 microglobulin) [6] [7] [14]. 
In addition, a network of lymphatic vessels aids in the removal of fluids and solutes from the 
interstitium. The fluid absorption occurs primarily through stomata in the subdiaphragmatic area. 
Several physiologic factors can alter the rate of lymphatic uptake, such as, intraperitoneal hydrostatic 
pressure, body posture, and pharmacological agents [14]. 
PD involves the insertion of a permanent abdominal catheter through which the peritoneal cavity 
is filled with dialysis fluid, left to dwell and then drained out, removing uraemic toxins and excess water 
(Figure 2). This home-based treatment is undertaken daily by the patients, who can perform continuous 
ambulatory PD (CAPD) during the day, or use a machine overnight to perform automated PD (APD), 
also referred to as continuous cycling PD (CCPD). Both methods enable the patient to remain at home, 
promoting self-management and preserving vascular access, which hemodialysis diminishes 
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[4][18].Thus, this enables patient autonomy and reduces the cost of the medical treatment compared 
with hemodialysis.  
In conclusion, the peritoneal dialysis system has three major components: the peritoneal 
microcirculation, the peritoneal membrane, and the dialysate compartment, which includes the 
composition of the solution and the modalities of delivery. All of these components may have an 
important effect on the final performance of the technique [19]. 
 
Figure 2 – Peritoneal dialysis representation and principle, from the insertion of dialysis fluid, solute and fluid exchange 
between peritoneal capillary blood and dialysis solution to final drainage.  
2.1- Solute and water transport across the PM 
 The PD involves diffuse and convective transports as well as osmosis through the highly 
vascularized PM [20]. Solute and fluid transport through diffusion is driven by a concentration gradient 
(from the high-concentration to a lower-concentration compartment), whereas convection 
(ultrafiltration) is driven by osmotic or hydrostatic pressure gradients [18]. Ultrafiltration, i.e., the 
amount of water removed from the patient, depends on the presence of an osmotic agent (most often 
glucose) in the PDF [21]. The pathways available for solute and water exchange between the plasma in 
the peritoneal capillaries and the fluid in the peritoneal cavity include, i) anatomic peritoneum (more 
precisely the mesothelium), ii) the cell-interstitial matrix or space, and iii) blood capillary endothelium 
lining vasculature, which is distributed within the tissue, and can be functionally described as TMP 
(Figure 3A and 3B) [16] [22]. 
The solute exchange occurs according to the TPM, through ultra-small pores, small pores and 
large pores. The ultra-small pores located in endothelial cells account (the only ones located inside the 
endothelial cells) for about of 2% of the total ultrafiltration (UF) coefficient (LpS, or hydraulic 
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conductance) and are permeable to water but impermeable to solutes (Figure 3B and 3C-i)[16]. The 
transcellular water permeability is mediated by AQP-1 channels, a membrane protein essential for water 
removal across the PM that allows transport of solute-free water in response to a crystalloid-induced 
osmotic pressure. In clinical practice, such water movement is termed free water transport [18]. The 
small pores (located between the endothelial cells) account for ∼90% of the LpS and 99.5% of the total 
pore area available for solute transport. The large pores (thought to correspond to interendothelial gaps) 
account for 5–8% of the LpS, occupying <0.5% of the total pore area[16][23] (Figure 2.1B). 
 
Figure 3- A- The capillary dialysis system: capillary, interstitium, mesothelium, and peritoneal cavity. Potential barriers 
separating the dialysis solution in the peritoneal cavity from plasma flowing within the microvasculature distributed within 
the subperitoneal tissue. B- Structure of the PM and representation of the TPM. During PD, the microvascular endothelium 
(arrows, stained in red) represents the functional barrier for the transport of solutes and water from the blood of the patient 
to the dialysate that has been instilled in the peritoneal cavity. The Starling forces (P, hydrostatic pressure; Π, oncotic 
pressure) operating across each type of pore are indicated. Å, angström (10−10m); r, functional radius. C-Transcapillary UF 
in the TPM, i) Fractional fluid flows across the peritoneum under normal conditions with no dialysis. In the absence of an 
osmotic agent, (ii) With glycerol as the osmotic agent, (iii) With glucose as the osmotic agent, (iv) In a conventional 
icodextrin PD solution and v) Backfiltration after gradient dissipation. Aquaporin (AQP), Small Pore (SP) and Large Pore 
(LP). Figure adapted from Devuyst et al. [16] and Flessner et al. [22]. 
The Starling forces (P, hydrostatic pressure; Π, oncotic pressure) can be considered as the forces 
operating across each different type of pore. Under normal conditions, with no dialysis and in the 
absence of an osmotic agent, ∼60% of the transcapillary fluid flow occurs through small pores, where 
the Starling forces are close to equilibrium. Approximately 40% of the capillary UF occurs across large 
pores where there is hardly any colloid osmotic pressure counteracting the transcapillary hydrostatic 
pressure gradient (Figure 3C-i)[16].  
However, transcapillary UF in the TPM can change in different conditions of PD. That is, fluid 
removal can be markedly enhanced by the presence of an osmotic agent in the peritoneal cavity. With 
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glycerol and glucose as the osmotic agent, ~55% and ~45% of the transperitoneal water flow occurs 
through water-only pores (AQP), respectively; and 45% and 55% through the small pores, respectively. 
Glucose is relatively inefficient as an osmotic agent across the small-pore pathway. However, when 
compared with glycerol (also relative inefficient) it is 50% more efficient than glycerol (Figure 3C-ii 
and 3C-iii)[16].  
The glucose in the dialysis solution, once introduced into the peritoneal cavity, generates 
crystalloid osmotic pressure which, along with transmembrane hydrostatic pressure, promotes 
convective water and solute transport from the capillary blood to the dialysis solution. The effectiveness 
of glucose in promoting water and solute transport during convection is determined by the resistance 
offered by the PM to glucose transport from the peritoneal cavity to the capillaries. This resistance is 
expressed as the osmotic reflection coefficient. By definition the reflection coefficient is 1.0 for a solute 
with complete resistance, such that the solute cannot cross the membrane, and 0 when the membrane 
offers no resistance to solute movement. [18].  
Icodextrin, a glucose polymer, has been introduced as an alternative to the glucose in PD 
solutions because it provides better UF during long dwells and reduces the metabolic effects [24]. Being 
a macromolecule, induces colloidal osmosis. Due to its size, is unable to cross capillary walls, generating 
an oncotic pressure that pulls fluid in its direction. Icodextrin induces fluid transport in its direction at 
the capillary level even in an isotonic or hypotonic state. Consequently, dialysis solution containing 
icodextrin draws fluid out of capillary blood despite low osmotic force, through the small pores. In 
contrast, icodextrin fails to draw water via AQP due to low numbers relative to electrolytes and 
extremely low osmotic force compared to glucose. In addition, icodextrin stays in the PD fluid for long 
periods due to extremely slow metabolism and poor absorption from the peritoneal cavity, drawing fluid 
into the peritoneal compartment for a longer period than glucose-based solution and does not cause 
sodium sieving [18]. Therefore, with a conventional icodextrin PD solution, ∼25–30% of the molecules 
(∼3mm) act as a colloid, implying a reflection coefficient close to unity. A 3 mM of high-molecular-
weight icodextrin produce approximately, a colloid osmotic pressure of 58mmHg (3 × 19.3mmHg (for 
solutes with a reflection coefficient of 1, each 1 milliosmole (mOsm) exerts an osmotic pressure of 19.3 
mm Hg according to Van’t Hoff’s law [18]), which is sufficient to counteract the plasma colloid osmotic 
pressure (22–26mmHg) exerted by ∼1mm of negatively charged plasma proteins (Figure 3C-iv). Thus, 
the type of osmotic agent used markedly affects the mechanisms of osmosis [16]. 
Back absorption of fluid into capillaries follows Starling forces, whereas lymphatic absorption 
is convective and driven by the negative force created by expansion of the chest wall during inspiration. 
Back absorption across the small pores occurs when the crystalloid (glucose) osmotic gradient has totally 
dissipated, usually after 4h. The net Starling fluid balance is biased toward reabsorption across the small 
pores in PD and some across AQP-1. On the other hand, a minute UF still occurs across the large pores 
(figure 3C-v) [16]. 
In conclusion, transport of solutes and water across the peritoneal membrane during PD can be 
Chapter I |General Introduction 
9 
 
influenced by, i) the exchange frequency and volume of the dialysate; ii) the osmolality of the dialysate; 
(iii) the peritoneal blood flow; iv) the effective peritoneal vascular surface area (EPSA) and v) the 
microvascular intrinsic permeability [25]. The main transport parameters across the PM are routinely 
evaluated using the peritoneal equilibration test (PET), which is based on the rate of small solutes 
transport during an exchange (described in section 2.2). Therefore, and based on these basic principles, 
any increase in the transport of small solutes across the membrane leads to a rapid dissipation of the 
osmotic gradient (due to increased reabsorption of glucose, the osmotic gradient) and loss of the UF, 
causing fluid overload in uremic patients [21]. Thus, the capacity of osmotically-induced UF across the 
PM is a major predictor of outcome and mortality in PD patients, and failure of the UF capacity the most 
frequent abnormality and the main reason for technical failure in long-term PD patients [21]. 
2.2- Peritoneal equilibration test 
The peritoneal equilibration test (PET) is a standardized test used to assess the transport 
properties of the PM in individual patients treated with PD enabling the characterization of the functional 
state of this biological membrane and the assessment of the required dialysis dose. These measurements 
are useful due to intra- and inter-individual variabilities of the patients [26]. The principle of PET was 
standardized by Twardowski et al in 1987 as explained below [27].  
Firstly, the exchange preceding PET must dwell for 8-12 hours, this pre-test exchange is 
completely drained over 20 min with the patient in the sitting position, a dialysate and a blood sample 
are obtained at the end of drainage. Then a sample of dialysis solution is taken from the test bag to be 
infused, and a 2 L of 2.5% dialysis solution is infused with the patient in the supine position in portions 
of 400 mL every 2 min. The patient is rolled from side to side after each infusion to mix residual volume 
and infused solution, and this procedure takes a total of 10 min. Exactly 10 min after the start of infusion, 
when the infusion is completed (0 dwell time), 200 mL of solution is drained into the bag, mixed well, 
a 10 mL sample of dialysate is taken and the remaining 190 mL reinfused. Posteriorly, samples of 
dialysate are taken with the same technique after 30 min, 60 min, 120 min, and 180 min of dwell time. 
After a 4-hour dwell time, the dialysate is drained over 20 min with the patient in the sitting position. 
At the end of the drainage, the total volume drained is measured and a dialysate and blood sample are 
taken. The total time of the equilibration exchange is 270 min. Finally, a sample of dialysis solution is 
taken from a post-test exchange bag to be infused, and 2 L of fresh solution is infused over 10 min with 
the same technique as for the equilibration exchange; 200 ml of dialysate is immediately drained into 
the bag, a 10 ml sample is collected and the remaining 190 ml reinfused [27].  
After a PET has been performed it is possible to measure the low molecular weight solute 
transfer and net ultrafiltration. Details of the process of fluid transport are important from a clinical point 
of view because of the high prevalence of complications related to water removal which is the reason 
for the change of PD modality and/or schedule or the change from PD to HD [28]. The PET was the 
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first standardized method to evaluate PM characteristics but there are numerous techniques for 
measuring peritoneal transport, based on the measurement of parameters, such as, PM transport, total 
protein clearance, residual renal function, ultrafiltration and nutritional status. 
Summing up, the aims of evaluating PM function are:  
 Optimization of the treatment prescription with regard to small-solute clearances, 
volume regulation and reduction of uraemic toxicity; 
 To assess membrane characteristics not related to small solutes: osmotic conductance 
of glucose, aquaporins, hydraulic conductance, large-solute flow, lymphatic 
reabsorption; 
 To evaluate the evolution of peritoneal function over time. 
Therefore, assessment of PM characteristics, specifically solute transport rate and UF capacity, is 
fundamental to PD prescription, as this will guide the prescription [29]. Some of the parameters assessed 
are described in the following sections. 
2.2.1-Dialysate/plasma ratios and peritoneal transporter classification 
Measurements performed during PETs include dialysate-to-plasma ratios of urea (D/P urea), 
creatinine (D/P Cr) at 4 h and the ratio of dialysate glucose concentrations at 0 and 4 h, dialysate240/initial 
dialysate ratio of glucose (D/D0) (Figure 4). These are calculated and used as parameters of solute 
transport [26][30].  
 
Figure 4- Twardowski Curves: Transport status based on the PET. (Left) dialysate creatinine versus plasma creatinine at 4-
hours (D/P); Middle) ratio of dialysate glucose at time zero (D/D0); (Right) Drain volume after 4-hours for the different 
membrane classifications. The figure was adapted from Hoffman et al. [31]. 
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Patients are categorized into low (L), low-average (L.A.), high-average (H.A.) and high (H) 
transporters according to the values of solute transport calculated after PET procedure. A patient with 
H transporter is defined with either a D/P Cr exceeding the mean + 1 SD, or a D/D0 of less than the mean 
D/D0 ˗1 SD. H.A transporters have a D/P Cr between the mean and mean + 1 SD, or a D/D0 between the 
mean and mean ˗1 SD. The L. and L.A are defined in the same way [26].  
There is a considerable variability for both solute transport and UF capacity among PD patients. 
Therefore, the PD therapy should be tailored to the specific needs of the patients in terms of ideal length 
of dwell, the number of dwells and the type of dialysis solutions used, as described in Table 1. An 
inappropriate prescription can lead to substantial underachievement in terms of solute clearance an UF 
or unnecessary exposure to hypertonic solutions. [29]. 
Table 1- Dialysis regimen based on PET procedure. Adapted from Twardowski [33]. 
Transport type D/P creatinine UF Solute clearance Preferred Regimen 
High (Fast) >0.80 Poor Adequate APD regimens (eg, NIPD, CCPD, PD plus) 
High-average 0.65-0.80 Adequate Adequate Standard PD (any regimen) 
Low-average 0.55-0.64 
High Adequate Standard dose CAPD 
High Inadequate High dose PD 
Low (slow) <0.55 Excellent Inadequate 
High dose PD, longer dwell CAPD (or 
hemodialysis) 
Abbreviations: PD (peritoneal dialysis); APD (automated peritoneal dialysis); NIPD (nocturnal intermittent peritoneal dialysis); CCPD 
(continuous cyclic peritoneal dialysis); CAPD (continuous ambulatory peritoneal dialysis) 
It is important that, PETs carried out within the first month of PD are considered as preliminary 
and are confirmed by a PET 4 weeks later, because peritoneal transports characteristics change 
significantly within the first month of PD. This has been shown in a prospective study of 50 patients in 
whom the results of PETs obtained after 1 week and 1 month were compared. Significant differences 
were observed in the measurement of D/P urea, D/P Cr and D/D0 glucose between 1 week and 1 month. 
In addition, PET measurements performed more than 1 year following PD commencement generally 
agreed closely with 1-month measurements, and poorly with 1-week measurements [30]. 
Peritoneal transport has an impact on clinical outcomes, however it is not constant in PD patients 
[32] since PM characteristics can change with time in therapy. Some patients develop neo-angiogenesis, 
vasculopathy and submesothelial and interstitial fibrosis, that leads to decreased UF capacity and an 
increase in the transport rate for small solutes. Therefore, membrane transport characteristics should be 
evaluated at least once a year in order to make sure that the prescription still matches the needs of the 
patient [29].  
In addition, large-scale longitudinal studies focusing in the differences of peritoneal transport 
among patients are needed. Recently, a study was published by Jiang et al. [32] with the aim of 
elucidating the changing trend of peritoneal transport and its impact on patient outcomes. For this 
purpose, survival rates of a cohort of 470 patients, with a mean age of 63.2 ± 14.3 years and a 40% 
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diabetes occurrence, were analysed for up to 10 years. The main conclusion based in D/P Cr were that, 
(i) D/P Cr mean dropped significantly in the first year and remained constant thereafter; (ii) a slow 
increasing trend was observed after year 5 and (iii) in the first few years, D/P Cr declined significantly 
in the H. and H.A. transport patients and increased in the L.A. and L. transport patients. Interestingly, 
there was no significant difference in patient and technique survival rates according to baseline transport 
groups. Moreover, D/P Cr only was considered a significant risk factor for mortality from year 3 onwards. 
Additionally, H.A. patients were associated with poorer outcomes only after the first few years of PD. 
Finally, the authors concluded that the initial peritoneal transport status was not a determinant factor of 
patient survival in long-term PD [32] 
In addition, a meta-analysis study carried out to characterize the relationship between D/P Cr and 
mortality and technique failure in PD patients, showed a relative risk of 1.15 for every 0.1 increase in 
D/P Cr. This result equated to an increased mortality risk of 21.9 % for L.A, 45.7 % for H.A, and 77.3% 
for H, as compared with patients with L. transport status. Regarding the relative risk for death-censored 
technique failure was 1.18, for every 0.1 increase in the D/P Cr. This meta-analysis demonstrated that a 
H.A. solute transport rate is associated with a higher mortality risk and a trend to higher technique failure 
[34]. 
Nevertheless, deterioration of clinical parameters (volume overload, UFF and malnutrition) and 
biochemical parameters (haemoglobin, serum albumin, urea and creatinine) can be caused by an 
inappropriate PD regimen, as a consequence of a change in PM characteristics. Thus, is very important to 
re-evaluate the PM characteristics and to adapt the treatment accordingly [29]. 
2.2.2- Ultrafiltration capacity /Net ultrafiltration 
PD needs to provide patients with both solute clearance and fluid removal, that is, UF. Failure 
to provide adequate levels of either or both of these parameters accounts for approximately 18% of 
overall technique failure and transfer to HD [35].  
Net ultrafiltration (net UF) in PD refers to the difference between the osmotically induced UF 
into the peritoneal cavity and the fluid loss from the cavity during dialysis [36]. Fluid loss is made up 
primarily of hydrostatic pressure-driven convection to the tissues surrounding the peritoneal cavity and 
a lesser amount of lymph flow. The cellular and blood capillary sources of water are distributed in an 
interstitial matrix, which decreases the effective osmotic pressure in the vicinity of the microvasculature. 
The interstitial matrix makes the process of fluid removal far less efficient than it would be if the blood 
capillaries were actually in direct contact with the peritoneal fluid. Osmotically driven water transport 
occurs chiefly across the blood capillary endothelium into the interstitium and ultimately out into the 
peritoneal cavity [37]. Net UF is calculated as the difference between the drained and the instilled 
volume [26],[37], as can be seen in the following equation:  
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Net UF =
𝐷𝑟𝑎𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒−𝐹𝑖𝑙𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝐷𝑤𝑒𝑙𝑙 𝑡𝑖𝑚𝑒
                                                                                       (1) 
This equation does not tell what mechanisms or forces govern the transfer of fluid. Small solute 
(MW=6,000 Da) transfer occurs in both directions across the membrane in accordance with the mass 
transfer-area coefficient (MTAC), 
Solute transfer = MTAC∙(Cplasma –Cpd)                                                                                            (2) 
where Cplasma = solute concentration in plasma; Cpd = solute concentration in the dialysate. UF 
across any membrane follows the classic Starling equation, 
Fluid transport = Kf A∙[Pplasma – Ppd – (πplasma – πpd)]                                                               (3) 
where Kf  = membrane filtration coefficient; P = hydrostatic pressure; π= effective osmotic 
pressure. However, the simple membrane model cannot account for all processes that ultimately result 
in the measured net UF [37].  
The transfer of fluid to and from the peritoneal cavity is more complex than the simple 
membrane model. The net UF is made up of two components, 
Net UF = Osmotically-driven filtration – fluid loss                                                            (4) 
where fluid loss = fluid transfer from the cavity = direct lymph flow + hydrostatic pressure (P)-
driven convection to the surrounding to the surrounding tissues. From the tissue, transfer into the blood 
capillaries or intra-tissue lymphatics carries the fluid back to the plasma compartment [37]. 
Importantly, the amount of UF rate has been correlated with patient survival in PD patients [38]. 
Signs of UFF include loss of solute-free UF and general decrease in UF below 400 ml with a 4-h dwell 
of hypertonic dialysate [37]. 
2.3- Dialysis dose adequacy  
One of the most important parameters measurements in PD, is the Kt/Vurea, this unit-less 
measurement is determined by (i) K, the clearance of urea (mL/min) during a dialysis treatment; (ii) t, 
the time (min) of the treatment and (iii) V, the volume of distribution of urea (mL), which is 
approximately the total body water. Given that several factors can affect Kt/Vurea (blood flow rate, 
dialysate flow rate and the size of the PM) the time spent on treatment is the most easily modifiable 
variable to achieve for the dialysis dose adequacy [39].  
Following the recently reviewed and published clinical practice guidelines for peritoneal 
dialysis a combined urinary and peritoneal Kt/Vurea of 1.7/week or a creatinine clearance of 
50L/week/1.73 m2 should be considered as minimal treatment doses for adults [40]. Despite the fact that 
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many guidelines agree with the minimum target of total weekly Kt/Vurea of >1.7, it has been evidenced 
that increasing small solute clearance beyond this level does not guarantee better survival. Furthermore, 
dialysis adequacy cannot be merely determined by one biochemical marker. Instead, comprehensive 
understanding of dialysis adequacy is required to improve clinical outcomes. This should encompass 
adequate fluid balance, optimal blood pressure control, maintaining acid-base homeostasis, correction 
of anemia, malnutrition, and calcium-phosphorus mineral disturbances, decreasing inflammation, and 
improving middle molecule clearance [41].  
2.4- Peritoneal protein clearance 
Peritoneal protein clearance (PPCl) is another clinical parameter that must be taken in 
consideration, being dependent on vascular supply and size selective permeability [42]. Recently, a 
multivariate analysis study correlated some factors associated with increasing PPCl, such as, (i) longer 
dwell times of CAPD, (ii) greater peritoneal creatinine clearance and faster PET transport, (iii) increased 
log N-terminal brain natriuretic peptide (NT-proBNP), (iv) extracellular water (ECW)/total body water 
(TBW) ratio and (v) estimated dietary protein intake and muscle mass, suggesting a link to sodium 
intake and sodium balance, increasing both ECW and conduit artery hydrostatic pressure resulting in 
greater vascular protein permeability [42]. 
In addition, protein/albumin loss it is an important predictor of survival in PD patient, and 
presumably a marker of endothelial dysfunction and, as such, a reflection of general atheromatosis or of 
subclinical inflammation. [29]. Therefore, peritoneal protein loss can be determined to discriminate fast 
transport status caused by large surface area (low protein loss) from fast transport status due to 
inflammation (high protein loss) [29]. Moreover, PPCl rather than faster transport status was suggested 
as an outcome predictor in PD patients, since a higher PPCl was associated with increased risk of death, 
even after patients underwent transplantation or transferred to hemodialysis [43]. Furthermore, given 
the fact that fast PM transport status may be due to inflammation or increased peritoneal membrane 
surface area, PPCl has been purposed to distinguish fast PM transport status as a consequence of PM 
inflammation and assess its impact on patient survival. The results show that peritoneal transport status 
no longer predicted survival, whereas PPCl remained a predictor [44]. 
2.5- Peritoneal dialysis effluent CA 125 marker 
The loss of MCs from the basement membrane is one of the major characteristics in peritoneal 
membrane structural change. Thus, if the reduction of peritoneal MC mass in PD patients is monitored, 
signs of UFF and peritoneal fibrosis can be detected early [45]. MCs secrete surfactant-like lubrication 
for the peritoneum, are active in modulating host defence, and have been shown to produce cancer 
antigen (CA) 125 [46]. Therefore, concentration or appearance rate of CA125 in peritoneal dialysis 
effluent (PDE) has been used for many years as a biomarker for mesothelial cell mass in patients on PD 
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[47]. The concentration of this high molecular weight glycoprotein is determined after a standardized 
dwell. Serum CA125 is normal in PD patients, but its concentration in PDE suggests local release. 
Besides that, large amounts are found during peritonitis, due probably to necrosis of mesothelial cells. 
However, a decrease with time on PD suggests loss of MCs [42]. The CA125 concentration can be 
measured directly in U/mL or calculated as the CA125 appearance rate, which is the amount of CA 125 
in the total drained effluent volume divided by the dwell time [45]. The CA125 appearance rate can be 
calculated using the following equation: 
CA125 appearance rate (U/min) = 
𝐶𝐴125 (
𝑈
𝑚𝐿
)×𝑣𝑜𝑙𝑢𝑚𝑒 𝑒𝑓𝑓𝑙𝑢𝑒𝑛𝑡 (𝑚𝐿)
𝑑𝑤𝑒𝑙𝑙 𝑡𝑖𝑚𝑒 (min)
 
2.6 -Residual kidney function 
Residual kidney function (RKF) is another parameter that must be taken into consideration with 
incremental of PD The RKF, both in terms of clearance and in terms of diuresis, should be monitored 
on a regular basis by 24-h urine collection and calculation of the mean of urea and creatinine clearance. 
The rationale of incremental PD is to treat symptoms of renal failure by a combination of dialysis and 
RKF. Thus, with the further decline of kidney function the dialysis dosage should be continually 
increased [29],[39]. This approach brings several advantages: (i) given significant RKF (3-10 mL/min) 
even a small amount of PD tends to improve uremic symptoms; (ii) a reduced burden/ less intensive 
regimen, gives the patient time to adjust to PD; (iii) Glucose exposure of peritoneum can be minimized 
from the beginning and (iv) rationale incremental PD might better conserve RKF [39]. 
However, intentionally leaving patients overhydrated to preserve RKF is strongly discouraged. 
Overhydration also results in faster decline of RKF and is by itself an important factor leading to 
cardiovascular mortality. On other hand, dehydration should be avoided, since it can also cause faster 
deterioration of RKF [29]. 
Patients with a rapidly declining RKF often also have a faster deterioration of the PM [29]. 
Patients with preserved RKF are more likely to have well-controlled blood pressure, euvolemia, better 
nutritional status, less inflammation, and better phosphate and middle molecule clearance as compared 
to anuric patients. Maintaining euvolemia is also of extreme importance as fluid overload is associated 
with an increased cardiovascular risk such as high blood pressure, cardiac dilatation and hypertrophy, 
and congestive heart failure. Therefore, RKF and fluid balance are indeed two most important 
determinants of clinical outcomes in dialysis patients. For this reason, these two should be incorporated 
into measures of dialysis adequacy [41]. 
3- Complications related to Peritoneal Dialysis therapy  
During the early years of RRT, PD provides an equivalent, if not superior, mode of dialysis 
when compared with HD, for a substantial number of patients. However, this appears to be limited to 
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the first three or four years, and the majority of patients switch therapy to HD due to treatment failure. 
[15]. PM degrades with time and its short-to-medium survival outcome is up to five years [48]. PM 
failure increases from 5% patient-years in the beginning of the treatment to 25% patient-years in the 
third year [48]. The causes of this treatment failure are multifactorial and include recurrent episodes of 
peritonitis, loss of RKF, and loss of peritoneal function [15]. Additionally, continuous exposure to bio-
incompatible PD solutions (hyperosmotic, hyperglycemic, and acidic dialysis solutions), mechanical 
stress connected with dwelling practice, and episodes of peritonitis or hemoperitoneum may cause acute 
and chronic inflammation and injury to the PM, which progressively undergoes fibrosis, angiogenesis, 
vasculopathy, loss of the protective hyaluronan layer on the peritoneal peritoneal surface of 
mesothelium, loss of MCs, mesothelial-to-mesenchymal transition (MMT), ultimately, leading to UFF 
[49][50][51]. Importantly, all these changes are interconnected factors associated with alterations on 
fluid and solute removal. These changes ultimately lead to different spectra of PM ultrafiltration failure 
(UFF) types (type I–IV) (Figure 5) (described in Section 3.2), which compromises treatment efficacy 
(due to extracellular volume overload) and patient outcomes.  
3.1-Inducers of peritoneal membrane degradation 
The efficacy of the PD depends on the morphological and functional PM integrity. However, 
this integrity is compromised during long-term PD due to different factors such uremia, recurrent 
peritonitis (bacterial and fungal infections), hemoperitoneum, and especially, long-term exposure to 
large volumes of bio-incompatible solutions containing glucose degradation products (GDPs) [23],[52]. 
GDPs that are potentially toxic to the PM are formed during heat-sterilization and prolonged storage. 
GDPs are rapidly absorbed into the circulation and increase systemic advanced glycation end products 
(AGEs)[17]. In turn, AGEs can bind to receptors of AGE (RAGE), activating intracellular signals that 
produce oxidative stress and synthesis of inflammatory cytokines, growth factors, and ECM 
components, contributing to PM alterations [50],[53].  
Moreover, AGEs appearance in peritoneal effluents of PD patients is correlated with the time 
on PD treatment. Biopsy studies have confirmed the accumulation of AGE in peritoneal tissues of PD 
patients and the intensities of AGE accumulation is associated with fibrosis and ultrafiltration 
dysfunction [50]. In addition, the uremic status contributes to AGE accumulation and some circulating 
mediators such as, nitric oxide (NO), VEGF and inflammatory cytokines (IL-1β, tumor necrosis factor-
alpha (TNFα), IL-6) that can significantly increase, influencing the structure and function of PM [52]. 
Uremia per se leads to thickening of the sub-mesothelial zone and mild vasculopathy [38] (Figure 5).  
Furthermore, some factors other than those related to the PDF can have important effects on the 
PM, and can result in variability in peritoneal function. For example, i) the degree of glycaemic control 
rather than diabetes per se can cause changes to the PM, ii) a high salt intake can induce changes in 
hypertonic exchanges leading to PM changes and iii) PM characteristics can be influenced by genetic 
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polymorphisms. However, many of these factors are modifiable, and attention should be given to them 
in clinical practice in order to maintain the PM integrity [54]. Altogether, these factors lead to 
morphological alterations of peritoneum, undergoing inflammation and infection, MC loss, mesothelial 
to mesenchymal transition, increase of the submesothelial extracellular matrix (ECM) deposition 
(fibrosis), angiogenesis and lymphangiogenesis, as described in the following sections. 
 
Figure 5- The pathways of PM injury and progressive UFF can be divided into 3 phases: drivers, mechanisms, and 
functional consequences. EMT, epithelial-to-mesenchymal transition; GDPs, glucose degradation products; IL, 
interleukin; MCP, monocyte chemoattractant protein; TGF, transforming growth factor; TNF, tumor necrosis factor; 
VEGF, vascular endothelial growth factor. The figure was adapted from Davies [53]. 
3.1.1- Inflammation and infection 
As described in the previous section, several factors can trigger peritoneal inflammation, inducing an 
immunological response in the peritoneal cavity that involves MCs, mast cells dermal fibroblast, macrophages, 
lymphocytes and neutrophils. When stimulated, these cells produce a wide variety of cytokines, chemokines and 
growth factors, such as TNF𝛼, interleukin (IL)-1, IL-6, IL-8, IL-17, TGF𝛽, VEGF, fibroblast growth factor (FGF)-
2, monocyte chemotactic protein (MCP)-1 and many others (Table 2), thereby increasing inflammation and 
causing structural and functional alterations [50]. 
The MCs are capable of recognizing pathogen and tissue damage, and initiating inflammatory 
response through antigen presentation, cytokine production, interaction with immune cells like 
macrophages, and through tissue repair and adherence formation [56]. 
In acute peritonitis, a first wave of polymorphonuclear neutrophils (PMN) recruited by 
chemoattractants of bacterial origin (lipopolysaccharide (LPS)) is progressively replaced by a 
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population of mononuclear cells, composed of monocytes/macrophages and lymphocytes[49]. This 
temporal switch in the pattern of leukocyte is crucial in the clearance of infection, with involvement of 
the IL-6 as a key mediator in this regulation. This IL-6 response depends on the presence of the soluble 
IL-6 receptor (sIL-6R), to form the sI-6RL/IL-6 complex (transsignaling mechanism), allowing IL-6 
signaling in cell types lacking the cognate IL-6R, through the ubiquitously expressed transducing 
molecule, gp130. The transsignling mechanism, modulates the expression of specific chemokines and 
adhesion molecules, and regulates the process of apoptosis, thereby influencing the leukocyte 
recruitment [49], [57]. This control primarily results from chemotactic cytokine production by MCs, 
contributing to proinflammatory cytokine-driven activation and synthesis of a large amount of IL-6 
during inflammation. However, MCs not express the cognate IL-6R, so they regule chemokine synthesis 
only when exposed to the agonistic sIL-6R/IL-6 complex [57]. 
Table 2- Types of cytokines produce by different cells in peritoneum, their relevance to PD. Adapted from Shi el al.[55] 
Types of cytokines 
Cellular 
source in 
peritoneum 
Relevance to PD 
VEGF (angiogenic factor) 
Mast cells 
VEGF and VEGFR are crucial for angiogenesis ECs 
MCs 
Angiopoietin2 (angiogenic factor) ECs Angiopoietin2 signalling involved in TNF-α induced peritoneal angiogenesis 
IL-6 (angiogenic/inflammatory 
factor) 
Macrophages 
IL-6 is positively correlated with VEGF in plasma and dialysate ECs 
MCs 
IL-1 (inflammatory factor) 
Macrophages IL-1 increases vessel-like structures by enhancing VEGF production, and 
augments proliferation when added to ECs MCs 
IL-8 (inflammatory factor) 
Macrophages 
IL-8 enhances EC proliferation and capillary tube formation Mast cells 
MCs 
TNF-α (inflammatory factor) 
Macrophages 
TNF-α causes neoangiogenesis both in vitro and vivo Mast cells 
MCs 
MCP-1 (chemokine) 
Macrophages MCP-1-induced protein enhances ECs proliferation, migration, and other pro-
angiogenic genes, leading to capillary-like tube formation ECs 
ICAM-1 (adhesion molecules) 
ECs 
Induced by IL-6 and TNF-α after EC injury, promoting new capillary 
formation VCAM-1 (adhesion molecules) 
TGF-β (growth factor) 
Mast cells TGF-β triggers the expression of VEGF via EMT and conversely amplifies its 
own secretion MCs 
Abbreviations: VEGF (vascular endothelial growth factor); IL-1 (interleukin-1); IL.6 (interleukin-6); IL-8  (interleukin-8); TNF-α (tumor 
necrosis factor –α); MCP-1 (monocyte chemotactic protein-1); ICAM-1 (intercellular adhesion molecule-1); VCAM-1 (vascular cell 
adhesion molecule-1); TGFβ (transforming growth factor-β); MCs (mesothelial cells); ECs (endothelial cells). 
In summary, as can be seen in Figure 6, during acute inflammation, leukocyte recruitment is 
characterized by an initial infiltration of neutrophils, which are later replaced by a more sustained 
mononuclear cell influx [58]. This process is mediated through activation of proinflammatory cytokines 
(TNF-α, IL-1, and IFN-γ) and subsequent changes in chemokine expression. In addition, it is believed 
that the initial attraction of neutrophils by proinflammatory cytokine-driven expression of CXC 
chemokine, MIP-1/KC, is followed by the release of sIL-6R shed from neutrophils, facilitating the 
formation of sIL-6R/IL-6 complexes [58]. On the other hand, these complexes suppress the release of 
other CXC chemokines, ensuring clearance of neutrophils, and simultaneously promoting the secretion 
of the CC chemokines, such MCP-1 and RANTES, triggering the recruitment of mononuclear 
leukocytes [57]. Involvement of the IFN-γ in the control of PMN recruitment and modelling of IL-6 
Chapter I |General Introduction 
19 
 
signalling through sIL-6R to promote their apoptosis and clearance has also been demonstrated. Thus, 
IFN-γ has an important role in regulating innate immunity through control of both the recruitment and 
clearance phases of PMN trafficking [59]. Another study, using knock-in mice expressing mutant forms 
of the IL-6 signal transducer molecule gp130 [60], showed that IL-6/sIL-6R signalling also selectively 
promotes T cell recruitment into the peritoneal membrane through a gp130-dependent, STAT1/3-
dependent activation pathway [57].  
 
Figure 6- Representation of IL-6 and sIL-6R signaling in the regulation of leukocyte trafficking. The regulation of leukocyte 
trafficking in the peritoneal cavity is mediated by proinflammatory cytokine–driven (IL-1, TNF-α, and IFN-γ) activation of 
IL-6/sIL-6R transsignaling mediated through control of STAT3 activation that results in differential control of chemokine 
secretion (that is responsible for mononuclear leukocyte and T cell recruitment) and polymorphonuclear neutrophils (PMN) 
apoptosis. Image taken from Devuyst et al. with permission [57]. 
However, the unphysiologic composition of PDFs used adversely affects peritoneal host defence 
and may thus contribute to the development of PD-related peritonitis [61]. The viability of PMN, 
monocytes, peritoneal macrophages and MCs is severely depressed by conventional PDFs, and therefore 
the production of inflammatory cytokines and chemoattractants by these cells are markedly affected. 
The recruitment of circulation leukocytes in response to an infectious stimulus is also hampered, and 
phagocytosis, respiratory burst, and bacterial killing are lower when PMN, monocytes, and peritoneal 
macrophages are exposed to these solutions [61].  
Summing up, while the transition from innate immunity to acquired immunity facilitates the 
resolution of inflammation and the clearance of bacterial infection in the peritoneum during acute 
inflammation, through the sI-6RL/IL-6 complex, dysregulation of this pathway as occurs in chronic 
inflammation or after repeated infections also contributes to inflammation-induced peritoneal damage 
[57].  
3.1.2- Mesothelial to Mesenchymal Transition 
Epithelial and mesenchymal cells have distinct characteristics. Epithelial cells form layers of 
cells that are closely adjoined through tight junctions, adherens junctions, desmosomes and gap 
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junctions. In addition, epithelial cells have apical–basolateral polarization, which manifests itself 
through the localized distribution of adhesion molecules (cadherins and certain integrins), the 
organization of cell–cell junctions as a lateral belt, the polarized organization of the actin cytoskeleton, 
and the presence of a basal lamina at the basal surface [62]. Contrarily, mesenchymal cells do not form 
an organized cell layer, nor do they have the same apical–basolateral organization and polarization of 
the cell-surface molecules and the actin cytoskeleton as epithelial cells. They contact neighbouring 
mesenchymal cells only focally, and are not typically associated with a basal lamina [62].  
Regarding cell motility, epithelial cells are motile and can move away from their nearest 
neighbours while remaining within the epithelial layer, but do not detach and move away from the 
epithelial layer under normal conditions. Contrarily, mesenchymal cells present high motility in vitro, 
but not necessarily in vivo. In fact, there is plasticity in the way that mesenchymal cells migrate. These 
cells might migrate together as chains, or as individual cells that exhibit either cyclic extension–
adhesion–retraction translocation or amoeboid-type crawling. [62]. 
These cell types can be partially or fully interconverted through the processes of epithelial-to-
mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) [62]. EMT is an 
essential process in embryogenesis, and is beneficial in normal wound healing, but is pathogenic in 
fibrosis [57]. The reverse process, MET, occurs during somitogenesis and nephrogenesis. EMT is 
characterized by disrupted cell–cell adhesion and apical–basolateral polarity, cytoskeletal 
reorganization, detachment from basement membranes, and the generation of motile mesenchymal cells 
[63]. Therefore, EMT can be described as a series of events during which epithelial cells lose many of 
their epithelial characteristics and take on properties that are typical of mesenchymal cells, which require 
complex changes in cell architecture and behaviour. However, this does not necessarily refer to a lineage 
switch, given that the transition from epithelial- to mesenchymal-cell characteristics encompasses a 
spectrum of inter- and intracellular changes, all of which are not always seen during EMT [62],[64]. 
As described in the previous sections, MCs are epithelial‐like cells lining the peritoneal cavity. 
MCs have junctional complexes and apical–basolateral polarity, and adhere to a basement membrane. 
In normal development, some MCs undergo MMT to form vascular smooth muscle. MCs are not typical 
epithelial cells, so the biological characteristics of MMT and EMT may not be identical [63]. Therefore, 
the EMT of MCs is more properly named as MMT [64].  
The pathophysiologic mechanisms that are involved in peritoneal structural alterations can have 
origins from new fibroblastic cells that may arise from local conversion of MCs by MMT during the 
inflammatory and repair responses induced by PD [50]. These alterations happen soon after PD is 
initiated, with peritoneal MCs showing a progressive loss of epithelial morphology through the 
dissociation of intercellular junctions, as a result of downregulation of adhesion molecules (such, E-
cadherin, claudins, occludins, zona occludens-1, and desmoplakin), and with the loss of microvilli and 
apical-basal polarity [50], [64]. Then the cells adopt a front-back polarity as a result of cytoskeleton 
reorganization, and acquire myofibroblast-like characteristics with migratory and invasive capacities 
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with the up-regulation of α2 integrins and α-smooth actin (α-SMA). In the latest stages the cells acquire 
the capacity to degrade the basement membrane and to invade the fibrotic stroma by upregulating the 
expression of MMPs. In addition is also observed during the transition is a downregulation of 
cytokeratins, upregulation of vimentin, N-cadherin, and transcription factor snail; and increased 
production of ECM components (Figure 7)[50], [64]. The decrease in the expression of cytokeratins and 
E-cadherin occurs through and induction of the transcriptional repressor snail [64]. The objective of this 
process is to repair tissue wounds by promoting the recovery of ancestor capabilities of epithelial cells. 
The process is conducted by TGF-β and the representative cell form is the myofibroblast [65].  
 
Figure 7- Representation of the peritoneal membrane suffering structural abnormalities such as, loss of mesothelial cells 
monolayer, increasing number of fibroblasts, submesothelial fibrosis, and augmented number of vessels. The key steps and 
effectors for the epithelial-to-mesenchymal transition (EMT) and for mesenchymal-to-epithelial transition (MET) are also 
represented. Furthermore, common markers for epithelial and mesenchymal cells, resident fibroblasts and myofibroblasts, 
are also represented. Figure adapted from Aroeira et al. [50]. 
The myofibroblast can be defined as cells with intermediate features between a fibroblast and 
smooth muscle cells and are characterized by the expression of α-SMA. The submesothelial 
myofibroblasts can originate from activated resident fibroblasts, fibrocytes (circulating cells that are 
recruited to injured tissues), and from MCs through MMT. The myofibroblastic conversion of MCs can 
be observed by immunohistochemical analysis, which reveals the presence of fibroblast-like cells 
embedded in the compact zone expressing mesothelial markers such as cytokeratins, intercellular 
adhesion molecule-1 (ICAM-1), and calretinin. Peritoneal myofibroblasts express VEGF, ECM, and 
cyclooxygenase-2 (COX-2), indicating that these cells are implicated in peritoneal structural alterations 
that are induced by PD [50].  
Interestingly, these fibroblasts present different markers. Resident fibroblast show an intense 
expression of CD34, and antigen characteristic of bone marrow stem cells. On the other hand, expression 
of CD34 gradually disappears in PD patients with the degree of peritoneal fibrosis and it seems to 
correlate with the appearance of myofibroblast phenotype [66]. Moreover, tissue CD34+ fibroblasts are 
closely related to circulating CD34+ fibrocytes and reflect a bone marrow origin. Fibrocytes represent a 
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small subpopulation of circulating leukocytes that express collagen I, CD45RO, CD13, CD11b, CD34, 
CD86, and MHC class II, which transform into myofibroblasts when exposed to TGF-β in vitro. In 
contrast, peritoneal CD34+ fibroblasts do not express these fibrocyte markers, suggesting that they are 
simply residual embryonic mesenchymal cells that remained in the peritoneal tissue after organogenesis 
[50] (Figure 7).  
As was already discussed, several endogenous and exogenous factors can stimulate the immune 
system and MCs in the peritoneal cavity to induce MMT. The MMT progression is regulated by complex 
signaling pathways that together accelerate or complete the transdifferentiation. These signaling 
pathways are, i) inflammation ii) delta-like jagged Notch, iii) integrins, iv) receptors for TGF/Smads, 
and v) tyrosine kinase receptors and vi) Janus kinase (JAK)- signal transducer (Figure 8). 
Inflammatory cells (as described in Section 3.1.2.1) secrete large numbers of cytokines, growth 
factors, and chemokines to establish a complex network that feeds back, resulting in sustained chronic 
inflammation. In addition, during inflammation, IL-6 can promote EMT through JAK-signal transducer 
and activator of transcription (STAT)3-induced SNAIL1 expression [67]. 
In Notch and Hedgehog signalling, glioma 1 can induce SNAIL1 expression, and the 
intracellular domain of Notch can activate SNAIL2 expression, hence downregulating E-cadherin, by 
inducing growth arrest and survival, which confer selective advantage to migrating trans-differentiated 
cells. In turn, the integrin pathway is able to activate the integrin-linked kinase (ILK), by β1 integrins, 
inducing the serine/threonine kinase AKT, which inhibits glycogen synthase kinase (GSK)-3β inducing 
MMT. Phosphorylated-AKT triggers NF-kB activation, which in turn induces the expression of Smad 
7, an inhibitory Smad molecule that interferes with the phosporylation of Smad 2 and 3, and of snail, a 
key regulator of MMT. The phosphorylation of GSK-3 by ILK results in its inhibition and subsequent 
stabilization of β-catenin, released from the adherent junction, and of AP-1. Stabilized b-catenin, in 
conjunction with Lef-1/Tcf, may by itself induce MMT, and AP-1 activates MMP-9 expression inducing 
the invasion of ECM [65], [67]. 
The TGFβ/Smads pathway is able to activate different routes, such as, i) through the 
phosphorylation of the adaptor protein SRC homology 2 domain-containing-transforming A (SHCA), 
that creates a docking site for growth factor receptor-bound protein 2 (GRB2) and son of sevenless 
(SOS), which initiates the RAS-RAF-MEK-ERK pathway (also necessary for the induction of snail 
expression) or, ii) through the p38 MAPK and JNK activation, another TGFβ-induced route, resulting 
from the association of TNF receptor-associated factor 6 (TRAF6) with the TGFβ receptor complex, 
which activates TGFβ-activated kinase 1 (TAK1) and, as a result, p38 MAPK and JNK[67] In addition, 
a Smad-independent signalling cascade triggered by TGF-β receptor I ligation, is the RhoAp160ROCK 
pathway that regulates cytoskeleton remodelling and cellular migration/ invasion. Moreover, RhoA 
induces the expression of α-SMA in a ROCK-independent manner [65]. 
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Figure 8- Representation of the signalling pathways that regulate MMT progression. These signalling pathways are, i) 
inflammation ii) delta-like jagged Notch, iii) integrins, iv) receptors for TGF/Smads, and v) tyrosine kinase receptors and 
vi) Janus kinase signal transducer. Abbreviations: MMT (mesothelial-to-mesenchymal transition); TGFβ (transforming 
growth factor-β); MMPs (matrix metalloproteinases); GSK3β (glycogen-synthase kinase-3β); β-catenin-Lef/Tcf (lymphoid 
enhancer factor/T cell factor); ILK (integrin-linked kinase); MAPK (mitogen-activated protein kinase); RAS–RAF–MEK–
ERK pathway, extracellular signal-regulated kinases (MEK: Mitogen-activated protein kinase kinase. ERK: extracellular 
signal–regulated kinase); NF-kB (nuclear factor-kB); TAK1 (TGF-beta activated kinase 1); VEGF (vascular endothelial 
growth factor); ECM (extracellular matrix); Notch-IC (intracellular fragment of Notch); COX-2 (cyclooxygenase); CKs 
(cytokines); SHCA (adaptor protein SRC homology 2 domain–containing-transforming A); GRB2 (growth factor receptor–
bound protein 2); SOS (son of sevenless); TRAF6 (TNF receptor-associated factor 6); α-SMA (alpha smooth muscle actin); 
AKT (protein kinase B); RhoA (Ras homolog gene family member A); ROCK (Rho-associated protein kinase); STAT3 
(signal transducer and activator of transcription 3); t-PA (tissue plasminogen activator); AP-1 (activator protein-1); and LPS 
(lipopolysaccharide). Figure adapted from Aguilera et al. [65] and González-Mateo et al. [67]. 
The activation of the receptor tyrosine kinases (RTKs) can occur in response to several growth 
factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), hepatocyte growth 
factor (HGF), and VEGF, leading to the activation of a major pathway, the RAS-RAF-MEK-ERK 
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MAPK signalling cascade. Once this pathway is activated, ERK1 and ERK2, MAPK pathway cell 
motility and invasion are activated [67]. 
Finally, MCs lose their basoapical and basolateral polarity, acquire migratory capacity to 
synthesize large amounts of ECM and angiogenesis through increased synthesis of VEGF [67].The 
increase in total VEGF production may increase the VEGF-C levels, which are directly implicated in 
lymphogenesis [68].  
3.1.3- Angiogenesis and Lymphangiogenesis 
Blood vessels deliver oxygen and nutrients, remove waste and CO2, whereas lymphatic vessels 
drain the interstitial fluid collected in the tissues to maintain the interstitial environment, and serve as 
conduit for immune cell trafficking and fat absorption [69].  
In regard to peritoneal angiogenesis, it is a process characterized by the formation of new 
capillaries, increasing the effective surface area of exchange, which results in a decrease in the glucose-
driven osmotic pressure [23]. Besides that, it has been shown that local production of the proangiogenic 
and vasoactive factor VEGF during PD plays a central role in increased solute transport across the 
peritoneum and ultrafiltration failure [50]. The biological effect of VEGF is mediated by three VEGF 
receptors (VEGFRs): VEGFR-1/Flt-1, VEGFR-2/KDR, and VEGFR-3/Flt4, which share a similar 
structure composed by seven extracellular immunoglobulins (Ig)-like domains, one transmembrane 
region, and an intracellular tyrosine kinase domain that, once activated via ligand-triggered 
dimerization, leads to different signal transduction pathways (Figure 9) [70]. The VEGFR2 is the 
specific receptor distributed on the surface of the ECs that binds VEGF and recruits EC migration to 
anoxic and vascular areas. As the ECs proliferate and differentiate, angiogenic remodelling occurs where 
the vessels enlarge and mature [55].  
Additionally, VEGF activity is also regulated by neuropilins (Nrps), a family of cell surface 
glycoproteins composed of two members, Nrp1 and Nrp2 (Figure 9). The Nrp-1 has been described as 
an isoform-specific VEGF co-receptor expressed in endothelial and tumour cells, enhancing VEGF 
binding to VEGFR-2 and its bioactivity. On another hand, Nrp-1 may also signal independently of 
VEGFR-2 in endothelial cells to VEGF-triggered migration and adhesion. Moreover, Nrp-1 may also 
interact with other growth factors, such as FGF and TGF-β1. Besides the neurons and ECs, Nrp-1 
expression was also described in MCs [70]. Remarkably, in a study performed by Pérez-Lozano et al., 
it has been shown that the expression patterns of VEGFRs and co-receptors change in MCs during 
MMT, with a strong induction of VEGF and Nrp-1, and downregulation of VEGFR-1 and VEGRF-2. 
In addition, MCs which have undergone an MMT proliferate less and acquire an increased invasion 
capacity compared with epithelial-like MCs. Furthermore, it has been shown that this enhanced invasion 
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could be partially inhibited by treatment with anti-VEGF or anti-Nrp-1b antibodies, strongly suggesting 
that the interaction of VEGF with Nrp-1 may have a role in MCs invasion [70]. 
 
Figure 9- Scheme of VEGF receptors and co-receptors and processes in which they are involved. Figure adapted from 
Pérez-Lozano et al.[70]. 
Lymphangiogenesis, which represents the growth of lymphatic vessels from pre-existing vessels 
[71] is a poorly analysed process in PD. However, it is known that excessive lymphatic fluid drainage 
from the peritoneal cavity may be related with the macromolecule and isosmotic solutions reuptake and 
convective reabsorption of solutes that were cleared from plasma by diffusion [23]. The lymphatic 
capillaries develop during the progression of tissue fibrosis in various clinical and pathological 
situations, such as CKD, peritoneal injury PD, tissue inflammation, and tumour progression [72]. 
Therefore, inflammation is an important contributor to lymphangiogenesis in PD, and macrophages in 
particular have been suggested to stimulate lymphangiogenesis through the production of VEGF-C and 
VEGF-D. VEGF-C is one of the most important mediators of lymphangiogenesis, and it has been shown 
that its content in the PDE is positively correlated with the membrane transport rate. Thus, if VEGF-C 
concentration in the PDE increases, the PM transport rate will be higher [23].  
Interestingly, VEGF production is associated with blood and lymphatic vessels proliferation, 
while lymphangiogenesis specifically is mainly regulated by VEGF-C and VEGF-D [23]. In addition, 
VEGF receptor (VEGFR)-3 is also part of this signalling pathway, in that it represents the central 
molecular mechanism for lymphangiogenesis [72].  
Importantly, TGF-β is another key player, and is responsible for inducing peritoneal fibrosis in 
association with PD, and also peritoneal neoangiogenesis through interaction with VEGF-A. On the 
other hand, TGF-β has a direct inhibitory effect on lymphatic endothelial cell growth. Therefore, a 
possible mechanism of the TGF-β–VEGF-C pathway in which TGF-β promotes VEGF-C production in 
tubular epithelial cells, macrophages, and MCs, leading to lymphangiogenesis in renal and peritoneal 
fibrosis, has been recently proposed [72].  
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Moreover, it has been shown in cultured macrophages and fibroblasts that VEGF-D increases 
by prostaglandin E2 (PGE2) and by inflammatory cytokines, while VEGF-D has been reported to be 
down-regulated by TGF-β. In addition, although cultured human MCs strongly express VEGF-C, they 
do not express VEGF-D. Thus, either VEGF-C or VEGF-D induce growth of the lymphatic vessels via 
activation of VEGFR-3, which is localized on the surface of lymphatic ECs [23]. In addition, CTGF is 
also involved in fibrosis-associated renal lymphangiogenesis through interaction with VEGF-C, in part 
by mediating TGF-β signalling [72]. Therefore, signalling via VEGF-C and VEGF-D/VEGFR3 
represents the most central pathway for lymphangiogenesis and survival of ECs, providing a new 
therapeutic target to increase net UF by suppression of lymphangiogenesis and lymphatic absorption 
[23]. 
Furthermore, angiogenesis and fibrosis seem to be intimately linked through common initiating 
growth factors and inflammatory cytokines and the EMT process. Understanding the mechanisms of 
fibrosis and the interaction with angiogenesis is, therefore, important to developing therapeutic 
strategies to preserve the peritoneum as a dialysis membrane [57]. 
3.1.4- Peritoneal fibrosis, sclerosis and EPS 
Peritoneal fibrosis (or sclerosis) consists of the deposition of ECM proteins (collagen I, III, V, 
VI, fibronectin, tenascin) in the interstitium, with increased number of fibroblasts (some presenting 
myofibroblastic characteristics) and inflammatory cell infiltration. In addition, it is usual to find 
extracellular accumulation of collagen IV and laminin in the basement membrane, proteoglycans, 
polysaccharides, and glycoproteins [67]. The fibrotic thickening of the peritoneum increases resistance 
to fluid flux and ultimately decreases water flow through the interstitium. Thus, it appears that the 
gradual loss of peritoneal UF with time is initially related to increased solute transport leading to 
proportional dissipation of the osmotic gradient. Fibrosis that develops at later stages affects the osmotic 
conductance from solute transport, resulting in the reduction of UF. Neovascularization plays also a key 
role in this scenario, both contributing to increased small-solute transport and fuelling fibrosis[73]. 
Peritoneal fibrosis is a term that includes a wide spectrum of structural alterations, ranging from 
mild inflammation to severe sclerosing peritonitis (SSP) and encapsulating peritoneal sclerosis (EPS), 
the most severe and dangerous manifestation [67]. The most commonly used criteria for differential 
diagnosis is the peritoneal thickness. The normal thickness of human peritoneum is 20 μm, but after a 
few months on PD, it may reach up to 40 μm in simple peritoneal sclerosis (SS) cases. The SSP is a 
progressive sclerosis characterized by a dramatic thickening of the peritoneum (up to 4000 μm), 
accompanied by inflammatory infiltrate, calcification, angiogenesis, and vasodilatation of blood and 
lymphatic vessels [67][74]. 
In regard to signs of peritoneal fibrosis, these are detected in 50% to 80% of patients within one 
to two years. Usually, peritoneal alterations are limited and a result of SS, generally correlated with the 
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length of exposure to PD solutions, being reversible when PD is interrupted [49]. Moreover, SS can be 
considered as an intermediate stage of peritoneal fibrosis, it is the most common lesion found in patients 
after few months on PD and may represent the beginning of SSP [67]. Long-term PD treatment can lead 
to EPS, an exaggerated fibrogenic response of the PM, that leads to encapsulation of the bowels and 
intestinal obstruction and progresses even if the patient is removed from PD [12][50].Therefore, while 
it is generally accepted that PD should be discontinued in patients with EPS, the utility of continuing 
intermittent peritoneal lavage may aid in the removal of noxious mediators such MMPs, that have been 
implicated in the pathogenesis [75]. The observation that some cases of EPS arise after cessation of PD 
has also contributed to the notion that continued peritoneal lavage may be beneficial[35]. The frequency 
of EPS increases with the duration of PD, patients on for > 8 years are at higher risk [76].  
Regarding the mechanism behind the aberrant response to injury through fibrosis, some 
pathways and molecules have been found to be associated with this process. The MMT of MCs is an 
important mechanism involved in peritoneal fibrosis, and the TGF-β1 is considered central in this 
process [77]. As described in Section 3.1.2, MMT generates some myofibroblasts that can drive the 
fibrosis through the expressing α‐Smooth muscle actin (αSMA)[63]. In the case of TGF-β1, the 
upregulation has been correlated to worse PD outcomes. In addition, other proinflammatory and 
profibrotic cytokines, as well as angiotensin II (AngII) have shown to be upregulated during peritonitis 
episodes and may contribute to peritoneal fibrosis [50].  
A key role for macrophages (Mφ) in fibrosis has also been suggested. Depending on the cytokine 
microenvironment, Mφ can adopt a proinflammatory (M1) or a profibrotic (M2) phenotype 
characterized by the expression of cell surface proteins such CD206 and CD163 and soluble factors, 
such as CC chemokine ligand 18 (CCL18)[78]. Thus, M2 may participate in peritoneal fibrosis through 
the stimulation of fibroblast cell growth and CCL18 production. High concentrations of CCL18 are 
associated with functional deficiency and fibrosis of the PM[78], [79]. Furthermore, M2 expressing 
CD163+ have been demonstrated as one of the dominant cell populations in EPS peritoneal biopsies 
[80]. 
In addition, IL-17, a potent and best characterized member of the IL-17 family of cytokines, that 
led to the identification of a distinct type of T helper (Th) cells, may be critically involved in initiating 
peritoneal fibrosis. IL-17 is produced primarily by γδT cells and possibly by other innate-like tissue-
resident lymphocytes. The increase in IL-17 is associated with increased peritoneal levels of IL-6, TGF-
β, and retinoic acid-related orphan receptor-γt (RORγt), leading to the formation of additional IL-17-
secreting Th17 cells in a vicious circle. Moreover, Th17 cells release CCL20, a chemokine that boosts 
the recruitment of further Th17 cells. In the peritoneum of PD patients, IL-17 promotes thickening of 
the submesothelial compact zone. In rodents, the attenuation of IL-17-mediated responses reduces the 
extent of peritoneal fibrosis.[73].  
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3.2- Peritoneal membrane failure 
Ultrafiltration failure (UFF)/membrane failure is one of the important reasons for technique 
failure in PD [38]. UFF is the commonly used term for a situation, where netUF, i.e., the difference 
between the drained and the instilled volume is less than expected in the PD population. As the glucose 
concentration of the dialysis solution is an important determinant of netUF by osmosis, normal values 
are related to the glucose concentration of the dialysate [81]. UFF should be considered in patients 
presenting clinical findings of volume overload in whom noncompliance with diet or the dialysis regime, 
defects of the abdominal cavity boundary, and uncompensated loss of kidney function have been 
eliminated as possible causes [35]. Although the original PET allows accurate estimation of small-solute 
transport (expressed by D/Pcreat and D/D0) and ultrafiltration capacity, it does not provide sufficient 
information to discriminate between causes of UFF. To assess that information a PET with a 3.86% 
glucose solution is recommended in order to determine the evolution of D/Psodium during the dwell. This 
allows evaluation of the function of the aquaporins by the assessment of ‘sodium sieving’ [29] There 
are four main causes of UFF than can be distinguished: (a) fast transport of low molecular weight solutes, 
reflecting the presence of a large peritoneal vascular surface area; (b) decreased osmotic conductance to 
glucose; (c) an extremely small peritoneal surface area; and (d) the presence of a high disappearance 
rate of intraperitoneally administered macromolecules (“effective lymphatic absorption”) (Figure 10) 
[82]. The true UFF is defined by the “rule of fours”: failure to achieve at least 400 ml of netUF during 
a 4 h dwell using 4.25% dextrose [35]. 
These four types of UFF present different pathophysiologic features. Thus, knowing the specific 
pathophysiology of the various causes of UFF aids the diagnosis.  
Increased peritoneal exchange surface area (type-I UFF) represents the most common form 
of UFF arising as a consequence of changes in the PM over time causing a transition to a very rapid 
transport status [35], and is characterized by a high solute transport, with a D/P of creatinine > 0.81. The 
PM shows an inflammatory process with subsequent hyper-permeability. This type of UFF can also be 
observed in patients with inherent high transport characteristics of PM and during the episodes of 
peritonitis [38]. These anatomical changes are probably due to both tissue fibrosis and angiogenesis 
giving rise to a large effective exchange surface area, which results in the rapid dissipation of the osmotic 
gradient and consequently poor ultrafiltration [23],[35]. This hyper permeability has been demonstrated 
as a predictor of an increase in the mortality and technique failure in long-term PD patients. Patients’ 
survival is inferior in high / high average transport status groups as compared to patients in low/ low 
average transport status group [38]. 
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Figure 10-Clinical characteristics of the different types of UFF and accepted therapeutic option for UFF. Creatinine mass 
transfer coefficient (Cr-MTC); dialysate-to-plasma ratio (D/P). Adapted from González-Mateo et al.[23].  
Low osmotic conductance to glucose (type-II UFF), leading to inadequate water removal via 
aquaporins (AQP-1 channels dysfunction), AQP-1 channels account for 40 to 50% of the total UF across 
the PM [23]. The clinical characteristic of this UFF is attenuation of sodium sieving, that is, the 
dampening of the decrease in dialysate sodium during the first hour of a dwell with 3.86% glucose [35].It 
is characterized by low/high average solute transport, with a D/P of creatinine =0.5-0.8 [23]. This 
selective defect in water transport has been attributed to AQP-1 dysfunction, rather than deficiency in 
PM [38]. The cause of the functional alteration is yet to be elucidated; there is much speculation on the 
roles of glycosylation or endothelial NO [35]. The NO regulates vascular tone and permeability [83] 
whereas, endothelial NO synthase (eNOS) is a dimeric enzyme that is likely to be uncoupled in pro-
oxidant states, thus changing its functional activity, giving rise to superoxide formation instead of NO 
[84]. AQP1 and eNOS show a distinct regulation within the endothelium lining peritoneal capillaries. 
In acute peritonitis, the upregulation of eNOS and increased release of NO dissipate the osmotic gradient 
and result in UFF, despite the unchanged expression of AQP1. Giving the critical role of AQP1 in PD, 
manipulating AQP1 expression may be used to increase water permeability across the peritoneal 
membrane [21]. 
Diminished peritoneal exchange surface area (type-III UFF) represents the least common 
form of UFF, and is characterized by a low solute transport rates, with a D/P of creatinine < 0.5[23]. 
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Anatomically, there is a severe reduction in effective PM surface area and permeability. The clinical 
characteristics that may be present are, volume overload, symptoms of inadequate solute removal or 
both [35]. The diffuse hypo permeability of the PM appears to be caused by the effects of pro-fibrotic 
mediators such as TGFβ and as a consequence of MMT suffered by MCs [23]. This is observed in 
patients who have recurrent and relapsing peritonitis, sclerosis of PM (sclerosis peritonitis), and intra-
abdominal adhesions [52]. In simple sclerosis of the PM, there is a diminution in peritoneal transport 
but without more serious clinical consequences. However, in a more severe form, this may culminate in 
the most extreme complication of PD, the EPS, characterized by bowel obstruction through persistent 
PM adhesions, frequently associated with calcification [35].  
Increased lymphatic absorption rate (type-IV UFF), is responsible for low effective UF, with 
alterations in dialysate solute concentrations. The D/P creatinine ratio does not change with increased 
lymphatic flow, although net UF can be considerably reduced. Increased lymphatic flow, netUF and 
solute clearance are inversely related to lymphatic fluid absorption [52]. The total fluid that leaves the 
peritoneal cavity via lymphatics absorption is no more that 10-30% [37].The magnitude of fluid loss can 
be estimated by examining the rate of egress of radiolabelled albumin from the peritoneal cavity. Yet, 
this analysis is relatively difficult to perform and is not routinely available clinically. However, as 
icodextrin is removed from the peritoneal cavity via the lymphatics, and since even rapid transporters 
will usually achieve UF with the use of icodextrin, it has been suggested that failure to achieve UF with 
icodextrin may be construed as indirect evidence for a high rate of fluid absorption from the peritoneal 
cavity [35]. The pathogenesis of this form of UFF is poorly understood. It has been suggested that TGF-
β1 may play a role in promoting lymphangiogenesis in a rat model [85].This condition is relatively rare, 
which is fortunate as there is little to offer therapeutically and PD must often be discontinued [35]. 
Therefore, functional alterations in the dialysis capacity of the membrane, leading to UFF, are 
associated with increased morbidity and mortality and represent a major obstacle to successful long-
term PD therapy [16]. UFF diagnosed at the initiation of PD has been insufficiently characterized and 
few longitudinal studies have analysed the time course of water transport in patients with this 
complication. A recent prospective study shows that patients with UFF at the start of PD, suffer from a 
disorder of peritoneal water transport affecting both free water transport (FWT) and small-pore 
ultrafiltration (SPUF). After 1 year of follow-up the FWT increased systematically. In contrast, the 
evolution of SPUF was less predictable. However, an improvement of SPUF seemed to reverse this 
complication [86]. 
NetUF has been shown to decrease by as much as 30%-40% from the baseline in most patients 
on PD for more than 3-4 years, with peritoneal clearance of small solutes increasing or being stable. A 
study conducted by Prakash et al. [87] has reported UFF as the most common (15.5%) non-infectious 
complication of CAPD in their study[38]. 
Therefore, to improve PM longevity in PD, it is mandatory to diminish or block the up-
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regulation of the molecular mechanisms implicated in the onset of the UFF [23].  
3.3- Stability of peritoneal membrane transport over time 
PM function at the start of PD treatment, measured as solute transport rate and UF capacity, 
varies considerably between individuals, and even if this can be correlated to clinical factors such as age 
and body habitus it accounts for little of the variance seen. [88]. Additionally, the underlying 
pathophysiology that leads to morphologic and functional changes in the PM over time among patients 
on PD is not well understood [89]. Transport characteristics and UF capacity of the PM vary among 
patients, and deleterious changes in the membrane occur over time. The degree to which these changes 
are a direct consequence of currently available PD solutions, recurrent infectious episodes, genetic 
differences among patients, or a combination thereof is the subject of intense study[6]. In addition to 
these factors, adverse consequences resulting from systemic and local metabolic effects of 
intraperitoneal glucose exposure, infection of the PDF, PD catheter dysfunction, and patient burnout 
from self-care affect the long-term success of the therapy [6]. 
Although, initial PM changes are not life threatening, they tend to cause an increase in transport 
of solute both to and from the peritoneal cavity. As a result of the increased glucose uptake, UF becomes 
difficult, but can usually be managed by a change in prescription and occasional “resting” the peritoneal 
membrane with transient HD [90]. In addition, one PD-patient’ prescription does not fit all. The potential 
ultrafiltration volume/dwell varies based on dwell time, transport type, instilled volume, and the osmotic 
agent used in that instilled dialysis fluid. Thus, optimization of drain volume and the sodium content in 
that drain is dependent on the physician being aware of these factors and adjusting the prescription to 
be able to accomplish these patient specific goals [90] 
Importantly, some conventional interventions can be conducted to attenuate progressive 
peritoneal membrane injury and preserve peritoneal function, such as i) prevention of peritonitis, ii) 
timely removal of the peritoneal catheter in the face of non-resolving peritonitis, iii) use of 
biocompatible PDF, and iv) limitation of total glucose exposure by avoiding hypertonic dextrose 
solutions. In addition, some other attempts to preserve PM consist in; i) inhibition of the renin-
angiotensin-aldosterone and vascular endothelial growth factor systems, ii) peritoneal resting, iii) 
combined PD and HD, and N-acetylcysteine, and iv) gene therapy [89]. 
Summing up, the most common change in peritoneal function is a loss of UF capacity, although 
a reduction in solute clearance is not an infrequent occurrence. There is increasing evidence that such 
functional changes are related to changes in the structure of the PM, which correlates in most patients 
with the longevity of dialysis. Structural changes include loss of MCs, thickness of the submesothelial 
compact zone, and a plethora of vascular changes [15], as already described.  
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Therefore, to improve PM longevity in PD it is important to monitor its functional characteristics 
with respect to time. The data obtained could be useful for tailoring dialysis adequacy, analysis of 
clinical problems such as ultrafiltration failure or to predict the development of peritoneal sclerosis [91]. 
The fight against PM damage begins with the improvement in PDF biocompatibility, as described in the 
following section [67]. In addition, an alternative approach to preserve the PM might be the use of 
pharmacological agents or molecular strategies, as presented in Section 3.3.2. 
3.3.1- Biocompatibility of the Peritoneal Dialysis Fluids 
 PDF can be broadly divided into conventional PDF and novel solutions with more 
biocompatible characteristics (e.g. neutral-pH, low GPDs solutions). Conventional PDF are 
characterized by several undesirable characteristics, including acidic pH (5.2-5.5), high glucose 
concentrations (13.6-42.5 g/L), hyperosmolarity (360-511 mOm/ kg) and relatively high concentration 
of GDPs. Conventional PDF contain an osmotic agent, electrolytes, and lactate as a buffer [92], as 
follows: 
Osmotic agent: high levels of glucose (dextrose; 75.5–214 mmol/L) are used in conventional 
PDF in order to achieve fluid removal, with different dextrose concentrations (e.g. 0.5 or 0.55%, 1.36 
or 1.5%, 2.27 or 2.5% and 3.86 or 4.25% for anhydrous or hydrous dextrose, respectively) and with 
varying osmolalities (345–484 mOsm/L). Whilst glucose is a reasonable osmotic agent because it is 
cheap, easily metabolized, readily available [93], easily sterilized and associated with an excellent long‐
term safety profile, the quantity of glucose required for effective UF can be problematic [92]. Absorption 
of 100-200 g of glucose per day from PDF worsens metabolic and nutritional problems, such as impaired 
glucose tolerance, hyperinsulinemia, hyperlipidaemia, and, in some patients, abdominal obesity [93]. 
Buffer: conventional PDF contain lactate (30–40 mmol/L) as a buffer and are acidic (pH 5.2–
5.5). Lactate diffuses into the bloodstream and is rapidly metabolized into bicarbonate. As conventional 
PDF use a single‐chamber delivery system, it is not possible to store bicarbonate‐buffered solutions, 
since calcium and bicarbonate will precipitate to form calcium carbonate. Lactate has been shown to 
inhibit key cellular functions involved in peritoneal defence mechanisms, including phagocytosis, 
bacterial killing and secretion of cytokines [92]. 
Electrolyte composition: the concentrations of Na+, Cl-, Ca2+ and Mg2+ are kept close to 
those of serum concentrations. Removal of these ions is therefore almost completely dependent on 
convection due to the low diffusion gradient. For a decilitre of fluid removed in a 4‐h dwell, 
approximately 10 mmol of Na+ and 0.1 mmol of Ca2+ are removed, given that serum Na+ and Ca2+ 
are within the reference ranges [92].  
GDPs: include 3‐deoxyglucose, 3,4‐dideoxyglucosone‐3‐ene (3,4‐DGE), 5‐hydroxymethyl 
furaldehyde, formaldehyde and acetaldehyde, which have been shown to have adverse effects on both 
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the peritoneal membrane and systemically, are produced during the heat sterilization process and/or 
prolonged storage [92].  
In summary, conventional PDF are characterized by several undesirable characteristics that have 
been shown to result in adverse clinical outcomes, including PM injury. To diminish PM alterations 
related to the use of conventional glucose-based PDF, newer PDF has been developed. They are more 
biocompatible, having fewer negative local and systemic effects than conventional PDFs (Figure 11) 
[92], [93].  Some of these new PDFs have a neutral pH with low content of GDPs and bicarbonate-
lactate as buffers [94]. Other strategies include the use of non-glucose osmotic agents, such icodextrin 
and amino acid-based formulae, and the use of modern double chamber PDF with fewer GDPs, for the 
achievement of long-term preservation of the PM [52], [94].  
 
Figure 11- Schematic presentation of the potential beneficial effects of newer PDF. Abbreviations: AGE, advanced 
glycation end products; PD, peritoneal dialysis; PDF, peritoneal dialysis fluid; PM, peritoneal membrane; RRF, renal 
residual function; UF, ultrafiltration. Adapted from García-Lopez et al. [93]. 
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 Neutral-pH with low GDP solutions: was achieved through the development of a multi-
chamber technology, where lactate and/or bicarbonate are separate, from the glucose, which is kept in a 
different chamber and sterilized at a very low pH (2.8–4.2), minimizing GDPs production. The 
remaining solution is kept at an alkaline pH (8.0–8.6) in the other compartment. Prior to administration, 
the contents of the two compartments are allowed are mixed, resulting in the infusion of neutral pH 
(6.8–7.3) [17],[92]. Depending on the manufacturing process, GDP formation is substantially reduced 
but still varies considerably between different brands [17]. 
Icodextrin and amino acid-based formulae: along with modern multi-chambers, are 
suggested as the first step to achieve long-term preservation of the PM, avoiding the use of glucose [52]. 
PDF with an alternative osmotic agent contain icodextrin, a glucose polymer, is slowly absorbed via the 
lymphatics and the resultant osmotic gradient dissipates slowly compared to glucose, which is absorbed 
via the small pores of the PM. This provides a much greater net UF during the long dwell and can 
therefore be used for a single long dwell per day, especially in patients with high transporter status [94], 
thereby improving the patient´s hydration status. In addition, treatment using icodextrin has been shown 
to achieve UF equivalent to fluid removal achieved with 4.25% glucose exchange during longer PD 
dwells (10–16 h) [17],[92].  
Another alternative to glucose-based PDF are solution containing amino acid, which are free of 
GDP and with a slightly acidic pH of 6.7 [17]. As already described, PD causes loss of protein and 
amino acids in the dialysate and so contributes to the development of protein and energy malnutrition 
in PD patients. Amino acids-based PDF are osmotically equivalent to 1.5% glucose PDF, although their 
use is limited to a single daily exchange due to a risk of worsening systemic acidosis and uraemia [95]. 
For optimized nutrition of malnourished patients and to prevent increased serum nitrogen levels and 
metabolic acidosis, they should be applied at a ratio of 1–4 with glucose-containing PDF [17].  
Glucose- or GDP-sparing strategies are often hypothesized to confer clinical benefits to PD 
patients. Icodextrin solution seems to improve peritoneal UF and reduce the risk of fluid overload, but 
these beneficial effects are probably the result of better fluid removal rather than being glucose sparing 
[96]. Although frequently used for glucose sparing, the role of amino acid–based solution in this regard 
has not been thoroughly tested. Regarding the use of glucose-free solutions in a combination regimen, 
results suggested that glycemic control was improved significantly in diabetic PD patients, and there are 
probably beneficial effects on peritoneal function[96]. 
Limited progress has been achieved during the past 50 years of PD treatment regarding PDF 
technology and mainly consists of a reduction of the GDP content, pH neutralization, introduction of a 
bicarbonate buffer and of two alternative osmotic compounds. Glucose-based PDF still predominates, 
and PD treatment still confers major local peritoneal and systemic toxicity [17]. Therefore, newer PDF 
seems to have systemic benefits, as represented in Figure 11; however, it is still not clear whether the 
newer PDF can exert beneficial effects on patient-level outcomes, such as peritonitis, technique and 
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patient survival [93],[96],[97]. A recent study performed by Tawada et al. suggested that pH-neutral 
solution prevents the morphological and functional peritoneal changes induced by long-term PD 
treatment [98]. Moreover, neutral pH–low GDP fluids have been convincingly shown to preserve RRF 
and urine volume [96],[97].  
As suggested by Misra et al. an ideal biocompatible PDF solution is one that delivers: i) 
prolonged and sustained UF and solute clearance, ii) no adverse consequences with absorption, and 
possible beneficial nutritional and metabolic effects if absorbed, iii) no alterations in peritoneal host 
defences, and no induction of peritoneal and systemic inflammation, and iv) no long-term alterations in 
PM function with use [99]. Since none of the currently available PDF are perfect, more biocompatible 
PDF, ideally using a non‐glucose osmole agent, which is non‐toxic, easily metabolized, easily 
manufactured, cost‐effective and metabolically efficient needs to be developed [92]. Complementary to 
this, an alternative approach to preserve the PM might use pharmacological agents or molecular 
strategies, as described in following section. 
3.3.2-Pharmacological preservation of the peritoneal membrane 
As already described in the previous sections, several processes are involved in the deterioration 
of the PM. However, different strategies have been tested ex vivo, in vivo, and in vitro targeting different 
processes to achieve PM amelioration [67]. Thus, the use of pharmacological agents to protect the 
mesothelium or targeting inflammation and fibrosis is an alternative and complementary approach to 
the effort aimed at improving PDFs biocompatibility. These drugs might be administrated orally or 
intraperitoneally, but most of the experiments are performed in animal models [100]. 
Pharmacological agents might interfere in several ways, such as, i) playing a direct role in 
lessening chronic inflammation; ii) acting on several mediators such cytokines, growth factors and 
hormones that play a key role in PD-mediated tissue remodelling and iii) they can up- or down regulate 
cellular signalling pathways induced by activation of peritoneal cells (MCs and recruited leukocytes) 
during PD therapy [101]. Some interventional studies have explored the efficacy of peroxisome 
proliferator-activated receptor-γ (PPAR-γ) agonists, cyclooxygenase (COX)-2 inhibitors, renin–
angiotensin system (RAS) targeting and bone morphogenic protein (BMP)-7 in protecting the PM [100], 
and many more agents with different mechanisms of action as described in Table 3. 
Although therapeutic interventions have been investigated with the aim of preventing 
complications such as inflammation, fibrosis and angiogenesis involved in peritoneal remodelling [101], 
the efficacy of many therapeutic agents is uncertain because there are insufficient good-quality clinical 
studies [102]. In addition, most studies are performed in vitro or in animals and less is known about the 
effects that these pharmacological interventions may have on human peritoneum[101]. Therefore, it is 
important to perform better quality clinical and basic research studies within this area, in order determine 
the most appropriate therapeutic approach for processes of PM damage [23], [102]. 
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Table 3 Potential pharmacological interventions to block different processes implicated in the alterations suffered in the peritoneal membrane during peritoneal dialysis. Adapted from 
Gónzalez-Mateo [23]. 
Agents Drug Mechanism Target molecules Other processes blocked/ Other actions 
Targeting AGEs 
Benfotiamine Transketolase activation and direct anti-oxidative effects AGEs Reduction of inflammation and angiogenesis [103] 
Rosiglitazone PPAR-γ agonist AGEs Reduction of inflammation, angiogenesis and fibrosis [104]–
[106] 
Aminoguanidine Inhibition of diamine oxidase and NO synthase. Acts by lowering the levels of 
AGEs through interaction with 3-deoxyglucosone 
AGEs Reduction of angiogenesis and fibrosis [107] 
Alagebrium AGE crosslink breaker, breaks preformed peritoneal AGEs AGEs Reduction of AGEs formation in the capillaries, enhancing of 
endothelial function [108], [109] 
Zopolrestat Inhibitor of aldose reductase activity (glucose is reduced to sorbitol by aldose 
reductase, with the eventual formation of AGEs) 
AGEs Prevention of peritoneal fibrosis and angiogenesis [110] 
Pyridoxamine Inhibitor of AGEs and “carbonyl stress,” the inhibitory mechanism remains elusive AGEs Reduction of AGEs accumulation and angiogenic cytokine of 
VEGF and FGF-2 [111] 
Anti-fibrotic 
Captopril ACE inhibitors AngiotensinII Less production of TNF-α and IL-1, attenuation of VEGF 
concentration [112] 
Enalapril ACE inhibitors AngiotensinII Peritoneal thickness is not completely inhibited, peritoneal 
histology and function preserved [112] 
Losartan ARB inhibitors AngiotensinII Less production of TNF-α and IL-1 [112] 
Pentoxifylline Inhibition of ECM production TGF-β Inhibition human peritoneal MCs growth and collagen synthesis 
[113] 
Dipyrodamole Inhibition of TGF‐β production TGF-β Inhibits TGF-β–induced collagen gene expression in human 
peritoneal MCs [114] 
Emodin Inhibition of ECM production PKCα  Amelioration of the undesirable effects of concentrated glucose 
on human peritoneal MCs via suppression of PKC activation 
and CREB [115] 
Simvastatin Increases fibrinolytic activity, through synthesis of the fibrinolytic enzyme tPA 
and decreases PA-1 
PA-1 Prevent EMT, preserved UF and reduce the thickness of the PM 
[116]–[118] 
BMP-7 TGF-β blockade TGF-β Prevent and reduces fibrosis and negatively regulates EMT 
[64],[119] 
Tamoxifen Estrogen receptor modulation TGF-β, VEGF and 
leptin 
Inhibition of MMT and angiogenesis [120], [121] 
Anti-angiogenic 
and Anti-
lymphangiogenic* 
TNP-470 Decreases VEGF expression VEGF Reduction of fibrosis, suppression of myofibroblast proliferation 
[122] 
Celecoxib* Inhibition of COX-2 , modulating the VEGF expression VEGF Reduction of lymphangiogenesis, fibrosis and inflammation. 
Improved UF [123], [124] 
Sunitinib* Inhibits tyrosine kinase, blocking VEGF signalling VEGF Reduction of lymphangiogenesis [125]  
Endostatin 
peptide* 
Inhibits VEGF-VEGFR-binding and ATPase activity VEGF Reduction of lymphangiogenesis and fibrosis [126], [127], 
[128], [129] 
Suramin Inhibition of cytokines or growth factors/receptors interaction and ECM 
deposition 
TGF-β and VEGF, 
α-SMA 
Reduction of fibrosis and improve UF [103] 
FG-3019 CTGF antagonist CTGF Reduction of fibrosis [130] 
Fasudil, Y-
27632 
Inhibition of Rho/ROCK pathway VEGF Reduction of fibrosis [131] 
Blocking 
peptides (p17 
and p144) 
TGF-β blockade TGF-β Reduction of fibrosis [131] 
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Calcitriol and 
paricalcitol 
Vit D receptor activator TGF-β (and 
inflammatory cells) 
Reduction of proteinuria and improved UF (paricalcitol) [132]. 
Smad7* Inhibition of TGF-β/Smad pathway TGF-β Reduction of fibrosis [133], [134] 
Kallistatin* Serine protease inhibition VEGF and AGEs Reduction of lymphangiogenesis [135], [136] 
LMWH* HIF-1α blockade VEGF and HIF-1α Reduction of lymphangiogenesis and fibrosis [137], [138] 
mTOR 
blockade* 
Rapamycin  HIF-1α Reduction of lymphangiogenesis [139]–[142] 
Nebivolol β1-AR blockade β1-AR Reduction of fibrosis, inflammation, MMT and increased 
fibrinolytic capacity [143] 
Abbreviations: ACE, angiotensin converting-enzyme; AGE, advanced glycation end products; ARB, angiotensin II receptor blockers; β1-AR, β1-adrenergic receptor ; CTGF, connective tissue growth factor; COX-
2, cyclooxygenase; CREB, cAMP-responsive element binding protein ; HIF-1α, hypoxia inducible factor;  IL-1, Interleukin-1; BMP-7, bone morphogenetic protein 7; ECM , extracellular matrix; PPAR-γ, peroxisome 
proliferator-activated receptor-γ; PKCα, protein kinase C; LMWH, low molecular weight heparin; PAI-1, plasminogen activator inhibitor 1; TGF-β, transforming growth factor β; TNF-α, tumor necrosis factor α; 
VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; MMT, mesothelial to mesenchymal transition; FGF-2, Fibroblast growth factor; EMT, epithelial-to-mesenchymal 
transition; ROCK, Rho-activated kinase; α-SMA, α-smooth muscle actin; tPA, tissue plasminogen activator; mTOR, mammalian target of rapamycin; MC, mesothelial cell; NO, nitric oxide; UF, ultrafiltration. 
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4- Early detection of peritoneal response 
Currently there are no non-invasive methods for early prediction of PM failure. Therefore, 
parameters such as urea and creatinine concentrations, glucose transport and net ultrafiltration are used 
to follow-up the PM outcome, yet they do not change until a very late stage, when PM function is no 
longer recoverable [10][144]. The only way to follow PM failure is based on peritoneal biopsies, which 
allow the assessment of morphologic changes. However, it is an invasive procedure that may lead to 
temporary discontinuation of PD therapy. Moreover, uncertainty exists about sampling errors, 
reproducibility, and the risk of scarring [144][145]. 
The understanding of peritoneal functional outcome in response to PD requires a deep 
knowledge of the starting point because of initial functional diversity of the human peritoneum. 
Moreover, it can be hypothesized that the diversity in solute and water transports at PD initiation may 
represent different tissue responses to similar components of dialysates. Furthermore, different starting 
points followed by diverse reactions to PD at midterm can generate a wide spectrum of peritoneal 
morphofunctional scenarios [50]. Finally, the recent development of PDE biomarkers in PD has 
predominantly been hypothesis driven and is based on pathologies and pathomechanisms that are found 
to be relevant to the course of PD disease [146].  
Thus, the following section is shows some of the actual known biomarkers primarily associated 
with the process, such as, chronic inflammation and peritoneal infection., fibrosis, angiogenesis and 
peritoneal membrane remodelling.  
4.1-Implementation of biomarker use in clinical practice 
 In a clinical context a biomarker is a characteristic that can be objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological 
response to a therapeutic intervention [146]. A good biomarker should have a large intra- and a low 
inter-individual variability, a high sensitivity and specificity for the clinical outcome of interest [147]. 
PDE represents an underestimated biochemical window into the peritoneum and a useful 
reservoir of potential clinical biomarkers [148] that have recently received attention by the medical 
community as a potential target to follow PM evolution. At present, integration of PDE biomarkers in 
the routine clinical practice of PD is still modest [144]. 
Implementation of effluent biomarkers in patient care is a goal for the near future as peritoneal 
transport studies provide insufficient information on the development of PM alterations (such as the, 
development of EPS). A feasible approach could include some biomarkers (limited to 2 or 3, easily 
measured in effluent) in routine clinical assessment of peritoneal function, providing more information 
than currently available [144]. Potential biomarkers can be divided in those that represent mesothelial 
mass, cytokines, growth factors and those that may represent tissue remodelling and peritoneal fibrosis, 
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some metalloproteinases and their inhibitors [147]. Currently, CA125, reflecting mesothelial cell mass, 
and IL-6, representing peritoneal inflammation, are at a stage at which their measurement can be easily 
included in peritoneal function tests [144]. 
CA125, a glycoprotein, is the most extensively studied biomarker whose levels may indicate 
severe mesothelial cell damage, trans-differentiation, or increased risk of the development of EPS [144]. 
However, it cannot be used as an early predictor. In addition, IL-6, an interleukin protein, is probably a 
biomarker for local peritoneal inflammation in the absence of clinical peritonitis. As yet, no good 
biomarker for the extent of peritoneal fibrosis has been identified with certainty [144]. Also hyaluronic 
acid and MMP2, initially from PD biocompatibility research, can be used to obtain information about 
peritoneal integrity. However, their potential information is unspecific and limited [52]. 
Recently, a consensus article was published by members of the European Training and Research 
in Peritoneal Dialysis Network (EuTRiPD) reviewing the current status of biomarker research in PD, 
suggested a selection of biomarkers that can be relevant to PD patient care and are directly accessible in 
PDE. The authors proposed a biomarker research defined by a hypothesis-driven approach in selected 
candidate biomarkers, reflecting cellular mechanisms of interest, in the experimental setting and then 
translated into the clinical context. Clinical phenotypes to be assessed with molecular signatures 
(PAMSs) as biomarkers were suggested to be divided into pro-inflammatory and PM damage-associated 
phenotypes. The pro-inflammatory phenotype was further divided into acute peritonitis and post-
peritonitis–triggered chronic inflammation. The membrane-damage phenotype was further divided into 
MMT and changes in PM function determined by PET [146]. 
Therefore, combining clinical and peritoneal transport data with the measurement of molecular 
biomarkers would improve the complex diagnosis and management of PM failure. Recently, a study 
performed by Ossorio et al suggested that sustained low peritoneal effluent chemokine CCL18 levels 
are associated with the preservation of PM function in PD. The authors suggest CCL18 as a new marker 
and mediator of this serious condition as well as a new potential therapeutic target [79]. Similarly, other 
markers have been established or suggested as a potential target to follow PM evolution, as represented 
in Table 4. 
The possibility of identifying and following changes in the PM at the molecular level by 
peptidomics and proteomics has been proposed through longitudinal studies, as being of prime 
importance to unravel morphological and biochemical changes in long-term PD [48]. Hence, 
longitudinal studies to follow changes in PM at molecular level by peptidomics and proteomics 
was performed in chapter 6. 
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Table 4- Candidate effluent biomarkers in peritoneal dialysis. Table adapted from Barreto et al. [144], Bajo et al. [94] 
Processes Biomarker Involvement/Evidence Local production 
(+/-) 
Evidence 
Coagulation and 
Fibrinolysis 
Fibrin monomers Coagulation and fibrinolysis + Decreasing tendency of FM in first 2 years of PD treatment [149] 
PA-1 Fibrosis (inhibitor of fibrinolysis) + Linear increasing tendency during 4-h PET [150]; during peritonitis, expression is augmented [151]; 
elevated levels are present in homogenates of peritoneal tissue of patients with intra-abdominal 
adhesions [152], [153]; Lower effluent concentrations with biocompatible PD solutions [154]; tendency 
to increase with PD duration [155] 
Cytokines 
IL-6 Pro- and anti-inflammation, induces 
synthesis of hepatic acute-phase 
proteins 
+ Increased plasma concentrations during acute-phase reactions are associated with mortality in 
hemodialysis and PD patients; intraindividual coefficient of variation of 28% [156]; variable results 
with regard to correlations with peritoneal solute transport [157]–[160]; longitudinal and conventional 
vs biocompatible PDF [161]–[163] 
TNF-α Angiogenesis, fibrosis, acute-phase 
inflammation 
- Signs of local production during acute phase of peritonitis; no difference between patients treated with 
biocompatible vs conventional PDF [164] 
Growth Factors 
CTGF Angiogenesis, cell adhesions, and 
fibrosis 
+ Increased levels in PD patients with high peritoneal transport; In vitro induction of ECM [165] 
TGF-β Angiogenesis, fibrosis and ECM 
formation 
+ Present in inactive form; induction of EPS-like peritoneal alterations after adenoviral vector gene 
transfer [166]; no difference in levels between conventional vs biocompatible PDF [167]; stimulation 
ECM formation [168] 
VEGF Angiogenesis and increases 
vascular permeability 
+ An increasing tendency with duration on PD [169] ; Not a predictor of EPS [170]; Increased dialysate 
VEGF concentrations associated with high peritoneal solute transport [157] 
Matrix and Tissue 
Remodelling 
CCL18 Fibrosis - Elevated levels in EPS patients [171]; Low levels are associated with preservation of PM function [79] 
HA Connective tissue turnover, fibrosis + Elevated levels in the acute phase of peritonitis [172] and in patients with fast transport status [173], 
[174]; not a predictor of EPS,  but low levels may predict survival of CAPD patients [175]; increased 
levels are associated with both high peritoneal transport and time in PD [173] 
MMP-2 EMT, fibrosis, tissue remodelling + High values of MMP-2 in patients with EPS were found in multicenter study [145]; positive relationship 
with PD duration and with tissue inhibitor of metalloproteinase 1 has been reported; also, a negative 
association with FWT in prevalent PD patients is present; associated with the amount of peritoneal 
fibrosis in EPS-like rat model [155] 
Procollagen peptides Fibrosis + Modest elevation during peritonitis [176]; exposure to biocompatible PDF either led to an increase of 
effluent procollagen peptides [154] or had no effect[164] 
Mesothelium CA125 Mesothelial cell mass + Long-term PD may be associated with the loss of mesothelial cell mass [177] and may be absent or 
severely reduced in patients with abundant fibrosis [156]; Dialysate CA125 decreases during time on 
PD [178]; exposure to biocompatible PDF for up to 2 years led to increase in effluent CA125 [154], 
[167], [179]–[181] 
Endothelial 
Dysfunction 
E-selectin Cell-adhesion +/- Correlation between percentage of FWT and E-selection attributed to local production [144] 
Abbreviations: CA125, cancer antigen 125; CAPD, continuous ambulatory peritoneal dialysis; CCL18, CC chemokine ligand 18; CTGF, connective tissue growth factor; ECM, extracellular matrix; EPS, 
encapsulating peritoneal sclerosis; HA, hyaluronan; IL-6, interleukin 6; MMP-2, matrix metalloproteinase 2; PAI-1, plasminogen activator inhibitor 1; PD, peritoneal dialysis; TGF-β, transforming growth factor β; 
TNF-α, tumour necrosis factor α; VEGF, vascular endothelial growth factor; EMT, epithelial-to-mesenchymal transition; MMP, matrix metalloproteinase. 
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5-Mass spectrometry 
Fundamentally, MS measures the mass-to-charge ratio (m/z) of gas-phase ions. This quantity is 
formed by dividing the mass of an ion (in Dalton (Da) units) by the number of charges carried by the 
ion [182]. Mass spectrometers consist of an ion source that converts analyte molecules into gas-phase, 
a mass analyser that separates ionized analytes on the basis of the m/z ratio, and a detector that records 
the number of ions at each m/z values [183]. The mass analyser is central to MS technology. For 
proteomic research, four types of mass analysers are commonly used, time-of-flight (TOF), quadrupole 
(Q), ion trap and orbitrap analysers. These are very different in design and performance, with their own 
strengths and weaknesses. In the context of proteomics, the key parameters are mass accuracy, mass 
resolution, sensitivity and the ability to generate information-rich ion mass spectra from peptide 
fragments (MS/MS spectra) [184].  
The mass accuracy is usually the most important parameter and refers to the ability to assign 
the actual mass of an ion. Mass accuracy is usually presented in parts per million (ppm) and is typically 
expressed as an error value. For example, 20 ppm means that the real mass of an ion measured to 1000 
Da has a predicted error margin of ± 0.020 Da. [185]. On the other hand, whereas mass accuracy is the 
closeness of the agreement between the result of a measurement and a true value (exact mass), mass 
precision is the closeness of agreement between independent mass measurement results [186]. Mass 
accuracy depends on mass spectral signal-to-noise ratio and digital resolution [187]. 
The mass resolution (resolving power), of a given ion signal is defined as the mass spacing at 
which peaks can be clearly separated, and is reported in Daltons. The term “resolution” actually refers 
to “resolving power”, which is measured as m/δm, with m the mass of the peak center and δm the 
resolution (often defined as the width of a peak at half height or Full Width at Half-Maximum (FWHM)). 
Resolving power is a unitless parameter [185].  
Sensitivity, is defined as the slope of intensity/moles of sample plot. It is often incorrectly used 
to refer to the limits of detection, which is the smallest amount of sample that can be used to achieve a 
detectable signal [185]. Therefore, sensitivity is the capability of responding reliably and measurably to 
changes in analyte concentration, and the detection limit of an analytical method must be lower than the 
concentrations to be measured [188]. 
In MS, mass resolving power, mass resolution, mass accuracy, and mass precision are used to 
characterize the performance of high-resolution accurate-mass mass spectrometers. For precise mass 
determination the mass spectrometer needs to pass through mass calibration to ensure the best mass 
precision and mass accuracy. Furthermore, the mass capacity of the analyser must be considered, if the 
mass resolution of the mass spectrometer is sufficient to separate ions of interest from the chemical 
background, the molecular ions can be measured with high precision and accuracy in a wide range of 
Eduardo Araújo 
42 
 
complex samples in different matrices [186]. In addition, the recalibration of the data on “internal 
standards” contained in every proteomics data, is important to make the best use of the mass precision 
offered by the instrument. Each data set should also be  accompanied by a plot of mass errors from 
which appropriate maximum mass deviation can be chosen [189].  Finally, satisfactory mass precision 
can be achieved only if the system provides enough mass resolution and thus the ability to distinguish 
and separate the peak of interest from adjacent signals [186]. 
5.1-Mass spectrometry analysers 
 A mass spectrometry analyser is defined as the section of the mass spectrometer where the 
ionized molecules of protein or peptides are separated based on their mass-to-charge ratio by electric 
and/or magnetic fields or by measuring the time taken by an ion to reach a fixed distance to the 
detector[190]. As already mentioned above and described herein, different types of analysers are 
available for the separation of molecules, as can be seen in Figure 12. The instrumentation represented 
in the Figure 12, was used in the PDE sample analysis, and the analyser types are described here. 
A quadrupole mass analyser is a four-electrode device. The four rod-like electrodes are 
positioned symmetrically around the ion axis and parallel to one another. Quadrupole mass analysers, 
resolve m/z by applying radio frequency (RF) and DC voltages, allowing only a narrow mass/charge 
range to reach the detector. Ions with the incorrect m/z undergo trajectories that eventually cause them 
to presumably strike the rods where they are annihilated, never reaching a detector or a second mass 
analyser. These type of analysers are usually limited in mass range and have low resolution. However, 
it is a versatile and sensitive mass analyser for the mass range m/z 10-4000 and the MS/MS scan modes 
are powerful [191], [192]. 
TOF analysers, accelerate the ions by using a short voltage gradient and measure the time ions 
take to traverse a filed free flight tube, the flight time is proportional to the square root of the m/z, given 
a constant acceleration voltage (time of flight = k√(𝑚/𝑧)) [182], [192]. Thus, smaller the molecule the 
faster it will travel the distance of the flight tube to the detector. With respect to the resolution and hence 
mass accuracy, the performance of linear TOF analyser is related to the ionizing conditions within the 
ion source and to the length of the flight tube. TOF analysers afford a high sensitivity and theoretically 
and unlimited mass range (practical limit is determined by the detection efficiency of the ions arriving 
at the detector) [182]. 
An ion trap analyser consists of three electrodes with hyperbolic surfaces, the central ring 
electrode and two adjacent end-cap electrodes [193]. Ion traps analysers can trap and accumulate ions 
over time in a physical device. The ion trap technology is characterized by MS/MS capacities, by 
performing sequential mass analysis measurements, with unmatched sensitivity and fast data acquisition 
[194]. High mass resolution (>106 at m/z >1000) is accessible through slow scans, but mass 
measurement accuracy is relatively poor [193]. 
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Figure 12- Schematic representation of three different MS instruments: A- MALDI LIFT-TOF/TOF; B-Q-Exactive HF 
(Hybrid Quadrupole-Orbitrap Mass Spectrometer); and C-Orbitrap Fusion (Tribrid Mass Spectrometer). Figure A, was 
adapted from Suckau et al. [195] and Figure B was taken with permission from, Michalski et al. [196] and Figure C was 
taken from the instrument view software. Thermo Fisher Scientific is acknowledged as an author of the Thermo Fisher 
material. 
An orbitrap analyser can trap and separate ions in an oscillating electrostatic field. The 
electrostatic attraction towards the central electrode is compensated by a centrifugal force that arises 
from the initial tangential velocity, forcing the ions to move in complex spiral patterns. The axial 
component of the oscillations is independent of initial energy, angles and positions. A Fourier transform 
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is employed to obtain oscillation frequencies for ions with different masses, resulting in an accurate 
reading of their m/z. With respect to mass accuracy and resolution, measurements in the low ppm-sub 
ppm range can be achieved and with an extremely high resolution [194], [197]. The MALDI TOF/TOF-
MS mass spectrometer was used in articles 1-3 (Chapters 3-5), and Q-Exactive HF and Orbitrap 
Fusion in article 5 (Chapter 6). 
5.2-Ionization methods 
MS spectrometry was restricted for a long time to small and thermostable compounds because 
of the lack of effective techniques to softly ionize and transfer the ionized molecules from the condensed 
phase into the gas phase without excessive fragmentation [194]. During the 1980s the study of proteins 
and peptides using mass spectrometry became popular as the electrospray ionization (ESI) technology 
was mature enough to allow reliable analysis of complex biological samples [198]. Also, during the 
same period the so called matrix-assisted laser desorption ionization (MALDI) method was developed 
[191].  
 
Figure 13- Soft ionization techniques, A- Matrix-assisted Laser Desorption Ionization (MALDI); B- Electrospray Ionization 
(ESI). Figure adapted from [199], [200]. 
In the case of MALDI, the ions are created by mixing the analyte with a small, organic molecule 
called a matrix, that absorbs light at the wavelength of the laser. The analyte becomes incorporated into 
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the crystallized matrix and is then irradiated with a laser, causing the desorption and ionization of the 
matrix and analyte, either by protonation (positively charged ions) or by deprotonation (negatively 
charged ions). The ions are then accelerated into a MS analyser [182], as can be seen in Figure 13-A.The 
ESI technique enables the formation of ions from molecules directly from samples in solution, that is 
then nebulized, with the resulting charged droplets being made to undergo desolvation and the resulting 
gas-phase ions being mass analysed [201], as can be seen in Figure 13-B. For a desorption (phase 
change) ionization (charge-state change) experiment, it has long been known that, precharged species 
give exceptionally high yields. On other hand, if the analyte is neutral when it leaves the surface, 
subsequent gas-phase chemical reactions are needed to yield ions and the yields drop correspondingly. 
The spray ionization experiments do not require matrix because this is essentially provided by the 
solvent in which the sample is carried [201]. In addition, another important difference between the 
MALDI and ESI methods is the charge state in which the analyte is formed, with MALDI experiments 
presenting spectra dominated by singly charged ions and ESI presenting multiply charged ions. These 
multiple charged ions are originated due to the evaporation of water from a microdroplet that has ionic 
constituents (buffer, a non-neutral pH), so the analyte tends to take a number of charges in proportion 
to the size of the molecule [201]. MALDI was the ionization source used in articles 1-3 (Chapter 3-
5) and ESI in article 5 (Chapter 6). 
5.3-Fragmentation methods 
Fragmentation in a mass spectrometer consists of the physical process of dissociation of 
molecules into fragments, the spectrum thus obtained is unique to the molecule or ion. Collision induced 
dissociation (CID) it is a process whereby an ion of interest, named precursor ion, is selected, isolated, 
excited and fragmented by collisions with an inert gas within the mass spectrometer [182]. CID and 
higher-energy collisional dissociation (HCD) selectively cleave the most labile bonds in a protein, 
typically resulting in a limited sequence coverage [202]. In addition, alternative fragmentation 
techniques based on electron transfer of the ions present in the collision cell were developed to improve 
peptide sequencing. Electron capture dissociation (ECD)[203] and electron transfer dissociation 
(ETD)[204] yield fragments that are complementary to the CID fragmentation, these tend to be more 
evenly distributed over the entire peptide backbone and are particularly useful in localizing post-
translational modifications (PTMs). [194]. However, ETD strongly depends on charge density, and ETD 
tandem mass spectra are often dominated by unreacted and charge reduced precursors [202]. New-
generation mass spectrometers (such as, Orbitrap Fusion) introduced an electron-transfer/higher-energy 
collision dissociation (EThcD) peptide fragmentation methodology that combines HCD and ETcaD 
(also called ETciD) into one fragmentation event [205]. The advantage is that the peptide backbone 
fragmentation is improved and that dual fragmentation generates data-rich MS/MS spectra containing 
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both b/y and c/z ions, improving peptide sequence coverage and PTM localization confidence [206]. 
The CID and HCD-EThcD were the fragmentation methods used in article 4 (Chapter 6). 
6-Mass spectrometry-based proteomics 
The term “proteome” represents the entire collection of proteins encoded by a genome, cell, 
tissue or organism at a certain time, under defined conditions. Proteomics is the study of the proteome, 
the understanding of the structure, function, and interactions of the entire protein content of an organism 
[182] and it requires modern technology for the identification and quantification of the proteins present 
in a cell tissue or an organism [207]. Mass spectrometry (MS) has evolved into an indispensable tool for 
proteomics research, and the desire to understand the proteome has led to the development of new 
technologies that push the boundary of MS capabilities and allowed MS to address an ever-increasing 
array of biological questions [183]. Nowadays, proteomics comprises the large-scale analysis of proteins 
by modern mass spectrometry analysis methods capable of identifying and quantifying thousands of 
peptides/proteins in a fast high-throughput manner [208]. However, this task is challenging because the 
proteome has a large and unknown complexity, with the number of proteins far exceeding the number 
of correlated genes. This diversity arises from the fact that a particular gene can produce multiple distinct 
proteins, as a result of alternative splicing, the presence of sequence polymorphisms, PTMs and other 
protein-processing mechanisms [194].  
There are two general approaches in proteomics for identification and characterization of 
proteins. On the one hand, the bottom-up (peptide level) or shotgun proteomics is based on the mass 
spectrometry sequencing of tryptic peptides derived from a proteolysed proteome and relies on 
algorithms for amino acid sequence assignments [209][192]. This approach is often referred to as liquid-
based protein discovery. On the other hand, the top-down (intact protein level) approach 
separates/analyses intact proteins prior to proteolysis and MS identification mainly by two-dimensional 
gel electrophoresis [210]. 
MS can be used in two different ways, firstly to indicate the composition and secondly the 
structure of a given analyte. The first instance is performed in MS mode, where the actual mass of the 
analyte is measured [182]. However, this single-stage mass spectrum is composed of peaks 
corresponding to peptide precursor ions and is insufficient for distinguish ambiguous protein 
identification [211]. In the second instance the mass spectrometer is used in MS/MS mode, in this mode, 
the analyte is fragmented within the mass spectrometer to yield structural information [182]. In other 
words, after selection and further fragmentation of the single precursor ion a MS/MS spectrum is 
generated. In a MS/MS spectrum, there are generally two types of peaks: peaks generated from amino-
terminal fragment ions (“b” ions) and peaks generated from carboxyl-terminal fragment ions (“y” ions). 
The combination of precursor m/z and its MS/MS spectrum is used to determine peptide sequences, and 
proteins are then inferred from the identified peptides [211]. 
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The application of mass spectrometry and MS/MS to proteomics takes advantage of the vast and 
growing array of genome and protein data stored in databases. The information obtained by the mass 
spectrometer, list of peak intensities and mass-to-charge (m/z) values, can be used and compared with a 
“theoretical, in-silico” digestion of a protein or a “theoretical, in-silico” fragmentation of a peptide [192]. 
Therefore, in shotgun proteomics, the computational procedure for protein identification has two main 
steps, the protein identification and protein inference. In peptide identification, the experimental MS/MS 
spectra is searched against a protein sequence database to obtain a set of peptide-spectrum matches (as 
described above), or using the de novo sequencing to determine the peptide sequences without using the 
protein database. On the other hand, protein inference  assembles identified peptides into a set of 
confident proteins [211].  
In summary, MS-based shotgun proteomics is a strategy that offers fast, high-throughput 
characterization of complex protein mixtures [211]. An example MS-based shotgun proteomics 
experiment is based on, i) enzymatic digestion of proteins into peptides, with a protease, such trypsin 
(because it is stable, cost-effective, and relatively specific), ii) the peptides generated are subsequently 
separated using an isoelectric focusing technique; iii) analyse by Reverse Phase High-Performance 
Liquid Chromatography (RP-HPLC) coupled to tandem MS (MS/MS) and finally, iv) the resulting 
peptide sequence data generated from MS/MS spectra are compared through using sophisticated 
mathematical algorithms against protein databases [212]. 
Ideally, all peptides eluted from the RP-HPLC should be captured by the mass spectrometer. 
However, this does not happen because peptides compete for efficient ionization and therefore, abundant 
peptides are more likely to be analysed by the mass spectrometer than those less abundant peptides. 
Finally, peptides are quantified (either relatively or absolutely) to generate protein abundance. These 
protein abundances are then interpreted and further used for biomarker discovery or protein–protein 
interaction network construction [211].  
6.1-Mass spectrometry-based approach to study the PDE proteome and peptidome 
Prior to mass spectrometry sample analysis some pre-analytical factors influencing the results 
must be considered, namely sample collection, sample processing and sample storage [210]. A challenge 
when working with complex proteomes, is that proteins span a concentration range that exceeds the 
dynamic range of any single analytical method or instrument [194]. The concentration range of plasma 
proteins for example, can exceed more than 10 orders of magnitude in concentration from the high 
abundance proteins (HAP) to the low abundance proteins (LAP) [213]. This problem, to some extent, 
can be expected for PDE samples [214]. However, MS instrumentation performs analysis with up to 
four orders of magnitude of the dynamic range in the untargeted mode, in a stark mismatch with the 
proteome dynamic range. Moreover, in shotgun proteomics, the dynamic range of signal intensities of 
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peptides resulting from the proteome's digestion is at least an order of magnitude larger than that of the 
original proteome, which makes the above mismatch even more contrasting [215]. 
Another major drawback associated with the analysis of complex biological samples is the wider 
range of protein abundance, with a particular cell having only few copies of a given protein, but with 
millions of copies of other ones [216]. This complexity of proteome translates into analytic complexity 
for individual proteins, especially LAP [217]. As can be seen in Figure 14, a proteome's abundance 
distribution represents a nearly symmetric bell‐shape curve on the logarithmic copy number scale [215]. 
Regarding the most abundant proteins, for every order of magnitude increase in sensitivity or sample 
amount, the number of proteins detected increase. However, when approximately half of the expressed 
cellular proteome (i.e. approximately 5000 proteins) is detected, the slope of the distribution inverts, 
and every order of magnitude increase yields progressively smaller increments in protein number. The 
challenge is the analysis of the approximately 1000 least abundant proteins, and the increasing sample 
size required to reach the depth of >9000, with >1 mg of sample corresponding to >5 million cells [215].  
Therefore, an inherent challenge when working with complex samples is the issue of HAP. More 
than 95% of serum proteome is composed of HAP, that hampers the detection of LAP, which are most 
likely to be biologically relevant as markers of a disease state. To address the issue of HAP, MS 
instruments with wider dynamic ranges have been developed [218]. Additionally, to have a complete as 
possible portrait of the proteome of any type of samples, the HAP should be, at least partially removed 
so the complexity of the sample can simplified [216]. The removal of HAP from complex proteomes 
samples can be done using different methods of protein fractionation or protein depletion, which are 
generally followed by concentration of the fractionated/depleted fraction [219].  
 
Figure 14-Distribution of protein abundances is a bell‐shape curve on a logarithmic copy number scale. Conventional 
proteomics analysis detects highly abundant proteins (about four orders of magnitude). Deeper proteome analysis requires 
a much larger sample size. The very low abundant proteins (red part) is the most challenging detection part of the proteome 
(approximately 1000 least abundant proteins). Figure adapted from Zubarev et al.[215]. 
Summing up, MS is the most powerful tool for systematic and unbiased detection of a full set 
of proteins present in tissues and cells. However, it is limited by the need for multiple sample preparation 
stages, including depletion of HAP, liquid chromatography, and trypsin digestion, resulting in multiple 
analytic steps. [217]. Therefore, in order to improve resolution, sensitivity and reproducibility of peptide 
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identification and protein matches, a combination of depletion, fractionation prior to MS/MS is 
recommended [216], as described in the following section. 
6.1.1-Sampling strategy and sample preservation 
 Body fluids are an important source of information about the biochemistry of living organisms. 
For example, cerebrospinal fluid is in direct contact with the central nervous system and thus has long 
been considered as a biopsy reflecting dynamic changes in this system. Other body fluids such blood, 
saliva and urine, are easily available and commonly used for clinical proteomics [216]. Although a PDE 
sample is not a “pure” body fluid (it is peritoneal fluid highly diluted in PDF), it presents the same 
advantages as those described above because it is in direct contact with the peritoneum and it is easily 
accessible. Therefore, PDE should be an excellent fluid to disclose what it is happening to the 
peritoneum when it is chronically exposed to PDF. It could allow i) follow-up the evolution of each 
patient’s therapy, ii) search for candidate biomarkers and iii) performing a case-by-case therapy.  
Some factors during sampling and then during sample preservation, must first be taken into 
consideration prior to further sample handling to effectively process the sample. Transport of samples 
from the hospital to the laboratory must be done in a standardized manner (on ice) and as quickly as 
possible, and long-term storage should be in low temperature-controlled freezers [220]. After a 4 -hour 
PD session∼ 2300 mL of PDE are drained from the patient. Of this volume, only 100 mL are collected 
in two 50 mL tubes supplemented with protease inhibitors (sodium fluoride and ethylene diamine tetra 
acetic acid, EDTA). Before storage at -80 °C samples are centrifuged to remove cell debris. Then, each 
100 ml sample is aliquoted into subsamples of 10 mL. 
In general, supplementation of specific protease inhibitors, such as, phenylmethylsulfonyl 
fluoride (PMSF), aminoethyl benzylsulfonyl fluoride (AEBSF), EDTA, pepstatin, benzamidine, 
leupeptin, aprotinin or cocktails with a broader activity spectrum is recommended. This supplementation 
during sample preservation is important because, if not inhibited, liberated/activated endogenous 
proteases are responsible for uncontrolled enzymatic proteins degradation. Such proteolysis may 
produce artefacts and hence further complicate the analysis [216]. 
In addition, PDE samples are highly diluted due to the high volume of PDF that is inserted per 
PD session (2000mL). Therefore, after 100 mL have been collected, centrifuged and aliquoted, PDE 
concentration and desalting have to be performed by centrifugal ultrafiltration. Thus, centrifugal 
concentrators with 10 KDa cut-off membrane have to be used in order to concentrate the samples prior 
to any proteomic step. After performing centrifugal ultrafiltration, this methodology enables the 
obtaining of two fractions, the proteome (> 10 kDa) and the peptidome (< 10 kDa), allowing thus further 
analysis of the proteome and the endogenous peptidome. 
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The performance of the PDE concentration and desalting using centrifugal concentrators 
is presented in Chapter III. The best conditions obtained then are used in the PDE proteome and 
PDE peptidome studies done in Chapters I-VI. 
6.1.2- Protein depletion and protein concentration strategies applied to PDE samples 
The challenges of complexity and dynamic range of protein concentrations can be addressed 
with different methods for reducing the HAP in biological fluids, including immune depletion or 
chemical assisted protein equalization and/or depletion.  
The HAP tend to mask the presence of LAP since the loading capacity of analytical methods 
are limited. Therefore, the removal of human serum albumin together with immunoglobulin G, both 
representing between 60–80% of the total serum protein content, would increase the LAP loading 
capacity and would thereby contribute to improving the detection sensitivity of LAP [221]. To overcome 
the aforementioned problem, the Multiple Affinity Removal System (MARS) was developed, in both 
spin-column and LC column formats, combining polyclonal antibodies targeting seven, twelve, 
fourteen, or twenty of the most abundant proteins present in plasma. Of the MARS available, antibody 
columns for removal of fourteen, twenty or more medium and HAP are the most effective, removing 
circa 95% of the total protein content [222]. In our case, the MARS LC column format targeting 
fourteen abundant proteins was the depletion method selected to be used with the PDE samples 
in study four (Chapter VI). 
Another alternative to deal with HAP is depletion, and rapid acetonitrile (ACN)‐based depletion 
method was first reported by Kay et al. [223], which reproducibly deplete high abundance and high 
molecular weight proteins from serum prior to MS. The combination of ACN depletion and one‐
dimensional nano‐LC/MS/MS enabled the detection of the low abundance serum protein, insulin‐like 
growth factor‐I (IGF‐I), which has a serum concentration in the region of 100 ng/mL, in the region of 
the LAP. Moreover, the one‐dimensional sodium dodecyl sulphate/polyacrylamide gel electrophoresis 
(1D-SDS‐PAGE) analysis of the depleted serum demonstrated the efficiency of the method for the 
depletion of high molecular weight proteins, with the absence of bands corresponding to proteins with 
a MW above 75 kDa. Additionally, the total protein analysis of the ACN extracts revealed that 
approximately 99.6% of all protein is removed from the serum.  
On the other hand, a chemical assisted equalization method was proposed by Warder et al. [224], 
and is based on the use of a low volume of concentrated reducing agent, such as dithiothreitol (DTT) or 
tris (2-carboxyethyl)phosphine (TCEP), to rapidly and reproducibly precipitate high-abundance 
disulphide-rich proteins, including albumin and transferrin, from serum and plasma. Further precipitate 
removal via centrifugation and identification of protein content revealed an albumin-enriched pellet. 
Moreover, the supernatant analysis by MALDI-TOF-MS afforded peptidome and small protein profiles 
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with enhanced features and minimal ionization of full-length albumin. In addition, the author considered 
that this method distinguishes itself from immunoaffinity resin-based approaches, since it could be 
scaled to large millilitre quantities and it is compatible with plasma. 
Interestingly, the combination of a chemical sequential depletion method based in two protein 
precipitations with ACN and DTT was later suggested by Fernández-Costa et al. [225] as an alternative 
method for the depletion of HAP in human plasma. This method was proposed as as inexpensive, of 
easy implementation and allowing a fast sample throughput. In addition, for the MS analysis of human 
serum proteins Fernández-Costa et al. also reported the comparison of the two different chemical  
methods, using ACN or DTT, with the protein equalization obtained with the ProteoMiner kit (Bio-Rad) 
[226]. Results showed how ACN depletion was efficient for depleting high molecular weight proteins 
(over 75 kDa), whereas DTT depletion primarily promotes the precipitation of proteins rich in disulphide 
bonds (mainly albumin), as previously reported by Kay et al.[223] and Warder et al. [224]. In addition, 
it was further confirmed that the use of DTT produces an extract compatible with protein equalization 
rather than with protein depletion, as high abundant proteins are not fully depleted. 
The performance on the PDE samples of the chemical assisted depletion with ACN and 
the chemical assisted equalization with DTT was investigated in Chapters IV and V, and in the 
Chapter III, IV and V, respectively. 
6.1.3- Protein digestion strategies applied to PDE samples 
Digestion of complex proteomes can be done through two main methods, the gel-based 
electrophoresis approach in the first or in the second dimension, and in the in-solution digestion. In-gel 
digestion specifically degrade proteins into fragments that fit the effective molecular mass separation 
range of the mass analysers [227]. The in-gel digestion method was established by Rosenfeld et al. 
[228]. Several changes in the method have contributed to increase peptide yield and improvement of the 
quality of MS data. Essential steps such as, destaining, reduction and alkylation of cysteines, enzymatic 
cleavage of proteins into peptides, and extraction of peptides from the gel, are crucial for the acquisition 
of high-quality mass spectra [227].  
Therefore, a classical in-gel digestion protocol for a protein band or spot stained with Coomassie 
brilliant blue (CBB), consists of the following steps: i) protein bands or spots are excised from the 
polyacrylamide gel, ii) Destaining of the CBB stained proteins is achieved by incubation of the excised 
gel bands or spots in a mixture of an organic solvent (typically ACN) and ammonium bicarbonate, iii) 
in order to increase the digestion efficiency and the sequence coverage, reduction of disulphide bridges 
(e.g. with DTT) and to prevent reformation of disulphide bonds, successive alkylation of the SH groups 
is done with iodoacetamide, IAA; iv) proteins are subsequently digested with proteolytic enzymes, 
typically trypsin, cleaving at the amino acid residues arginine (R) and lysine (K), v) the resulting 
peptides are extracted from the polyacrylamide matrix, usually with two sequential steps performed to 
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ensure extraction of peptides with different properties, with ammonium bicarbonate and ACN, formic 
acid or trifluoroacetic acid, and then vi) the peptide solution can be further purified for analysis by MS 
[227].The in-gel digestion was the methodology used in studies two and three (Chapter IV-V). 
The second most common method of complex proteome digestion is in-solution digestion. The 
conditions of digestion, i.e., pH, protein concentration, digestion buffers, additives, the proteolytic 
enzyme, and enzyme/substrate ratio, can be altered or adapted for in‐solution digestions more easily 
than for in-gel digestion, and the recovery of the digestion products is more efficient [229]. Similarly, 
to in-gel digestion, prior to in-solution protein digestion the proteins need to be denatured, reduced and 
alkylated, for the proteolytic enzyme to be able to efficiently cleave the peptide chains of the proteins 
[230]. Trypsin is the most commonly used enzyme for in-solution digestion as it has a well-defined 
specificity, hydrolysing only the peptide bonds in which the carbonyl group is contributed by either an 
R or a K residue, except when they are bound to proline (P). Other enzymes like chymotrypsin, pepsin, 
Lys-C, Asp-N and Glu-C can also be used for protein digestion [231]. In-solution digestion was used 
in the studies presented in Chapters III, IV and V.  
In-solution digestion with trypsin is performed at an optimal pH in the range 7.5-8.5, and is 
normally carried out overnight (12-16h) at 37 °C. Prior to the addition of trypsin, a buffer is added, 
usually 12.5 mM ammonium bicarbonate buffer to provide an optimal pH for the enzymatic cleavage 
[230]. The enzyme to protein ratio needed for digestion of a protein sample is crucial to ensure an 
enzyme amount sufficient to perform the digestion, but not so high as to produce trypsin autolysis 
products. Usually the ratio of enzyme to substrate is 1:20 [231]. The proteome digestion process is the 
most time consuming step in the proteomics sample preparation workflow and different techniques to 
accelerate this procedure have been developed [230], involving ultrasound-, heating-, infrared- and 
microwave-assisted digestion, immobilized digestion using, filter-aided sample preparation (FASP) and 
immobilized trypsin microreactors [231], [232].  
Technological improvements in apparatus to deliver ultrasonic energy have led to the 
development of a device called a sonoreactor, that offers some advantages over the ultrasonic probe and 
the ultrasonic bath since it combines their benefits but not their drawbacks. The sonic energy generated 
by the sonoreactor is lower than an ultrasonic probe, but higher than the energy produced by a common 
ultrasonic bath, a fact that is critical, because it speeds in-gel protein digestion without the gel 
degradation that occurs when an ultrasonic probe is used. Thus, as suggested by Rial-Otero et al., a fast 
and high-throughput in-gel trypsin digestion of proteins using sonoreactor technology can be achieved, 
with just 120 seconds to digest the sample, and able to handle up to six samples at once [233]. 
Interestingly, the sonoreactor and the ultrasonic probe devices were also suggested for in-solution 
protein digestion by Santos et al.[234]. Thus, it has been demonstrated that ultrasonic probe and 
sonoreactor can be used for accelerating the sample treatment for protein digestion for protein 
identification by PMF using MALDI-TOF-MS from 24 h to 15 min (5 min per each step of protein 
alkylation, protein reduction, and protein enzymatic digestion) without compromising the number of 
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peptides matched or the protein sequence coverage obtained [234]. The performance of the 
sonoreactor device applied to PDE samples for ultrasonic in-solution digestion is presented in 
Chapters III, IV and V.  
Another methodology that provides favourable conditions for proteolytic digestion is a method 
developed by Hughes et al. [235], termed Single-Pot Solid-Phase-enhanced Sample Preparation (SP3). 
Basically, the method consists of the addition of an organic solvent (ACN) to an aqueous solution 
containing paramagnetic beads, in order to promote the trapping of proteins and peptides in a solvation 
layer on the hydrophilic surface of the beads. Thus, immobilization on the bead surface permits rinsing 
(while on a magnetic rack) and removal of contaminating substances (such as detergents and chaotropes) 
with a combination of solutions (70% ethanol and 100% ACN), prior to proteolysis, fractionation or MS 
analysis. Furthermore, all steps in a conventional proteomics protocol (cell lysis, protein clean up and 
digestion, peptide labelling, desalting, fractionation, and concentration) can be completed entirely in a 
single tube with SP3, maximizing throughput while minimizing potential sample loss [235]. The 
performance of the SP3 methodology was also investigated on PDE samples in the study presented 
in Chapter VI. 
6.1.4- Gel-based electrophoresis strategies for protein and peptide fractionation of PDE 
samples 
Gel-based electrophoresis is mainly used in proteomics to separate and interrogate the proteins 
of proteomes [236]. In polyacrylamide gel electrophoresis, also known as gel electrophoresis in the first 
dimension, 1D-PAGE, proteins migrate in response to an electrical field through pores present in a 
polyacrylamide gel matrix. The pores of the matrix size decrease with the acrylamide concentration. 
The combination of pore size and protein’s charge, size, and shape determines the migration rate of the 
protein [236]. The denaturation of the proteins in a solution of sodium dodecyl sulphate (SDS) allows 
avoiding charge variation between proteins as charge density becomes the same. Therefore, the proteins 
are then separated only according to molecular weight [207]. The 1D-SDS-PAGE method is presented 
in Chapters III and IV. 
On the other hand, two-dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (2D-SDS-PAGE) separates proteins by molecular charge in the first dimension and by 
molecular size in the second one. The first-dimension consists of protein isoelectric focusing (IEF) in 
an immobilized pH gradient (IPG), with proteins submitted to a high voltage within a pH gradient [237]. 
Thus, amphoteric analytes, such as proteins and macropeptides, are separated according to their 
isoelectric point (pI) values in a stable and linear pH gradient. The gradient increases from a low pH 
(anodic end) to a high pH (cathodic end). When an electric field is applied, each protein migrates through 
the pH gradient, becoming increasingly less charged when arriving at a pH equal to its pI, where its net 
charge is zero, and therefore will not migrate further in the electric field. Thus, each protein is focused, 
into a narrow zone at its pI position, where it remains as long as the electric field is maintained [238]. 
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Proteins present in complex to be separated are first denatured and then loaded onto the IPG 
strip, which has a linear pH gradient. IPG strips are polyacrylamide-based, and upon rehydration, 
proteins are driven into the strip along with the buffer [239]. Thus, proteins are first solubilised in a 
denaturing buffer, usually urea, keeping the hydrophobic proteins in solution and avoiding protein-
protein interactions. However, because urea is not so effective at breaking hydrophobic interactions, 
membrane proteins can be poorly solubilised. Nevertheless, a urea/thiourea mixture can help with this 
matter. In addition, the denaturation buffer also contains a neutral chaotrope agent, a zwitterionic or 
neutral detergent. As a general rule, CHAPS is often the zwitterionic detergent chosen, because of its 
high purity and it increases the solubility of hydrophobic proteins. Additionally, a reducing agent, such 
as DTT, is also used [182].  
Once proteins have been separated in the first dimension, the IPG strips containing the proteins 
need to undergo an equilibration step (with DTT and IAA), to ensure complete protein unfolding. Then, 
a second dimension, 2D, separates proteins by molecular size using gel polyacrylamide electrophoresis. 
Once the 2D had been completed, each protein has a unique isoelectric point/molecular size coordinate. 
After visualisation using a staining agent (generally CBB), proteome changes are revealed by gel image 
analysis. Then, the protein spots are excised, the pieces of gel are treated as explained in the Section 
6.1.3, and the pools of peptides are used to identify the proteins by mass spectrometry analysis [237]. 
The 2D-SDS-PAGE method is presented in Chapter III. 
High resolution isoelectric focusing (HiRIEF) is another prefractionation method based on the 
use of IPG strips [240]. This method allows sample complexity reduction prior to MS- analysis via 
reproducible fractionation of the proteome. In contrast to 2D-SDS-PAGE, and SP3 methods, the protein 
digestion is performed (as described in section 6.1.3) before employing the extensive separation of 
peptides on 24 cm HiRIEF IPG strips. Then the strip is divided into 72 fractions and the peptides 
contained in each fraction are extracted and subsequently analysed by LC-MS. Thus, when compared 
to a regular 2D-SDS-PAGE methodology, this methodology differs in the fractionation of peptides (after 
SP3 digestion) instead of proteins, and there is no need of performing a second dimensional fractionation 
step. The results obtained using the HiRIEF method are presented in Chapter V. 
6.1.5-RP-HPLC strategy for fractionation of PDE samples 
HPLC is currently the most used and versatile separation technique in proteomics. It can easily 
be coupled to MS, which makes it a perfect tool for separation of peptides directly prior to mass analysis 
[216]. Each chromatography involves two phases, the mobile phase and stationary phase. The mobile 
phase drives compounds to flow through the surface of the stationary phase and the movements of 
compounds are delayed by interaction with stationary phase. Hence, compounds are delayed 
differentially according to the interaction strength and finally are separated [241]. The RP-HPLC was 
named due to the reversed polarity between mobile phase and the stationary phase if compared with 
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normal phase chromatography. In normal phase chromatography, the mobile phase is an organic solvent 
and the stationary phase is hydrophilic resin, whereas RP-HPLC uses hydrophobic adsorbents as 
stationary phase [241]. 
Therefore, RP-HPLC separates proteins based on the hydrophobicity of the molecules, resulting 
in a separation based on the mass, because retention time increases with hydrophobic (non-polar) surface 
are of the molecule resulting in a separation based on the actual protein size. In this chromatography, 
the stationary phase consists of ligands that bind reversibly with the hydrophobic proteins [190]. The 
separation depends on the hydrophobic binding of the solute molecule of the mobile phase to the 
immobilized hydrophobic ligands attached to the stationary phase (the sorbent). Separations can easily 
be manipulated by changing the gradient slope, the operating temperature, the ionic modifier, or the 
organic solvent composition [242]. Elution can proceed either by isocratic conditions where the 
concentration of organic solvent is constant, or by gradient elution, in which the amount of organic 
solvent (usually acetonitrile) containing an ionic modifier (trifluoroacetic acid) is increased over a period 
of time. The solutes are thus, eluted in order of increasing molecular hydrophobicity[190], [242].  
Regarding the type of stationary phase used in RP-HPLC, it consists of a nonpolar material such 
as, hydrocarbon chains containing eight carbon aliphatic chains (C8), 18 carbon aliphatic chains (C18 
or ODS), or phenyl groups, bonded on a porous silica support. Concerning the mobile phase, it is a 
variable aqueous-organic solution and it is more polar than the stationary phase. The solute molecules 
are in equilibrium between the more polar mobile phase and the hydrophobic stationary phase. The 
retention depends mainly on three factors: structure of the analyte molecule, solvent polarity, and the 
type of stationary phase used [243]. The results obtained with the RP-HPLC strategy for 
fractionation of PDE samples is presented in Chapter V. 
7-Quantitative mass spectrometry-based proteomics 
Quantitative mass spectrometry-based proteomics can be absolute or relative. Absolute 
quantification determines changes in protein expression in terms of an amount or concentration of each 
protein present, whereas relative quantification determines the up- or down-regulation of a protein 
relative to a given control sample, and the results are expressed as “fold” increases or decreases 
[244],[245]. Quantification can be performed through labelling or by label free methodologies. 
Labelling can be achieved by the application of combinatorial isotopologues of C, H, N, and O. These 
can be introduced into proteins through chemical derivatization, using enzymes or through metabolic 
processes [246][247]. Chemical derivatization procedures can be applied to any sample at either the 
protein or the peptide level. Enzymatic labelling is probably the most straightforward and universal in 
vitro labelling method [216][247]. 
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The isotope coded affinity tags (ICAT) was developed in the late 1990s as strategy of isotopic 
labelling for differential expression. The method consists in the mass spectrometry comparison of two-
samples labelled separately with a molecular tag containing a heavy or light isotope, then mixed together 
and analysed simultaneously [248]. This approach was later refined with a method called iTRAQ 
(isobaric tag for relative and absolute quantification) [249]. Stable isotope labelling by amino acids in 
cell culture (SILAC) is also an MS-approach for quantitative proteomics that depends on metabolic 
labelling in vivo (metabolic derivatization) of whole cellular proteome. The proteomes of different cells 
grown in cell culture are labelled with a “light” or “heavy” form of amino acids and differentiated 
through MS [207].  
Stable isotope derivatization methods (with the exception of isobaric mass tags) introduce a 
small mass difference to identical peptides from two or more samples so they can be distinguished in 
the MS1 spectrum. The relative-abundance ratio of peptides is experimentally measured by comparing 
heavy/light peptide pairs, and then protein levels are inferred from statistical evaluation of the peptide 
ratios [244], [246].  
Isobaric mass tags include families of stable isotope chemicals that are used for labelling of 
peptides, generating relative quantitative information in an isobaric labelling-based quantification 
strategy [246]. The most commonly used isobaric mass tags are the iTRAQ and tandem mass tags 
(TMT). The iTRAQ method uses isobaric amine-specific to label all peptides in up to eight different 
samples simultaneously. TMT is a reproducible and highly accurate quantification method, that provides 
both comparative and absolute MS/MS-based quantification of proteins and peptides in biological 
samples. TMT labelling produces data to calculate the relative abundance of proteins, making it possible 
to evaluate differential protein expression in two to eleven samples in a single experiment [250].  
The advantage of these methods is that tags are isobaric, meaning that peptides labelled with 
isotopic variants of the tag appear as a single composite peak at the same m/z value in an MS1 scan with 
identical liquid chromatography (LC) retention time. The fragmentation of the modified precursor ion 
during MS/MS event generates two types of product ions: (a) reporter ion peaks and (b) peptide fragment 
ion peaks [244],[246]. The quantification is accomplished by directly correlating the relative intensity 
of reporter ions to that of the peptide selected for MS/MS fragmentation. The fragment ion peaks 
observed at higher m/z are specific for peptide amino acid sequence and are used for peptide 
identifications, which are eventually assigned to the proteins that they represent. Since every tryptic 
peptide can be labelled in an isobaric labelling method, more than one peptide representing the same 
protein may be identified, thereby increasing the confidence in both the identification and quantification 
of the protein [246].  
Label-free quantification is the quantification of MS peptide signals in LC/MS/MS data without 
an isotopic labelling reagent [250]. Label-free methods aim to compare two or more experiments by (i) 
comparing the direct mass spectrometric signal intensity for any given peptide or (ii) using the number 
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of acquired spectra matching to a peptide/protein as an indicator of their respective abundance in a given 
sample[251]. Interestingly, the principle of most label-free methods is the recognition that most complex 
samples have a large group of unchanging species that can be used as the source of normalizing factors 
(used to correct the sample-to-sample and run-to-run variation in signal intensities for the species of 
interest). However, a key barrier to quantitation with MS involves the fact that while the intensity of an 
ion does reflect its abundance, corrections must be made for differences in mass spectrometer response, 
sample loading, and ionization efficient that can occur between experiments [220]. Therefore, any 
variability in sample preparation, LC, or MS more strongly affects label-free quantification than it does 
isotopically labelled techniques where differently labelled peptides co-elute. In addition, it provides the 
lowest throughput because of a lack of multiplexing. Finally, peptides might have different levels of ion 
suppression across the various samples, leading to a decrease in quantification accuracy [250].  
In summary, the great advantage of iTRAQ and TMT as compared to other quantification 
methods is the multiplexed analysis of several samples within a single LC–MS/MS run, decreasing MS 
time analysis and variations during sample preparation, chromatography and MS acquisition. On the 
other hand, commercial labelling reagents are expensive and an additional labelling step has to be 
introduced in the analytical workflow [252]. In addition, various factors, such as ratio compression, 
reporter ion dynamic range, and others, cause an underestimation of changes in relative abundance of 
proteins across samples, undermining the ability of the isobaric labelling approach to be truly 
quantitative [246].  
Label-free proteomics is cost-efficient and no additional sample preparation steps are needed. 
However, samples need to be handled separately until the final LC–MS/MS analysis and all these steps 
ranging from sample preparation to MS acquisition can introduce variations that can bias the quantitative 
analysis. Furthermore, a quantitative analysis is comparatively time-consuming, as a multiplexed 
analysis is not possible in case of label-free proteomics [252]. Nevertheless, label-free quantification it 
still worth consideration because: (i) there is no principle limit to the number of experiments that can be 
compared, (ii) unlike most stable isotope labelling techniques mass spectral complexity is not increased 
which, in turn, might provide for more analytical depth because the mass spectrometer is not occupied 
with fragmenting all forms of the labelled peptide and (iii) label-free methods provide higher dynamic 
range of quantification than stable isotope labelling and therefore may be advantageous when large and 
global protein changes between experiments are observed [253]. 
In conclusion, each of these quantitative MS proteomic approaches have their particular 
strengths and weaknesses. However, MS is not inherently quantitative because proteolytic peptides 
exhibit a wide range of physicochemical properties such as size, charge, hydrophobicity, etc., together 
leading to large differences in mass spectrometric response. Therefore, accurate comparisons between 
two samples must be based on the same individual peptide in LC-MS/MS experiments conducted under 
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the same conditions [253], [254]. The results obtained with the TMT and Label-free quantification 
approaches are presented in Chapter VI. 
8-Bioinformatic analysis of mass spectrometry-based data sets 
The computer analysis of MS data is key for large-scale and high-throughput protein analysis 
and it has allowed proteomic studies. A principal method in shotgun proteomics analysis of proteins 
mixtures is the database searching of MS/MS data of peptides. The method is based on predicting the 
fragmentation pattern of the peptide and then comparing the predicted pattern to the fragments in the 
tandem mass spectrum. Scoring of a match based on cross-correlation, fragment ion frequencies, and 
hypergeometric probability, is then attributed [255]. Moreover, intensity models in correlation analyses 
improve matches between sequence and spectra and probability-based methods provide a statistical 
measure for the fit between sequence and spectrum. The statistical relevance for quantitative 
comparisons can be determined through empirical analysis of known data sets and establishing scoring 
cut-offs for a statistical confidence level [255].  
However, proteomic analyses can generate large amounts of data and thus have a need for a 
high level of automation in the data analysis. Thus, the major bottlenecks in proteomics can be 
considered as the data processing and analysis, with a huge amounts of data generated, but with an 
enormous challenge to figure out how to actually analyse this data and generate real biological insights. 
Also, the necessity of an integrated pipeline for processing and analysis of complex proteomics data sets 
has therefore become critical [256]. In addition, to facilitate the dissemination of the raw experimental 
data and inferred biological results, centralized data repositories have been developed in order to make 
the data and results accessible to proteomics researchers and biologists alike [257]. The main existing 
repositories are: the Global Proteome Machine Database (GPMDB) [258], PeptideAtlas [259], the 
PRoteomics IDEntifications database (PRIDE) [260], Tranche, and NCBI Peptidome [261], providing 
a highly valuable source for bioinformatics data mining [262].  
The information generated in a typical proteomics experiment can be organized in three different 
levels, i) raw data; ii) processed results, including peptide/protein identification and quantification 
values; and iii) the resulting biological conclusion obtained with Protein Knowledge-bases, such as, the 
Universal Protein Resource (Uniprot) [263]. Uniprot is among the most used of the protein sequence 
and functional annotation providers, it integrates, interprets and standardizes data from the literature and 
resources to achieve the most comprehensive catalogue possible of protein information [264], and is 
essential for the subsequent Gene Ontology term (GO-term) analysis, as described in the section below. 
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8.1- Gene Ontology term identification and enrichment analysis 
The output of a proteome analysis is usually a long list of identified factors, that have a 
probability score and ideally also a quantitative value associated to them. In order perform a functional 
analysis of a large protein list, the list has to be further classified and filtered. Thus, the first step for a 
functional analysis is to connect the protein name to a unique identifier (specific for that given protein) 
[265]. Some databases like the Uniprot knowledge base [266] and Ensembl [267] can be used for this 
purpose, using protein identifiers as input to retrieve the corresponding Uniprot or Ensembl identifiers. 
Later, these identifiers can be used to perform the GO-term identification and enrichment analysis. 
Therefore, the GO-term analysis, is obtained through the association of the protein identifiers 
with its associated Gene Ontology Terms [268]. These GO-terms, are associated with functional terms 
that describe the biological process, molecular function or cellular component which have a unique 
identification number. For larger data sets and systematic approaches some database search algorithms 
for proteomic data such as MaxQuant, Proteome Discoverer and X!tandem have implemented a GO-
term annotation step [265]. After performing the GO-term annotation, the GO-term enrichment can be 
performed to compare the abundance of specific GO-terms in the dataset with the natural abundance in 
the organism or a reference dataset [265]. Software available for annotation enrichment analysis can be 
categorized into three major classes according to their underlying enrichment algorithms. These are the 
singular enrichment analysis (SEA), gene set enrichment analysis (GSEA), and modular enrichment 
analysis (MEA) [269].  
The SEA enrichment is the most traditional approach (tools such, BinGO [270] and EasyGO 
[271]), that tests GO-terms one at time against a list of genes for enrichment. Annotation terms passing 
the enrichment p-value threshold are reported. This is a simple and very efficient strategy to extract the 
major biological meaning behind large gene list. However, the linear output of the terms can be very 
large and overwhelming. On the other hand, GSEA method (such as, GSEA/P-GSEA [272], [273] and 
GeneTrail [274]) adopts a “no-cut-off” strategy, taking all genes into account without selecting 
significant genes. GSEA methods need biological values such as fold changes for each of the genes as 
input. However, sometimes is difficult to summarize many biological aspects of a gene into one value 
when the experiment design is complex. Finally, the MEA method (such as, DAVID [275], Ontologizer 
[276], topGO [277]) considers relationships between GO-terms during enrichment, which can reduce 
redundancy and prevent the loss of potentially important biological correlations due to lack of 
relationships [265], [269]. The MEA disadvantage is that some terms or genes with weak relationships 
to neighbouring terms or genes could be left out from the analysis [269].  
Another common approach for the analysis of large datasets is the pathways analysis, allowing 
a reduction of complexity and increasing explanatory power. Therefore, it has become good approach 
for gaining insight into the underlying biology for a given gene or protein list, similarly to the previously 
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described GO-term enrichment analysis. However, examining protein or gene lists for pathway 
abundances might be more meaningful because it moves the data interpretation away from the gene-
centric view towards the identification of functional biological processes [265], [269]. A large number 
of resources and databases is available to extract pathways from biological data. Some of the popular 
and freely available pathway databases (for academic users) are KEGG [278], Reactome [279] and 
PANTHER [280], whereas other databases, such Ingenuity Pathways Knowledge Base [281] and iPath 
[282] are commercial [283]. Although, the enrichment analyses are available with almost all pathway 
database resources, the identification of pathways affected under certain conditions is highly dependent 
on the algorithm, similar to what happens regarding GO-term annotation [265]. 
Furthermore, the analysis of protein-protein interactions (PPIs), is also important, because the 
majority of proteins do not act as isolated entities, but rather function in complexes as multiprotein-
protein machines. Since their assembly is largely mediated by PPIs, functional interactions within a 
proteome may revealed by PPIs analysis. Functional interactions include sharing a common substrate in 
a pathway, regulating each other at the transcriptional level or indirect binding through participation in 
larger multi-protein assemblies[283]. Therefore, information regarding PPIs is deposited in interaction 
databases, such as MINT [284], BioGRID [285], IntAct [286] or HPRD [287], associated with the 
biological process in which they are functionally important.  
In addition, a resource used for PPIs data is STRING [288], which is a database itself, but is 
able to connect to other data resources and is also capable of literature mining. Moreover, is also capable 
of showing simple protein networks based on the provided gene list and the available interactions in its 
databases[265]. Another popular one-source program for visualizing protein or gene networks is 
Cytoscape [289], offering several plugins that can be useful for specific types of analysis. Similar 
platforms offer also the possibility to explore and manipulate large pathways and graphs, such Gephi 
[290] or the recent NeVOmics [291], that can also build different network-based graphical 
representations from the enrichment results. 
Computational proteomics can be considered multidisciplinary, attracting scientists from many 
fields and incorporating other disciplines like statistics, machine learning, efficient scientific 
programming, and network and time series analysis. Additionally, the integration of proteomics data 
with other biological high-throughput data is increasingly gaining importance [292]. The GO-term 
enrichment, pathways and PPIs analysis were used in Chapters IV and VI. 
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1-Objectives 
Although a number of molecules have been identified as being involved in PM alterations, a 
global peptidomics/proteomics study to identify biomarkers of PM alterations has not yet been fully 
addressed. The present project is aimed at revealing novel peptides and proteins involved in peritoneal 
changes in patients on long-term peritoneal dialysis, helping in the early detection of such alterations 
and delaying UFF. Moreover, the study is primarily focused towards proteins highlighting signs of 
peritoneal processes of lesion. The analysis of PDE based on peptidomics and proteomics is projected 
to allow identification of new biomarkers for the early detection of peritoneal changes in patients of 
long-term peritoneal dialysis. Thus, the objectives are: 
 Elaborate an atlas of the evolution of the proteome and peptidome content of the 
peritoneal dialysate (P3DEVOATLAS) during PD, which is potentially valuable for 
clinical diagnosis and prognosis.  
 Link the changes observed in the P3DEVOATLAS with other medical variables of the 
peritoneal membrane and some candidate biomarkers present on PDE, such as, cancer 
antigen 125, plasminogen activator inhibitor 1, and interleukin 6, etc. These are some 
examples of candidate effluent biomarkers in PD that have been already proposed, as 
can be seen in Table 4.1 (Section 4.1, Chapter I). 
 Establish relative/absolute quantitative relations between peptides / proteins to unravel 
potential biomarkers of peritoneal changes in patients on long-term PD; 
 Integration of the P3DEVOATLAS in the understanding of the global biochemistry 
processes involved in the evolution of the peritoneal membrane. 
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2-Working Plan 
Pre-analytical considerations 
A group of ten new patients in the first year of PD and ten others in the second year but still 
within the first stage of PD have been followed for 3 years. In addition, another 20 patients already at 
different stages of dialysis have been followed during the same period. For all the patients in the 
beginning of PD, samples were taken after the first month of dialysis, when the first peritoneal 
equilibration test (PET) was done. Then, samples were taken 6 months after the first PET, one year after 
the second PET and one year after the third PET. For those patients already at different stages of dialysis, 
samples have been taken once a year. Additionally, patients were grouped according to the peritoneal 
transport characteristics based on the PET into (i) fast, (ii) fast-average, (iii) slow-average and (iv) slow 
transporter.  
Samples were collected at the Hospital Garcia de Orta, Portugal. A proteases inhibitor cocktail 
was added to the samples and then samples were preserved on ice until centrifugation. Once in the 
laboratory, the samples were centrifuged, aliquoted and then stored at -80ºC until further analysis. 
Afterwards the PDE was submitted to ultrafiltration with a 10kDa cut-off membrane, thus the peptidome 
fraction (MW<10 kDa) and the proteome fraction (MW>10 kDa) were obtained. 
Work-package 1 – To elaborate a proteome atlas of peritoneal changes in patients on long-
term PD (P3DEVOATLAS). 
The proteome fraction (MW > 10 kDa) was studied and analysed using different proteomic 
techniques in order to evaluate sample complexity. Thus, different methodologies of protein depletion 
(to diminish/remove high abundance proteins) and protein/peptides fractionation techniques were 
assessed to improve the coverage of the proteome fraction.  
Deliverables: Methodologies to diminish sample complexity and improve proteome coverage. 
List of proteins differentially expressed across time-points. Linking these proteins to membrane 
evolution for diagnostics and prognosis. 
Work-package 2 – Development of a peptidome atlas of peritoneal changes in patients on 
long-term PD (P3DEVOATLAS).  
The term peptidome refers to the study of naturally occurring peptides. These peptides present 
in the peptidome fraction (MW<10 kDa) were pre-concentrated and cleaned by strong cation-exchange 
solid-phase extraction (SCX-SPE), then resulting peptide mixtures were analysed by LC-MS/MS on an 
Orbitrap Fusion mass spectrometer. All MS/MS spectra data were processed with Proteome Discoverer 
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(v2.2) using the PMI-Byonic node (V3.2.0) and Data files were searched for in the UniProt human 
canonical database (November 2018; 42,344 entries). 
Samples from different time-points were analysed and the number and class of peptides 
identified followed. Evolution over time was estimated with Label free quantification of peptides using 
the sample taken first within the sampling plan as reference. 
Deliverables: List of peptides differentially expressed over time. Elaboration of a relative scale 
of peptide abundance linked to membrane evolution for diagnostic use. 
Work-package 3 – Establish relative quantitative relations between proteins to unravel 
potential biomarkers of peritoneal changes in patients on long-term PD 
Proteins were quantified using TMT10plex. The TMT quantification data was used to elaborate 
a scale of membrane evolution similar to the one done in work-package 1 to assists physicians in 
diagnosis and prognosis. 
Deliverables: Quantitative Scale of membrane evolution as a function of differentially 
expressed proteins. 
Work-package 4 – Integration of peptidome/proteome biomarkers for diagnosis and 
prognosis of peritoneal changes 
Data analysis was carried out integrating the data obtained in the previous work-packages using 
data mining software such as Cytoscape and Reactome plug-in, in order to identify peptides and or 
proteins that may indicate and predict changes in the peritoneal membrane in patients on long-term 
peritoneal dialysis. 
Deliverables: Final elaboration of the P3DEVOATLAS. Biochemical and medical integration 
of all data obtained in work-packages 1 to 3. Elaboration of a theory to explain peritoneal membrane 
degradation with time. Proposal of potential therapies to extend the lifespan of peritoneal dialysis. 
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3-Thesis Output 
3.1-Papers published in international scientific journals 
3- Title: Classifying patients in peritoneal dialysis by mass spectrometry-based profiling 
Authors: J. E. Araújo, S. Jorge, R. Magriço, A. Ramos, F. Teixeira-Costa, M. Reboiro-Jato, F. Fdez-
Riverola, C. Lodeiro, J. L. Capelo, H. M. Santos 
Journal: Talanta (2016) DOI: 10.1016/j.talanta.2016.02.026 
Presented in Chapter V 
2- Title: A cost-effective method to get insight into the peritoneal dialysate effluent proteome 
Authors: J. E. Araújo, S. Jorge, F. Teixeira-Costa, A. Ramos, C. Lodeiro, H. M. Santos, J. L. Capelo 
Journal: Journal of Proteomics (2016) DOI: 10.1016/j.jprot.2016.05.010 
Presented in Chapter IV 
1- Title: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based profiling as 
a step forward in the characterization of peritoneal dialysis effluent 
Authors: J. E. Araújo, T. Santos, S. Jorge, T. M. Pereira, M. Reboiro-Jato, R. Pavón, R. Magriço, F. 
Teixeira-Costa, A. Ramos, H. M. Santos  
Journal: Analytical Methods (2015) DOI: 10.1039/C5AY00620A 
Presented in Chapter III 
3.2-Paper in preparation  
1- Title: In-depth analysis of peritoneal dialysis effluent proteome and peptidome: a longitudinal follow-
up study 
Authors: J. E. Araújo, R.M. Branca, I. Siavelis, G. Mermelekas, M. Pernemalm, M. Stahl, M. Sousa,.F. 
Teixeira-Costa, A. Ramos, H. M. Santos, J. L. Capelo, J. Lehtiö 
In preparation, Presented in Chapter VI 
3.3-Participation in national and international conferences 
7. Title: Proteomics analysis of the peritoneal dialysis effluent by HiRIEF and TMT: a longitudinal study 
Chapter II | Thesis Output 
 
83 
 
Authors: J. E. Araújo, R.M.M. Branca, F. Teixeira e Costa, A. Ramos, M. Pernemalm, C. Lodeiro, J. L. 
Capelo, J. Lehtio 
Congress: XII Eupa Congress, Translating genomes into biological functions, June 16th – June 20th, 
Spain, EUPA 2018 
Participation: Poster presentation 
6. Title: Unraveling peritoneal dialysis effluent proteome through cost-effective sample treatment 
methods applied to biomarkers discovery and MALDI-MS-based profiling techniques 
Authors: J. E. Araújo, S. Jorge, F. Teixeira e Costa, A. Ramos, H. M. Santos, C. Lodeiro, J. L. Capelo 
Congress: 2nd International Caparica Christmas Congress on Translational Chemistry, December 4th – 
December 7th, Portugal, IC3TC 2017 
Participation: Poster presentation 
5. Title: Unraveling peritoneal dialysis effluent proteome evolution 
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spectrometry protein data 
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Capelo-Martínez 
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EFFLUENT1 
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Abstract 
 The aim of this study was to differentiate patients with glomerulonephritis and diabetic 
nephropathy using (i) peritoneal dialysate effluent, (ii) matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) and (iii) bioinformatics tools. Profiles of peritoneal 
dialysate effluent were obtained using (a) sample preparation consisting of protein concentration 
through centrifugal concentrators and chemical-assisted protein depletion using DL-dithiothreitol, and 
(b) MALDI-TOF MS. A free open-source bioinformatics tool, Mass-UP, was used to classify such 
profiles using principal component analysis and hierarchical clustering. The methodology proposed here 
allows for classifying two different groups of patients with kidney failure, one with chronic 
glomerulonephritis and other with diabetic nephropathy. 
Keywords: N/A 
1-Introduction 
The utilization of profiles to classify samples has been used in analytical chemistry since 
decades ago [1]-[3]. In proteomics, mass spectrometry, MS, profiling of complex proteomes comprises 
three main steps. First, an appropriate sample treatment developed for each particular type of sample is 
needed. Second, an adequate mass spectrometer is necessary. High throughput, cost-effectiveness and 
robustness are characteristics of Matrix-Assisted Laser Desorption Ionization time of flight (MALDI)-
based MS [4]. Third, bioinformatics tools are needed, either through commercial or free/open-source 
software to handle large sets of data provided by MALDI-MS-based profiling. As both, bioinformatics 
and MALDI-MS have reached maturity, currently the bottleneck in proteome profiling remains sample 
treatment. Recently, our group has proposed a number of fast, cheap and robust methods to deplete 
and/or to equalize the protein content of serum samples to speed disease profiling for patient 
classification and diagnostic purposes [5]. Renal insufficiency is a medical condition in which the 
kidneys fail to filter waste products adequately from the blood, eventually leading to death. Therapy for 
renal failure can be done by effective methods such as peritoneal dialysis (PD) and haemodialysis, both 
of which effectively remove waste products from blood [6]-[9]. Indeed, PD is a highly effective, 
convenient and reasonably safe treatment modality for patients with end-stage renal disease. PD is based 
on the use of the peritoneal membrane as a replacement of the kidney. This is possible because the 
peritoneal membrane can function as a dialyzing membrane, allowing it to mimic the kidney capabilities 
for cleaning solutes and waste products from the blood [10],[11]. Although PD replaces the function of 
the kidney, pathologic damage to the peritoneum frequently results in decrease of the dialysing capacity 
and then, the patient is forced to move to haemodialysis. At this stage, the patient's condition gets worst 
slowly but constantly, leading to the death of the patient [11]-[13].Peritoneal dialysate effluent (PDE) 
renders a sample rich in proteins and metabolites. This sample is a potential source of clinician 
information and, as such, it deserved to be interrogated for diagnosis and classification purposes. This 
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work presents a novel approach to such aims based first on protein separation and concentration using 
centrifugal concentrators and then on protein equalization using DL-dithiothreitol, DTT. Then, the 
samples are trypsinated using a fast ultrasonic approach reported by us previously [14]. Finally, the pool 
of peptides is profiled using MALDI-MS and then the sets of data generated are treated with free/open-
source software by principal component analysis and hierarchical clustering (Mass-Up: 
http://sing.ei.uvigo.es/mass-up/ last time accessed June, 2015). As a proof-of-concept, peritoneal 
dialysate collected from patients with diabetic nephropathy and chronic glomerulonephritis was used. 
2-Materials and methods 
2.1-Reagents 
All reagents used were of HPLC grade or electrophoresis grade. Albumin, from bovine serum 
(BSA), N, N, N’, N’-tetramethylethylene-diamine (TMED), glycine, b-mercaptoethanol, glycerol 86–
88%, acrylamide/bis-acrylamide 30% solution (37.5:1), mineral oil, the bradford reagent, DL-
dithiothreitol (DTT), iodoacetamide (IAA), sodium fluoride (NaF), trifluoroacetic acid (TFA), trypsin 
(proteomics grade) and acetonitrile (ACN, LC-MS CHROMASOLV(R)) were purchased from Sigma-
Aldrich (St. Louis, USA). EDTA and bromophenol blue were purchased from Riedel-de Haen (Seelze, 
Germany). Ammonium bicarbonate (Ambic) and formic acid were purchased from Fluka (Steinheim, 
Germany). α-Cyano-4-hydroxycinnamicacid puriss for MALDI-MS (Fluka, Germany) was used as the 
MALDI matrix. Peptide calibration standard II from Bruker Diatonic GmbH was used as the mass 
calibration standard for MALDI-TOF MS.  
2.2-Peritoneal dialysate effluent samples 
Peritoneal dialysis effluent samples from ten anonymous patients from the Garcia de Orta 
Hospital, Portugal were collected in centrifuge sterile tubes supplemented with sodium fluoride and 
EDTA. Four patients with glomerular chronic nephritis, GNC, and six with diabetic nephropathy, DN, 
were enrolled in this study. For further details, refer to Table 1 of the supplementary material. The 
patients were informed about the project and their consent was requested in written. Once in the 
laboratory, the samples were centrifuged at 9000g for 20 min to remove insoluble solids and stored at -
80 ºC until use. 
2.3-Apparatus 
PDE samples were collected and aliquoted in centrifuge sterile tubes of 50 mL and 15 mL, 
respectively (Ratiolab, Germany). Protein concentration was done in Vivaspin centrifugal concentrators 
of 50 mL from Sartorius Stedim Biotech (Bohemia, U.S.A.) and protein digestion was done in safe-lock 
tubes of 0.5 mL from Eppendorf (Hamburg, Germany). A vacuum concentrator centrifuge model 
UNIVAPO 150 ECH SpeedVac and a vacuum pump model UNIJET II (Munich, Germany) were used 
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for sample drying and sample pre-concentration. A mini incubator from Labnet (New Jersey, U.S.A.) 
was used for protein reduction and for protein alkylation steps. Centrifuge MPW-350 from MPW Med. 
Instruments (Warsaw, Poland), vortex models ELMI CM70M-09 Sky Line (Southern California, 
U.S.A.) and Labnet vortex mixer VX-200 (New Jersey, U.S.A.) were used throughout the sample 
treatment. An ultrasonic bath, Elma model Transsonic TI-H-5 (Singen, Germany), was used to facilitate 
protein depletion and peptide solubilization. A sonoreactor model UTR200 from Dr Hielscher (Teltow, 
Germany) was used to accelerate enzymatic protein digestions. Protein identification was done in an 
Ultraflex II MALDI-TOF/TOF instrument from Bruker Daltonics. 
2.4-Peritoneal dialysate concentration 
PDE concentration and desalting was performed in centrifugal concentrators Vivaspin 15R 
MWCO 10 kDa. 10 mL of PDE were concentrated until a final volume ranging from 150 µL to 300 µL, 
by centrifugation at 5000 × g for 20 min at 4 ºC. The concentrated PDE was transferred into a clean 
safe-lock tube. The Vivaspin 15R MWCO 10 kDa membrane was washed with 50 mL of MQ-Water 
and then the water was added to the safelock tube with the concentrated PDE (Figure 1). The total protein 
content was determined using a Bradford protein assay. Once the samples were quantified, they were 
divided into aliquots of 20 µL and stored in 0.5 mL safe-lock tubes at -80 ºC. 
2.5-Protein depletion with DTT 
Protein depletion from sera samples was performed with DTT according to the protocol 
described by Warder et al.[15] with minor modifications as described by Fernández et al. [16]. In brief, 
to 20 mL of serum, 2.2 µL of 500 mM DTT were added and the resulting mixture was vortexed for 20 
s. The samples were then incubated for 1 h until a white precipitate was observed. Then, the samples 
were pelleted by centrifugation at 14 000 × g (2 × 20 min at 18 ºC). This process was performed with 
five aliquots for each patient. Then, the supernatants were pooled in a clean safe-lock tube and the total 
protein content was determined using a Bradford protein assay, using BSA as the standard protein. 
2.6-2D gel electrophoresis 
The samples were resuspended in 8 M urea, 2% (w/v) CHAPS, 0.2% (v/v) IPG buffer pH 4–7, 
50 mM DTT and traces of bromophenol blue. The samples were incubated on ice for 30 min and 
sonicated using a 1 mm diameter probe for 6 × 10 seconds on ice at 50% sonication amplitude. Insoluble 
matter was removed by centrifugation (20 minutes 14 000 × g at 20 ºC). The protein concentration was 
determined using a Bradford protein assay using BSA as the protein standard. IPG strips, pH 4–7 and 7 
cm size, were rehydrated overnight at 20 ºC with 135 mL of rehydration  
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Figure 1- PDE sample treatment chart. (1) Concentration of proteins: the protein content of 10 mL of PDE is 
concentrated to ca. 150 µL using protein concentration tubes Vivaspin 15R MWCO 10 kDa. (2) Protein 
depletion: the sample treatment to equalize the proteome content consists of DTT depletion. The resulting pellet 
is discarded and the supernatant (SN) is withdrawn and stored at -80 ºC until analysis. (3) Sample trypsination: 
samples are digested using the ultrafast protein digestion, which was performed in a sonoreactor with the 
following operating conditions: 50% ultrasonic amplitude and 2.5 min ultrasonic time (twice). Then, the sample 
was vacuum centrifuged until dryness. (4) MALDI Profiling: for sample analysis, the peptides were re-
suspended, hand-spotted onto a MALDI target plate and analyzed by MALDI-TOF MS. Finally, the Mass-Up 
program was used, as it was designed to support the pre-processing [(i) baseline correction; (ii) normalization; 
(iii) smoothing; (iv) peak detection; (v) peak matching] and analysis of MALDI-TOF mass spectrometry data 
through principal component analysis and hierarchical clustering analysis.  
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buffer containing 8 M urea, 0.5% (w/v) CHAPS, 0.2% (v/v) IPG buffer pH 4–7, 10 mM DTT and traces 
of bromophenol blue. Sample loading onto the IPG strip was carried out using the cup-loading method. 
IPG strips were removed from the rehydration tray; the oil was drained, and the gel was placed side up 
into the focusing tray's channels. The movable electrode assemblies were carefully positioned on top of 
the strips at the anode and cathode ends; after that, the sample loading cups were placed near the cathode. 
Afterwards, 50 mL of the protein-containing solution (2 mg mL -1) were loaded in the sample-loading 
cup and then overlaid with mineral oil. The focusing tray was placed into the PROTEAN IEF Cell. The 
isoelectric focusing was performed in three steps as follows: step 1: 250 volts for 30 min, rapid voltage 
ramping; step 2: 4000 volts for 60 min, slow voltage ramping; step 3: 4000 volts, 7468 | 10 000 V h. For 
the three steps, the current was limited to 50 mA per gel. After IEF, gel strips were removed and 
incubated with equilibration buffer (6 M urea, 75 mM Tris pH 8.8, 20% glycerol (v/v), 2% (w/v) SDS, 
and traces of bromophenol blue) and then again incubated with 2.5 mL of equilibration buffer containing 
2% (w/v) of DTT for 15 min, followed by another 15 minutes’ incubation with 2.5 mL of equilibration 
buffer containing 2.5% (w/v) of IAA. The IPG strips were removed from the equilibration tray and 
clipped briefly into a graduated cylinder containing running buffer. The strip was placed side up and 
onto the back plate of the SDS-PAGE gel. The IPG well of the gel was overlaid with agarose sealing 
solution (0.5% w/v prepared with 50 mL of Laemmli running buffer and traces of bromophenol blue). 
After agarose solidification, the electrophoresis was conducted at 200 V (constant voltage) for 55 
minutes. After completion of the gel electrophoresis, the gel was mixed for 30 minutes with 40% (v/v) 
ethanol and 10% (v/v) acetic acid and then stained overnight with colloidal coomassie blue G-250. Gels 
were rinsed for 4 × 20 min with 100 mL of distilled water and further washed twice with 100 mL of 0.5 
M sodium chloride until a clear background was observed. Gel imaging was carried out with a ProPicII-
robot using 16 ms of exposure time and a resolution of 70 mm. Gel piking was done with the same 
equipment. 
2.7-In-gel protein digestion 
After spot piking, the spots were transferred to 0.5 mL low adhesion tubes. Gel spots were 
washed twice with 200 µL of water and then with 3 × 200 µL of 50% (v/v) acetonitrile/25 mM 
ammonium bicarbonate and sonicated at 60% ultrasonic amplitude for 10 min using an ultrasonic bath. 
Then, the gel pieces were dehydrated with 200 µL of acetonitrile. Subsequently, 15 µL of trypsin (20 
ng mL-1 in ammonium bicarbonate 12.5 mM/2% (v/v) acetonitrile) was added to the gel spots and 
incubated for 60 min on ice, then covered with 20 mL of 12.5mM ammonium bicarbonate/2% (v/v) 
acetonitrile and incubated for 12 h at 37 ºC. Finally, 25 mL of 5% (v/v) formic acid was added and the 
supernatants were transferred to new low adhesion tubes. Peptides were further extracted from the gel 
matrix with 2 × 50 mL of 50% (v/v) acetonitrile/0.1% trifluoroacetic acid and sonicated at 60% 
ultrasonic amplitude for 5 min using an ultrasonic bath. The samples were dried-down and stored at -20 
ºC until MALDI-TOF MS analysis.  
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2.8-In-solution protein digestion 
Ultrasonic in-solution digestion was performed according to the ultrafast proteolytic digestion 
protocol previously developed in our laboratory [17]. Before protein digestion, the pH of the samples 
obtained in Section 2.5 was adjusted to 8.0 by adding 1 µL of 0.5 M Ambic. Protein disulfide bonds 
were reduced with 2 µL of 110 mM DTT, samples were then vortexed and incubated for 45 min at 37 
ºC. The resulting cysteines were then blocked with 2 µL of 400 mM IAA. The samples were vortexed 
and incubated for 45 min at room temperature in the dark. For protein digestion, the reduced and 
alkylated samples were diluted to 0.04 mg mL-1 (2 mg of protein in a volume of 50 mL of 12.5 mM 
AmBic). Afterwards, trypsin was added twice according to the ratio 1:20 (w/w) (addition of 2.5 µL of 
trypsin, ultrasonic sonoreactor digestion, addition of another 2.5 µL of trypsin and then a final ultrasonic 
digestion with the sonoreactor). Once the trypsin was added, the digestion was performed in the 
sonoreactor with the following operating conditions: 50% ultrasonic amplitude and 2.5 min ultrasonic 
time. Finally, 5 µL of formic acid 50% (v/v) were added to stop the enzymatic activity (Figure 1), and 
the digested PDE was evaporated to dryness. 
2.9-MALDI-TOF-MS analysis 
Prior to analysis, samples were solubilized in 10 µL of 0.3% formic acid and 0.5 mL of sample 
was hand-spotted onto a MALDI target plate (384-spot ground steel plate) and then 1 µL of a 7 mg mL-
1 solution of a-cyano-4-hydroxycinnamic acid matrix in 0.1% (v/v) TFA and 50% (v/v) ACN was added 
and allowed to air dry. The mass spectrometer was operated in positive ion mode using a reflectron, and 
thus, spectra were acquired in the m/z range of 600–3500. A total of 500 spectra were acquired for each 
sample at a laser frequency of 50 Hz. External calibration was performed with the [M + H]+ 
monoisotopic peaks of bradykinin 1–7 (m/z 757.3992), angiotensin II (m/z 1046.5418), angiotensin I 
(m/z 1296.6848) substance P (m/z 1758.9326), ACTH clip 1–17 (m/z 2093.0862), ACTH18–39 (m/z 
2465.1983) and somatostatin 28 (m/z 3147.4710). Peptide mass fingerprints (PMF) were searched with 
MASCOT search engine with the following parameters: (i) SwissProt Database2012_04 (535698 
sequences; 190107059 residues); (ii) molecular weight of protein: all; (iii) one missed cleavage; (iv) 
fixed modifications: carbamidomethylation (C); (v) variable modifications: oxidation of methionine and 
(vi) peptide tolerance up to 100 ppm after close-external calibration. The significance threshold was set 
to a minimum of 95% (p # 0.05). A match was considered successful when the protein identification 
score is located out of the random region and the protein analysed scores first. 
2.10-Principal component analysis (PCA) 
Each sample was spotted in the MALDI plate five times. The corresponding raw-data spectrum 
of each sample was pre-processed with the Mass-Up open source program (http:// sing.ei.uvigo.es/mass-
up/) using the following parameters: (i) intensity transformation (square root), (ii) smoothing (none), 
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(iii) baseline correction (snip), (iv) standardization (total ion current), (v) peak detection (MALDIquant: 
SNR (3), Half-WindowSize (60)), and (vi) minimum peak intensity (0.001). Peaks were matched with 
the following parameters: (i) intrasample matching (MALDIquant: tolerance (0.002)), without the 
selection of the “generate consensus spectrum” box, and (ii) inter-sample matching (MALDIquant: 
tolerance (0.002)). Then, the PCA was run with the following parameters: (i) max. components (-1, for 
no maximum number of components), (ii) variance covered (0.95), (iii) normalize, and (iv) discretize. 
2.11-Hierarchical clustering analysis 
An agglomerative hierarchical clustering analysis was applied as a complement to the PCA. 
Using the same handling of data as described above for the PCA, the clustering analysis operation of 
the Mass-Up software was executed with the following parameters: (i) minimum variance (0), (ii) 
peptide list (null), (iii) distance function type reference (average), (iv) conversion values (presence), 
distance function type function (hamming), and (v) intra-sample minimum presence (0), deep clustering 
(no). 
3-Results and discussion 
3.1-Sample treatment 
Unravelling the peritoneal dialysate effluent, PDE, proteome presents some challenges in terms 
of sample treatment, as PDE is a relatively diluted solution of proteins, containing hundreds of them, 
with their concentrations spanning several orders of magnitude. To overcome this problem, 
concentrating low abundance proteins whilst diluting high abundance ones is mandatory. In our case, 
such tasks were accomplished as follows. First, we focused in concentrating the proteins. Proteins can 
be separated and concentrated from a solution using different approaches such as precipitation of 
proteins[18], using magnetic beads [19] or centrifugal concentrator tubes [20]. In previous reported 
work[18],we have used deoxycholate (DOC) / Trichloroacetic acid (TCA) precipitation to concentrate 
proteins from PDE, however this method requires chaotropic agents like urea or thiourea and detergents 
to solubilize protein pellets. The use of such reagents is required to solubilize protein samples before 2D 
gel electrophoresis. On the other hand, high concentrations of chaotropic agents and detergents are 
contaminants for mass spectrometry analysis, requiring a further purification step before analysis. To 
overcome the use of urea and detergents, concentration of proteins was accomplished using centrifugal 
concentrator tubes with a cut-off membrane of 10 kDa. Through this process, the protein content was 
concentrated from 10 mL to 150–300 mL. The second step was to overcome the problems related to 
high abundance proteins. For mass spectrometry-based applications, the presence of major proteins 
makes the detection of other less abundant proteins difficult [16], [20]-[22],. Different strategies are 
currently used to solve this problem, from which selective major protein depletion with chemical 
reagents, such as ACN or DTT, has been recently proposed as an economic and fast method to 
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accomplish this task [5], [23], [24]. Indeed, as we have suggested, the use of ACN to deplete proteins in 
sera samples renders an extract rich in apolipoproteins whilst the use of DTT renders an extract rich in 
immunoglobulins. Furthermore, depletion with DTT renders a serum with a higher concentration of high 
abundance proteins than when ACN is used [5], [23]. Because profiling is the main aim of this work, 
major proteins must be diluted from the target sample as much as possible but not totally. Through this 
way, the m/z signals originated from such proteins in the MALDI spectrum are drastically decreased, 
both in number and intensity, but are not totally eliminated. For the aforementioned reasons, the 
application of DTT was selected for this work. To this end, first the samples were concentrated with the 
centrifugal concentrators and then they were depleted using DTT as described in Section 2.5. The 
samples were then left to stand for about 1 h [23].We recommend making this process at temperatures 
above 25 ºC otherwise precipitation will take longer than 1 h. After depletion, the pellet was discarded 
and the supernatant was interrogated using 2D gel electrophoresis. The result of this study is presented 
in Figure 2, where a typical gel image from a pooled sample can be seen along with the distribution of 
the type of protein found. A complete list of the proteins identified is provided in Table 2 of the 
supplementary material. As may be seen in Figure 2, the type of protein present in the PDE clearly 
indicates a complex mechanism of membrane transportation through the peritoneum. It can be also noted 
that a significant fraction of those proteins are linked to regulation and response to a stimulus. A total 
of 50 proteins were identified, of which 12 (24%) were included in the top-20 of the most abundant 
proteins. This was an excellent result and further confirmed that DTT selectively depletes high 
abundance proteins from complex proteomes. Furthermore, protein AMBP, vitamin D-binding protein, 
α1-antitrypsin and pigment epithelium-derived factor, identified in our experiments, have been 
associated with diabetic nephropathy [24]. Moreover, the Ig mu chain C region and the fibrinogen 
gamma chain have been correlated with GNC [25].  
3.2-Profiling PDE samples 
Once confirmed the rationale of the method used for depleting major proteins from PDE 
samples, the next step was to apply the method to a number of samples from patients on PD treatment. 
The main aim of this work was to obtain for each patient a MALDI-MS profile of the pool of peptides 
belonging to the proteins obtained as described in Section 3.1. The number of patients as well as their 
individual characteristics is listed in Table 1 of the supplementary material. The complete sample 
treatment is depicted in Figure 1. The approach presented therein takes advantage of the ultrasonic 
energy as a tool to boost the enzymatic cleavage of proteins. Such approach is fast, cheap and easy to 
handle [14], [17], [26]. An additional advantage for clinical applications is that ninety-six samples can 
be treated in one day. This sample treatment has been described previously by our team [14], [17], [26], 
[27]. A typical MALDI-MS profile obtained using this protocol is shown in Figure 1. The profiling 
method renders a number of MALDI-m/z signals, which in practical terms can be considered as a series 
of numbers. For each sample, a series is obtained. Such series are interrogated with bioinformatics 
Chapter III | Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based profiling as a 
step forward in the characterization of peritoneal dialysis effluent 
95 
 
programs using PCAs or hierarchical clustering analysis in our case, once all samples were profiled; a 
free/open-source software developed in collaboration with the SING group (http://sing.ei.uvigo.es) 
named Mass-Up was used. PCA and clustering analysis were the statistics tools used to study the 
samples. The Mass-Up software is available free of charge at http://sing.ei.uvigo.es/mass-up/ (last time 
accessed June, 2015). The software is easy to use and only requires to up-load the m/z values 
corresponding to the profiles as an excel file. A tutorial is available in the same web page from which 
the program is downloaded. Figure 1 shows the PCA analysis (Figure 1 of supplementary material) 
obtained for the two groups of patients profiled in this work. As may be seen, the groups are well 
classified. The two diseases assessed (a) diabetic nephropathy and (b) chronic glomerulonephritis alter 
the peritoneum membrane in a different way. As a consequence, the proteins that cross the membrane 
are also different. This difference is reflected in the pool of peptides obtained and thus the MALDI m/z 
values of each sample are also expected to have differences. The utility of the concept here proposed 
was further demonstrated by using hierarchical cluster analysis, which is shown in Figure 1 and in Figure 
2 of supplementary material. As may be seen, the groups are again well classified. The hierarchical 
clustering suggests that both diabetic nephropathy and chronic glomerulonephritis can be readily 
distinguished.  
 
Figure 2- 2D-SDS-PAGE image from a pooled PDE sample of ten patients after protein concentration and 
depletion. Representative pie charts of: (A) biological processes; (B) cellular components; (C) molecular 
function of the identified proteins. The pie charts were generated with the STRAP 1.5 software. 
This result opens new horizons in the research of the peritoneum degradation as a consequence 
of dialysis. Furthermore, differences in the peritoneum of each patient as a result of a long period of 
dialysis treatment are anticipated, thus helping physicians in preventing early peritoneum degradation. 
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4-Conclusions 
We have demonstrated that the introduction of mass spectrometry-based profiling can provide 
a powerful, fast, cheap and accurate tool to classify patients with renal failure. It has been demonstrated 
that a workflow combining (i) sample preparation consisting in protein concentration through 
centrifugal concentrators and chemical-assisted protein depletion using DTT, and (ii) MALDI-TOF MS 
and the Mass-Up software is an effective method to classify patients with glomerular chronic nephritis, 
and diabetic nephropathy, thereby helping physicians in defining the etiology of the kidney disease. 
Although the approach is promising, large international trials to provide extensive spectra databases are 
needed to make this kind of profiling methodology a useful tool for the nephrology community. We are 
currently working to address this issue. 
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Abstract 
 Protein depletion with acetonitrile and protein equalization with dithiothreitol have been 
assessed with success as proteomics tools for getting insight into the peritoneal dialysate effluent 
proteome. The methods proposed are cost-effective, fast and easy of handling, and they match the 
criteria of analytical minimalism: low sample volume and low reagent consumption. Using two-
dimensional gel electrophoresis and peptide mass fingerprinting, a total of 72 unique proteins were 
identified. Acetonitrile depletes de PDE proteome from high-abundance proteins, such as albumin, and 
enriches the sample in apolipo-like proteins. Dithiothreitol equalizes the PDE proteome by diminishing 
the levels of albumin and enriching the extract in immunoglobulin-like proteins. The annotation per 
gene ontology term reveals the same biological paths being affected for patients undergoing peritoneal 
dialysis, namely that the largest number of proteins lost through peritoneal dialysate are extracellular 
proteins involved in regulation processes through binding. Significance: Renal failure is a growing 
problem worldwide, and particularly in Europe where the population is getting older. Up-to-date there 
is a focus of interest in peritoneal dialysis (PD), as it provides a better quality of life and autonomy of 
the patients than other renal replacement therapies such as haemodialysis. However, PD can only be 
used during a short period of years, as the peritoneum lost its permeability through time. Therefore, to 
make a breakthrough in PD and consequently contribute to better healthcare system it is urgent to find 
a group of biomarkers of peritoneum degradation. Here we report on two cost-effective methods for 
protein depletion in peritoneal dialysate effluent (PDE). The use of ACN and DTT over PDE to deplete 
high abundant proteins or to equalize the concentration of proteins, respectively, performs well and with 
similar protein profiles than when the same chemicals are used in human plasma samples. ACN depletes 
de PDE proteome from large proteins, such as albumin, and enriches the sample in apolipoproteins. DTT 
equalizes the PDE proteome by diminishing the levels of large proteins such as albumin and enriching 
the extract in immunoglobulins. Although the number and type of proteins identified are different, the 
annotation per gene ontology term reveals the same biological paths being affected for patients 
undergoing peritoneal dialysis. Thus, the largest number of proteins lost through peritoneal dialysate 
belongs to the group of extracellular proteins involved in regulation processes through binding. As for 
the searching of biomarkers, DTT seems to be the most promising of the two methods because acts as 
an equalizer and it allows interrogating more proteins in the same sample. 
Keywords: Peritoneal dialysis effluent, Protein depletion, High-abundance proteins, Sample 
preparation, Acetonitrile, Dithiothreitol and Proteomics 
1-Introduction 
Peritoneal dialysis (PD) is a life-sustaining therapy used by more than 100,000 patients 
worldwide with end-stage renal disease and acute kidney injury [1]. During peritoneal dialysis, a 
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dialysate is introduced into the peritoneal cavity where it comes into contact with capillaries perfusing 
the peritoneum and viscera. Molecules and ions diffuse from the blood through the capillaries into the 
dialysate and, as a result, peritoneal dialysis effluent (PDE) is a rich source of potential biomarkers. As 
a matter of fact, PDE is easily accessible and contains a variety of protein and peptides for monitoring 
disease and therapy [2], [3]. However, medical-driven decisions based on proteomics analysis of PDE 
have been hampered by its complex plasma-like composition [4]. For example, detection and 
identification of proteins present in PDE, as in any other complex proteome, is often biased by the 
presence of high-abundance proteins, HAP. The performance of any downstream analytical workflow 
is challenged as the complexity of the proteome increases. For the particular case of human serum, it is 
known that the top 10 most abundant proteins account for about 90% of the total protein content, whereas 
other proteins are present in a very wide dynamic range, covering more than ten orders of magnitude 
[5]. For the reason mentioned above, depletion of HAP is often used as an efficient way to increase 
sensitivity in the detection and identification of low-abundance proteins. Nowadays, several methods 
are employed to compress the dynamic range of protein concentration in complex biological samples, 
the process being possible while maintaining the entire proteome [6]. Nevertheless, these work do not 
entirely solve the problem, mostly due to unspecific binding, which might result in partial or complete 
loss of proteins of interest. Furthermore, the proteins retrieved from different depletion methods are not 
the same since the type, and characteristics of the proteins depleted are different [7]. Recently, 
acetonitrile, ACN, and dithiothreitol, DTT, have been reported as simple, reproducible and cost-
effective methods to remove high-abundance proteins from complex matrices, such as serum [7]-[9]. 
Indeed, serum protein depletion with acetonitrile or protein equalization with DTT has proven to be 
convenient to enrich selectively serum extracts in apolipoproteins and immunoglobulins, respectively. 
However, two questions remain to be answered. First, may ACN and DTT be used as proteomics tools 
in PDE? Second, is the information retrieved using each method the same? Herein, we report on the 
performance of ACN- and DTT-based methods over PDE samples as proteomics tools before analysis 
by two-dimensional gel electrophoresis and mass spectrometry. 
2-Materials and methods 
2.1-Reagents and apparatus 
All reagents used were HPLC grade or electrophoresis grade. Albumin, from bovine serum 
(BSA), (N,N,N′,N′-tetramethylethylene-diamine (TMED), glycine, β-mercaptoethanol, glycerol 86–
88%, Bradford reagent, coomassie blue R-250 (CBB), DL-dithiotreitol (DTT), iodoacetamide (IAA), 
trypsin sequencing grade, trifluoroacetic acid (TFA), acrylamide/bis- acrylamide 30% solution (37.5:1) 
and mineral oil were purchased from Sigma-Aldrich (Basel, Switzerland). Formic acid, ammonium 
bicarbonate (Ambic), ammonium persulphate (APS) and α-Cyano-4-hydroxycinnamic acid were 
purchased from Fluka (Basel, Switzerland). Hydrochloric acid (HCl), glacial acetic acid, tris–base, 
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sodium dodecyl sulphate (SDS), methanol and acetonitrile were purchased from Panreac (Barcelona, 
Spain). Bromophenol blue was from Riedel-de Haën (Basel, Switzerland). Molecular weight marker for 
gel electrophoresis Precision Plus Protein™ All Blue was purchased from Bio-Rad (USA). Vivaspin® 
15R centrifugal concentrator 10,000 MWCO from Sartorius were used for protein pre-concentration. 
The ultrasonic processor UP50H from Dr. Hielschler (Germany) and multi-frequency ultrasonic bath 
Transsonic TI-H from ELMA Schmidbauer GmbH (Germany) was used for sample re-suspension and 
gel destaining, respectively. Protean IEF cell, IPG strips pH 4–7 (7 cm), cup loading tray and mini-
PROTEAN Tetra Cell were from Bio-Rad (USA). Gel image acquisition and spot picking were 
performed using a PROPIC II DigiLab Genomic Solutions (USA). Protein digestion was done in low 
adhesion safe-lock tubes from Deltalab (Barcelona, Spain). A vacuum concentrator centrifuge model 
UNIVAPO 150 ECH SpeedVac and a vacuum pump model UNIJET II were used for sample drying and 
sample pre-concentration. A mini incubator from Labnet was used for gel washing, for protein reduction 
and for protein alkylation steps. The centrifuges MPW-350 and MPW-65R were from MPW Med. 
Instruments. A microplate reader LT4000 equipped with 595 nm filters from Labtech was used for 
Bradford protein assay. Mass Spectrometry protein identification was done in an Ultraflex II MALDI 
TOF/TOF instrument from Bruker Daltonics. 
2.2-96-well plate Bradford protein assay 
PDE samples were quantified using the Bradford protein assay adapted from [10]. Briefly, a 
BSA standard curve (0, 1, 5, 10, 15, 20, 25 μg/mL) was generated in duplicate. To each well being used, 
150 μL of each standard were mixed with 150 μL Bradford reagent. The unknown samples were diluted 
with water to an approximate concentration between 5 and 20 μg/mL and then 150 μL of each unknown 
were mixed with 150 μL Bradford reagent. Finally, the samples were incubated at room temperature for 
20 min, and then absorbances were measured at 595 nm. 
2.3-Sample collection and pre-preparation 
PDE samples were collected from consenting PD patients following a peritoneal equilibrium 
test. All the samples were supplemented with a protease inhibitor cocktail, 10 mM NaEDTA and 1 mM 
NaF and centrifuged within 30min of collection at 9000 ×g for 20min to remove insoluble solids. Before 
downstream use, 10mL of PDE were concentrated by duplicate using Vivaspin® 15R centrifugal 
concentrator 10,000 MWCO until approximately 300 μL [11]. The protein-enriched fractions were 
collected to clean low adhesion tubes and the centrifugal concentrators membrane were washed with 50 
μL of water to maximize protein recovery. Finally, a Bradford protein assay (595nm) was carried out to 
determine the total amount of protein in the PDE concentrated samples. 
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2.4-Protein depletion with acetonitrile 
Protein depletion with acetonitrile (ACN)was adapted from the protocol described by Kay et al. 
[12]. Briefly to 20 μL of concentrated PDE were diluted with 44 μL of ultrapure water and then 85μL 
of acetonitrile were added to obtain a solution containing 57% (v/v) of acetonitrile. Afterwards, samples 
were sonicated for 2 × 10 min in an ultrasonic bath (35 kHz and 100% ultrasonic amplitude) and then 
the protein precipitates were pelleted by centrifugation at 12,000 ×g for 10 min at 20 °C. The ACN 
depletion was done in quadruplicate. The four supernatants were transferred to a clean low adhesion 
tube and evaporated to dryness in a vacuum concentrator centrifuge without heating. 
2.5-Protein depletion with DL-Dithiothreitol 
Protein depletion with DL-Dithiothreitol (DTT) was performed as described by Fernández et al. 
[7]. Briefly, 2.2 μL of fresh DTT 500 mM was added to 20 μL of concentrated PDE and the samples 
were then incubated for 60 min at 37 °C until a viscous white precipitate persisted. The protein 
precipitates were pelleted by centrifugation at 14,000 ×g for 20 min. The protein depletion protocol was 
done in quadruplicate. The four supernatants were transferred to a clean low adhesion tube and 
evaporated to dryness in a vacuum concentrator centrifuge without heating. 
2.6-1D-SDS-PAGE 
Protein samples were re-suspended in 10 μL of water plus 10 μL of sample buffer (65.8 mM 
Tris–HCl pH 6.8, 2.1% SDS (w/v), 26.3% (w/v) glycerol, 0.01% (w/v) of bromophenol blue and 10% 
(v/v) β-mercaptoethanol) and then heated in a dry bath at 100 °C for 5 min. The denatured proteins were 
loaded in 12.5% polyacrylamide gels with 1 mm thickness. Proteins were separated at 200 V (constant 
voltage) until the tracking dye front reaches the bottom of the gel [13], [14].  
2.7-2D-gel electrophoresis 
Samples were re-suspended in 8M urea, 2% (w/v) CHAPS, 0.2% (v/v) ampholytes pH 4–7, 
50mM DTT and traces of bromophenol blue. Samples were incubated on ice for 30 min and sonicated 
using a 1 mm diameter probe for 6 × 10 s on ice at 50% sonication amplitude. Insoluble mater was 
removed by centrifugation (20 min 14,000 ×g at 20 °C). Protein concentration was determined using a 
Bradford protein assay. IPG strips pH 4–7, 7 cm were rehydrated overnight at 20 °C with 135 μL of 
rehydration buffer containing 8 M Urea, 0.5% (w/v) CHAPS, 0.2% (v/v) ampholytes pH 4–7, 10 mM 
DTT and traces of bromophenol blue. Sample loading onto the IPG Strip was carried out using the cup 
loading method. IPG strips were removed from the rehydration tray; the oil was drained, and placed gel 
side up into the focusing tray's channels. The movable electrode assemblies were carefully positioned 
on top of the strips at the anode and cathode ends, after that, the sample loading cups were placed near 
the cathode. Afterwards, 50 μL of the protein containing solution (2 mg/mL) were loaded in the sample-
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loading cup and then overlaid with mineral oil. The focusing tray was placed into the PROTEAN IEF 
Cell. The isoelectric focusing was performed in three steps as follows: step 1250 Volts for 30 min, rapid 
voltage ramping; step 2: 4000 Volts for 60 min, slow voltage ramping; Step 3: 4000 Volts, 10,000 V–
hr. For the three steps the current was limited to 50 μA/gel. After IEF, gel strips were removed and 
incubated with equilibration buffer (6M urea, 75mMTris pH 8.8, 20% glycerol (v/v), 2% (w/v) SDS, 
traces of bromophenol blue) as follow 15 min incubation with 2.5 mL of equilibration buffer containing 
2% (w/v) of DTT, followed by 15 min incubation with 2.5 mL of equilibration buffer containing 2.5% 
(w/v) of IAA. The IPG strips were removed from the equilibration tray and clip briefly into the graduated 
cylinder containing running buffer. The strip was placed side up and onto the back plate of the SDS-
PAGE gel. The IPG well of the gel was overlay with agarose sealing solution (0.5% w/v prepared with 
50 mL of Lammeli running buffer and traces of bromophenol blue). After agarose solidification, the 
electrophoresis was conducted at 200 V (constant voltage) until the tracking dye front reaches the bottom 
of the gel [12], [13]. 
2.8-Gel staining and image analysis 
Finished the gel electrophoresis, the gel was fixed for 30 min with 40% (v/v) ethanol and 10% 
(v/v) acetic acid and then stained overnight with colloidal coomassie blue G-250. Gels were rinsed 4 × 
20 min with 100 mL of distilled water and further washed twice with 100 mL of 0.5 M sodium chloride 
until a clear background was observed [15]. Gel imaging was carried out with a ProPicII–robot using 
16 ms of exposure time and a resolution of 70 μm. Gel piking was done with the same equipment. 
2.9-In-gel protein digestion 
After spot piking the spots were transferred to 0.5 mL low adhesion tubes. Gel spots were 
washed twice with 200 μL of water and then with 3×200 μL of 50% (v/v) acetonitrile/25mM ammonium 
bicarbonate and sonicated at 60% ultrasonic amplitude for 10 min using an ultrasonic bath. Then the gel 
pieces were dehydrated with 200 μL of acetonitrile. Subsequently, 5 μL of trypsin (60 ng/μL in 
ammonium bicarbonate 12.5 mM/2% (v/v) acetonitrile) was added to the gel spots and incubated for 60 
min on ice, then covered with 20 μL of 12.5 mM ammonium bicarbonate/2% (v/v) acetonitrile and 
incubated 12 h at 37 °C. Finally, 25 μL of 5% (v/v) formic acid was added and the supernatants were 
transferred to new low adhesion tubes. Peptides were further extracted from the gel matrix with 2 × 50 
μL of 50% (v/v) acetonitrile/0.1% trifluoroacetic acid and sonicated using at 60% ultrasonic amplitude 
for 5 min using an ultrasonic bath. Samples were dried-down and stored at −20 °C until MS analysis. 
2.10-Mass spectrometry analysis 
Before MS analysis, samples were re-suspended in 10 μL of formic acid 0.3% (v/v) and 0.5 μL 
of sample was hand-spotted onto a MALDI target plate (384-spot ground steel plate) then 1 μL of a 5 
mg/mL solution of α-cyano-4-hydroxycinnamic acid matrix in 0.1% (v/v) TFA and 50% (v/v) ACN was 
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added and allowed to air dry. The MALDI TOF/TOF mass spectrometer was operated in positive ion 
mode using a reflectron, and thus, spectra were acquired in the m/z range of 600–3500. A total of 500 
spectra were acquired for each sample at a laser frequency of 50 Hz. External calibration was performed 
with the [M+H]+ monoisotopic peaks of bradykinin 1–7 (m/z 757.3992), angiotensin II (m/z 1046.5418), 
angiotensin I (m/z 1296.6848) substance P (m/z 1758.9326), ACTH clip 1–17 (m/z 2093.0862), 
ACTH18–39 (m/z 2465.1983) and somatostatin 28 (m/z 3147.4710). Peptide mass fingerprints (PMF) 
were searched with MASCOT search engine with the following parameters: (i) SwissProt 
Database2012_04 (535,698 sequences; 190,107,059 residues); (ii) molecular weight of protein: all; (iii) 
one missed cleavage; (iv) fixed modifications: carbamidomethylation (C); (v) variable modifications: 
oxidation of methionine and (vi) peptide tolerance up to 50 ppm. The significance threshold was set to 
a minimum of 95% (p ≤ 0.05). A match was considered successful when protein identification score is 
located out of the random region. 
3-Results and discussion 
3.1-Performance of centrifugal concentrators 
There are some factors to consider when using protein concentrators that can affect sample 
treatment reproducibility. Such factors are (i) membrane pore size and material, (ii) range of molecular 
weight cut-off, (iii) sample volume range, (iv) centrifuge tube size and (v) concentration factor. 
Therefore, reproducibility of protein pre-concentration from PDE samples using 10,000 MWCO 
centrifugal concentrators, MWCO, was first investigated. To accomplish this task, samples collected 
from ten patients were first interrogated for total protein content. The protein concentration dynamic 
range was found to vary (n=2) between 0.40 ± 0.02 mg/mL and 1.80 ± 0.01 mg/mL. Then, the samples 
were ultrafiltrated as described in section 2.3. Two technical replicates were carried out for each sample. 
It was verified that the volumes obtained after pre-concentration were larger for those samples with 
higher protein content. This is in agreement with MWCO manufacturer specifications [16]. As the 
protein concentration of PDE samples was different for each patient as well as sample volume obtained 
after pre-concentration, it was necessary to normalize the final result somehow. Therefore, it was 
decided to present our data as the ratio between the protein content after and before sample pre-
concentration. The results are presented in Figure 1A, and it is shown that when centrifugal 
concentrators are used, samples are pre-concentrated in a reproducible manner, as all samples were 
successfully pre-concentrated with relative standard deviations lower than 15%. Figure 1A also shows 
that pre-concentration factors have a large variation, ranging from one to two orders of concentration. 
Another question to be answered was how efficient and reproducible the protein recovery was through 
the pre-concentration process.  
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Figure 1- Reproducibility of protein recovery after centrifugal ultrafiltration: (A) Ratio of protein concentration 
after concentration (P a.c) and before concentration (P b.c). Protein concentrations were determined by Bradford 
Protein Assay (595 nm). Centrifugal ultrafiltration was performed in duplicates. The error bars represent the 
standard deviation of protein concentration between two replicates of the same sample. (B) % of protein 
recovery after centrifugal ultrafiltration. The error bars represent the standard deviation of recovery between 
two replicates. 
The utilization of ultrafiltration devices to enrich the protein content in PDE samples reveals to 
be very effective with a mean protein recovery of 100% and with a mean standard deviation of 8 ± 4% 
(10 samples × 2 replicates). As may be seen in Figure 1B, protein recoveries were higher than 97%, 
which is in accordance to manufacturer's specifications. It is worth to mention that Zhang et al. reported 
a 2.14-fold lower recovery when they worked over PDE samples with 3000 MWCO centrifugal 
concentrators [17]. Furthermore, our results are in agreement with those previously reported by other 
authors [17], [18]. Therefore, once it was demonstrated that the pre-concentration step was done in an 
efficient and reproducible manner, we move forward to study the use of ACN- and DDT- based sample 
treatments over pre-concentrated PDE samples. 
3.2-Use of acetonitrile- or dithiothreitol-based sample treatments over PDE samples  
ACN- and DTT-based sample treatments have been reported in literature as tools to remove 
high abundant proteins or to equalize the sample's protein levels, respectively, in human biofluids like 
serum and plasma [7], [12], [19]. Notwithstanding this fact, the systematic assessment of both sample 
treatments over PDE samples has not been done yet. To cover this gap, a pool of PDE samples was 
prepared as described in sections 2.3–2.5. The protein content of this pool was 30 ± 1 mg/mL (Bradford 
protein assay). Then, eight aliquots of 20 μL of the PDE pool were used for studying the performance 
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of protein equalization using DTT (4 aliquots) or protein depletion using ACN (4 aliquots). Thus, first, 
the resulting supernatants after equalization or depletion were quantified. Results showed that 
equalization with DTT removes 34 ± 3% (n = 4) of the total amount of protein and that protein depletion 
with ACN removes 88 ± 8% (n = 4) of the total amount of protein present in PDE. Regarding protein 
concentration, it was found that both ACN- and DTT- based methods are highly reproducible, as the 
total protein content found in the supernatant after treatment was 20±1 mg/mL (n=4) and 3.8±0.3mg/mL 
(n=4), respectively. To further assess the reproducibility of the depletion process, the results were further 
confirmed using 1D SDS- PAGE. This study showed a similar profile among the four replicates (Figure 
1C). As it can be seen, ACN promotes the depletion of proteins, mostly large ones, as it is revealed by 
the absence of intense bands in the zone corresponding to proteins with higher masses. On the other 
hand, it is possible to observe that DTT only partially removes proteins from the upper zone (in contrast 
with ACN), leading to a sample with a larger number of gel bands. Aimed at this excellent result, we 
evaluated the ACN- and DTT- based methods using 2D-GE. For comparative purposes, it was used a 
pool of samples over which no selective removal of proteins was done. 2D-gels are shown in Figure 2.  
 
Figure 2- Colloidal coomassie stained 2D SDS-PAGE of a pool of peritoneal dialysate effluent without HAPs 
depletion and after HAPs depletion with DTT and ACN. 
In-depth 2D-gel analysis using SameSpots software (TOTALLAB) revealed 112 ± 10 (n = 2) 
detected spots for the non-depleted sample whereas the gels of the samples depleted with ACN and DTT 
shown 119 ± 16 (n = 2) and 184 ± 12 (n = 2) detected spots, respectively, see Figure 3 for further details. 
All the detected 2D-spots were excised digested and analysed by MALDI-MS. Figure 3 illustrates the 
number of uniquely identified proteins obtained for each method: 54, 37 and 19 proteins for the DTT, 
no depletion- and ACN-based methods respectively. A group of 10 proteins are identified using any of 
the three methods, 26 proteins are unique for the DTT method, 10 proteins are exclusive for the method 
without depletion and six proteins are identified only in samples depleted with ACN. Immunoglobulins 
are abundant in the sample depleted with DTT while apolipoproteins are abundant in the sample depleted 
with ACN. This result is in agreement with the previous one reported by us using 1D gel electrophoresis 
and serum samples [7]. 
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Figure 3- Number of detected spots, number of identified proteins and number of unique identified proteins for 
the samples without HAPs depletion, after depletion with ACN and DTT. Venn diagram of the unique identified 
proteins in each treatment and percentage of immunoglobulins and apolipoproteins enriched identified in each 
treatment. 
3.3-Clinical significance 
Removal of major abundant proteins, such as albumin, from complex samples, is a usual first 
step in the analysis of serum and serum like proteomes [20]- [22]. Albumin is known to bind other 
proteins and peptides. Therefore, it is expected to observe changes in the proteome upon removal of 
albumin and other major abundant proteins [20]. On the other hand, the albuminome proteins might 
provide relevant biological information in peritoneal dialysis. Our approach benefits from the 
combination of three methods that together provides a better comprehension of the peritoneal dialysate, 
as we have an overall representation of the proteins of the whole proteome, the DTT equalized proteome, 
and the ACN depleted sample, rendering the identification of 72 unique proteins (Supplementary 
Information). Although the number and type of proteins identified are different, the annotation per gene 
ontology term reveals the same biological paths being affected for patients undergoing peritoneal 
dialysate. Thus, each method, regardless the number of proteins identified, address the same 
information, namely that the largest number of proteins lost through peritoneal dialysate are extracellular 
proteins involved in regulation processes through binding, see Figure 4. 
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Figure 4- Annotation per gene ontology term obtained with the Software Tool for Researching Annotations of 
Proteins (STRAP). Bar chart of (A) Biological process GO term annotations, (B) Cellular component GO term 
annotations and (C)Molecular function GO term annotations. STRING Protein interaction network of the 
proteins identified in PDE. The proteins dashed in red denote involvement in (A1) Regulation, (B1) 
Extracellular and (C1) Binding. The network uses a confidence view. Thicker lines represent stronger 
associations. 
Many proteins lost in PDE could have potentially harmful consequences. For instance, one of 
the proteins found in PDE is vitamin-D binding protein, which is involved in many regulatory processes, 
the most significant being calcium homeostasis and modulation of inflammatory responses, both playing 
an important role in the early morbidity and mortality of peritoneal dialysis patients [23]. We have 
identified several proteins that modulate the inflammatory response, including inhibition of lysosomal 
proteases that are released during the destruction of cells, namely (i) α-2-macroglobulin, (ii) α-1-
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antitrypsin, and (iii) direct binding of lipopolysaccharide-like α-1-acid glycoprotein. Other proteins 
found were binding metals proteins with antioxidant action such as haptoglobin and ceruloplasmin[23]. 
Ceruloplasmin and haptoglobin are two proteins directly linked to iron transport and activity in blood. 
Low levels of these proteins might lead to an excess of free iron in the blood, which then gets deposited 
in the retina, liver, and pancreas leading to loss of vision, cirrhosis and endocrine abnormalities, 
respectively. 
On the other hand, removal of other proteins such as adipokine proteins by peritoneal dialysis 
could have potential benefits. As an example, the accumulation of zinc-α2-glycoprotein in serum may 
have detrimental metabolic consequences [24]-[26]. Likewise, high levels of retinol binding protein 4 
have been correlated with oxidative stress, inflammation, and metabolic syndrome [27]. Thus, removal 
of this protein by PD may be beneficial to acutely ill patients [25]. 
4-Concluding remarks 
The use of ACN and DTT over PDE to deplete high abundant proteins or to equalize the 
concentration of proteins, respectively, performs well and with similar protein profiles than when the 
same chemicals are used in human plasma samples. ACN depletes de PDE proteome from large proteins, 
such as albumin, and enriches the sample in apolipoproteins. DTT equalizes the PDE proteome by 
diminishing the levels of large proteins such as albumin and enriching the extract in immunoglobulins. 
Although the number and type of proteins identified are different, the annotation per gene ontology term 
reveals the same biological paths being affected for patients undergoing peritoneal dialysate. Thus, the 
largest number of proteins lost through peritoneal dialysate belongs to the group of extracellular proteins 
involved in regulation processes through binding. As for the searching of biomarkers, DTT seems to be 
the most promising of the two methods because acts as an equalizer and it allows interrogating more 
proteins in the same sample.  
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Abstract 
 Protein equalization with dithiothreitol, protein depletion with acetonitrile and the entire 
proteome were assessed in conjunction with matrix assisted laser desorption ionization time of flight 
mass spectrometry-based profiling for a fast and effective classification of patients with renal 
insufficiency. Two case groups were recruited as proof of concept, patients with chronic 
glomerulonephritis and diabetic nephropathy. Two key tools were used to develop this approach: protein 
concentration with centrifugal concentrator tubes with 10 KDa cut-off membranes and chemical assisted 
protein equalization with dithiothreitol or chemical assisted protein depletion with acetonitrile. In-house 
developed software was used to apply principal component analysis and hierarchical clustering to the 
profiles obtained. The results suggest that chemical assisted protein equalization with dithiothreitol is a 
methodology more robust than the other two ones, as the patients were well grouped by principal 
component analysis or by hierarchical clustering. 
Keywords: Peritoneal dialysate, Profiling, Mass spectrometry, MALDI, PCA and Hierarchical 
clustering 
1-Introduction 
In a typical matrix-assisted laser desorption ionization time of flight mass spectrometry, 
MALDI-TOF, experiment of trypsinated proteomes, first the proteome is treated to isolate the proteins 
from other molecules and then proteins are cleavage with an enzyme, commonly trypsin[1]. Through 
this way a pool of peptides is obtained which is then mixed with the so-called matrix and spotted in a 
MALDI target plate, where a sample-matrix crystal is formed [2]. Then a laser is fired over the sample 
and a plum of peptides is obtained, which is directed towards a time of flight analyser. Through the 
aforementioned process, a number of signals corresponding to the m/z peptide ratios are obtained. As 
for the majority of the peptides the net charge is +1, in practical terms each signal corresponds to the 
effective mass of the peptide. Such m/z signals can be treated as series of numbers. Each series can be 
considered as a “profile” of the sample under study [2], [3]. Profiles can be interrogated with modern 
bioinformatics tools using a number of features such as principal component analysis or clustering. 
However, both, the large number of proteins as well as the large variation in their concentrations make 
profiling of human samples by MALDI-TOF a challenge [4], [5]. The presence of the so-called major 
proteins severely affects profiling, hampering an effective implementation of this approach in large 
scale. As an example, 20 proteins accounts for more than 99% of the nominal mass of serum. If a sample 
containing these proteins is profiled, the majority of the m/z signals obtained using MALDI-TOF are 
anticipated to belong to them. Thus, the profiles between samples will be very similar and the possibility 
to work with them, for instance, for classification purposes, is severely limited. To overcome this 
problem different sample treatments have been developed by the analytical community. Thus, protein 
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depletion and protein equalization are ways to selectively deploy major proteins from human samples 
[6], [7]. Although these methods lack a standard definition there is a growing consensus about them. By 
protein depletion it is understood the selective removal of a protein or group of proteins from the sample 
of interest and by protein equalization it is understood the selective partial removal of a protein or group 
of proteins. Serum protein depletion with acetonitrile and protein equalization with DTT are convenient 
methods to selectively enrich serum extracts in apolipoproteins and immunoglobulins, respectively. As 
a matter of fact, the sequential use of both methods has been recently reported as a successful method 
in discovering new biomarkers for the diagnostic of osteoarthritis [8]. As a result, a new term has been 
coined called sequential depletion. 
The bottleneck in proteomics uses to be sample treatment. The classic sample treatment for 
protein trypsination used to last for 12 h (overnight). However, ultrasonic energy and microwave energy 
have been proposed as a way to overcome this problem by boosting enzymatic protein cleavage from 
hours to some minutes [9]. Ultrasonic energy is gaining momentum in the proteomics arena as it can be 
delivered into the sample indirectly through the container´s walls, it allows high sample throughput, it 
is of easy handling and it can be afforded at a reasonable cost. A detailed step-by-step tutorial is available 
in literature [9].  
Profiling cannot be accomplished without good bioinformatics tools, in other words, the amount 
of data generated when a high number of samples are profiled is too large to deal manually with it. This 
is the reason why there are many commercial software packages available to handle data. However, they 
are expensive and as a general role they require a training course. Currently, many labs develop their 
own in-house software to deal with their own samples.  
Renal insufficiency is a medical condition in which kidneys fail to adequately filter waste 
products from the blood, eventually leading to dead. Therapy for renal failure can be done by methods 
such as peritoneal dialysis (PD) and haemodialysis, both of which effectively remove blood´s waste 
products [10]-[13]. PD is based on the use of the peritoneal membrane as a replacement of the kidney. 
This is possible because the peritoneal membrane can function as a dialyzing membrane, allowing to 
mimic the kidney capabilities for cleaning solutes and waste products from the blood [14], [15]. 
Although PD replaces the function of the kidney, pathologic damage of the peritoneum frequently results 
in decreasing of the dialysing capacity and then, patient is forced to move to haemodialysis. At this 
stage, the patient's condition gets worst slowly but constantly, leading to the death of the patient 
[16],[17]. To enlarge the lifespan of the peritoneum membrane the prediction of its degradation is of 
critical importance. The PD renders a sample reach in proteins and metabolites, which has been scarcely 
studied in terms of profiling.  
The present work aims to compare the performance of chemical assisted depletion with 
acetonitrile versus equalization with DTT in PD extracts for MALDI-TOF-based profiling. For 
comparative purposes samples with the entire proteome are also used. In house made software is used 
to obtain principal component analysis and clustering [18]. To accomplish all these tasks two groups of 
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patients in peritoneal dialysis were recruited, patients with chronic glomerulonephritis and diabetic 
nephropathy. 
2-Material and methods 
2.1. Reagents 
All reagents used were HPLC grade or electrophoresis grade. Albumin, from bovine serum 
(BSA), Bradford reagent, DL-dithiothreitol (DTT), iodoacetamide (IAA), trifluoroacetic acid (TFA), 
Trypsin (sequencing grade) and acetonitrile (ACN, LC-MS CHROMASOLV(R)), were purchased from 
Sigma-Aldrich (St. Louis, USA). Ammonium bicarbonate (Ambic) and formic acid were purchased 
from Fluka (Steinheim, Germany). α-Cyano-4-hydroxycinnamicacid puriss for MALDI-MS 
(Fluka,Germany) was used as MALDI matrix. Calibration 1, 4700 Proteomics Analyzer Calibration 
Mixture from ABSciex (Framingham, MA, USA) was used as a mass calibration standard for MALDI-
TOF/TOF-MS measurements. 
2.2-Samples 
Peritoneal dialysis effluent samples from ten anonymous patients from the Garcia de Orta 
Hospital, Portugal were collected in centrifuge sterile tubes supplemented with sodium fluoride and 
EDTA. Four patients with glomerular chronic nephritis, GNC, and six with diabetic nephropathy, DN, 
were enrolled in this study. For further details, refers to Table 1 of supplementary information. The 
patients were informed about the project and their consent was requested in written. The local ethics 
committee approved the procedure. Once in the laboratory, the samples were centrifuged at 9000 g for 
20 min to remove insoluble solids and stored at 80 °C until use. 
2.3-Apparatus 
PDE samples were collected and aliquoted in centrifuge sterile tubes of 50 mL and 15 mL, 
respectively (Ratiolab, Germany). Protein concentration was done in Vivaspin centrifugal concentrators 
of 50 mL from Sartorius Stedim Biotech (Bohemia, U.S.A.) and protein digestion was done in safe-lock 
tubes of 0.5 mL from Eppendorf (Hamburg, Germany). A vacuum concentrator centrifuge model 
UNIVAPO 150 ECH SpeedVac and a vacuum pump model UNIJET II (Munich, Germany) were used 
for sample drying and sample pre-concentration. A mini incubator from Labnet (New Jersey, U.S.A.) 
was used for protein reduction and for protein alkylation steps. Centrifuge MPW-350 from MPW Med. 
Instruments (Warsaw, Poland), vortex models ELMI CM70M-09 Sky Line (Southern California, 
U.S.A.) and Labnet vortex mixer VX-200 (New Jersey, U.S.A.), were used throughout the sample 
treatment. An ultrasonic bath, Elma model Transsonic TI-H-5 (Singen, Germany), was used to facilitate 
protein depletion and peptide solubilization step. A sonoreactor model UTR200 from Dr. Hielscher 
(Teltow, Germany) was used to accelerate enzymatic protein digestions. Protein identification was done 
in an Ultraflex II MALDI-TOF/TOF instrument from Bruker Daltonics. 
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2.4-Peritoneal dialysate concentration 
After PDE centrifugation at 9000 ×g for 20 min at 4 °C cell debris was discarded. PDE 
supernatant (SN) was aliquoted in 15 mL tubes and stored at -80 °C. PDE concentration and desalting 
was performed in centrifugal concentrator's tubes with 10 KDa cut-off membrane. Centrifugation at 
5000×g for 20 min at 4 °C was used to concentrate 10 mL of PD until a final volume ranging from 150 
µL to 300 µL was obtained. Then, the concentrated PD was transferred into clean safe-lock tubes. Then, 
the 10KDa membrane was washed with 50 µl of MQ-Water and then the water was added to the safe-
lock tube with the concentrated PDE (see Figure 1 for further details). Then, the sample was quantified 
using the Bradford method according to the protocol described by [19]. Once the samples were 
quantified, they were splitted in aliquots of 20 mL and stored in 0.5 mL safe-lock tubes at -60 °C. 
2.5-Protein depletion with ACN 
Protein depletion with ACN was performed according to the protocol described by Kay et al. 
with minor modifications [20], [21]. In brief, ten samples from the same number of patients were used. 
For each patient, five stored aliquots as described in 2.4 were used. Each aliquot was diluted with 44 µL 
of water and then samples were vortexed during 30 s. Then 85 µL of ACN were added to each aliquot 
and each sample was sonicated for 10 min in an ultrasonic bath (100% amplitude, 35 kHz, 50 W). Then, 
the samples were vortexed 30 s and then sonicated 10 min again. Once the precipitate was formed, the 
samples were pelleted by centrifugation at 14.000×g for 10 min at 18 °C. Then, the five supernatants 
were pooled into a clean safe-lock tube and then the pool was pre-concentrated until 10 µL, in a vacuum 
concentrator centrifuge without heating (Figure 1). Finally, this sample was then quantified using the 
Bradford method. 
2.6-Protein equalization with DTT 
Protein equalization from PDE samples was performed with dithiothreitol, DTT, according to 
the protocol described by Warder et al. [22] with minor modifications as described by Fernández et al. 
and Araújo et al.[21], [23]. Ten samples from the same number of patients were used. For each patient, 
five stored aliquots as described in 2.4 were used. In brief, to 20 µL of serum, 2.2 µL DTT 500 mM 
were added and the resulting mixture was vortexed for 20 s. The samples were then incubated for 1 h 
until a white precipitate was observed. Then the samples were pelleted by centrifugation at 14.000×g 
(2×20 min2 at 18 °C) (Figure 1). This process was performed with five aliquots for each patient. Then, 
the supernatants were pooled in a clean safe-lock tube and total protein content was determined using a 
Bradford protein assay. 
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Figure 1- PDE sample treatment chart (Adapted from Araújo et al. [23]). Sample pretreatment: the protein 
content of 50 ml of PDE is concentrated to c.a. 150 µL using protein concentration tubes. Sample treatment: 
(A) Protein depletion with ACN, was used to avoid the presence of major protein. (B) Protein equalization with 
DTT, was used to equalize the proteome content. (C) Without depletion, no pre-treatment was used to avoid 
major protein or equalize the protein content. The pools of proteins obtained for all the three treatments were 
quantified and then trypsinated using ultrafast protein digestion. Sample Analysis: Peptides were analyzed by 
MALDI-TOF MS. Finally, the Mass- Up program was used to support the pre-processing and analysis of 
MALDI-TOF mass spectrometry data. 
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2.7-In-solution protein digestion 
Ultrasonic in-solution digestion was performed according to the ultrafast proteolytic digestion 
protocol previously developed in our laboratory [24]. Before protein digestion, the pH of the samples 
obtained in 2.5 were adjusted to 8.0 adding 1 μl of Ambic 0.5 M. Protein disulfide bonds were reduced 
with 2 μl 110mM DTT, the sample was then vortexed and incubated (Labnet incubator) during 45 min 
at 37 °C. The resulting cysteines were then blocked with 2 μl IAA 400 mM, the sample was again 
vortexed and incubated during 45 min at room temperature in the dark. The sample was diluted to a final 
volume of 100 μl with AmBic 12.5 mM. For protein digestion, the reduced and alkylated samples were 
diluted to 0.04 mg/mL (2 mg of protein in a volume of 50 mL of AmBic 12.5 mM). Afterwards, trypsin 
was added according to the ratio 1:20 (w/w) twice (addition of 2.5 µL of trypsin, ultrasonic sonoreactor 
digestion, addition of another 2.5 µL of trypsin and then a final ultrasonic digestion with sonoreactor). 
Once the trypsin was added, the digestion was performed in the sonoreactor with the following operating 
conditions: 50% ultrasonic amplitude and 2.5 min ultrasonic time. Finally, 5 μl of formic acid 50% (v/v) 
were added to stop the enzymatic activity (Figure 1), and the digested PDE was evaporated to dryness. 
2.8-MALDI-TOF-MS analysis 
Prior to analysis, samples were resuspended in 10 μL of formic acid 0.3% and 0.5 μL of sample 
was hand-spotted onto a MALDI target plate (384-spot ground steel plate) then 1 μL of a 7 mg/mL 
solution of a-cyano-4-hydroxycinnamic acid matrix in 0.1% (v/v) TFA and 50% (v/v) ACN was added 
and allowed to air dry. The mass spectrometer was operated in positive ion mode using a reflectron, and 
thus, spectra were acquired in the m/z range of 600–3500. A total of 500 spectra were acquired for each 
sample at a laser frequency of 50 Hz. External calibration was performed with the [M+H]+ monoisotopic 
peaks of bradykinin 1–7 (m/z 757.3992), angiotensin II (m/z 1046.5418), angiotensin I (m/z 1296.6848) 
substance P (m/z 1758.9326), ACTH clip 1–17 (m/z 2093.0862), ACTH18–39 (m/z 2465.1983) and 
somatostatin 28 (m/z 3147.4710). Peptide mass fingerprints (PMF) were searched with MASCOT 
search engine with the following parameters: (i) SwissProt Database2012_04 (535698 
sequences;190107059 residues); (ii) molecular weight of protein: all; (iii) one missed cleavage; (iv) 
fixed modifications: carbamidomethylation (C); (v) variable modifications: oxidation of methionine and 
(vi) peptide tolerance up to 100 ppm after close external calibration. The significance threshold was set 
to a minimum of 95% (pr0.05). A match was considered successful when protein identification score is 
located out of the random region and the protein analysed scores first. 
2.9-Principal component analysis (PCA) 
Each sample was spotted in the MALDI plate five times. The corresponding raw-data spectrum 
of each sample was pre-processed with the Mass-Up v1.0.9 open source program 
(http://sing.ei.uvigo.es/mass-up/) using the following parameters: (i) Intensity transformation (Square 
root), (ii) Smoothing (None), (iii) Baseline correction (Snip), (iv) Standardization (Total Ion Current), 
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(v) Peak detection (MALDIquant: SNR (3), HalfWindowSize (60)), (vi) Minimum peak intensity 
(0.001). Peaks were matched with the following parameters: (i) Intra-sample matching (MALDIquant: 
tolerance (0.002)), without select the “generate consensus spectrum” box, (ii) Inter-sample matching 
(MALDIquant: tolerance (0.002). Then the PCA was run with the following parameters: (i) Max. 
Components (1, for no maximum number of components), (ii) Variance Covered (0.95). 
2.10-Hierarchical clustering analysis 
An agglomerative hierarchical clustering analysis was applied as a complement to the PCA. 
Using the same data as pre-processing as described above for the PCA, the clustering analysis operation 
of the Mass-Up software was executed with the following parameters: (i) Minimum variance (0), (ii) 
Peak List (NULL4for no peak filtering), (iii) Cluster Reference Value (Average), (iv) Distance Function 
(Hamming), (v) Conversion Values (Presence), (vi) Intrasample Minimum Presence (0) (vii) Deep 
Clustering (No). 
3-Results and discussion 
3.1-Sample treatments 
The literature dealing with the protein content of peritoneal dialysate extract, PDE, is currently 
scarce. Cuccurullo et al. claim a number of proteins as large as 151 to be present in PD extract [25]. To 
avoid the presence of major proteins in serum we have previously reported protein depletion with 
acetonitrile, ACN, and protein equalization with dithiothreitol, DTT [21].With the aim to get insight 
into the proteome of PD extracts we tried the same approach. As can be seen in Figure 2a the use of 
ACN in concentration circa 57% V/V selectively depletes proteins with masses higher than 75KDa. The 
major proteins belong to this group. Although the mechanism involved in ACN-promoted protein 
depletion has not been well established yet, the supernatant is rendered reach in apolipo-type proteins 
when this depletion is used in PDE (see Figure 2b). Interestingly, DTT diminish the content of major 
proteins in sera samples as well, but only in some extent as can be seen in Figure 2a. Furthermore, DTT 
renders an extract reach in immunoglobulin-type proteins. These results are in agreement with the ones 
obtained previously by our team [21], [23]  and they suggest that ACN and DTT perform in a similar 
manner when they are applied to complex proteomes. This is shown in Figure 2b. This conclusion is 
important because it suggests that both reagents can be universally used for protein depletion and 
equalization, respectively, regardless of the type of sample. A third sample treatment was also tested in 
this work in which the samples were used with the entire protein content. As the sample rendered by 
each method is rich in different types of proteins, it was anticipated different MALDI-TOF profiles for 
each one. An example of such profiles is presented in Figure 2c. Differences can be noted even by naked 
eye. As for previous works developed in our laboratory the number of times that one sample must be 
spotted in the MALDI-plate for profiling purposes is five [26]. Therefore, all the samples were spotted 
into the MALDI target five times, then the spectra were normalized and aligned with the Mass-Up 
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program [18]. Then the spectra were used for analysing the samples using principal component analysis 
and hierarchical clustering. 
 
Figure 2-(A) 1D-SDS-PAGE, 12.5% polyacrylamide gels with 1 mm thickness: Molecular Weight standard 
(first lane), PDE Pool without treatment (second lane), DTT-treated samples (3–6 lanes) and ACN-treated 
samples (57%) (6–10 lanes). (B) Bar charts with the comparative percentage of immunoglobulins and 
apolipoproteins identified in each treatment (DTT and ACN) and for different samples (Serum and PDE). (C) 
MALDI-TOF-MS-based profiles obtained for the same patient with different treatment methods (without 
depletion, DTT, ACN). 
3.2-Principal component analysis and hierarchical clustering analysis 
Figure 3 shows the PCAs for the three sample treatments used in this work. The PCAs were 
obtained using the Mass-Up program[18]. It may be seen that the classification is only achieved with 
the profiles obtained using chemical assisted equalization with DTT. Depletion of major proteins using 
ACN does not bring benefits in terms of class separation and when the sample is used with the entire 
proteome the results are similar. This suggests that total removal of major proteins, such as when ACN 
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is used, or their non-removal, such as when all the proteome remains in the sample, are not adequate 
approaches if PDE samples are going to be classified using MALDI mass spectrometry-based profiling. 
The PCA result was further confirmed using hierarchical clustering.  
 
Figure 3- Mass-Up 3D Principal Component Analysis (PCA) for each sample treatment method. 
As may be seen in Figure 4, only the profiles obtained with the DTT-chemical assisted 
equalization allows for classifying the patients correctly using either PCA or hierarchical clustering. For 
the case of ACN we hypothesize that depletion of mayor proteins concomitantly depletes some minor 
proteins as well, thus some important m/z signals for classification are then missed. When no depletion 
is used, the presence of peptides from major proteins hides the signals that are needed for classification. 
Because DTT only partially depletes major proteins, m/z signals for classification are retained. 
 
Figure 4- Mass-Up Hierarchical Clustering Analysis for each sample treatment method. 
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4-Conclusions 
Chemical assisted depletion with acetonitrile, chemical assisted equalization with dithiothreitol 
and the use of the entire proteome were tested in peritoneal liquid extract to investigate their performance 
to obtain MALDI-TOF-MS-based profiles in order to classify two groups of patients, namely patients 
with chronic glomerulonephritis and diabetic nephropathy. The results suggest that chemical assisted 
protein equalization with DTT is a methodology more robust than the other two ones, as the patients 
were well grouped by principal component analysis or by hierarchical clustering. This result suggests 
that successful MALDI-MS-based profiling of PDE samples relies in the selection of an appropriate 
sample treatment to compress the complexity of the proteome appropriately. We propose protein 
depletion with DTT as such treatment. 
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Abstract 
 Long-term peritoneal dialysis (PD) leads to morphological and functional alterations in the 
peritoneal membrane (PM), reducing the lifespan of this renal replacement therapy. Unfortunately, non-
invasive ways to anticipate PM failure unavailable, and even though routine PD parameters are used to 
follow the PM condition, they may only change in a very late stage, when PM function is no longer 
recoverable. Peritoneal dialysis effluent (PDE) represents a useful reservoir of potential clinical 
biomarkers that may help to identify those patients at a higher risk for PD-related complications. Here, 
we perform for the first time longitudinal PDE proteomics and peptidomics studies on samples from 45 
patients, attempting to unravel the morphological and biochemical changes occurring during long-term 
PD. We employed high-resolution peptide isoelectric focusing (HiRIEF) combined with LC-ESI-Q-
Exactive Orbitrap MS/MS analysis. This approach rendered a total of 5478 proteins identified, greatly 
increasing the protein PDE coverage On the other hand, label-free quantitative approach was applied 
for the first time in the analysis of PDE endogenous peptides, rendering a total of 5246 peptides 
identified. Thus, this study represents the most complete proteome and peptidome coverage ever 
achieved. 
Concerning the longitudinal analysis, three clinical case studies are discussed. For case study 1, 
with fungal peritonitis as a reason for PD therapy dropout, the proteome analysis revealed a diminished 
capacity of the peritoneal host response, with a decreasing trend of proteins within pathways of immune 
response, such as “class I MHC mediated antigen processing presentation” and the “Il-6, -7, pathway”. 
For this particular case, the proteomic analysis revealed that, for instance, following the IL-6 levels 
could have been useful for a clinical decision. On the other hand, for case study 2, with ultrafiltration 
failure as a reason for PD therapy dropout, the longitudinal analysis pinpointed a decreasing trend for 
protein homeostasis and a panoply of metabolic pathways; and an increased trend for pathways related 
with extra cellular matrix (ECM). In contrast, case study 3 represents a good patient response to PD 
therapy, in that many of the proteins and proteases identified orchestrate and regulate the process of both 
synthesis and degradation of matrix within the peritoneal cavity in a well-balanced way. 
Thereby, this study sheds some light on the main molecular pathways associated with long-term 
PD, and contributes with valuable information for the proteomic and clinical research community in 
future studies using PDE samples. 
Keywords: Peritoneal dialysis, Peritoneal dialysis effluent, HiRIEF, Longitudinal data, Proteomics, 
Peptidomics, Protease prediction.  
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1-Introduction 
 To date there is focus of interest in peritoneal dialysis (PD), as it provides a better quality of life 
and autonomy to patients than other renal replacement therapies (RRT) such as hemodialysis and is cost-
effective. Despite these benefits, the utilization of PD has not been increasing [1], [2]. In the last decade, 
approximately 196,000  end stage renal disease (ESRD) patients were performing PD worldwide, 
representing 11% of the dialysis population [3].Nowadays, the number of people suffering from chronic 
kidney diseases and requiring dialysis treatment is rising at a constant rate of around 6% annually, with  
more than 3.4 million patients expected in 2018, and approximately 4.9 million by 2025 [4]. Therefore, 
to move PD therapy forward some strategies need to be implemented to facilitate PD utilization, such 
as, policies and incentives favouring PD, appropriate training for nephrologists to increase PD utilization 
and to decrease the rates of technique failure. In addition, the PD community should undertake clinically 
meaningful studies with a strong focus on technique survival [1], [2]. 
 PD is based on using the peritoneum because it is a semipermeable membrane through which 
ultrafiltration (UF) and diffusion of circulating compounds occur [5], [6]. However, long-term PD leads 
to morphological and functional alterations in the peritoneum, reducing the lifespan of this dialysis to 
five years at most, and forcing the replacement of PD by other renal replacement therapies [6], [7]. The 
most commonly observed morphological and functional alterations in the peritoneal membrane (PM) of 
long-term PD patients are; peritoneal fibrosis varying from mild, moderate to severe cases [8]; 
progressive mesothelial cell loss, increase of submesothelial extracellular matrix (ECM) and mesothelial 
to mesenchymal transition (MMT)[9]; neovascularisation and thickening; chronic inflammation and 
angiogenesis [8], [10]. The PM failure due to fibrosis may potentially be induced by sterile inflammation 
caused by ongoing cellular stress due to prolonged exposure of the peritoneum to peritoneal dialysis 
fluids (PDFs) [11] with high concentrations of glucose, glucose degradation products (GDP), lactate and 
acidic pH [12]. The use of more biocompatible PD solutions to address this problem is promising, 
although further morphologic studies in patients using these solutions are needed [13]. In addition, the 
impact of neutral-pH, low-GDP fluids regarding PM long-term integrity and function remains uncertain 
[12]. Besides PDF composition, other risk factors need to be considered when assessing PM adequacy, 
such as, duration of end-stage renal disease, diabetes mellitus and time on PD that has been proved to 
be a significant factor [8].  
 Currently there are no non-invasive ways to predict PM failure; even though parameters such as 
urea and creatinine concentrations, glucose transport and net ultrafiltration are used to follow the PM 
condition, they do not change until a very late stage, when PM function is no longer recoverable [1], 
[14]. The only way to follow PM failure is based on peritoneal biopsies, that allow the assessment of 
morphologic changes. However, these are invasive procedures that may lead to temporary 
discontinuation of PD therapy. Moreover, uncertainty exists about sampling errors, reproducibility, and 
the risk of scarring [14], [15]. 
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 Nowadays, medical diagnostics and treatment is advancing from a one size fits all strategy to a 
case by case patient treatment. This transition to personalized medicine arises from incorporation of 
more analytical techniques into medical practice giving a holistic view of patient’s condition [11]. 
Therefore, PD therapy requires biomarkers as tools to identify patients who are at the highest risk for 
PD-related complications and to guide personalized interventions that may improve clinical outcome in 
the individual patient [16]. In addition, peritoneal dialysis effluent (PDE) represents an underestimated 
biochemical window into the peritoneum and a useful reservoir of potential clinical biomarkers. The 
possibility to identify and follow changes in the peritoneal membrane at the molecular level by 
proteomics and peptidomics in a longitudinal setting has been proposed to be of prime importance to 
unravel morphological and biochemical changes in long-term PD [7].  
The present work is such a longitudinal study aiming to unravel the evolution of the proteome 
and peptidome of the PDE over time, to identify specific molecular changes that can be particularly 
interesting for the understanding and early detection of long-term PM alterations. To achieve this goal, 
high-resolution peptide isoelectric focusing (HiRIEF) [17] was applied for the first time to PDE samples, 
allowing a reproducible fractionation and leading to a reduction of PDE proteome complexity prior to 
LC-ESI-Orbitrap MS/MS analysis. In parallel, label-free quantitative approach was applied for the first 
time in the analysis of PDE native peptides. Furthermore, protease prediction analysis was performed 
to extend our knowledge about proteases that might be related with protein cleavage occurring inside 
the peritoneum. This study sheds some light on the main molecular pathways associated with long-term 
PD, such as, dysregulated metabolic pathways, complement and coagulation cascades activation, ECM 
organization, formation of fibrin clot clotting cascade and contributes with valuable information for the 
proteomic and clinical research community in future studies using PDE samples. In addition, some 
longitudinal case studies are here discussed, presenting particular cases where the proteomic analysis 
gives some insights about patients’ health condition. 
2-Material and Methods 
2.1-Reagents and apparatus 
All reagents used were HPLC grade or electrophoresis grade. Albumin, from bovine serum (BSA), 
(N, N, N′, N′-tetramethylethylene-diamine (TMED), DL-dithiotreitol (DTT), Chloroacetamide (ClAA), 
trypsin sequencing grade, trifluoroacetic acid (TFA), Urea and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were purchased from Sigma-Aldrich (Basel, Switzerland). 
Formic acid and ammonium bicarbonate (Ambic) were purchased from Fluka (Basel, Switzerland). 
Hydrochloric acid (HCl), sodium dodecyl sulphate (SDS), methanol, ethanol and acetonitrile were 
purchased from Panreac (Barcelona, Spain). Bromophenol blue was from Riedel-de Haën (Basel, 
Switzerland). Amicon® Ultra-4 10 K Centrifugal Filter Devices 10,000 MWCO from Millipore were 
used for protein pre-concentration and buffer exchange. Immobilized pH gradient (IPG) strips pH 3–10 
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(24 cm-long IPG), IPG Pharmalyte carrier ampholytes (pH 3-10) and mineral oil were from GE 
Healthcare Bio-Sciences (Sweden). Strata™ -X-C 33 µm Polymeric Strong Cation and TMT10plex™ 
Isobaric Label Reagent Set were purchased from ThermoFisher Scientific (Massachussetts,USA).  
The isoelectric focusing was performed using the Ettan IPGphor IEF cell from GE Healthcare 
(Sweden). Peptide extraction was performed using liquid-handling robotics (a modified GE Healthcare 
Ettan Digester). Protein digestion was done in eppendorf safe-lock tubes from Eppendorf (Germany, 
Hamburg). A vacuum concentrator centrifuge from Thermo Scientific, model Digital Series 
SpeedVac™ Systems SPD111V, was used for sample drying. An incubator-shaker CERTOMAT™IS 
from Sartorius was used for protein digestion. The refrigerated centrifuges, Thermo Scientific Sorvall™ 
ST 16R Centrifuge Series and ScanSpeed 1730R were used for sample preparation. A Thermo 
Scientific™ Multiskan™ GO Microplate Spectrophotometer reader was used for BCC protein assay.  
2.2-Ethical statement and samples collection  
The study was approved by the Hospital ethical committee and followed the Helsinki declaration. 
The patients were informed about the study and gave their written informed consent. PDE samples were 
collected from consenting PD patients from the Garcia de Orta Hospital (Portugal), following a 
peritoneal equilibrium test (PET). All the samples were collected in centrifuge sterile tubes 
supplemented with a protease inhibitor cocktail, 10 mM NaEDTA and 1 mM NaF. Once in the 
laboratory, samples were centrifuged at 9000 ×g for 20min at 4ºC to remove insoluble pellets. PDE 
supernatant was aliquoted in 15 mL tubes and stored at - 80 °C. Further details concerning the patients 
enrolled in this study can be seen in the Table 1, Figure 1 and in Electronic Supplementary material 
(ESM) Table ESM1. 
2.3-PDE concentration 
Before downstream use, PDE samples were desalted and concentrated using centrifugal concentrator's 
tubes with 10 kDa cut-off membrane (Amicon® Ultra-4 10 K Centrifugal Filter Devices), as previously 
described by Araújo et al. [18] with some minor changes. Centrifugation at 4000×g for 10 min at 4 °C was 
used to concentrate 5 mL of PDE by duplicate, until a final volume ranging from 50 µL to 100 µL was 
obtained. The protein-enriched fractions were collected to clean low adhesion tubes and the fraction below 
10 kDa was stored at -80ºC for further use (peptidome analysis). Finally, a BCC protein assay (750 nm) 
was carried out to determine the total amount of protein in the PDE concentrated samples, as described in 
the section 2.4. From now on the Material and methods is distinct for the Proteome and Peptidome analysis, 
with the exception of the following section that is performed in the same way in both experiments (see 
Figure 2). 
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Table 1- Demographic data and clinical characteristics of the PD patients cohort at the baseline. 
  Reference Values 
Number of patients, N (%) 45 (100.0) --- 
Age [years], mean ± SD  
--- 
 
<49 (n=9) 34.6 ± 8.1 
>= 49 & <70 (n=18) 61.1 ± 6.7 
>=70 (n=18) 74 ± 3.20 
Male sex, N (%) 34 (75.5) --- 
Height [cm], mean ± SD 167 ± 9 --- 
Weight [kg], mean ± SD 70.6 ± 11.4 --- 
Primary Renal Disease, N (%)  
--- 
 
ADPKD-Autosomal dominant polycystic kidney disease 4 (8.9) 
ANCA vasculitis 2 (4.4) 
Chronic glomerulonephritis 2 (4.4) 
Chronic interstitial nephritis 2 (4.4) 
Congenital Anomalies of the Kidney and the Urinary Tract (CAKUT) 3 (6.7) 
Diabetic nephropathy 11 (24.4) 
Hypertensive nephrosclerosis 5 (11.1) 
IgA  nephropathy 4 (8.9) 
Lupus Nephritis 2 (4.4) 
Obstructive uropathy 1 (2.2) 
Paroxysmal nocturnal hemoglobinuria 1 (2.2) 
Secondary focal segmental glomerulosclerosis 1 (2.2) 
Unknown 7 (15.5) 
Comorbidities, N (%)  
--- 
 
Diabetes 13 (28.9) 
Ischemic heart disease 10 (22.2) 
Cerebrovascular disease 4 (8.9) 
D/P Creatinine at 4-hr PET (mL/min), mean ± SD 0.70 ± 0.11 >0.60 mL/min 
Profile transporter, N (%)  
--- 
 
High 9 (20) 
High-average 25 (55.6) 
Low-average 11 (24.4) 
Peritoneal ultrafiltration (mL/ 4h), mean ± SD 716.5 ± 399.6 >400 mL/4h 
Diuresis (mL/day), mean ± SD 1232.5 ± 793.6 The higher the better 
Creatinine clearance (mL/min), mean ± SD 90.7 ± 34.1 >60 mL/min 
Kt/v, mean ± SD 2.4 ± 0.5 1.7 
Serum albumin (mg/dL), mean ± SD 3.8 ± 0.3 > 3.0 (mg/dL) 
CA 125 (kU/L), mean ± SD 18.9 ± 12.1 ---  
Parathyroidism hormone (PTH) (pg/mL), mean ± SD 419.2 ± 285.5 <800 
Glomerular filtration rate (mL/min/1.73 m2), mean ± SD 6.5 ± 4.0 --- 
Darbepoetin-alfa, N (%) 27 (60)  --- 
Antagonists of the renin-angiotensin system, N (%) 29 (64.4)  --- 
Statins, N (%) 30 (66.7)  --- 
Beta Blockers, N (%) 21 (46.7)  --- 
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2.4-96-well plate BCC protein concentration measurement assay 
Peritoneal dialysis effluent (PDE) samples were quantified using the BioRad BCC assay according 
to the manufactures. Briefly, a BSA standard curve (8, 4, 2, 1, 0.5, 0.25, 0.125 mg/mL) was generated 
in triplicate. To each well being used, 25 μL of reagent A was added as described by manufactures. 
Then, 5 μL of each standard and samples were added and mixed with the already added reagent A. 
Finally, 200 μL of reagent B were added to each well used and the plate was gently agitated and left to 
incubated at room temperature for 15 min. After incubation absorbance’s were measured at 750 nm. 
Once the samples were quantified, they were divided in aliquots and stored in safe-lock tubes at −80 °C 
until further use.  
2.5-Proteome analysis of PDE samples 
2.5.1-Multiple Affinity Removal Column Human 14 
Given the plasma-like composition of PDE samples, with a very wide protein dynamic range 
covering more than ten orders of magnitude between high abundance proteins (HAPs) and the low 
abundance ones, it is crucial to compress the dynamic range so as not to hamper the proteomic analysis 
[19]. Thus, the Agilent Human 14 Multiple Affinity Removal Column (MARS14) was used to remove 
fourteen interfering high-abundance proteins following the manufacturer’s instructions, in order to 
improve the subsequent HiRIEF LC/MS analysis by effectively expanding the dynamic range of the 
analysis. After depletion, a buffer exchange and sample concentration step through centrifugal 
concentrators was performed (as described in section 2.5.1.2) (see Figure 2). 
2.5.2-Buffer Exchange/Concentration Samples 
After the MARS14 runs, both fractions (depleted and bound) obtained per sample were collected to 
centrifugal concentrators of 10 kDa and reduced to ~100 µl by centrifugation for 30 min at 4000 ×g. 
Samples were diluted with 2 mL of 50mM HEPES buffer, pH 7.6 and then concentrated again to ~100 
µl by centrifugation for 30 min at 4000 ×g. This step was repeated once and then samples were 
transferred to an Eppendorf and stored on ice for further protein concentration measurement. 
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Figure 1. Longitudinal cohort description. Per patient starting date of peritoneal dialysis (PD) and Peritoneal Equilibration Test (PET) sample collection. Active and non-
active patients are highlighted in different shapes. For non-active patients, the documented date of the last peritoneal dialysis is displayed. 
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Figure 2- PDE sample treatment chart for the Proteome and Peptidome fractions. Pre-treatment: PDE samples are first centrifuged to remove insoluble pellets and then 
desalted and concentrated using centrifugal concentrator's tubes with 10 kDa cut-off membrane, thus obtaining the Proteome (> 10 kDa) and Peptidome (< 10 kDa) fractions. 
The Proteome fraction (Proteome analysis), was subjected to protein depletion of the HAPs using the MARS14 approach. After the MARS14 runs, the depleted fraction 
was collected to centrifugal concentrators of 10 kDa to perform the buffer exchange and sample concentration before proceeding with the SP3-clean-up and digestion. Then, 
SP3-clean-up was performed and the peptides obtained after SP3 digestion were quantified and labelled with TMT 10-plex and the samples pooled. Afterwards, the pooled 
samples were fractionated with HiRIEF approach and then, the LC-MS/MS analysis (using Q-Exactive) of the 72 HiRIEF fractions performed. Finally, the longitudinal 
analysis of the data (using TiCoNE software) and the enrichment analysis were performed. The Peptidome fraction (Peptidome analysis) clean-up and peptide concentration 
was done using SCX cartridges. The concentration of the endogenous peptides was further quantified and analysed through LC-MS/MS (using Orbitrap Fusion), with CID 
and EThcD fragmentation methods. Finally, the data base searching and peptide identification was performed, and the peptides obtained were analysed with the Proteasix 
software (protease prediction tool). 
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2.5.3-Sample clean-up with Sera-Mag Speed beads (SP3) and protein digestion 
The sample clean-up was performed following the protocol described by Hughes et al. with 
minor changes [20]. Firstly, all samples with a volume of approximately 50-100 µl and 200 µg of 
protein, were diluted in lysis buffer (4% SDS, 25mM HEPES pH 7.6, 1 mM DTT) in a ratio of 
1:2 (protein solution: lysis buffer) and heated at 95ºC during 5 min with constant shaking. Then, 
10µl of 0.4M chloroacetamide was added to every 100µl of protein solution (200µg of protein) 
to obtain a final concentration of 40mM Chloroacetamide, samples were vortexed and spun down. 
The SP3 beads solution was prepared according to the protocol described by Hughes et al. [20]. 
Briefly, after vigorously shaking the container bottles (until the suspensions look homogeneous), 
50 µl of Sera-Mag speed beads P/N 65152105050250 and 50 µl of Sera-Mag speed beads P/N 
45152105050250 (GE Healthcare) were collected to a fresh Eppendorf tube and were washed 3x 
with 500µl of milliQ water on the magnetic rack. The beads were finally resuspended in 500µl of 
milliQ water to make the stock SP3 bead suspension. This was added to protein solution at a ratio 
of 1:5 (beads suspension: protein solution) and mixed gently by pipetting. Then, ACN was added 
to the mixture to obtain a final ACN composition of 70% and mixed gently by pipetting, samples 
were incubated for 20min in the rotating rack. After incubation the tubes were placed in the 
magnetic rack and incubated for 2 min, the supernatant was removed and discarded. Then, 200µl 
of 70% EtOH was added and samples were incubated for 30s in magnetic rack, the supernatant 
was then removed and discarded. This EtOH wash step was repeated once. Then, 180µl of ACN 
was added to samples and incubated for 15s in magnetic rack, the supernatant was then removed 
and discarded, beads were allowed to air dry for 30s. Finally, 100µl of trypsin solution (50mM 
HEPES pH7.6, 4µg trypsin) was added to each sample and incubated at 37C for 14h with mild 
shaking. Peptide concentration was determined as described in 2.4 (see Figure 2). 
2.5.4-TMT (10 plex) Labelling of peptides 
The resulting peptides were labelled with TMT reagent 10 plex, accordingly manufactures’ 
protocol. Each TMT set was loaded with eight samples and two internal pooled standards, which 
were prepared by equal mixing of peptide aliquots from all samples (see Figure 2). TMT reagents 
were allowed to reach room temperature before use. Regarding sample preparation, 
triethylammonium bicarbonate buffer (TEAB) was added to peptide samples to reach a final 
concentration of 100 mM and pH confirmed to be in the range of 8-8.5. TMT reagent vials 
preparation consisted in the addition of 250 µl of ACN to each TMT reagent vial with 5 mg. The 
reagent was dissolved for 5 min with occasional vortexing and spun briefly. Then, the content of 
each TMT reagent vial set was transferred to each sample tube accordingly with the study design. 
All tubes were vortexed, spinned and the pH confirmed to make sure that was above 7.5. Finally, 
tubes were incubated at room temperature for two hours, after half of the incubation time tubes 
were vortexed and the pH checked once again. 
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2.5.5-SCX cleaning of the proteome fraction 
After pooling, all the TMT10plex peptide sets were cleaned by strong-cation exchange-solid-
phase extraction (SCX-SPE, strata-X-C, P/N 8B-S029-TAK-TN from Phenomenex), as follows. 
Firstly, 10% formic acid was added to all the TMT10plex pools to ensure pH <3. Before adding 
the samples, the strata-X-C columns were washed with 600 µl 100% methanol and then 
equilibrated with 600 µl wash MilliQ water. Then, samples were added to the columns and after 
that step they were washed with 600 µl of washing solution (30% MeOH, 0.1% formic acid). 
Before eluting the peptides, tubes were prepared and then 600 µl of elution solution (30% MeOH, 
5% ammonium hydroxide) was added (see Figure 2). The eluate containing the salted peptides 
was divided into different aliquots and dried in a speed vacuum. 
2.5.6-High-resolution isoelectric focusing (HiRIEF) 
The HiRIEF pH range employed was 3–10, 24-cm-long IPG (immobilized pH gradient) gel-
strip (P/N GE-17-6002-44, GE Healthcare Bio-Sciences) (see Figure 2). Each peptide mixture set 
with 400 µg, was redissolved in 250 μl rehydration solution containing 8 M urea, 1% IPG 
Pharmalyte, pH 3–10 (P/N GE-17-0456-01, GE Healthcare Bio-Sciences). The peptide mixture 
set was loaded on the IPG tray, the IPG strip was placed above and allowed to absorb the sample 
overnight. The gel bridge was applied at the cathode (acidic) end of the IPG strip, and IEF was 
run on an Ettan IPGphor (GE Healthcare) until at least 150 kV-h. After focusing was complete, a 
well-former with 72 wells was applied onto each strip, and liquid-handling robotics (GE 
Healthcare prototype) proceeded with peptide extraction and transferred the 72 fractions into a 
microtiter plate (96 wells, V-bottom, Corning cat. #3894), which was then dried in a SpeedVac. 
2.5.7-Proteome MS analysis 
Prior to each LC-MS run of the 72 fractions, the auto sampler (Ultimate 3000 RSLC system, 
Thermo Scientific Dionex) dispensed 20 µl of mobile phase A (95% water, 5% dimethylsulfoxide 
(DMSO), 0.1% formic acid) into the corresponding well of the microtiter plate (96 well V-bottom, 
polypropylene, Greiner), mixed by aspirating/dispensing 10 µl ten times, and finally injected 10 
µl into a C18 guard desalting column (Acclaim pepmap 100, 75 µm × 2 cm, nanoViper, Thermo). 
After 5 min of flow at 5 µl min−1 with the loading pump, the 10-port valve switched to analysis 
mode in which the NC pump provided a flow of 250 nL min−1 through the guard column. The 
slightly concave curved gradient (curve 6 in the Chromeleon software) then proceeded from 3% 
mobile phase B (90% acetonitrile, 5% DMSO, 5% water, 0.1% formic acid) to 45% B in 50 min 
followed by wash at 99% B and re-equilibration. Total LCMS run time was 74 min. We used a 
nano-EASY-Spray column (pepmap RSLC, C18, 2 µm bead size, 100 Å, 75 µm internal diameter, 
50 cm long, Thermo) on the nano electrospray ionization (NSI) EASY-Spray source (Thermo) at 
60 °C. Online LC-MS was performed using a hybrid Q-Exactive mass spectrometer (Thermo 
Scientific). FTMS master scans with 70,000 resolution (and scan range 300–1600 m/z) were 
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followed by data-dependent MS2 (35,000 resolution) on the top 5 ions using higher energy 
collision dissociation (HCD) at 30% normalized collision energy. Precursors were isolated with 
a 2 m/z window. Automatic gain control (AGC) targets were 1e6 for MS1 and 1e5 for MS2. 
Maximum injection times were 100 ms for MS1 and 450 ms for MS2. The entire duty cycle lasted 
~1.5 s. Dynamic exclusion was used with 60 s duration. Precursors with unassigned charge state 
or charge state 1,7,8, >8 were excluded. An underfill ratio of 1% was used. 
2.5.7.1-Proteome data search 
All the raw MS/MS files were converted to mzML format and corrected for mass shifts 
using the msconvert tool (mzRefiner filter) from the ProteoWizard suite [21]. Spectra were then 
searched by MS-GF+[22], and post processed with Percolator [23] in a Nextflow [24] pipeline, 
using a concatenated target-decoy strategy. The full pipeline (version ee45bf6) is available at 
https://github.com/lehtiolab/galaxy-workflows/. 
The reference databases used were the Swissprot human protein database downloaded from 
uniprot.org at 2018-07-18. MSGF+ settings included precursor mass tolerance of 10ppm, fully-
tryptic peptides, maximum peptide length of 50 amino acids and a maximum charge of 6. Fixed 
modifications were TMT-10plex on lysines and N-termini, and carbamidomethylation on cysteine 
residues, a variable modification was used for oxidation on methionine residues. Quantification 
of TMT-10plex reporter ions was done using OpenMS project's IsobaricAnalyzer [25]. TMT 
ratios were calculated in each PSM using the average intensity of the two reporter ion channels 
loaded with internal pooled standard. PSMs found at 1% PSM- and peptide-level FDR (false 
discovery rate) were used to infer gene identities, which were quantified using the medians of 
per-channel median-normalised PSM quantification ratios. Inferred gene identity false discovery 
rates were calculated using the picked-FDR method [25], whereas the FDR for protein level 
identities was calculated using the -log10 of best-peptide q-value as a score [25]. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the 
PRIDE [26] partner repository with the dataset identifier PXD016853. 
2.5.8-PDE vs plasma analysis 
The PDE proteome dataset was compared with normal plasma (n=10) and nephropathy 
plasma  (n=10) datasets. These datasets were in-house generated, for each plasma dataset, sample 
treatment was performed in the same way as was done for PDE samples. Thus, MARS14 
depletion and HiRIEF approaches, were chosen for the protein depletion and peptides 
fractionation, respectively.  
For the gene centric approach, quantified protein groups in at least one sample were median 
summarized by gene symbol or uniprot gene name depending on the analysis. MS1 set intensities 
(i.e. precursor peak areas) or MS2 sample intensities (i.e. TMT reporter ion ratios) were used as 
per need of absolute or relative quantification values, respectively. We note that the number of 
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quantified proteins differ in each level (MS1: n = 4549, MS2: 5338) because of inherent mass 
spectrometer limitations (e.g. ill-shaped MS1 peaks, not permitting area integration, but sufficient 
signal for decent MS2 fragmentation). 
Datasets from nephropathy plasma data2 and normal plasma samples were in-house generated 
using HiRIEF method. Shared proteins across studies were identified and median MS1 intensity 
across sets was used as overall quantitative proxy to calculate Spearman correlations between the 
respective datasets. To detect outliers, we linearly regressed each protein profile from plasma 
dataset on PDE abundance values and highlighted estimated residuals lower than two standard 
deviations from the residuals’ distribution. 
For the protein abundance ranking abundance, proteins quantified and summarized as 
described above– were ordered according to their MS1 intensities and divided into four groups –
(non-)unique for PDE, (non-)shared across patients– with neuropathy dataset 2 as mentioned 
before. 
2.6-Peptidome analysis of PDE samples 
2.6.1-SCX cleaning of the peptidome fraction 
After centrifugal concentration, the fraction below the 10 kDa containing the PDE 
endogenous peptides was submitted to SCX-SPE in order to clean-up and concentrate the 
peptides. Therefore, to each 4 mL of PDE sample was added 800µL of 10% formic acid in order 
to reach a pH< 3. The acidified samples were then added to the cartridges and the same procedure 
was done as described before in the section 2.5.1.5 (proteome PDE analysis). After elution the 
supernatant was dried in a speed vacuum and the pellet resuspended in 100 µl Milli-Q water. The 
peptide concentration measurement was performed with BBC assay as described in section 2.4. 
2.6.2-Peptidome MS analysis 
 For the peptidomics analysis, endogenous peptides were analyzed using a Ultimate 3000 
RSLC system coupled to an Orbitrap Fusion mass spectrometer running in positive mode. LC-
MS run was started with the injection of 5 µl into a C18 guard desalting column (Acclaim pepmap 
100, 75 µm × 2 cm, nanoViper, Thermo). After 5 min of flow at 5 µl min−1 with the loading 
pump, the 10-port valve switched to analysis mode in which the NC pump provided a flow of 250 
nL min−1 through the guard column. The slightly concave curved gradient (curve 6 in the 
Chromeleon software) then proceeded from 3% mobile phase B (90% acetonitrile, 5% DMSO, 
5% water, 0.1% formic acid) to 45% B in 50 min followed by wash at 99% B and re-equilibration. 
Total LC-MS run time was 87 min. We used a nano-EASY-Spray column (pepmap RSLC, C18, 
2 µm bead size, 100 Å, 75 µm internal diameter, 50 cm long, Thermo) on the nano electrospray 
ionization (NSI) EASY-Spray source (Thermo) at 60 °C. For each sample two different LC-MS 
runs were performed using two different fragmentation methods: i) CID only and ii) HCD 
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combined with EThcD. In both cases, FTMS master scans were performed with 60,000 resolution, 
a scan range 350-1550 m/z, an AGC target of 5e5, a maximum injection time of 100 ms, precursor 
isolation with a 2 m/z window, dynamic exclusion with 30 s duration, and precursors with 
unassigned charge state or charge state 1 were excluded. Then, for i), data-dependent MS2 
acquisition was done with CID activation on the top 10 ions (10 scans) at 35% normalized 
collision energy, with an AGC target of 1e4, and a maximum injection time of 100msThe entire 
duty cycle lasted ~1.2 s. Regarding ii), HCD alternating with EThcD fragmentations were 
performed on the top 10 ions (10 scans), at a 40% and 25% normalized collision energy, 
respectively. For both HCD and EThcD AGC target was 2e5, and the maximum injection time 
was 120 ms. The entire duty cycle lasted ~2.4 s  
2.6.2.1-Peptidome data search 
All MS/MS spectra were processed with Proteome Discoverer (v2.2) using the PMI-Byonic 
node (V3.2.0) and Data files were searched against UniProt human canonical database (November 
2018; 42,344 entries). Regarding spectrum selector and non-fragment filter node the parameters 
were set as default. For the Byonic analysis node, the precursor MS, HCD MS2 and EThcD MS2 
tolerances were set to 10 ppm with non-specific enzyme searching. Some post-translational 
modifications (PTMs), such as, i) oxidation of methionine and proline, ii) amidated (C-Term), iii) 
acetyl (N-Term) and iv) Gln→pyro-Glu (N-term Q), were set as dynamic modifications. Data 
was searched as a single batch with PSM and peptide FDR set 1% using a target decoy approach 
in Byonic. The target decoy PSM validator node parameters were set as default. 
2.6.3-Protease prediction analysis 
The Proteasix tool was used in order to perform protease prediction analysis based on the 
naturally occurring peptides in the PDE Peptidome samples. Proteasix is an open-source peptide-
centric tool that allows cleavage sites’ retrieval and protease associations from a list of peptides 
[27]. Therefore, from an input peptide list, Proteasix enables the automatic reconstruction of N- 
and C- terminal cleavage sites and identification of observed and predicted proteases involved in 
the proteolysis of these cleavage sites. The Proteasix Knowledge Database supports two 
operational modes (observed and predicted) to find proteases. The observed mode was the one 
used in our study, and consists in matching against cleavage site associations collected from the 
literature to find proteases. The input list requires the following information of each peptide: i) 
Peptide identifier: useful to track the data with large list of peptides; ii) Parent protein: UniProt 
identifier (ID) or UniProt accession (AC); iii) Start amino acid position in the Parent protein 
sequence and iv) Stop amino acid position in the Parent protein sequence. Finally, the output data 
contains, i) peptide identifier, ii) Parent protein, iii) Start amino acid, iv) Stop amino acid, v) 
Protease, vi) Cleavage site, v) Source and the vi) Plausible proteolysis.  
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2.7-Longitudinal study: clustering and enrichment analysis 
In order to perform the longitudinal analysis for each patient, we sorted each MS2 patient 
profile by time of collection and removed values above 0.1% percentile of the total quantified 
proteins that were considered as outliers. The remaining values were z-score transformed (mean 
= 0, standard deviation = 1). 
The time-series expression data analysis was performed with TiCoNE [28], an expert-centred 
approach for discovering temporal response pathways. With this approach, time-series expression 
data is clustered to identify groups of biological entities with coherent temporal responses. It is 
also possible to add, remove, merge, or split temporal patterns. The clustering analysis was 
performed with the following parameters, i) Discretization (standard): negative (10) and positive 
(10); ii) Clustering method: CLARA, number of clusters (15 for patients with more than 3 time 
points, 10 for less than 3 time points); iii) Prototypes: Mean Time Series; iv) Similarities: Time 
series (Pearson correlation).  
After obtaining the clusters, some cluster operations were performed, such as: i) Perform 
iteration until converge; ii) Modify clustering: Filter objects (least fitting objects sets) using as 
similarity method the “Shape (Pearson)” and selecting 10 percent of least fitting to be deleted. In 
addition, the cluster p-values were calculated selecting as a features for cluster fitness: Average 
object + prototype similarity, and as a conditional features: number of objects. The number of 
permutations was set for 5000. The resulting clusters for each patient, were subsequently enriched 
for gene sets in Molecular Signature Database (mSigDB) canonical pathways (v6.2) [29]. The 
enrichment analysis was performed patient- and cluster-wise using enricher function from 
ClusterProfiler R package with the following parameters: minGSSize = 10, maxGSSize = 200, 
pAdjustMethod = "BH", pvalueCutoff = 1, qvalueCutoff = 1 [30].  
Background proteome (universe) was individually estimated for each patient according to 
the quantified proteins. P-values of the enriched terms were subsequently Benjamini-Hochberg 
(BH) corrected and those with adjusted p-value < 0.25 were retained. 
3-Results and Discussion  
3.1-In-depth proteome analysis.  
PDE it is a useful reservoir for potential biomarkers, being easily accessible through a peritoneal 
equilibrium test and without constraints regarding the amount of sample that can be obtained, this 
sample represents and enormous and valuable source for long-term PD monitoring [7], [14]. 
However, PDE´s sample characteristics such as: i) highly diluted protein content, ii) complex 
plasma-like composition and iii) plasma-like wide dynamic range of concentrations between its 
component proteins, contribute to making the Proteome analysis a challenging task. The first step 
in sample preparation is to equalize the protein concentrations across all samples. Therefore, all 
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samples were first interrogated for the total protein content. The average of the protein 
concentration for the 136 samples analysed was 0.707±0.302 mg/mL and the range was found to 
vary between 0.327 and 1.913 mg/ml.  
The Proteome analysis identified 5478 proteins (Table ESM 2) over all samples, of which 
1828 were overlapped for all sets, with an average of 3119 proteins identified per set (ranging 
from 2803 to 3693), as shown in Figure 1 of the Supplementary Material. The total number of 
peptides were 59606, with an overlap of 9313 peptides between sets and an average of 26297 
peptides per set (ranging from 24736 to 29602) as shown in Figure 1 of the Supplementary 
Material. 
This is the largest number of proteins ever identified in a PDE Proteomics study, 
representing a 1.2-fold increase in PDE proteome coverage [31], [32]. An important PDE 
Proteomics study by Herzog et al. [32] applied a combinatorial peptide ligand library (CPLL) 
technique for depletion and enrichment approach, combining it with multiplex LC-MS analyses 
to explore the PDE [32], resulting in a total of 2506 proteins identified. Another important study, 
by Pearson et al. [31], determined the presence of extracellular vesicles (EVs) in PDE and 
subsequently characterized their proteome, identifying over 3700 proteins in total. The EVs in 
PDE were first isolated from PDE using differential centrifugation, then a further enrichment 
using size exclusion chromatography (SEC) and finally MS/MS were used to identify the marker 
proteins from the three types of EVs i.e. apoptotic bodies, ectosomes and exosomes.  
We should also note the volumes of sample used in the previous studies for proteomic 
analysis [31], [32], in which a starting volume of at least 300 mL, and up to 1000 mL of PDE 
were used per sample. These large volumes seriously limit the implementation of proteomics 
studies with large sample cohorts, due to the obvious storage issue. In contrast, our proteomic 
analysis was performed with a smaller starting volume of 10 mL per sample, allowing also the 
parallel analysis of the endogenous peptides from precisely the same sample (fraction <10 kDa 
after centrifugal concentration step, section 2.3, and as can be seen in Figure 2). 
Figure 3A shows an overview of the Proteome coverages of the present study compared 
to the two PDE Proteomics reference studies of Herzog et al and Pearson et al. The HiRIEF 
separation technique combined with the MARS14 depletion here proposed proved to be powerful 
tool obtain a deep insight into the PDE. Moreover, PDE HiRIEF-LC-MS analysis was compared 
with a previous data generated by our group (as described in section 2.5.1.9). Thus, two distinct 
groups of plasma samples (healthy donors and patients with nephropathy) were compared with 
PDE (Figure 3B). The previous study was performed under the same protocol conditions, with 
HiRIEF pH range of 3–10, 24-cm-long IPG gel-strip, allowing us to get some insights about how 
“plasma-like” are PDE samples when compared with plasma analysed under the same protocol 
conditions. The comparison allowed to discuss the pre-fractionation robustness of the HiRIEF 
technique. Moreover, the number of proteins found in PDE indicates that it is substantially more 
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complex than plasma, and suggests that it may not be as plasma-like as previously thought (Figure 
3B).  
 
Figure 3- Venn’s diagram comparison, A- This study vs PDE studies; B- PDE HiRIEF vs Plasma 
HiRIEF studies. 
Additionally, when performing correlation analysis between the plasma HiRIEF datasets 
and PDE, the results shown that the highest Spearman´s correlation, was the correlation of plasma 
nephropathy HiRIEF and plasma normal HiRIEF analysis (0.68). This is not surprising, given 
the fact that both are plasma samples, and the sample treatment was performed with the same 
technique (Figure 4-A). From the point of view of the PDE HiRIEF data, it showed higher 
correlation (Spearman 0.61) with the plasma nephropathy HiRIEF data (Figure 4-C), and slightly 
worse correlation with the plasma normal HiRIEF data (Spearman 0.57) (Figure 3-B). Thus, we 
hypothesize that plasma nephropathy is more correlated with PDE samples, most likely because 
both are derived from patients with kidney disease (uremic patients). Hence, we have focused on 
outliers of this correlation analysis (PDE vs plasma nephropathy), which are exclusive to PDE 
samples, in order to focus on locally produced proteins, not plasma related ones. 
Interestingly, when performing a correlation analysis of PDE and plasma nephropathy 
(HiRIEF), one of the outliers with highest score is SERPINE1 (plasminogen activator inhibitor 
(PAI-1)) (Figure 4-C). This glycoprotein functions as an inhibitor of fibrinolysis and is also 
involved in the inhibition of extracellular matrix turnover and stimulation of fibrosis, because it 
is upregulated by the transforming growth factor (TGF-β), an important mediator in many 
fibrotic processes. Furthermore, elevated levels of PAI-1 are present in intra-abdominal 
adhesions and the concentration of PAI-1 doubles transiently during acute peritonitis. Moreover, 
PAI-1 is present at higher levels with longer duration of PD and the appearance rate in effluent 
is a powerful predictor for encapsulating peritoneal sclerosis (EPS), with a predictive power of 
0.77, sensitivity of 100%, and specificity of 54%, that increases to 94% when in combination 
with impaired free water transport[33]. Therefore, we demonstrate that HiRIEF-MS method has 
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the analytical depth and capability to detect tissue leakage or locally produced proteins, as 
recently described by Pernemalm et al. [34].  
 
Figure 4- Correlation of PDE abundance (median MS1 intensity) and plasma abundance. A- HiRIEF plasma 
nephropathy versus normal plasma (plasma samples) (Spearman´s correlation =0.68). B- HiRIEF normal 
plasma versus PDE analysis (PDE vs plasma) (Spearman´s correlation =0.57). C- HiRIEF plasma 
nephropathy versus PDE (PDE vs plasma) Spearman´s correlation =0.61). 
With the purpose of going into deeper considerations within PDE samples, we compared 
the number of proteins identified and quantified across the different time-points and patients. 
From 5338 proteins, 1807 are common across all time-points/patients, with some proteins unique 
for some patients or time points (Figure 5).  
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Figure 5- Bar chart with the number of proteins identified per patient for the different time points. The 
protein groups are coloured with, i) light blue: proteins common among time points of each patient; ii) 
dark blue: protein uniquely identified for the first time point (T1); iii) light green: protein uniquely 
identified for the second time point (T2); iv) dark green: protein uniquely identified for the third time 
point (T3); v) pink: protein uniquely identified for the fourth time point (T4); v) red: protein uniquely 
identified for the fifth time point (T5). Dashed lines indicate the number of common protein identified 
across all samples in the study (n=1807) and the median of proteins identified (n=3136). 
Additionally, MS1 intensities of shared and unique proteins identified between time 
points/patients in the PDE samples as shown in Figure 6, were ranked and compared with the 
MS1 intensity of the plasma nephropathy HiRIEF dataset 2, because it was precisely the same 
method of fractionation, allowing us to have an idea of the technique reliability. Moreover, the 
plasma nephropathy HiRIEF dataset was the one chosen over the healthy plasma HiRIEF dataset, 
because of its closer correlation. Thus, this comparison was performed to get insights about the 
PDE proteins distribution, of proteins unique or shared across patients, that are found or not in 
plasma. The abundance ranking for a total of 4549 proteins is shown in Figure 6 (Table ESM 3).  
As expected, in terms of abundance, the proteins shared across patients and found in 
plasma are the most abundant group, followed by the group of proteins shared across patients 
but not found in plasma. However, in terms of number of proteins represented per group, the 
proteins not shared across PDE samples and not found in plasma, comprise the group with the 
highest number of proteins, with 2384 proteins. This suggests the peritoneal effluent locally 
produced proteome provided by the current set of patients is rather varied. And it implies that a 
wide variety of peritoneal membrane conditions are found across the patients and time points of 
sample collection. Finally, we note that many more proteins were found to be exclusive to PDE 
than those common with plasma (2987 versus 1562) meaning that PDE samples are substantially 
more complex than was previously thought.  
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Figure 6- PDE proteins ranked (using nephropathy plasma dataset 2) according to abundance and 
coloured accordingly with, Yellow, proteins shared across patients that are also found in plasma (1200 
proteins). Blue, proteins shared across patients but not found in plasma (603 proteins). Red, proteins not 
shared across patients but found in plasma (362 proteins). Purple, proteins not shared across patients nor 
found in plasma (2384 proteins). Some suggested literature PD candidate biomarkers that were identified 
and quantified with our methodology are highlighted in the abundance rank distribution. MMP-2, matrix 
metalloproteinase 2; SERPINE1, plasminogen activator inhibitor 1; CTGF, connective tissue growth 
factor; TGFB1, transforming growth factor beta 1; VEGFA, vascular endothelial growth factor A; AQP1, 
aquaporin-1; IL6, Interleukin-6; CCL18, C-C motif chemokine 18. 
3.2-PDE peptidome analysis 
 In contrast to proteomics, peptidomics mostly aims to elucidate the exact form of each 
peptide detected in the sample, reflecting the proteolytic cleavages, PTMs and the co-existence 
of different versions of peptides derived from the same gene or precursor [35]. The network of 
complex interplays between proteins and peptides arises from the fact that there are over 560 
genetically encoded proteases of different subfamilies and over 150 protease inhibitors encoded 
in the human genome. Thus, the peptidome is harder to predict in comparison with the genome 
and proteome [36]. Regarding PDE peptidome analysis, this presents also some challenges such 
as, i) complexity and large dynamic range of peptide concentration, ii) highly diluted peptide 
content, and iii) data analysis of the endogenous peptides.  
Although endogenous peptides analysis does not require enzymatic digestion of the 
sample, the use of proteomic techniques applied to peptidomics is not as straightforward as it 
may seem, due to some challenges. Namely, the range size of the endogenous peptides, from 2 
to over 100 amino acids (if precursor protein is cleaved into fragments, those are considered 
peptides); the charge state, which is not as uniform as for tryptic peptides. In other words, some 
endogenous peptides have no positive charge due to a blocked N-terminus and the absence of 
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Lys, Arg, or His residues, that make these peptides not detectable in positive ion mode. On the 
other hand, other endogenous peptides have charge states of 7+ or more [35]. Additionally, the 
endogenous peptides are originated from the activity of an array of often-unknown endogenous 
proteolytic enzymes, some without predictable cleavage sequence motifs [37]. Therefore, 
variations in peptide size and charge state and the lack of expected cleavage sites (such as K/ or 
R/ sites for tryptic cleavages used in trypsin-based Proteomics) complicate the analysis of 
endogenous peptides, and for these reasons, some adjustments to the proteomic analysis 
techniques used have to be done, in order to identify large numbers of endogenous peptides. 
Peptides were analysed employing multiple fragmentation methods such as CID and 
HCD-EThcD, (see section 2.11.1.2.). The analysis of 136 samples covered a total of 5246 unique 
peptide sequences mapping to 444 protein groups with a high overlap between the different 
fragmentation approaches, namely 91% at peptide level and 96% at protein level (Supplementary 
Material Figure S2). To the best of our knowledge, this study represents the highest number of 
peptides ever identified in PDE samples and the first performing protease prediction analysis in 
PDE samples, as described in the section below. 
3.2.1-Protease prediction  
The “input” peptide list of native peptides identified in PDE with CID fragmentation was 
submitted to Proteasix analysis [27], allowing for automatic cleavage site reconstruction and 
protease association, as described in section 2.6.1.4.. The analysis rendered a total of 74 proteases 
(Figure S2). Concerning the number of cleavage events and substrates cleaved per protease it is 
possible to observe that despite the higher number of cleavage events related to some proteases, 
such as, plasminogen (PLG) and collagenase 13 (MMP13), these are not the proteases acting on 
a large number of protein groups (14 only), (Figure 7 and Table ESM 4). Thus, these proteases 
seem to have a higher specificity when compared for example to Cathepsin K (CTSK) and 
Cathepsin L1 (CTSL) (with 49 and 39 target proteins, respectively). Interestingly, the protease 
activity of several MMPs reflects their importance on the process of tissue injury and remodelling 
of PM, during its prolonged exposure to peritoneal dialysis fluids, as mentioned in case study 
number 3, in section 3.3.1. Another interesting remark is the number of cleavage events and 
variety of proteases acting in some specific protein groups. The fibrinogen alpha chain, serum 
amyloid A-1 protein and collagen alpha-1(III) chain are some of the proteins suffering a rather 
large number of cleavage events, with 620, 425 and 391 cleavage events, respectively. In addition, 
vimentin, actin cytoplasmic 1 and collagen alpha-1 (I) chain proteins appear to be a target for a 
high number of proteases, with 18, 17 and 16, respectively (Tables ESM 4 and ESM 5).  
Additionally, is important to know that not all native peptides identified had an associated 
protease prediction, thus this protease prediction analysis does not cover all the data obtained and 
some of the endogenous peptides may arise from different processes of cleavage. 
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Figure 7- Bar chart with the predicted proteases for those peptides that had at least one protease prediction. For each protease the blue bar indicates the number of cleavage 
events, and the red bar the number of cleaved substrates that each protease is responsible for. The green and red labelling, means that the predicted protease is found or not 
found in the proteome, respectively. 
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 Recently, in a work published by Magalhães and colleagues [38], the authors applied 
Proteasix software [27] to predict the proteases involved in the generation of the naturally 
occurring peptides in plasma, serum, CSF, saliva, urine and tears. The peptidome data of the 
most studied human body fluids was collected from public databases and from experimental 
studies. The analysis highlights 132 putative proteases from four families with the predominance 
of serine proteases and metalloproteases. From these, 49 proteases were common to all fluids 
and mostly associated to ECM as well as protein/peptide hormone processing [38]. Although 
PDE samples are not a truly human body fluid, 74 proteases were predicted as involved in the 
generation of endogenous peptides, and from those, 54 are identified and quantified in the 
proteome analysis.  
3.3-Longitudinal study analysis.  
Although it has been proven that long-term instillation of PDF into peritoneum causes 
morphological alterations in the PM, such as, detachment of the mesothelial layer, increased ECM 
deposition, fibrosis and angiogenesis [10], only some candidate biomarkers associated with these 
morphological alterations are currently being considered as valuable tools for improving patient 
management. These prognostic peritoneal biomarkers might be of prime importance to guide 
therapeutic decisions and to enable the early discrimination of patients that are at high risk of 
suffering complications (such PM deterioration or peritonitis), after PD therapeutic interventions 
[16]. Additionally, and due to a wide diversity of peritoneal function between patients, both before 
the start and in response to PD therapy, the detailed elucidation of the pathophysiological 
processes could provide a better understanding of ultrafiltration (UF) failure, allowing therapeutic 
options to be refined [31]. Some biomarkers, such as, IL-6, IL-8, CA125, have already been 
associated with relevant pathomechanisms arising from long-term PD, such as chronic peritoneal 
inflammation, infection and PM remodelling [16]. The longitudinal analysis of the PDE proteome 
for each patient, aimed to study the evolution of the PDE over time, to identify specific molecular 
changes that can be particularly interesting for the understanding and early detection of long-term 
PM alterations, and to understand the PM-dependent dynamic response among patients to PD 
therapy. 
3.3.1-Clinical case studies 
The analysis of longitudinal data consisted in clustering of proteins with similar 
expression patterns, followed by pathways’ enrichment analysis of each cluster, revealing the 
most significant pathways related to these proteins, (see section 2.5.9.1.). This analysis was 
performed for patients with three or more time points and some of the most frequently significant 
pathways across patients are related with metabolic pathways, complement and coagulation 
cascades, ECM organization, formation of fibrin clot clotting cascade and integrin pathways 
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(Supplementary Table S1). For the clinical case examples described below, we focus particularly 
in vintage patients (those with more than 3 years of PD) or patients with at least three time points 
with particularly significantly enriched biological pathways. Thereby, with these case studies we 
intend to highlight the need of a case by case patient treatment, and the possibility of identifying 
and following changes in the PM during long-term PD.  
Case 1-Fungal peritonitis as a reason for PD therapy dropout 
The first case study (P01) represents a clinical case of a woman that initiated PD at age 
of 61 for the treatment of chronic kidney disease (CKD) due to hypertensive nephrosclerosis. 
This patient performed PD therapy for more than 3 years, experienced 2 episodes of peritonitis 
caused by Acinetobacter spp. and pseudomonas that were treated successfully. However, the 
patient was later on transferred from PD to hemodialysis (HD) therapy due to fungal peritonitis 
caused by Candida Parapsilosis. The peritoneal function, effluent biomarker CA125 and other 
clinical aspects such as serum albumin and parathyroidism hormone were assessed for each time 
point without any clinical alterations having been noted. The peritoneal function assessment 
showed a UF < 400 (ml/4h) for the last time point, and the patient performed PD therapy for two 
months before shifting to HD due to fungal peritonitis. The patient suffered from other 
comorbidities such as congestive heart failure (CHF) and stroke. In addition, statins and beta 
blocker drugs were prescribed as antagonists of the renin-angiotensin system. More details for 
this patient are noted in Figure 8 and Supplementary Table S2. 
Concerning the peritonitis as a PD dropout reason, it is already known that severe or 
recurrent peritonitis can be a factor limiting long-term use of PD and causing the impartment of 
the anatomical and functional integrity of the PM. Moreover, several factors can trigger 
peritoneal inflammation, inducing an immunological response in the peritoneal cavity that 
involves mesothelial cells (MCs), fibroblast, macrophages, lymphocytes and neutrophils[39]. 
The MCs are capable of recognizing pathogens and initiating inflammatory response through 
antigen presentation, cytokine production and interaction with immune cells (e.g. macrophages) 
[40]. However, it is also known that the use of conventional peritoneal dialysis fluids (PDFs) 
with non-physiologic composition adversely affects the peritoneal host defence and may thus 
contribute to the development of PD-related peritonitis [41]. However, with the use of newer 
PDFs the peritoneal defence mechanisms may improve [42]. These considerations relate with 
some of the enriched pathways observed for patient P01, such as “class I MHC mediated antigen 
processing presentation” and “Il-6, -7 pathways”, both presenting a decreasing profile (cluster 4, 
Figure 8), with a steep decline in the levels of the proteins of these pathways already prominent 
at the second time point but continuing to increase over time. Thus, based on the clinical and 
proteomic information, it is possible to hypothesize that patient P01 suffered a continued 
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depletion of peritoneal host defence capabilities culminating in a more severe episode of 
peritonitis caused by Candida Parapsilosis. The proteomics analysis shows that these immune 
system pathways were already in severe decline as early as six months after the beginning of PD 
treatment, and had some of these components (e.g. IL6 levels) been monitored during treatment, 
clinicians would have been aware early on of the increased risk for peritoneal infection. The 
strongest risk factors for fungal peritonitis in PD patients are prolonged use of antibiotics and 
previous bacterial peritonitis [28], that in fact occurred before the event that caused the dropout. 
In addition to the recognition of pathogens, MCs are also capable of recognizing tissue 
damage and initiating tissue repair and adherence formation [40]. The MCs play an important 
role in the adhesion formation via expression of cell adhesion molecules (CAMs), which also 
have an essential role in the inflammatory response. Some CAMS, such as selectins, integrins 
and immunoglobulin (Ig) gene family adhesion receptors, are selectively expressed by tissue 
cells, mediating the different steps of leukocyte attachment and migration to the inflammatory 
foci [43]. Some of enriched pathways such, “integrin3 pathway” and the “cytokine-cytokine 
receptor interaction” (presenting a stepwise increase, cluster 1, Figure 8) are related with the 
aforementioned process. 
In PD, cytokines play a role both in defence against the development of peritoneal 
infection, in the course of peritoneal infection an in the processes related to peritoneal tissue 
repair. Peritoneal tissue repair consists in a series of events that culminate in inflammation and 
restoration, in which the balance of fibrin deposition and degradation is vital. In this context, the 
overall role of cytokines is to shift the balance of fibrin deposition and degradation in favour of 
fibrin residues [44]. In addition, coagulation, as well as fibrin generation, are key processes in 
the remesothelialization, whereas fibrinolysis (fibrin-dissolving) is instrumental in the 
degradation of fibrin deposits [44]. Interestingly, a decreasing trend is observed for the 
“formation of fibrin clot clotting cascade” and “fibrinolysis” pathways (cluster 4, Figure 8), that 
seems to have the tendency to stabilize after the first 6 months of PD, as observed in cluster 4 
trend. Thus, we can hypothesize that these enriched pathways may be related with normal 
adaptive processes of the PM to the PD. In addition, it is known that following an injury to the 
peritoneum, fibrinolytic activity over the peritoneal surface decreases, leading to changes in the 
expression and synthesis of various cellular mediators and in the remodelling of the connective 
tissue [43].  
Furthermore, pathways related with the metabolism of proteins were also found enriched 
in this case study. Concerning the enriched “metabolism of proteins” pathway (cluster 4, Figure 
8), its components cover the full life cycle of a protein from its synthesis to its posttranslational 
modification (PTMs) and degradation at various levels of specificity. Also, within the 
“metabolism of proteins” a more specific pathway is enriched, “the unfolded protein response” 
(cluster 4, Figure 8) that is related to protein damage and protein turnover. However, this is not 
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surprising, because it is already known that PD has effects on protein metabolism by acutely 
inducing a new state in muscle protein dynamics, which is characterized by decreased turnover 
rates and a reduced efficiency of protein turnover, a condition which may be harmful in stress 
conditions, when nutrient intake is diminished or during superimposed catabolic illnesses [45]. 
In CKD patients, even a modest elevation in local insulin is followed by an anabolic muscle 
response, though the same effect is not observed during systemic hyperinsulinemia associated 
with substrate removal which occurs during PD. In this setting the anti-proteolytic effect of 
hyperinsulinemia is offset by a decrease in muscle protein synthesis due to amino acid deficiency. 
Thus, protein metabolism during PD is characterized not only by decreased, but also less 
efficient, turnover rates [46]. 
In addition, an enriched PTM pathway, more precisely, the O-linked glycosylation of 
mucins pathway, presents an increasing trend (cluster 3, Figure 8), with an overexpression of the 
MUC16 protein (see Supplementary Table 3 and Table ESM 2). Mucin-type O-glycans are found 
attached on the surface of secreted and extracellular matrix (ECM) proteins, and are thus 
positioned to modulate the recognition, adhesion, and communication events that occur between 
cells and the surrounding environment [47], [48]. Moreover, mucin-type O-glycosylation 
pathways have been associated with altered immune response, due to altered adhesive properties 
resulting in decreased (leukocyte) rolling on selectins[49].  
On the other hand, GCNT1 was also found with an increasing profile over time (cluster 
3, Figure 8). This glycosyltransferase catalyses the transfer of an N-acetylglucosamine moiety 
onto mucin-type core 1 O-glycan to form the branched mucin-type core 2 O-glycan [50]. Both 
core 1 and -2, are implicated in a diversity of immunological processes, such as, T cell 
contraction by apoptosis, antibody function, antigen receptor activation, and cell adhesion and 
trafficking [51]. In contrast to cells of the innate immune system, which often constitutively 
express the collection of enzymes that generate selectin ligands on their cell surface, the synthesis 
of core 2 O-glycans and the expression of L-selectin in T cells is highly dynamic. Importantly, 
the regulation of glycosyltransferase functional activity occurs largely at the transcriptional level, 
where the enhancement (or inhibition) of enzyme expression generally controls the surface 
glycan landscape of a cell. Thus, the signalling mechanisms that ultimately impact the 
transcriptional and/or epigenetic regulation of glycosyltransferase expression in both T cells and 
endothelial cell populations is critical for the overall understanding of how specific T cell 
populations are able to traffic into both lymphoid and non-lymphoid tissues [51]. Therefore, an 
increasing trend of MUC16 and GCNT1 within the “O-linked glycosylation of mucins pathway” 
may indicate an alteration of the recognition, adhesion, and communication events between cells 
and the surrounding environment altered by PDFs. 
Furthermore, Acute Myocardial Infarction (“AMI”) is another enriched pathway within 
cluster 4. Interestingly, this pathway may be related with congestive heart failure (CHF) and 
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stroke comorbidities. The adverse influence of CKD has been demonstrated in the setting of 
acute coronary syndromes (ACS), and among ACS patients, CKD doubles mortality rates and is 
third only to cardiogenic shock and CHF as a predictor of mortality [52]. Therefore, some drugs 
such as antagonists of the renin-angiotensin system (Valsartan), statins (Atorvastatin) and beta 
blockers (Carvedilol) were prescribed in order to ameliorate the patient’s condition. Importantly, 
Valsartan, Atorvastatin and Carvedilol have been shown to reduce the cardiovascular morbidity 
and mortality [53]–[55]. Within the AMI pathway, there are many proteins enrolled in 
coagulation processes such as fibrinogen beta chain (FGB), fibrinogen gamma chain (FGG) and 
prothrombin (F2, the thrombin precursor). Thrombin converts fibrinogen to fibrin by cleaving 
bonds after Arg and Lys, and, in complex with thrombomodulin, activates vitamin k-dependent 
protein C (PROC). Also, coagulation factor X (F10), a vitamin k-dependent glycoprotein that 
converts prothrombin to thrombin is found enriched in this pathway. PROC itself and PROS1 
(vitamin K-dependent protein S, an anticoagulant plasma protein that acts as a cofactor to 
activated PROC in the degradation of coagulation factors) are also enriched. All these proteins 
present a decreasing trend since the initiation of the PD therapy. This decreasing trend of proteins 
enrolled in the coagulation cascades is not all that surprising, considering the patient’s clinical 
panel, with a predisposition for strokes as secondary comorbidity. Thus, it is interesting to 
observe that dysregulated pathways related to secondary comorbidities are also revealed by 
analysing the PDE proteome, and that proteins formed in other parts of the body (which in this 
case reflect the underlying vascular comorbidity) to the peritoneal membrane can also be 
monitored by the PDE Proteomics analysis.  
After getting insights into the most significantly enriched pathways it is possible to 
conclude that for this particular case, as early as six months after commencing treatment, the 
patient showed predisposition to incur in peritonitis, and therefore, that the fungal peritonitis was 
not something unexpected, considering the proteomic panel here presented. The decreasing trend 
of proteins within pathways related with the immune response, such as, “class I MHC mediated 
antigen processing presentation” and “Il-6, -7, pathways”, assessed by the proteomic analysis 
could have been useful for a clinical decision, especially the Il-6 levels. In addition to Il-6, 
STAT1 and STAT3 were also found with a decreasing profile within “Il-6, -7, pathways” (cluster 
4, Figure 8), Supplementary Table S3. Il-6 trans-signalling is known to direct the transition 
between innate and acquired immune responses by orchestrating the chemokine-directed 
attraction and apoptotic clearance of leukocytes [56]. Moreover, Il-6 activation of STAT3 
promotes T cell recruitment. Thus, Il-6 bioactivity is tightly linked to the homing or migratory 
capacity of T cells. Il-6 deficiency specifically disrupts chemokine control of T cell trafficking 
[57]. Therefore, we consider that monitoring Il-6 levels could have been informative for the 
clinicians, and alert them to the patient’s increasing vulnerability to peritoneal infection caused 
by prolonged PD therapy.  
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Figure 8- Case study 1 (P01)- Cluster trends (time profiles) and respective bar plot with the most significant (-log10 adjusted p-value) enriched pathways for each cluster. 
Bar heights represent the adjusted p-value for each pathway. The log2 fold change represents the median of the differences between all proteins enriched for that specific 
pathway at the last time-point and the same proteins at the first time-point. Blue means decrease, and red increase. The dots represent the number of proteins identified within 
the pathway in a specific cluster, divided by the total number of proteins identified in a specific pathway for this specific patient proteome background (universe). Dashed 
line represents the threshold of the p-adjusted value (0.25). 
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Case 2-Ultrafiltration failure as a reason for PD therapy dropout 
Patient V16 is a clinical case of a man that initiated PD at age of 57 for the treatment of 
CKD due to autosomal dominant polycystic kidney disease (ADPKD). This patient performed 
PD therapy for more than 3 years. However, our proteomic follow-up for this patient started at 
month 14, and since then patient experienced one peritonitis episode caused by Staphylococcus 
epidermidis that was treated successfully. The peritoneal function, effluent biomarker CA125 
and other clinical aspects such as serum albumin and parathyroidism hormone (PTH) were 
assessed for each time point. A change in the profile transporter from high average to high was 
observed, and also creatinine clearance was <60 ml/min in the last time point. Concerning other 
comorbidities, this patient suffered also from ischemic cardiomyopathy. Since the last time point 
of our study, the patient performed PD therapy for three months before developing ultrafiltration 
failure (UFF). In addition, some drugs such as statins and beta-blockers were prescribed. More 
details for this patient can be seen in Figure 9 and Supplementary Table 2 
As already known [58], a progressive CKD results in retention of uremic toxins that can 
contribute to dysfunction of various metabolic systems. Some of these toxins participate in the 
disturbance of food breakdown and may downregulate other pathways, resulting in a reduced 
ability of free fatty acid breakdown. PD may even worsen metabolic functions, with 
complications such as: i) hyperglycaemia, caused by the use of PDF containing high 
concentrations of glucose; ii) hypernatremia, that is a result of short dialysate dwell times during 
the rapid exchanges of high-volume PD; iii) protein/amino acids loss into the dialysate, 
worsening the nutrition status of patients already depleted by CKD, and iv) hypercatabolism. 
Severe hypercatabolism caused by PD remains controversial and occurs because PD methods 
cannot provide an adequate dialysis dose for CKD patients[58]–[60]. For these reasons, an 
optimization of dialysis dose and nutritional counselling, together with the use of PD solutions 
without glucose, like icodextrin and amino acid based solutions, are some strategies to prevent 
and correct malnutrition when PD patients cannot comply with dietary requirements[59], [61], 
[62]. Likewise, the proteomic analysis of this particular case study revealed some clusters with 
relevant trends related with metabolic pathways, such as “metabolism of amino acid and 
derivatives” (cluster 3, Figure 9); “arginine and proline metabolism” and “phospholipid 
metabolism” (cluster 5, Figure 9); “pyruvate metabolism”; and “citric acid cycle TCA cycle” 
(cluster 10, Figure 9). All showed a decreasing trend.  
Interestingly, as observed in case study 1, “class I MHC mediated antigen processing 
presentation” appears also as an enriched pathway. The quantitative levels of surface MHC 
expression is a determinant of antigen-presenting capacity. It was found that resting human 
peritoneal MCs (HPMCs) constitutively expressed MHC I molecules, but there was no detectable 
MHC II [63]. However, Shaw et al. suggested that normal HPMCs have a significant inherent 
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phagocytic activity, and can be induced to produce MHC II, and constitutively express 
costimulatory molecules. Moreover, they can present antigen to autologous memory T 
Lymphocytes[63]. Therefore, HPMCs equipped with phagocytic and antigen presenting 
machinery have an important role in intraperitoneal immunity[63]–[65], and for this reason a 
decreasing trend in this machinery may indicate a compromised immune response for future 
infection events. 
In addition to the infectious peritonitis that this patient suffered, it is known that other 
factors such as, uraemia, high glucose concentrations in PDF, GDPs formed during heat 
sterilization, and the generation of AGEs, have all been implicated in ultrafiltration failure (UFF) 
development [66]. UFF is defined as failure to achieve at least 400 ml of net ultrafiltration during 
a 4 h dwell using 4.25% dextrose [67]. Four major causes of UFF have been described, such as, 
i) Highly effective peritoneal surface area, characterized by transition to a very rapid transport 
state with D/P creatinine >0.81; ii) Low osmotic conductance to glucose, characterized by 
attenuation of sodium sieving and decreased peritoneal free water clearance; iii) Low effective 
peritoneal surface area, manifests with decreases in the transport of both solute and water; and 
iv) High total peritoneal fluid loss rate, due to an increase in the rate of bulk absorption from the 
peritoneal cavity into lymphatics and into the local tissues[67]. 
Importantly, morphological and functional alterations in the PM, such as, local 
neoangiogenesis, vasculopathy, mesothelial to mesenchymal transition (MMT), and collagen 
deposition in the compact submesothelial ECM zone with subsequent PM thickening, are 
common in long-term PD patients. In this case study, cluster 6 (Figure 9) presents an increasing 
trend of enriched pathways related with ECM, such as, “matrisome”, “collagens” and “ECM 
matrix organization”. Additionally, “integrin3” pathway is also enriched. Specific integrin 
heterodimers preferentially bind to distinct ECM proteins to affect cell characteristics by signal 
transduction to the cell interior[68]. Integrins sense ECM-induced extracellular changes during 
pathological events, leading to cellular responses, which influence ECM remodelling[69]. β1 and 
β3 integrins serve essential roles in the progression of cancer-associated processes, including the 
initiation, proliferation, survival, migration and invasion[68]. Moreover, integrins regulate 
membrane trafficking and endocytosis, EMT, cell polarization, cytoskeletal rearrangements, 
activity and localization of MMPs [70].These enriched pathways observed for cluster 6 (Figure 
9), can be understood in the context of some the aforementioned morphological alterations, and 
can translate clinically into faster small-solute transport most often due to a combination of a 
rapid disappearance of the osmotic gradient and diminished osmotic conductance of the PM, 
meaning that there is less osmosis even though a gradient is present. Both effects are associated 
with a functional decline in the peritoneum as a dialyzing membrane[66], [71]. There is evidence 
that the decrease in the peritoneal osmotic conductance is related to aquaporin-1 (AQP1) 
dysfunction [72] and that the acceleration of small-solute transfer is related to the thickening of 
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the collagen layer and high vascular density[66]. Importantly, in this case study, the enriched 
collagen pathway, presents several collagens with an increasing trend (see Supplementary Table 
4), and that may lead later to UFF.  
Interestingly, UFF can be present shortly after the start of PD, for instance due to MMT, 
or later. Late UFF develops in 21% of long-term patients and a reduction of both free water 
transport (FWT) and small pore fluid transport (SPFT) is likely to occur in the majority of long-
term PD patients. Those patients developing encapsulating peritoneal sclerosis (EPS) should be 
considered as a separate subgroup, in which FWT is much more impaired than SPFT, probably 
due to interference of interstitial collagen-1 with the crystalloid osmotic gradient. This 
mechanism may also apply to other patients with reduced FWT[73]. Those with mainly impaired 
SPFT likely have a reduced hydrostatic filtration pressure due to vasculopathy. Therefore, 
measurement of peritoneal transport function should not only include netUF, but also separate 
determinations of FWT and SPFT to guide treatment options [73]. In this particular case study, 
a change in the profile transporter from high average to high was observed, and also creatinine 
clearance was <60 ml/min in the last time point. On the other hand, measurement of the effluent 
biomarker CA125 at the time of each PET showed an increase trend of this marker across time, 
indicating that there is no loss of mesothelial cell mass [74]. However, given the fact that the 
transcapillary movement of free water via aquaporin 1 accounts for 40 to 50% of total filtration 
across the PM, and that the aquaporin-1 function can be clinically estimated[67], it would be an 
important measure to improve the peritoneal function assessment. 
In addition, another enriched pathway in cluster 6 (Figure 9) is the “regulation of insulin-
like growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins 
(IGFBPs)”. The circulating IGFs are in complexes with IGFBPs, increasing the half-life of IGFs 
in the body, modulating availability of IGFs to target receptors for IGFs, and acting as signalling 
molecules independently of IGFs. Although structurally very similar to insulin, the IGFs act in a 
very different way, whereas insulin is stored in a specific gland and released when needed, the 
IGFs are stored outside of cells with soluble binding proteins [75]. The IGFBPs regulate cell 
activity by sequestering IGFs away from the type I IGF receptor, they may inhibit mitogenesis, 
differentiation, survival, and other IGF-stimulated events. However, IGFBP proteolysis can 
reverse inhibition or generate IGFBP fragments with novel bioactivity[76]. In addition, IGFBP 
interaction with cell or matrix components may concentrate IGFs near their receptor, enhancing 
IGF activity[76]. Therefore, proteolysis has pivotal role regarding this pathway, with an 
increasing trend of MMP2 and PLG proteases. Morever, the peptidome analysis and protease 
prediction may be useful to get some insights regarding the IGFBP-regulated pathways. 
Remarkably, within the enriched pathways several IGFBP (IGFBP2, -3, -4, -5 and -6) present an 
increasing trend. A study published by Lee et al.[77], showed that the IGF1/IGFBP3 ratio was 
significantly associated with inflammatory markers in incident automated peritoneal dialysis 
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(APD). Considering that chronic inflammation is implicated in cardiovascular morbidity in end 
stage renal disease (ESRD) patients, the authors suggested that the estimation of IGF system 
activity and inflammation could be of clinical relevance[77]. Moreover, increased serum IGFBP3 
in CKD patients, showed to be associated with decreased estimated glomerular filtration rate 
(eGFR) in both sexes[78]. In this case study, the patients presented a constant decrease of eGFR 
(Supplementary Table 2). Furthermore, it was demonstrated that adult dialysis patients have 
elevated IGF-I, IGFBP-1 and IGFBP-3 serum concentrations compared with subjects with 
normal renal function [79]. It was also suggested that extracorporeal losses (peritoneal and 
urinary) of IGF1 and IGFBP1 in adult continuous ambulatory PD (CAPD) do not influence their 
serum levels and that IGF1 may therefore be used as a marker of malnutrition[80]. 
Another cluster presenting an increasing trend is the Cluster 7, and some of the enriched 
pathways may be related with ischemic cardiomyopathy, which the patient has as comorbidity, 
such the muscle contraction and the hypertrophic cardiomyopathy pathways. Some of the 
myocardial markers within these pathways, such as, MYL2, MYL9, MYL3 and MYL1, are over 
expressed (Supplementary Table S4 and Table ESM 2). A study performed by Palomo-Piñón 
[76], suggested that inflammation and myocardial damage markers influence loss of residual 
renal function (RRF) in PD patients. Thus, it is interesting to observe that these myocardial 
markers that may influence the loss of RRF, can be also detected through the proteome analysis 
of the PDE, and with an increasing trend across time, suggesting aggravation of the cardiac 
condition during PD therapy, albeit not necessarily because of it. 
Another interesting enriched pathway in cluster 7 (Figure 9) is “Basigin interactions”. 
Basigin (BSG) is a transmembrane glycoprotein that belongs to the Ig superfamily and is highly 
enriched on the surface of epithelial cells. The BSG has a role in intercellular interactions 
involved in various immunologic phenomena, differentiation, and development, but the major 
function is the stimulation of synthesis of several matrix metalloproteinases (MMPs). BSG also 
induces angiogenesis via stimulation of VEGF production and interacts with a variety of other 
proteins like caveolin-1, cyclophilins, integrins and annexin II that play important roles in cell 
proliferation, energy metabolism, migration, adhesion and motion [81], [82]. In addition to the 
BSG, Caveolin-1 (CAV), integrin beta-1 (ITGB1) and neural cell adhesion molecule L1 
(L1CAM), are also within this enriched pathway supporting the aforementioned interactions, as 
can be seen in Table S4. Moreover, the “basigin interactions” pathway may be related with some 
enriched pathways already described for cluster 6, such as, “integrin3” and specially with “ECM 
matrix organization”, since BSG can stimulate synthesis of MMPs[82], [83] such as MMP2 and 
MMP15 that are found within this pathway. Higher dialysate levels of MMP2 are associated with 
PM dysfunction[84].  
In contrast, to the clusters mentioned before, cluster 8 (Figure 9) presents a decreasing 
trend, with enriched pathways such as “prefolding mediated transfer of substrate to CCT/TRiC”, 
Eduardo Araújo 
162 
 
through which unfolded actins and tubulins bound to prefoldin are transferred to CCT 
(chaperonin-containing t-complex polypeptide 1 (TCP-1 ring complex (TRiC, also called CCT)) 
via a docking mechanism[85]. This cylindrical complex contains a central cavity that binds to 
unfolded polypeptides and promote their folding in an ATP-dependent manner, sequestering the 
polypeptides from the cellular environment. Moreover, the TRiC is indispensable for cell 
survival because the folding of an essential subset of cytosolic proteins requires TRiC, and this 
function cannot be substituted by other chaperones[86], [87].Thus, CCT/TRiC plays a central 
role in maintaining cellular proteostasis and is also suggested to be involved in cell proliferation 
and tumor genesis[88]. Importantly, for the folding substrates that are dependent upon CCT for 
folding (obligate substrates), their functions are intrinsically linked to CCT folding activity. 
Therefore, if CCT fails to fold such a substrate correctly, then effects from the loss of function 
of the substrate could occur. Additionally, failure to fold substrate proteins could lead to a toxic 
gain of function where toxicity could arise from the formation of aggregates and misfolded 
proteins [89]. Following this line of thought, a decreasing trend of “prefolding mediated transfer 
of substrate to CCT/TRiC” may lead to formation of aggregates and misfolded proteins, gaining 
of toxicity and consequently PM injury. 
Other enriched pathway within this cluster is the Platelet-derived growth factor receptor 
beta (PDGFRB) pathway. The PDGFRB pathway, consists in a signalling transduction pathway 
mainly via JAK/STAT, PI3K, phospholipase Cγ (PLC-γ), or mitogen-activated protein kinase 
(MAPK) pathways, promoting gene expression and mediating the biological functions of the 
PDGF isoforms, such as proliferation, migration, and survival [90]. MAPK and STAT3, both 
important for the signalling pathways described above, are present within the enriched PDGFRB 
pathway, cluster 8 (decreasing trend). However, it is already known that high glucose activates 
the p38 MAPK pathway in cultured human peritoneal MCs (HPMCs), playing a role in the 
pathogenesis of peritoneal fibrosis[91]. Nevertheless, the decreasing trend of the enriched 
PDGFRB, may be in part explained by the fact that Simvastatin was prescribed to this patient. 
Simvastatin is a drug with cholesterol-lowering action, but has been demonstrated to be capable 
of abrogating EMT changes in glucose-treated HPMCs and PDF-stimulated PD rats [92]. 
Notwithstanding the fact that statins abrogation of EMT, was mediated, at least in part, by 
inhibiting isoprenylation of small GTPases, it is possible that statins may exhibit this favourable 
effect via other mechanisms. In particular, EMT can be induced by a variety of cytokines or 
growth factors including TGF-β, angiotensin II, fibroblast growth factor-2, epidermal growth 
factor and importantly, the platelet-derived growth factor[92]. Interestingly, the statins were not 
being prescribed at the moment of the first time point, starting only to be administrated after the 
second time point of the study, which may explain the decrease trend of the PDGFRB pathways. 
Even though our last time point was 3 months before the development of ultrafiltration 
failure, at this point the patient had already suffered a change of transporter profile from high 
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average to high and also creatinine clearance was < 60 (ml/min), being related with a worse 
prognosis. Additionally, at the proteomic level, we can pinpoint a decreasing trend for a panoply 
of metabolic pathways and protein homeostasis; and an increased trend for pathways related with 
the ECM. It is noteworthy to distinguish clusters 6 and 7 (Figure 9), in that ECM pathways in 
cluster 6 show an initial increase followed by a later stabilization, whereas cluster 7 increases 
constantly highlighting the worsening of the cardiac condition. On the other hand, for the clusters 
with decreasing trend, cluster 8 shows a tendency to stabilize, while clusters 3 and 10 decrease 
constantly, emphasizing the continuation of PD-related metabolic alterations over time. 
Nevertheless, with a three months’ gap between our last time point and the time-to-event (UFF), 
it is no possible to create a strong hypothesis about the cause of UFF, however the proteomics 
analysis does reveal a continued aggravation of the cardiac co-morbidity as well as continued 
alteration of the metabolic profile, likely compounding to the progressive deterioration of the PM 
condition. 
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Figure 9- Case study 2 (V16)- Cluster trends (time profiles) and respective bar plot with the most significant (-log10 adjusted p-value) enriched pathways for each cluster. 
Bar heights represent the adjusted p-value for each pathway. The log2 fold change represents the median of the differences between all proteins enriched for that specific 
pathway at the last time-point and the same proteins at the first time-point. Blue means decrease, and red increase. The dots represent the number of proteins identified within 
the pathway in a specific cluster, divided by the total number of proteins identified in a specific pathway for this specific patient proteome background (universe). Dashed 
line represents the threshold of the p-adjusted value (0.25). 
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Case study 3- Patient with a good response to PD therapy 
Patient P03 represents a clinical case of a man that initiated PD at age of 52 for the 
treatment of CKD due to hypertensive nephrosclerosis. This patient performed PD for more than 
3 years. The peritoneal function, effluent biomarker CA125 and other clinical aspects such as 
serum albumin and PTH were assessed for each time point without any significant clinical 
alteration, with the exception of the creatinine clearance that was <60 (ml/min) for the last time-
point. The patient is still performing PD therapy since the last time-point. More details for this 
patient can be seen in the Figure 10 and Supplementary Table S2. 
Regarding proteomic analysis, some clusters have important pathways already discussed 
above in case studies 1 and 2, such as “Post translational protein modification” and “O-linked 
glycosylation of mucins”, with an increasing trend (cluster 11, Figure 10); and “cytokine–
cytokine receptor interaction” with and increasing/stabilizing trend (cluster 14, Figure 10). 
Within cluster 7 (Figure 10), with a moderately increasing trend, the pathways enriched and 
proteins therein may suggest a well-balanced matrix homeostasis, with regards to collagen 
formation, ECM organization and degradation. In the healthy peritoneum, MCs play an important 
role in the finely regulated but continuous processes of both synthesis and degradation of matrix 
within the peritoneal cavity. However, during disease states, metabolism of the matrix proteins 
and the basal lamina can become uncontrolled, leading to fibrosis and sclerosis[93]. Excessive 
matrix proteins can result from increased synthesis or reduced degradation. This balance is 
modulated by a family of specific MMPs, that when acting together are capable of degrading all 
the constituents of the basement membrane. Therefore, the identity and regulation of these 
MMPS, as well as their specific inhibitors, known as Tissue Inhibitors of Metalloproteinases’ 
(TIMPs), are critical both in the normal turnover of the membrane constituents and during tissue 
injury that occurs during PD[93]. Therefore, in this particular case study, collagens and some 
MMPs such as, MMP2, MMP3 and MMP11 and their inhibitor, TIMP1, are found enriched 
within a steadily increasing trend over time, which may indicate a proteolytic/antiproteolytic 
balance.  
A study performed by Hirahara et al.[15], investigated the potential of MMP and TIMPs 
as indicator of peritoneal injury. The peritoneal equilibration test (PET) results correlated with 
MMP2, MMP3 and TIMP-1 levels in the drained dialysate. However, correlation coefficients of 
the peritoneal solute transport rate were higher with the level of MMP-2 than with the levels of 
MMP3 or TIMP1. Moreover, MMP-3 level was biased by gender difference or the etiology of 
ESRD. The TIMP1 level was also biased by gender difference. Furthermore, expression of 
TIMP1 is induced by various factors, such as Il-1, TNF-α and TGF-β, whereas MMP2 is usually 
expressed constitutively. Therefore, MMP3 and TIMP1 might be more easily affected by various 
factors than MMP2. In addition, correlation coefficient between MMP2 and TIMP1 levels in the 
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dialysate was higher than between MMP2 and MMP3. This may be attributed to the local 
production of MMP2 and TIMP1 in the peritoneal tissues besides transport from circulation. 
Thus, given that MMP2 is produced in the peritoneum and directly degrades peritoneal tissue, 
MMP2 levels in the drainage may reflect injury to the peritoneum, and thus be a useful marker 
of peritoneal injury or change in peritoneal solute transport rate (PSTR) [15], [94]. Concerning 
our case study, given the steadily increasing trend overtime of both MMP2 and TIMP1, we could 
speculate that this suggests a proteolytic/antiproteolytic balance. Yet, a study published by Cho 
et al. [84] showed that dialysate levels of MMP2 and TIMP1 concentration increased with longer 
PD duration. Higher MMP-2 levels were associated with faster PSTR and future peritonitis risk. 
Administration of biocompatible solutions exerted no significant effect on dialysate levels of 
MMP-2 or TIMP-1, but did counteract the increase in PSTR and the risk of peritonitis associated 
with the use of standard PD solutions [84]. Thus, it is important to understand and distinguish 
the involvement of MMP2 and TIMP1, as a part of the important and continuous balanced 
process of both synthesis and degradation of matrix within the peritoneal cavity, because 
MMP/TIMP ratio often determines the extent of ECM protein degradation and tissue 
remodelling[95]. Therefore, different levels of the MMPs and TIMPs in the PDE may reflect a 
normal PM wound healing process, or a PM dysfunction associated to high levels of MMP2 [84]. 
Interestingly, the core matrisome pathway is enriched for both cluster 7 and cluster 10 
(this latter with a decreasing trend) (Figure 10). It should be noted that proteins are not shared 
between different clusters, and proteins within clusters 7 and 10 are therefore different proteins 
despite belonging to the same enriched pathway, (Supplementary Table S5). Thus, for instance, 
whereas cluster 7 consists mainly of collagen proteins, in cluster 10 a wide variety of proteins 
are observed. The “ECM regulators” pathway enriched in cluster 14 (Figure 10), with an 
increasing/stabilizing trend, also supports the hypothesis that both synthesis and degradation of 
matrix are properly regulated, with the presence of some proteases within the pathway, such as, 
CTSF (Cathepsin F), MMP19 (Matrix Metalloproteinase-19), ADAMTS13 (a disintegrin and 
metalloproteinase with thrombospondin motifs 13); and also some inhibitors, such as SERPINF2 
(Alpha-2-antiplasmin ), SERPINA11 (Serpin A11) and ITIH3 (Inter-alpha-trypsin inhibitor 
heavy chain H3). Some of these proteases and protease inhibitors that have a pivotal role as ECM 
regulators play also a role in the complement and coagulation cascade. 
“Complement and coagulation cascades” is one of the most frequently enriched pathways 
found across our patients’ cohort (Table S5), and patient P03 is not an exception, presenting an 
increasing/stabilizing trend for this particular pathway (Cluster 14, Figure 10). Recently, 
Poppelaars et al. reviewed and summarized a comprehensive overview of the role of complement 
system in PD. The proposed mechanism of complement activation in PD patients, suggests that 
PD therapy decreases the expression of complement regulators produced and secreted by the 
MCs, such as CD55 and CD59, leading to local complement activation[96]. The cellular debris, 
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as a result of direct peritoneal damage by biocompatible PDFs, as well as antibodies against 
microorganisms could also contribute to local complement activation during PD. This activation 
results in the formation of anaphylatoxins (C3a, C5a), opsonins (C3b, iC3b), and the membrane 
attack complex (C5b-9)[96]. In this specific case study, complement factors such as C5 and C6, 
which are known to be produced and secreted by MCs [97] are found within the enriched 
“complement and coagulation cascades” pathway (cluster 14, Figure 10). Similarly, some 
anaphylatoxins, such as, C4A and C4B, both derived from proteolytic degradation of the 
complement C4, are also found, (Supplementary Table S5). In addition, the carboxypeptidase B2 
(CPB2), responsible for the cleavage of biologically active peptides such as anaphylatoxins, is 
also found within the pathway. Moreover, C8A, C8B and C8G, which are constituents of the 
membrane attack complex, are also found enriched.  
Importantly, complement activation leads to the influx of leukocytes, increases the 
production of thrombin anti-thrombin complexes and fibrin exudation on the surface of the 
injured peritoneum. In addition, complement activation during PD leads to peritoneum injury, 
can promote the progression to fibrosis after tissue injury and stimulate MCs to undergo EMT 
[96]. Interestingly, SERPINC1 (antithrombin-III) and SERPIND1 (heparin cofactor 2), are some 
thrombin inhibitors regulating coagulation cascades that are found within the pathway. In 
addition, SERPING1 (plasma protease C1 inhibitor) is also present, and plays a role in the 
regulation of complement activation, coagulation, fibrinolysis and the generation of kinins. 
Moreover, SERPINF2 (alpha-2-antiplasmin) and KNG1 (kininogen-1) are also some of the 
inhibitors found enriched in the complement and coagulation cascades pathways. On the other 
hand, PLAU (urokinase-type plasminogen activator) is responsible for the cleavage of the 
zymogen plasminogen to form the active enzyme plasmin and is also present within the pathway.  
However, this finding of complement activation was not exclusively observed for this 
particular case study, given the fact that was one of the main enriched pathways found 
dysregulated across several patients. In addition, these findings are in line with recent studies 
published by Bartosova et al.[98] and Boehm et al.[99], where the analysis of peritoneal biopsy 
and peritoneal surface proteomes in model rats of chronic PD, showed an increased complement 
activation related with glucose exposure. In summary, complement has a pivotal role in 
preventing infections, however, complement dysregulation drives pathology and measurement 
of specific PDE complement biomarkers might predict poor outcome and patient survival, as 
suggested by Zelek et al.[100]. 
Therefore, it is interesting to observe that many of these proteins and proteases identified 
and enriched for these pathways orchestrate processes related with ECM, and complement 
coagulation cascades. Thus, the use of complement biomarkers in the management of PD could 
be particularly useful, together with implementation of strategies to protect the peritoneum and 
to enable long-term PD. These strategies may pass through the use of PDF supplemented with 
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Alanyl-Glutamine-mediated membrane protection[99], or through the inhibition of membrane 
complement regulators by using of anti-C5a complementary peptides, which have been shown 
to ameliorate acute peritoneal injury by the neutralization of Crry and CD59 [101]. Even though 
these suggested approaches were not yet tested in a large patient cohort, the follow-up of some 
complement biomarkers identified in our study (namely C4A, C4B, C8A, C8B and CPB2, etc.) 
could add more information about PM condition and could be helpful to prevent PM injury 
related with complement activation.  
 
Chapter VI | In-depth analysis of peritoneal dialysis effluent Proteome and Peptidome: a longitudinal follow-up study 
 
169 
 
 
Figure 10- Case study 3- Cluster trends (time profiles) and respective bar plot with the most significant (-log10 adjusted p-value) enriched pathways for each cluster. Bar 
heights represent the adjusted p-value for each pathway. The log2 fold change represents the median of the differences between all proteins enriched for that specific pathway 
at the last time-point and the same proteins at the first time-point. Blue means decrease, and red increase. The dots represent the number of proteins identified within the 
pathway in a specific cluster, divided by the total number of proteins identified in a specific pathway for this specific patient proteome background (universe). Dashed line 
represents the threshold of the p-adjusted value (0.25). 
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4-Conclusions 
This longitudinal study presented in a PD patients’ cohort greatly increased the protein PDE 
coverage, giving new insights regarding PDE sample complexity. The analysis of longitudinal 
data performed for patients with three or more time points revealed that some of the most 
frequently significant pathways across patients are related with metabolic pathways, complement 
and coagulation cascades, ECM organization, formation of fibrin clot clotting cascade and 
integrin pathways. In addition, the need of a case by case patient treatment, and the possibility of 
identifying and following changes in the PM during long-term PD is here highlighted with three 
clinical case studies. Interestingly, our methodology used in parallel with PET measurements gave 
a holistic view of a patient´s condition, with the proteome analysis suggesting for patient case 
study 1, a diminished capacity of the peritoneal host response, with a decreasing trend of proteins 
within pathways of immune response, such as “class I MHC mediated antigen processing 
presentation” and the “Il-6, -7, pathway”. For this particular case, the proteomic analysis revealed 
that, for instance, following the IL-6 levels could have been useful for a clinical decision. On the 
other hand, for case study 2, the longitudinal analysis pinpointed a decreasing trend for protein 
homeostasis and a panoply of metabolic pathways; and an increased trend for pathways related 
with extra cellular matrix (ECM). In contrast, case study 3 represents a good patient response to 
PD therapy, in that many of the proteins and proteases identified orchestrate and regulate the 
process of both synthesis and degradation of matrix within the peritoneal cavity what it may 
reflect a normal PM wound healing process. Even though our study represents more an 
exploratory than a biomarker discovery study, it has the potential to be applied to a larger stratified 
cohort of patients and performed in a context of clinical biomarker discovery. Moreover, this 
knowledge could help to guide and develop case-by-case interventions that may improve clinical 
outcome in an individual manner, allowing to distinguish patients that respond well to therapy 
from those who are at the highest risk for PD-related complications such as, episodes of peritonitis 
or ultrafiltration failure. 
In addition, and to the best of our knowledge, this is the first analysis of PDE native peptides. 
The study of these naturally originated peptides through proteolytic activity of several proteases, 
is of great importance to shed some light on pathways at the “peptide level” that could be as much 
informative as the proteome. With this purpose, protease prediction analysis was performed to 
extend our knowledge about proteases that might be related with protein cleavage inside the 
peritoneum. Therefore, and as future prospects, the longitudinal analysis of the patients’ 
peptidome has to be performed and the protease prediction inferred by the native peptide 
information interrogated. Lastly, the protease prediction, proteome and peptidome longitudinal 
study have to be put together so as to develop a more complete picture about biological processes 
occurring within the peritoneum.  
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Thereby, this study shed some light about the main molecular pathways associated with long-
term PD, and contributed with valuable information for the proteomic and clinical research 
community in future studies using PDE samples. 
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Peritoneal membrane failure in patients with end stage renal disease submitted to PD therapy 
cannot be predicted and does not occur in every patient in the same sequence and to the same extent. 
Moreover, long-term PD leads to morphological and functional alterations in the PM, reducing the 
lifespan of this dialysis up to five years, and forcing the replacement of PD by other RRT. Although a 
number of molecules have been identified to be involved on PM alterations, a global 
peptidomics/proteomics study to identify biomarkers of PM alterations has not been fully addressed yet.  
Therefore, the present project aimed to develop longitudinal studies to unravel the evolution of 
the peptidome and proteome of the PDE with time, to identify specific molecular changes that can be 
particularly interesting for the understanding and early detection of long-term PM alterations. However, 
to achieve this goal, MS-based methods are needed to improve PDE proteome and peptidome analysis 
and to overcome some drawbacks that can arise from such a complex biological sample, and that can 
hamper the proteome and peptidome coverage. For this reason, this thesis focused also in the use of 
sample treatments and methodologies to reduce PDE sample complexity prior to MS analysis. 
Therefore, different methods of sample treatment were assessed with success as proteomics tools for 
getting insight into the PDE proteome and peptidome.  
Unravelling the PDE proteome presents some challenges in terms of sample treatment, as PDE 
is a relatively diluted solution of proteins, with their concentrations spanning several orders of 
magnitude. Therefore, the first sample treatment step that needed to be tested and optimized was the 
PDE concentration of the highly diluted samples, using centrifugal concentrators. This was investigated 
in chapter IV, and applied in all studies (chapter I-VI) as sample concentration methodology. Another 
major concern, was how to deal with the HAP present in these complex samples. In order to overcome 
this problem, two different methodologies, consisting in the DTT-based equalization, an ACN-based 
depletion, were tested on PDE samples, and applied before the 1D and 2D methodologies, and MALDI-
MS-based profiling, across the chapter III to V. 
Particularly, for the chapters III and V, chemical assisted DTT-based equalization, ACN-based 
depletion and the use of the entire proteome were tested for the first time in PDE to investigate their 
performance to obtain MALDI-TOF-MS-based profiles in order to classify two groups of patients, 
namely patients with chronic glomerulonephritis and diabetic nephropathy. In addition, samples were 
trypsinated using a fast ultrasonic approach, the pool of peptides profiled using MALDI-MS, and then 
the sets of data generated were treated with free/open-source software by principal component analysis 
and hierarchical clustering. The results suggested DTT-based equalization is a more robust methodology 
when compared with the other two, as the patients were well grouped by principal component analysis 
or by hierarchical clustering. This result suggests that successful MALDI-MS-based profiling of PDE 
samples relies in the selection of an appropriate sample treatment to compress the complexity of the 
proteome appropriately. These studies demonstrated also that the introduction of MS-based profiling 
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can provide a powerful, fast, cheap and accurate tool to classify patients with renal failure, using PDE 
samples.  
For the study presented in chapter IV, results of 1D and 2D gel electrophoresis methodologies, 
showed that the use of ACN and DTT over PDE to deplete HAP or to equalize the concentration of 
proteins, respectively, performs well and although the number and type of proteins identified are 
different, the annotation per gene ontology term reveals the same biological paths being affected for 
patients undergoing PD. Thus, the largest number of proteins lost through peritoneal dialysate belongs 
to the group of extracellular proteins involved in regulation processes through binding. However, for 
the searching of biomarkers, DTT seems to be the most promising of the two methods because it acts as 
an equalizer and it allows to interrogate more proteins in the same sample. 
On the other hand, for the study present in chapter VI, the approach used to deal with the HAP 
was with the Agilent Human 14 Multiple Affinity Removal Column (MARS14) in order to 
chromatographically remove fourteen interfering HAP. In addition, the high-resolution peptide 
isoelectric focusing (HiRIEF) technique was novelty applied to PDE samples, allowing a reproducible 
fractionation and leading to a reduction of PDE sample complexity prior to LC-ESI- Orbitrap MS/MS 
analysis. This sample treatment approach, effectively expanded the dynamic range of the analysis, and 
culminated in the result of highest proteome coverage ever achieved for this complex sample. Moreover, 
a label-free quantitative approach was applied for the first time in the analysis of PDE endogenous 
peptides, representing the most complete peptidome coverage ever achieved. In addition, the 
endogenous peptides were analyzed for the prediction of the proteases that might be the origin of these 
peptides, giving insights about the most active proteases within the peritoneal cavity. Furthermore, this 
research constitutes the first proteome-based longitudinal study of PD patient cohort. However, there is 
still work in progress concerning the data analysis. Currently this study represents more an exploratory 
than a biomarker discovery study but, nevertheless, it has the potential to be applied to a larger stratified 
cohort of patients and performed in a context of clinical biomarker discovery, allowing to distinguish 
patients that respond well to therapy from those who are at the highest risk for PD-related complications 
such as, episodes of peritonitis or ultrafiltration failure.  
In summary, the achievements and main remark conclusions of these studies are: 
 The potential of PDE as a reservoir of clinical biomarkers that may help to identify patients with a 
highest risk for PD-related complications, is directly linked to the sample treatment which is crucial to 
achieve the analysis depth needed for the early detection of peritoneal changes in patients of long-term 
PD; 
 The different methodologies to diminish/remove HAP and protein/peptides fractionation techniques 
assessed to improve the coverage of the proteome fraction have given a better notion about the PDE 
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proteome, revealing that the “plasma-like” concept used to describe this proteome is even more complex 
than previously thought. 
 Functional categorization analysis of the PDE proteome showed that the identified proteins are involved 
in different biological processes such as cellular processes and regulation. The cellular compartment of 
these proteins are mostly from extracellular, cytoplasm and nucleus, probably originated from PM cell 
detachment, and concerning the molecular function they are mainly associated with binding and 
catalytic activity; 
 The longitudinal data analysis revealed the most significant enriched pathways in the PD cohort related 
with metabolic pathways, complement and coagulation cascades, ECM organization, formation of fibrin 
clot clotting cascade and integrin pathways. This follow-up methodology used in parallel with PET 
measurements extended our knowledge about the pathophysiological biological processes occurring 
within the peritoneum; 
 Despite the inherent challenges of PDE peptidome analysis, such as the range size of the endogenous 
peptides, charge state and origin from the activity of an array of often-unknown endogenous proteolytic 
enzymes, it was possible to identify and generate a list of peptides differentially expressed over time for 
all the PD patient cohort. The list of peptides was further submitted for protease prediction analysis. 
Importantly, 73% of the proteases predicted as involved in the generation of the native peptides were 
identified and quantified in the proteome analysis. 
Regardless of the impressive amount of data generated, that will contribute with valuable 
information for the proteomic and clinical research community in future studies using PDE samples, 
some work and questions still need to be addressed. Therefore, some of the future perspective are: 
 Data mining of the peptidome data, and further link of the longitudinal analysis results obtained 
for the peptidome, with the proteome longitudinal study, in order to have a more complete 
information about the occurring processes linked to the membrane evolution. 
 Link the changes observed in the P3DEVOATLAS, with other medical variables of the 
peritoneal membrane and some candidate biomarkers present on PDE, such as, cancer antigen 
125, plasminogen activator inhibitor 1, and interleukin 6, etc.  
 Final elaboration of the P3DEVOATLAS, with biochemical and medical integration of all data 
obtained, potentially valuable for clinical diagnosis and prognosis. Elaboration of a panel of 
levels of proteins and /or peptides to be used and monitored as a quick indicator of the 
peritoneum status by selected/ multiple reaction monitoring mass spectrometry (SRM/MRM-
MS). 
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Supplementary material  
Figures 
 
Figure S1- Bar chart representation of the total number/overlap of peptides and proteins identified 
between sets.  
 
 
Figure S2-Venn diagrams comparison of the fragmentation techniques (CID and HCD-EthcD) applied 
for endogenous peptides analysis, with number of peptide sequences and parental proteins identified 
and proteases predicted. 
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Tables 
Table S1-Enriched pathways (terms) present across the patient’s cohort. Each pathway (term), has the frequency, that means the number of times that a pathway appears 
across the patients cohort, the patients that have that specific term, and the group (relation between the different pathways, if they are related the group number is the same). 
Term Frequency Patients Group 
NABA_CORE_MATRISOME 27 P02,P03,P05,P06,P07,P09,P10,P11,P23,V02,V04,V14,V15,V16,V17,V19 1 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 24 
P01,P02,P03,P05,P06,P07,P09,P10,P13,P15,P17,P18,P23,V02,V03,V07,V08,V
14,V15,V19 2 
NABA_ECM_GLYCOPROTEINS 23 P02,P03,P05,P06,P07,P09,P10,P11,P15,P18,P23,V14,V15,V16,V17,V19 1 
REACTOME_CELL_CYCLE 22 P01,P02,P03,P05,P07,P11,P17,P21,P23,V02,V03,V04,V08,V16,V17,V19 3 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 22 
P01,P02,P03,P05,P07,P09,P10,P11,P13,P17,P23,V03,V08,V14,V16,V17,V18,V
19 4 
REACTOME_GLUCOSE_METABOLISM 22 
P01,P02,P03,P05,P07,P09,P10,P13,P15,P17,P20,P23,V03,V08,V14,V15,V16,V
17,V18,V19 4 
REACTOME_CELL_CYCLE_MITOTIC 21 P01,P02,P03,P05,P07,P09,P11,P17,P23,V02,V03,V04,V08,V16,V17,V19 3 
REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 21 
P01,P02,P03,P05,P06,P07,P09,P10,P13,P17,P18,P23,V02,V03,V07,V08,V14,V
15,V19 5 
REACTOME_METABOLISM_OF_RNA 21 
P01,P02,P03,P04,P05,P07,P10,P11,P13,P18,P21,V02,V03,V04,V08,V16,V17,V
19 6 
PID_ERBB1_DOWNSTREAM_PATHWAY 21 P01,P02,P03,P05,P06,P07,P11,P20,P23,V02,V04,V08,V14,V16,V19 7 
PID_INTEGRIN1_PATHWAY 20 P01,P02,P05,P06,P07,P10,P11,P15,P18,P21,V07,V08,V14,V15,V17,V18 8 
REACTOME_METABOLISM_OF_MRNA 20 P01,P02,P03,P04,P05,P07,P10,P11,P13,P18,V02,V03,V04,V08,V16,V17,V19 6 
BIOCARTA_MPR_PATHWAY 20 
P02,P03,P04,P05,P06,P07,P09,P10,P11,P18,P20,P23,V04,V08,V14,V15,V16,V
18,V19 9 
BIOCARTA_CDC42RAC_PATHWAY 19 
P02,P03,P04,P05,P06,P07,P09,P10,P11,P18,P20,P23,V04,V08,V14,V15,V16,V
18,V19 9 
PID_PDGFRB_PATHWAY 19 P02,P03,P05,P06,P07,P09,P11,P20,P23,V08,V14,V16,V17,V19 7 
REACTOME_MRNA_PROCESSING 19 P02,P03,P04,P05,P07,P13,P17,P18,P20,P21,V03,V04,V08,V15,V19 10 
REACTOME_MRNA_SPLICING 19 P02,P03,P04,P05,P07,P13,P17,P18,P20,P21,V04,V08,V15,V19 10 
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA 19 P02,P03,P04,P05,P07,P13,P17,P18,P20,P21,V03,V04,V08,V15,V19 10 
PID_NFAT_3PATHWAY 18 P01,P02,P03,P05,P06,P07,P11,P17,P20,P23,V02,V03,V08,V16,V17,V19 11 
REACTOME_PROTEIN_FOLDING 18 P01,P02,P03,P04,P05,P07,P09,P11,P17,P21,P23,V03,V04,V08,V16,V17,V19 12 
BIOCARTA_INTRINSIC_PATHWAY 18 P01,P02,P04,P05,P07,P09,P10,P13,P18,P23,V02,V03,V07,V08,V14,V15,V19 5 
BIOCARTA_CHREBP2_PATHWAY 17 P01,P02,P03,P05,P06,P07,P17,P18,P20,P23,V02,V03,V08,V16,V17,V19 11 
REACTOME_GLYCOLYSIS 17 P01,P02,P03,P05,P07,P09,P10,P13,P15,P17,V08,V14,V16,V17,V18,V19 4 
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REACTOME_PHASE_II_CONJUGATION 17 P01,P02,P03,P07,P10,P11,P15,V04,V08,V14,V15,V16,V17,V18,V19 13 
BIOCARTA_CLASSIC_PATHWAY 17 P01,P03,P05,P06,P07,P09,P10,P15,P17,P18,P23,V07,V08,V14,V16,V19 2 
KEGG_CELL_CYCLE 17 P01,P02,P03,P05,P06,P07,P11,P17,P18,P20,V02,V03,V08,V16,V17,V19 11 
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 17 P02,P03,P05,P07,P10,P11,P17,V04,V08,V15,V16,V17,V18,V19 14 
REACTOME_METABOLISM_OF_PROTEINS 16 P01,P03,P07,P11,P13,V02,V03,V04,V08,V17,V19 6 
REACTOME_TRANSLATION 16 P01,P02,P03,P04,P05,P07,P10,P11,P13,P15,V03,V04,V08,V19 6 
KEGG_ECM_RECEPTOR_INTERACTION 16 P01,P02,P05,P06,P07,P10,P11,P15,V07,V08,V15,V16,V17 8 
REACTOME_BIOLOGICAL_OXIDATIONS 16 P01,P02,P03,P07,P10,P11,P15,V04,V07,V14,V15,V16,V18,V19 13 
REACTOME_GLUCONEOGENESIS 16 P01,P02,P03,P05,P07,P09,P10,P13,P17,P20,V03,V08,V14,V17,V18,V19 4 
NABA_ECM_REGULATORS 16 P01,P02,P03,P05,P07,P10,P11,P15,V04,V14,V15,V17,V19 15 
REACTOME_COMPLEMENT_CASCADE 16 P01,P03,P05,P06,P07,P09,P10,P15,P17,P18,V07,V08,V15,V19 2 
REACTOME_INFLUENZA_LIFE_CYCLE 16 P01,P02,P03,P04,P05,P11,P15,P18,V03,V04,V08,V16,V17,V19 6 
PID_CDC42_PATHWAY 16 P02,P03,P04,P05,P06,P07,P09,P11,P18,P20,V08,V14,V15,V16,V18,V19 9 
PID_RAC1_PATHWAY 16 P02,P03,P04,P05,P06,P07,P11,P18,P20,P23,V08,V14,V15,V16,V18,V19 9 
PID_FOXO_PATHWAY 16 P02,P03,P05,P06,P07,P11,P15,P17,P18,P20,V02,V03,V08,V16,V17,V19 11 
SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 16 P02,P03,P05,P06,P07,P11,P15,P17,P20,V02,V03,V08,V14,V16,V17,V19 11 
ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY 16 P02,P03,P05,P06,P07,P15,P17,P18,P20,V02,V03,V08,V16,V17,V18,V19 11 
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 15 P01,P02,P03,P04,P07,P10,P11,P15,P18,P20,V03,V04,V08,V19 6 
REACTOME_MITOTIC_G2_G2_M_PHASES 15 P01,P02,P03,P05,P07,P11,P17,P23,V02,V03,V08,V16 16 
KEGG_CITRATE_CYCLE_TCA_CYCLE 15 P01,P02,P03,P05,P07,P17,P23,V08,V15,V16,V17,V18,V19 17 
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 15 P01,P02,P03,P05,P07,P10,P17,P23,V08,V14,V15,V16,V17 4 
KEGG_PYRUVATE_METABOLISM 15 P01,P02,P03,P05,P07,P10,P11,P13,P23,V14,V16,V17,V18,V19 18 
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 15 P01,P02,P03,P05,P07,P11,P17,P23,V08,V14,V16,V19 19 
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE 15 P01,P02,P03,P05,P11,P23,V04,V14,V15,V16,V17,V18,V19 17 
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 15 P01,P02,P03,P05,P07,P23,V04,V14,V15,V16,V17,V18,V19 20 
REACTOME_INTRINSIC_PATHWAY 15 P01,P07,P10,P17,P18,P23,V02,V03,V07,V08,V14,V15,V16,V19 5 
REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 15 P01,P02,P03,P06,P07,P09,P17,P20,P23,V03,V14,V15,V16,V18 21 
BIOCARTA_RHO_PATHWAY 15 P02,P03,P04,P05,P07,P11,P20,P23,V04,V08,V14,V15,V16,V18,V19 9 
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 15 P02,P03,P05,P06,P07,P10,P18,V04,V08,V14,V15,V16,V18,V19 7 
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KEGG_SPLICEOSOME 15 P02,P03,P04,P05,P06,P07,P13,P17,P21,V04,V08,V15,V19 10 
PID_LKB1_PATHWAY 15 P02,P03,P05,P06,P07,P11,P17,P18,P20,V02,V03,V08,V16,V17,V19 11 
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 15 P02,P03,P05,P07,P09,P10,P13,P21,V08,V14,V16,V17,V18,V19 3 
SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES 15 P02,P03,P05,P06,P07,P15,P17,P18,P20,V02,V03,V08,V16,V17,V19 11 
REACTOME_HIV_INFECTION 14 P01,P02,P05,P11,P17,P21,P23,V02,V03,V04,V08,V16,V17 3 
REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 14 P01,P02,P03,P05,P07,P11,P17,P23,V02,V03,V08,V16 16 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLE
XES 14 P01,P02,P03,P05,P07,P11,P17,P23,V02,V03,V08,V16 16 
REACTOME_TRNA_AMINOACYLATION 14 P01,P02,P03,P05,P07,P11,P23,V08,V14,V16,V19 19 
BIOCARTA_EXTRINSIC_PATHWAY 14 P01,P02,P03,P04,P05,P07,P09,P23,V02,V03,V07,V15,V17,V19 5 
REACTOME_G1_S_TRANSITION 14 P01,P02,P03,P05,P07,P09,P21,V02,V03,V04,V08,V16,V17,V19 3 
REACTOME_MITOTIC_G1_G1_S_PHASES 14 P01,P02,P03,P05,P07,P09,P21,V02,V03,V04,V08,V16,V17,V19 3 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_
RICH_ELEMENTS 14 P01,P02,P05,P07,P09,P11,V02,V04,V08,V16,V17,V19 3 
REACTOME_METABOLISM_OF_NUCLEOTIDES 14 P02,P03,P05,P07,P15,V04,V08,V14,V15,V16,V17,V18,V19 22 
REACTOME_PEPTIDE_CHAIN_ELONGATION 14 P02,P03,P04,P05,P07,P11,P15,P18,V03,V04,V08,V14,V19 6 
PID_A6B1_A6B4_INTEGRIN_PATHWAY 13 P01,P07,P10,P17,P18,P20,V02,V08,V15,V17 23 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC 13 P01,P02,P03,P04,P23,V03,V04,V14,V16,V17,V19 12 
KEGG_PENTOSE_PHOSPHATE_PATHWAY 13 P01,P02,P03,P05,P06,P07,P13,V08,V14,V16,V17,V18,V19 4 
BIOCARTA_COMP_PATHWAY 13 P01,P03,P05,P06,P07,P10,P15,P18,P23,V07,V08,V19 2 
BIOCARTA_AMI_PATHWAY 13 P01,P02,P03,P04,P05,P06,P07,P09,P23,V02,V03,V07,V15 5 
REACTOME_COMMON_PATHWAY 13 P01,P02,P03,P04,P05,P06,P09,P23,V02,V03,V07,V15,V19 5 
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTIO
N_COMPLEX 13 P01,P02,P03,P04,P05,P07,P11,P15,P18,V04,V08,V19 6 
REACTOME_S_PHASE 13 P01,P02,P05,P07,P09,P21,V02,V03,V04,V08,V16,V17,V19 3 
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 13 P02,P03,P05,P07,P17,P23,V08,V14,V16,V19 19 
KEGG_RIBOSOME 13 P02,P03,P04,P05,P07,P11,P15,P18,V03,V04,V08,V19 6 
PID_BETA_CATENIN_NUC_PATHWAY 13 P02,P03,P05,P06,P07,P11,P15,P20,V03,V08,V16,V17,V19 11 
PID_INSULIN_GLUCOSE_PATHWAY 13 P02,P03,P05,P06,P07,P11,P17,P18,P20,V02,V16,V17,V19 11 
NABA_COLLAGENS 13 P02,P03,P05,P07,P10,P11,P21,V08,V15,V16,V17,V19 14 
PID_SYNDECAN_1_PATHWAY 13 P02,P03,P05,P07,P10,P11,P15,V03,V04,V08,V15,V16,V17 14 
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REACTOME_COLLAGEN_FORMATION 13 P02,P03,P05,P07,P10,P11,V08,V15,V16,V17,V19 14 
BIOCARTA_LECTIN_PATHWAY 12 P01,P03,P06,P07,P10,P15,P17,P23,V07,V08,V19 2 
REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATI
ON 12 P01,P02,P05,P07,P21,V02,V04,V08,V14,V16,V19 3 
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_ 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_DNA_REPLICATION 12 P01,P02,P03,P05,P07,V02,V03,V04,V08,V16,V17 3 
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 12 P01,P02,P05,P09,P21,P23,V02,V03,V04,V08,V16,V17 3 
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_SIGNALING_BY_WNT 12 P01,P02,P05,P07,P09,P21,V02,V04,V08,V16,V17,V19 3 
REACTOME_SYNTHESIS_OF_DNA 12 P01,P02,P05,P07,P09,P21,V02,V03,V04,V08,V16,V17 3 
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION 12 P03,P04,P05,P07,P11,P15,P18,V04,V08,V17,V19 6 
KEGG_OOCYTE_MEIOSIS 11 P01,P02,P03,P05,P06,P07,P18,P20,V03,V08,V19 24 
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 11 P01,P02,P07,P10,V04,V08,V16,V17,V18,V19 25 
BIOCARTA_ACTINY_PATHWAY 11 P02,P04,P05,P06,P09,P20,V04,V08,V15,V16 9 
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 11 P02,P03,P05,P06,P07,P10,P11,V14,V16,V19 26 
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING 11 P02,P03,P07,P09,P20,P23,V03,V14,V16,V19 21 
PID_MTOR_4PATHWAY 11 P02,P03,P05,P06,P07,P20,V02,V08,V16,V17,V19 11 
REACTOME_MITOTIC_M_M_G1_PHASES 11 P02,P03,P05,P07,P09,V02,V03,V04,V08,V16,V17 3 
REACTOME_REGULATION_OF_APOPTOSIS 11 P02,P05,P07,P09,P10,P21,V02,V03,V04,V08,V17 3 
REACTOME_NCAM1_INTERACTIONS 11 P02,P03,P05,P07,P10,P11,P15,V08,V15,V16,V17 14 
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_ME
MBRANE 11 P03,P04,P05,P07,P11,P15,P18,V04,V08,V19 6 
KEGG_FOCAL_ADHESION 10 P01,P02,P05,P07,P10,P21,V02,V15,V17 8 
KEGG_GLUTATHIONE_METABOLISM 10 P01,P03,P05,P07,P09,P10,V16,V17,V18,V19 13 
REACTOME_METABOLISM_OF_CARBOHYDRATES 10 P01,P05,P07,P10,P15,P17,V08,V14,V17,V18 27 
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 10 P01,P03,P06,P07,P10,P17,P23,V07,V16,V19 2 
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REACTOME_INNATE_IMMUNE_SYSTEM 10 P01,P05,P06,P09,P10,P18,V07,V08,V15,V16 28 
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION 10 P01,P02,P05,P07,P11,P21,V04,V08,V16,V19 3 
REACTOME_ER_PHAGOSOME_PATHWAY 10 P01,P02,P05,P07,P09,P21,V02,V04,V08,V17 3 
KEGG_PURINE_METABOLISM 10 P02,P03,P05,P07,P11,P15,V08,V16,V18,V19 22 
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM 10 P02,P07,P10,P11,P20,V15,V16,V17,V18,V19 27 
KEGG_SMALL_CELL_LUNG_CANCER 10 P05,P07,P09,P10,V08,V14,V15,V17,V18 23 
PID_AVB3_INTEGRIN_PATHWAY 9 P01,P02,P03,P10,P11,V08,V15,V16,V17 14 
PID_INTEGRIN3_PATHWAY 9 P01,P05,P07,P23,V03,V15,V16,V17 8 
REACTOME_APOPTOSIS 9 P01,P02,P05,P07,P17,P23,V04,V08 3 
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 9 P01,P02,P03,P05,P07,P10,P17,V04,V18 29 
KEGG_ARGININE_AND_PROLINE_METABOLISM 9 P01,P05,P07,P20,V03,V16,V17,V18,V19 30 
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 9 P01,P03,P07,P23,V04,V14,V17,V18,V19 13 
REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYL
SULFATASE_ACTIVATION 9 P01,P03,P04,P05,P07,P23,V02,V03,V17 31 
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_AP
C_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_PURINE_METABOLISM 9 P02,P05,P07,P09,P15,V08,V14,V16,V18 22 
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR 9 P02,P07,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_SULFUR_AMINO_ACID_METABOLISM 9 P02,P03,P07,P09,P10,V04,V14,V17,V18 25 
REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G 9 P02,P05,P09,P21,V02,V04,V08,V16,V17 3 
REACTOME_SIGNALING_BY_PDGF 9 P02,P03,P07,P10,P11,P15,V08,V15,V18 32 
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REACTOME_HEMOSTASIS 9 P03,P07,P09,P10,P23,V03,V14,V15 33 
REACTOME_MUSCLE_CONTRACTION 9 P10,P11,P15,P17,P21,V08,V16,V17,V19 34 
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING
_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S 8 P01,P03,P10,P11,P15,V04,V19 6 
KEGG_APOPTOSIS 8 P01,P02,P03,P05,P07,P10,P11,V18 35 
PID_TELOMERASE_PATHWAY 8 P01,P02,P05,P11,V14,V16,V17 36 
SIG_CHEMOTAXIS 8 P01,P02,P07,P11,V08,V14,V16,V19 37 
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 8 P01,P03,P07,P21,V04,V14,V17,V19 13 
BIOCARTA_FIBRINOLYSIS_PATHWAY 8 P01,P02,P07,P09,P23,V15,V16,V19 5 
REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION 8 P01,P03,P05,P07,P23,V02,V17 38 
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 8 P02,P21,V04,V14,V16,V18,V19 39 
PID_GMCSF_PATHWAY 8 P02,P05,P07,P10,P20,V14,V16 40 
SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES 8 P02,P05,P07,P11,V03,V08,V14,V19 37 
BIOCARTA_UCALPAIN_PATHWAY 8 P02,P03,P05,P18,V07,V16,V17,V19 41 
PID_CASPASE_PATHWAY 8 P02,P03,P05,P07,P23,V08,V19 42 
REACTOME_CELL_CYCLE_CHECKPOINTS 8 P02,P05,P09,P21,V02,V04,V08,V17 3 
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDO
SOMES 8 P02,P07,P21,V02,V04,V08,V16,V17 3 
REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 8 P02,P05,P07,P09,V02,V04,V08,V19 3 
REACTOME_M_G1_TRANSITION 8 P02,P05,P09,P21,V02,V04,V08,V17 3 
REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC 8 P02,P05,P21,V02,V04,V08,V16,V17 3 
PID_INTEGRIN2_PATHWAY 8 P02,P04,P05,P09,P10,V03,V07,V15 43 
PID_UPA_UPAR_PATHWAY 8 P02,P03,P04,P09,P18,P23,V15,V19 44 
KEGG_LYSOSOME 8 P02,P05,P07,P10,V04,V15,V17,V19 45 
NABA_BASEMENT_MEMBRANES 8 P07,P09,P10,P11,V14,V15,V18 23 
REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_
SYNTHESIS 7 P01,P09,P10,V03,V16,V19 27 
REACTOME_AXON_GUIDANCE 7 P01,P02,P07,V17,V18 46 
REACTOME_DEVELOPMENTAL_BIOLOGY 7 P01,P02,P07,P17,V17,V18 46 
REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 7 P01,P05,P10,V15,V16,V17,V19 27 
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE 7 P01,P02,P05,P07,V14,V16,V18 32 
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KEGG_STARCH_AND_SUCROSE_METABOLISM 7 P01,P03,P05,P07,P17,V15,V19 47 
BIOCARTA_LAIR_PATHWAY 7 P01,P06,P07,P10,V07,V15,V16 43 
PID_MYC_ACTIV_PATHWAY 7 P01,P02,P03,P05,P11,V14,V19 48 
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 7 P02,P05,P07,P18,V03,V08 49 
PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY 7 P02,P05,P07,P10,V14,V16,V18 49 
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES 7 P02,P05,P10,V02,V04,V16,V18 50 
BIOCARTA_HIVNEF_PATHWAY 7 P02,P05,P07,P11,P23,V08 42 
BIOCARTA_MCALPAIN_PATHWAY 7 P02,P05,P10,P11,V16,V17,V19 41 
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH 7 P02,P03,P07,P11,V08,V15,V17 14 
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_T
HE_43S_COMPLEX 7 P03,P05,P15,P20,V03,V16,V19 6 
REACTOME_CHYLOMICRON_MEDIATED_LIPID_TRANSPORT 7 P07,P09,P10,V14,V15,V17,V19 51 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 6 P01,P03,P18,V14,V16,V19 52 
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 6 P01,P02,P05,P10,V14,V18 53 
REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 6 P01,P03,P05,P17,V14,V19 54 
ST_INTEGRIN_SIGNALING_PATHWAY 6 P01,P02,P11,P23,V15,V16 37 
KEGG_TYROSINE_METABOLISM 6 P01,P03,V16,V17,V18 55 
REACTOME_GLUTATHIONE_CONJUGATION 6 P01,P02,P07,P09,P10,V18 13 
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT 6 P01,P05,P07,P10,P18,V07 2 
REACTOME_REGULATION_OF_COMPLEMENT_CASCADE 6 P01,P06,P10,V02,V15,V19 2 
REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS 6 P01,P03,P05,P07,V15,V19 56 
REACTOME_SIGNALING_BY_ILS 6 P01,P02,P05,P15,P20,V16 40 
REACTOME_GPCR_DOWNSTREAM_SIGNALING 6 P01,P10,P15,V04,V19 57 
REACTOME_ADAPTIVE_IMMUNE_SYSTEM 6 P02,P21,V03,V08,V16 58 
REACTOME_IMMUNE_SYSTEM 6 P02,P05,P07,V02,V07,V16 58 
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 6 P02,P05,P10,P15,P23,V19 18 
PID_AR_PATHWAY 6 P02,P05,V08,V14,V16,V19 59 
PID_CERAMIDE_PATHWAY 6 P02,P03,P05,V14,V16 60 
PID_ENDOTHELIN_PATHWAY 6 P02,P05,P07,V04,V18,V19 61 
PID_LIS1_PATHWAY 6 P02,P07,V02,V03,V17 62 
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PID_VEGFR1_2_PATHWAY 6 P02,P05,V14,V16,V17,V18 63 
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION 6 P02,P07,P21,V04,V08,V17 3 
REACTOME_SIGNALING_BY_ERBB2 6 P02,P05,P07,P09,V14,V18 32 
REACTOME_SIGNALLING_BY_NGF 6 P02,P05,P07,P10,V16,V19 32 
REACTOME_GLYCOSPHINGOLIPID_METABOLISM 6 P02,P11,P23,V04,V15,V17 64 
REACTOME_SPHINGOLIPID_METABOLISM 6 P02,P07,P11,P23,V04,V17 64 
KEGG_TRYPTOPHAN_METABOLISM 6 P05,P10,P13,P15,P20,V18 18 
KEGG_TGF_BETA_SIGNALING_PATHWAY 6 P05,P10,P17,P23,V07,V19 65 
REACTOME_STRIATED_MUSCLE_CONTRACTION 6 P06,P11,P15,P21,V16,V19 34 
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION 6 P07,P10,P23,V03,V15 33 
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ 6 P07,P10,P23,V03,V15 33 
KEGG_DILATED_CARDIOMYOPATHY 6 P07,P11,V15,V16,V17,V19 66 
REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT 6 P07,P23,V14,V15,V17,V19 51 
REACTOME_LIPOPROTEIN_METABOLISM 6 P07,P10,V14,V15,V17,V19 51 
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS 6 P10,P15,P21,P23,V04,V19 67 
REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION 5 P01,P02,P05,P07,V18 32 
BIOCARTA_MET_PATHWAY 5 P01,P02,P07,V14,V16 49 
KEGG_INSULIN_SIGNALING_PATHWAY 5 P01,P02,P05,P07,P09 68 
PID_MET_PATHWAY 5 P01,P02,P05,V14,V18 49 
REACTOME_APOPTOTIC_EXECUTION_PHASE 5 P01,P07,P17,P23,V08 42 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 5 P01,P02,P05,V17,V18 30 
KEGG_PRION_DISEASES 5 P01,P07,P10,P18,V07 69 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 5 P01,P07,P21,V17,V19 70 
REACTOME_UNFOLDED_PROTEIN_RESPONSE 5 P01,P07,P11,P17,V17 71 
BIOCARTA_INTEGRIN_PATHWAY 5 P02,P05,P07,V03,V16 41 
KEGG_PROPANOATE_METABOLISM 5 P02,P05,P07,P15,V18 18 
KEGG_PYRIMIDINE_METABOLISM 5 P02,P03,P05,P07,V19 22 
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION 5 P02,P05,P10,V03,V19 24 
REACTOME_SIGNALING_BY_EGFR_IN_CANCER 5 P02,P05,V14,V16,V18 32 
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REACTOME_SYNTHESIS_AND_INTERCONVERSION_OF_NUCLEOTIDE_DI_AND_TRIP
HOSPHATES 5 P02,P03,P05,P07,V17 72 
KEGG_CARDIAC_MUSCLE_CONTRACTION 5 P02,P11,P23,V16,V19 73 
NABA_ECM_AFFILIATED 5 P02,P11,P15,V15 74 
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES 5 P03,P05,P07,V03,V14 75 
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 5 P05,P06,V14,V16,V19 76 
PID_INTEGRIN_A4B1_PATHWAY 5 P05,P07,P10,V16,V17 77 
NABA_PROTEOGLYCANS 5 P05,P17,V04,V14,V17 78 
REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_B
Y_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS 5 P06,P10,P21,P23,V16 79 
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 5 P07,P09,P15,P23,V15 8 
KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM 5 P11,V15,V16,V17,V19 66 
KEGG_CELL_ADHESION_MOLECULES_CAMS 4 P01,P06,P07,P23 80 
KEGG_PATHWAYS_IN_CANCER 4 P01,P09,P23 81 
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 4 P01,P02,P06,V18 82 
KEGG_ERBB_SIGNALING_PATHWAY 4 P01,P02,V14,V18 32 
KEGG_O_GLYCAN_BIOSYNTHESIS 4 P01,P02,P07,V19 56 
KEGG_N_GLYCAN_BIOSYNTHESIS 4 P01,P17,P23,V19 38 
BIOCARTA_BIOPEPTIDES_PATHWAY 4 P01,P02,P05,P23 40 
PID_IL6_7_PATHWAY 4 P01,P05,P07,V15 83 
PID_REG_GR_PATHWAY 4 P01,P02,P06,P20 84 
REACTOME_DIABETES_PATHWAYS 4 P01,P17,P23,V17 71 
REACTOME_GPCR_LIGAND_BINDING 4 P01,P10,P15,V19 57 
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION 4 P02,P09,V03,V16 85 
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 4 P02,P05,P15,V19 86 
KEGG_VIBRIO_CHOLERAE_INFECTION 4 P02,P17,P18,V14 85 
REACTOME_INTERFERON_SIGNALING 4 P02,P05,P10,V02 50 
REACTOME_SIGNALING_BY_RHO_GTPASES 4 P02,P07,V16,V19 87 
REACTOME_SIGNALING_BY_SCF_KIT 4 P02,P05,P07,V16 40 
KEGG_ADHERENS_JUNCTION 4 P02,P05,V14,V16 88 
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KEGG_COLORECTAL_CANCER 4 P02,P05,V15,V19 81 
KEGG_GALACTOSE_METABOLISM 4 P02,P05,P10,V14 47 
PID_FAK_PATHWAY 4 P02,P05,P07,V17 49 
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE 4 P02,P05,P10,P17 28 
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNA
LING_REPERTOIRE 4 P02,P05,P10,P17 28 
REACTOME_RECYCLING_PATHWAY_OF_L1 4 P02,P05,V02,V19 82 
REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON
_TLR7_8_OR_9_ACTIVATION 4 P02,P05,P10,P17 28 
REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX 4 P02,P03,P17,V19 89 
REACTOME_HDL_MEDIATED_LIPID_TRANSPORT 4 P02,P07,P18,V14 51 
REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS 4 P02,P07,P11,V18 90 
REACTOME_PHOSPHOLIPID_METABOLISM 4 P02,P11,P23,V16 64 
REACTOME_AMYLOIDS 4 P02,P07,P09,V03 91 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 4 P04,P07,P23,V17 71 
BIOCARTA_NFAT_PATHWAY 4 P05,P23,V18,V19 92 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR 4 P05,P07,V14,V18 32 
PID_TGFBR_PATHWAY 4 P07,P11,V04,V14 65 
REACTOME_L1CAM_INTERACTIONS 4 P07,P17,V02,V15 82 
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM 4 P10,V15,V17,V19 27 
REACTOME_SIGNALING_BY_GPCR 4 P10,P15,V18,V19 57 
KEGG_PANCREATIC_CANCER 3 P01,P23,V18 81 
NABA_SECRETED_FACTORS 3 P01,V08,V19 52 
PID_SHP2_PATHWAY 3 P01,P09,V19 93 
BIOCARTA_AGR_PATHWAY 3 P01,V15,V17 41 
KEGG_LEISHMANIA_INFECTION 3 P01,V15,V16 94 
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY 3 P01,P02,V17 95 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 3 P01,P05,P07 28 
KEGG_WNT_SIGNALING_PATHWAY 3 P01,V15,V17 96 
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOA
DING_OF_CLASS_I_MHC 3 P01,P07,V14 70 
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KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS 3 P02,P05,V19 35 
KEGG_PARKINSONS_DISEASE 3 P02,P05,V18 20 
PID_IL12_2PATHWAY 3 P02,V04,V08 97 
PID_IL2_1PATHWAY 3 P02,P05 40 
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM 3 P02,P05,P20 50 
REACTOME_IRON_UPTAKE_AND_TRANSPORT 3 P02,P05,V16 85 
ST_B_CELL_ANTIGEN_RECEPTOR 3 P02,P05,V14 53 
KEGG_DRUG_METABOLISM_OTHER_ENZYMES 3 P02,P05,V15 98 
KEGG_HUNTINGTONS_DISEASE 3 P02,V16,V19 20 
KEGG_LYSINE_DEGRADATION 3 P02,P10,V17 18 
KEGG_RENAL_CELL_CARCINOMA 3 P02,P10,V14 49 
PID_THROMBIN_PAR1_PATHWAY 3 P02,V15,V19 61 
REACTOME_ACTIVATED_TLR4_SIGNALLING 3 P02,P05,P17 28 
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS 3 P02,P04,V19 99 
REACTOME_MEMBRANE_TRAFFICKING 3 P02,V14,V19 99 
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING 3 P02,P05,P10 28 
REACTOME_SEMAPHORIN_INTERACTIONS 3 P03,P07,V15 100 
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM 3 P03,P05,V19 67 
KEGG_GLIOMA 3 P03,V18,V19 101 
KEGG_VIRAL_MYOCARDITIS 3 P04,P10,V16 102 
PID_NECTIN_PATHWAY 3 P04,P11,V19 103 
BIOCARTA_MAPK_PATHWAY 3 P05,P10,V14 104 
KEGG_BLADDER_CANCER 3 P05,P17,P23 105 
KEGG_GAP_JUNCTION 3 P05,V14,V19 24 
KEGG_MELANOGENESIS 3 P05,P23,V16 24 
KEGG_P53_SIGNALING_PATHWAY 3 P05,P21,V14 106 
PID_RHOA_PATHWAY 3 P05,V08,V14 107 
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 3 P05,V16,V17 108 
PID_AP1_PATHWAY 3 P05,V04,V14 109 
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KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION 3 P07,P23,V03 110 
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS 3 P07,P10,P15 67 
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 3 P10,V14,V16 53 
REACTOME_ASPARAGINE_N_LINKED_GLYCOSYLATION 3 P10,P17,P23 38 
KEGG_TIGHT_JUNCTION 3 P10,V04,V19 86 
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING 3 P10,P18,V19 100 
REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAP
SE 3 P10,P13,V19 100 
KEGG_AXON_GUIDANCE 3 P10,P17,V19 46 
KEGG_HEMATOPOIETIC_CELL_LINEAGE 3 P15,V08,V15 111 
PID_NCADHERIN_PATHWAY 3 V08,V15,V19 103 
PID_TCPTP_PATHWAY 2 P01,V19 112 
REACTOME_HS_GAG_BIOSYNTHESIS 2 P01,P07 27 
REACTOME_HS_GAG_DEGRADATION 2 P01,V17 27 
PID_CXCR4_PATHWAY 2 P01,P02 113 
PID_INSULIN_PATHWAY 2 P01,V18 68 
PID_RET_PATHWAY 2 P01,P02 49 
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 2 P01,V16 114 
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 2 P01,P03 54 
KEGG_ALZHEIMERS_DISEASE 2 P01,P05 20 
REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS 2 P01,P06 115 
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 2 P02,P05 53 
PID_BCR_5PATHWAY 2 P02,P05 53 
PID_IL4_2PATHWAY 2 P02,P09 116 
PID_KIT_PATHWAY 2 P02,P05 40 
SIG_BCR_SIGNALING_PATHWAY 2 P02,P05 53 
KEGG_BETA_ALANINE_METABOLISM 2 P02,P15 18 
PID_ILK_PATHWAY 2 P02,V02 117 
PID_NETRIN_PATHWAY 2 P02,P05 49 
PID_P38_MK2_PATHWAY 2 P02,V08 11 
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REACTOME_ADVANCED_GLYCOSYLATION_ENDPRODUCT_RECEPTOR_SIGNALING 2 P02,V18 118 
REACTOME_NEURONAL_SYSTEM 2 P02,V04 119 
KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT 2 P02,P23 120 
PID_P75_NTR_PATHWAY 2 P03,V03 121 
PID_HNF3A_PATHWAY 2 P04,P10 122 
BIOCARTA_ECM_PATHWAY 2 P05,V15 41 
KEGG_LONG_TERM_POTENTIATION 2 P05,V14 24 
KEGG_VEGF_SIGNALING_PATHWAY 2 P05,V04 53 
PID_CMYB_PATHWAY 2 P05,V18 123 
PID_P73PATHWAY 2 P05,V15 124 
PID_SYNDECAN_2_PATHWAY 2 P05,P07 125 
REACTOME_DNA_REPAIR 2 P05,V16 126 
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK 2 P05,P10 57 
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 2 P05,V03 121 
REACTOME_SIGNALING_BY_ERBB4 2 P05,V18 32 
REACTOME_SIGNALING_BY_FGFR 2 P05,V18 32 
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 2 P05,P07 32 
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS 2 P05,P10 57 
REACTOME_TOLL_RECEPTOR_CASCADES 2 P05,P07 28 
ST_ADRENERGIC 2 P05,V18 127 
PID_DELTA_NP63_PATHWAY 2 P05,V19 128 
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AN
D_A_NON_LYMPHOID_CELL 2 P06,P07 80 
REACTOME_REGULATION_OF_INSULIN_SECRETION 2 P07,V19 67 
KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC 2 P07,P11 66 
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS 2 P07,V02 129 
REACTOME_CELL_CELL_COMMUNICATION 2 P07,V18 129 
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 2 P07,V02 129 
REACTOME_CELL_JUNCTION_ORGANIZATION 2 P07,V02 129 
KEGG_PROSTATE_CANCER 2 P09,V16 101 
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REACTOME_SIGNALING_BY_ROBO_RECEPTOR 2 P10,V18 130 
REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS 2 P10,V19 27 
WNT_SIGNALING 2 P11,V18 96 
PID_AVB3_OPN_PATHWAY 2 P15,P23 131 
REACTOME_SIGNALING_BY_NOTCH 2 P18,V04 132 
KEGG_ENDOCYTOSIS 2 P21,V04 133 
PID_ERA_GENOMIC_PATHWAY 2 P21,P23 122 
PID_AJDISS_2PATHWAY 2 P23,V19 88 
PID_FRA_PATHWAY 2 P23,V18 109 
REACTOME_KERATAN_SULFATE_DEGRADATION 2 V04,V17 78 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE 2 V15,V16 17 
REACTOME_KERATAN_SULFATE_KERATIN_METABOLISM 2 V17,V19 78 
PID_LYMPH_ANGIOGENESIS_PATHWAY 1 P01 134 
REACTOME_PI3K_CASCADE 1 P01 54 
REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS 1 P01 57 
BIOCARTA_P38MAPK_PATHWAY 1 P02 104 
KEGG_CHEMOKINE_SIGNALING_PATHWAY 1 P02 113 
PID_LYSOPHOSPHOLIPID_PATHWAY 1 P02 61 
REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING 1 P02 40 
KEGG_CHRONIC_MYELOID_LEUKEMIA 1 P02 81 
KEGG_FATTY_ACID_METABOLISM 1 P02 18 
PID_ERBB2_ERBB3_PATHWAY 1 P02 53 
PID_TRKR_PATHWAY 1 P02 49 
REACTOME_HIV_LIFE_CYCLE 1 P02 126 
REACTOME_LYSOSOME_VESICLE_BIOGENESIS 1 P02 99 
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_TRIC 1 P04 12 
BIOCARTA_SALMONELLA_PATHWAY 1 P05 9 
KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 1 P05 135 
PID_FCER1_PATHWAY 1 P05 53 
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PID_HIF1_TFPATHWAY 1 P05 136 
PID_IFNG_PATHWAY 1 P05 40 
REACTOME_FRS2_MEDIATED_CASCADE 1 P05 54 
REACTOME_NEPHRIN_INTERACTIONS 1 P05 137 
PID_ATF2_PATHWAY 1 P07 138 
REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL 1 P07 139 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_P
LATELET_PRODUCTION 1 P09 140 
PID_PTP1B_PATHWAY 1 P09 112 
KEGG_PPAR_SIGNALING_PATHWAY 1 P10 90 
PID_P53_DOWNSTREAM_PATHWAY 1 P10 106 
PID_ECADHERIN_NASCENT_AJ_PATHWAY 1 P11 103 
REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION 1 P11 90 
REACTOME_SMOOTH_MUSCLE_CONTRACTION 1 P17 34 
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 1 P23 141 
REACTOME_TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION 1 P23 38 
BIOCARTA_PROTEASOME_PATHWAY 1 V02 3 
KEGG_PROTEASOME 1 V02 3 
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION 1 V03 58 
BIOCARTA_EIF4_PATHWAY 1 V04 114 
KEGG_MAPK_SIGNALING_PATHWAY 1 V04 142 
PID_NOTCH_PATHWAY 1 V04 132 
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS 1 V08 42 
KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM 1 V14 143 
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLIS
M 1 V14 90 
KEGG_GLYCEROLIPID_METABOLISM 1 V14 144 
PID_ARF6_TRAFFICKING_PATHWAY 1 V15 145 
REACTOME_OTHER_SEMAPHORIN_INTERACTIONS 1 V15 146 
KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION 1 V16 101 
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PID_VEGFR1_PATHWAY 1 V16 63 
REACTOME_EGFR_DOWNREGULATION 1 V16 32 
REACTOME_TCR_SIGNALING 1 V16 95 
PID_GLYPICAN_1PATHWAY 1 V16 147 
PID_EPHA_FWDPATHWAY 1 V16 148 
REACTOME_BASIGIN_INTERACTIONS 1 V16 139 
KEGG_OTHER_GLYCAN_DEGRADATION 1 V17 149 
PID_SYNDECAN_4_PATHWAY 1 V17 125 
PID_TXA2PATHWAY 1 V17 61 
KEGG_ARACHIDONIC_ACID_METABOLISM 1 V18 150 
KEGG_MELANOMA 1 V18 101 
ST_FAS_SIGNALING_PATHWAY 1 V18 151 
PID_PI3KCI_AKT_PATHWAY 1 V19 11 
REACTOME_KERATAN_SULFATE_BIOSYNTHESIS 1 V19 78 
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING 1 V19 99 
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Table S2-Clinical parameters assess during the PET for the longitudinal case study patients. The values highlighted are out of the reference range values for that specific 
parameter (described at the bottom of the table). 
Patient PD duration D/Pcreat_ 
240min 
  
Profile 
Transporter 
Peritoneal 
UF 
Diuresis 
Creatinine 
clearance  
Kt/v 
Serum 
albumin  
CA 125 PTH  eGFR  
Diabetes 
Total episodes of 
 peritonitis until 
PET 
Incidence 
  (months) (years) (mL/4h)   (mL/min)   (mg/dL) (kU/L) (pg/mL) (mL/min)   (number/year) 
P01 
1 0,1 0,9 H 500 900 144,07 2,53 3,5 38,9 402 8,18 0 0 0,000 
6 0,5 0,69 H.A. 835 1480 104,51 2,15 3,6 42,8 238 8 0 0 0,000 
13 1,0 0,928 H. 600 1520 144,58 2,17 3,2 38,8 234 11,68 0 0 0,000 
25 2,1 0,67 H.A. 760 1070 110 2,07 3,5 45,1 125 8,39 0 1 0,472 
39 3,3 0,74 H.A. 350 990 107,39 1,9 3,7 39,9 422 7,88 0   0,306 
P03 
1 0,1 0,76 H.A. 700 460 66,39 2,05 3,9 6 151 1,73 0 0 0,000 
7 0,5 0,81 H. 620 1180 79,31 2,3 3,7 26,2 194 4,53 0 0 0,000 
19 1,6 0,71 H.A. 425 1500 79,05 2,25 4,3 28,9 466 6,16 0 0 0,000 
31 2,6 0,59 L.A. 570 1500 83,84 2,32 4,4 37,4 504,6 6,89 0 0 0,000 
45 3,7 0,6 L.A. 940 950 55,8 1,7 3,9 31,3 463,4 3,81 0 0 0,000 
V16 
14 1,1 0,73 H.A. 915 2260 71,39 2,1 3,7 6 1029 5,22 0 1 0,878 
27 2,3 0,78 H.A. 486 2000 68,39 1,95 3,8 12,7 696 3,63 0 1 0,443 
40 3,3 0,84 H. 919 2000 56,69 1,94 3,7 23,8 46 2 0 1 0,301 
Reference values >400 *N/A >60 1,7 >3,0  **N/A <800     
      * the higher the better   ** descending profile may indicate loss of MCs lining layer  
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Table S3- Patient P01-Enriched pathways for each cluster with the respective Gene Ratio, Background ratio (Bg Ratio), p-value, p-adjust, q-value, Gene Id and counts 
(number of genes (proteins) per pathways). The highlighted pathways were the one selected for the bar plots graphs. 
Cluster Description GeneRatio BgRatio pvalue p.adjust qvalue geneID Count 
1 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 9/53 54/1513 0,00006 0,01510 0,01364 
KITLG/CNTFR/PDGFRB/IFNAR1/INHBB/CSF1/TGFBR2/VEGFA/CCL
25 9 
1 REACTOME_HS_GAG_BIOSYNTHESIS 4/53 10/1513 0,00024 0,02898 0,02618 SDC1/NDST1/GPC1/AGRN 4 
1 PID_INTEGRIN3_PATHWAY 6/53 31/1513 0,00052 0,04165 0,03763 SDC1/PDGFRB/TGFBR2/VEGFA/COL4A1/CYR61 6 
1 PID_TCPTP_PATHWAY 4/53 17/1513 0,00228 0,13673 0,12353 LMAN1/PDGFRB/CSF1/VEGFA 4 
1 REACTOME_AXON_GUIDANCE 9/53 91/1513 0,00340 0,16297 0,14725 CLTA/GPC1/NCK1/MAP2K1/PLXND1/HFE2/AP2A1/COL4A1/AGRN 9 
1 REACTOME_HS_GAG_DEGRADATION 3/53 10/1513 0,00409 0,16378 0,14798 SDC1/GPC1/AGRN 3 
1 KEGG_PANCREATIC_CANCER 3/53 11/1513 0,00549 0,17251 0,15586 MAP2K1/TGFBR2/VEGFA 3 
1 REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 4/53 22/1513 0,00615 0,17251 0,15586 SDC1/NDST1/GPC1/AGRN 4 
1 KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 3/53 12/1513 0,00714 0,17251 0,15586 CD8A/NCK1/MAP2K1 3 
1 PID_AVB3_INTEGRIN_PATHWAY 5/53 36/1513 0,00719 0,17251 0,15586 SDC1/CSF1/TGFBR2/VEGFA/COL4A1 5 
1 REACTOME_DEVELOPMENTAL_BIOLOGY 9/53 104/1513 0,00835 0,18213 0,16456 CLTA/GPC1/NCK1/MAP2K1/PLXND1/HFE2/AP2A1/COL4A1/AGRN 9 
1 KEGG_CELL_ADHESION_MOLECULES_CAMS 6/53 54/1513 0,00981 0,19274 0,17414 SDC1/CD8A/VCAM1/SIGLEC1/CD99/PDCD1LG2 6 
1 
REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIR
ED_FOR_GAG_SYNTHESIS 3/53 14/1513 0,01124 0,19274 0,17414 SDC1/GPC1/AGRN 3 
1 REACTOME_SIGNAL_TRANSDUCTION_BY_L1 3/53 14/1513 0,01124 0,19274 0,17414 CLTA/MAP2K1/AP2A1 3 
1 KEGG_PATHWAYS_IN_CANCER 6/53 58/1513 0,01380 0,21840 0,19733 KITLG/PDGFRB/MAP2K1/TGFBR2/VEGFA/COL4A1 6 
1 NABA_SECRETED_FACTORS 7/53 76/1513 0,01456 0,21840 0,19733 KITLG/SCUBE3/INHBB/CSF1/VEGFA/CCL25/CRLF1 7 
1 PID_SHP2_PATHWAY 3/53 16/1513 0,01646 0,23239 0,20997 PDGFRB/MAP2K1/VEGFA 3 
1 REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION 3/53 17/1513 0,01950 0,24632 0,22255 PDGFRB/NCK1/MAP2K1 3 
1 
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_ME
MBRANE 3/53 17/1513 0,01950 0,24632 0,22255 CLTA/MAP2K1/AP2A1 3 
3 REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS 5/87 15/1513 0,00107 0,24924 0,24924 B3GNT7/GALNT10/GCNT1/MUC16/B3GNT9 5 
4 REACTOME_CELL_CYCLE 11/91 35/1513 0,00000 0,00068 0,00058 
LMNB1/PSMC2/NPM1/YWHAG/NUDC/PPP2R2A/HSP90AA1/PCNA/P
SME1/SKP1/TUBB4B 11 
4 BIOCARTA_AMI_PATHWAY 7/91 14/1513 0,00001 0,00068 0,00058 PROC/FGB/AHSP/F2/FGG/PROS1/F10 7 
4 PID_MYC_ACTIV_PATHWAY 8/91 23/1513 0,00003 0,00170 0,00144 EIF2S1/CAD/NPM1/HSPA4/NCL/HSP90AA1/HSPD1/PTMA 8 
4 REACTOME_UNFOLDED_PROTEIN_RESPONSE 7/91 19/1513 0,00006 0,00231 0,00196 EIF2S1/IGFBP1/CALR/SEC31A/HDGF/KHSRP/HSP90B1 7 
4 REACTOME_METABOLISM_OF_PROTEINS 17/91 104/1513 0,00008 0,00251 0,00213 
F9/PROC/EEF1B2/EIF2S1/PDIA3/F2/PABPC1/TCP1/CALR/EEF1A1/HS
PD1/SEC31A/PFDN4/PROS1/TUBB4B/F10/RPS3 17 
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4 REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 7/91 24/1513 0,00034 0,00989 0,00839 F9/PROC/FGB/F2/FGG/PROS1/F10 7 
4 PID_IL6_7_PATHWAY 5/91 13/1513 0,00062 0,01510 0,01280 IL6/STAT3/FGG/STAT1/HSP90B1 5 
4 
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRE
SENTATION 8/91 41/1513 0,00232 0,04532 0,03843 UBE2M/UBE2K/PSMC2/PDIA3/CALR/SEC31A/PSME1/SKP1 8 
4 BIOCARTA_FIBRINOLYSIS_PATHWAY 4/91 11/1513 0,00292 0,05344 0,04531 SERPINB2/FGB/F2/FGG 4 
4 BIOCARTA_EXTRINSIC_PATHWAY 6/91 10/1513 0,00001 0,00068 0,00058 PROC/FGB/F2/FGG/PROS1/F10 6 
4 REACTOME_COMMON_PATHWAY 6/91 11/1513 0,00001 0,00107 0,00091 PROC/FGB/F2/FGG/PROS1/F10 6 
4 REACTOME_CELL_CYCLE_MITOTIC 9/91 30/1513 0,00003 0,00170 0,00144 
PSMC2/YWHAG/NUDC/PPP2R2A/HSP90AA1/PCNA/PSME1/SKP1/TU
BB4B 9 
4 BIOCARTA_INTRINSIC_PATHWAY 7/91 18/1513 0,00004 0,00175 0,00149 F9/PROC/FGB/F2/FGG/PROS1/F10 7 
4 
REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATI
ON_AND_ARYLSULFATASE_ACTIVATION 5/91 12/1513 0,00040 0,01064 0,00902 F9/PROC/F2/PROS1/F10 5 
4 REACTOME_DIABETES_PATHWAYS 8/91 39/1513 0,00165 0,03722 0,03155 EIF2S1/IGFBP1/F2/CALR/SEC31A/HDGF/KHSRP/HSP90B1 8 
4 REACTOME_MITOTIC_G1_G1_S_PHASES 5/91 16/1513 0,00182 0,03801 0,03222 PSMC2/PPP2R2A/PCNA/PSME1/SKP1 5 
4 REACTOME_S_PHASE 4/91 14/1513 0,00770 0,13266 0,11248 PSMC2/PCNA/PSME1/SKP1 4 
4 KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 5/91 23/1513 0,01000 0,15452 0,13101 PDIA3/HSPA4/CALR/HSP90AA1/PSME1 5 
4 REACTOME_G1_S_TRANSITION 4/91 15/1513 0,01002 0,15452 0,13101 PSMC2/PCNA/PSME1/SKP1 4 
4 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOM
E_DEGRADATION 5/91 24/1513 0,01204 0,17637 0,14954 UBE2M/UBE2K/PSMC2/PSME1/SKP1 5 
4 REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION 8/91 54/1513 0,01321 0,18438 0,15632 F9/PROC/PDIA3/F2/CALR/SEC31A/PROS1/F10 8 
4 REACTOME_INFLUENZA_LIFE_CYCLE 5/91 25/1513 0,01435 0,18863 0,15993 CLTC/CALR/HSP90AA1/RAN/RPS3 5 
4 REACTOME_METABOLISM_OF_MRNA 7/91 46/1513 0,01757 0,18863 0,15993 PSMC2/PABPC1/PPP2R2A/RBM8A/PSME1/KHSRP/RPS3 7 
4 REACTOME_METABOLISM_OF_RNA 7/91 46/1513 0,01757 0,18863 0,15993 PSMC2/PABPC1/PPP2R2A/RBM8A/PSME1/KHSRP/RPS3 7 
4 BIOCARTA_BIOPEPTIDES_PATHWAY 3/91 10/1513 0,01855 0,18863 0,15993 STAT3/F2/STAT1 3 
4 KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 3/91 10/1513 0,01855 0,18863 0,15993 IL6/STAT1/SPP1 3 
4 PID_TELOMERASE_PATHWAY 3/91 10/1513 0,01855 0,18863 0,15993 NCL/HNRNPC/HSP90AA1 3 
4 REACTOME_DNA_REPLICATION 4/91 18/1513 0,01955 0,18863 0,15993 PSMC2/NUDC/PCNA/PSME1 4 
4 REACTOME_ER_PHAGOSOME_PATHWAY 4/91 18/1513 0,01955 0,18863 0,15993 PSMC2/PDIA3/CALR/PSME1 4 
4 REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 5/91 27/1513 0,01982 0,18863 0,15993 PSMC2/NPM1/PSME1/SKP1/RAN 5 
4 KEGG_PATHWAYS_IN_CANCER 8/91 58/1513 0,01996 0,18863 0,15993 LAMC1/IL6/STAT3/LAMB2/HSP90AA1/STAT1/FGFR1/HSP90B1 8 
4 KEGG_CELL_CYCLE 3/91 11/1513 0,02442 0,21041 0,17839 YWHAG/PCNA/SKP1 3 
4 KEGG_WNT_SIGNALING_PATHWAY 3/91 11/1513 0,02442 0,21041 0,17839 SFRP2/CTNNBIP1/SKP1 3 
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4 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_T
O_CCT_TRIC 3/91 11/1513 0,02442 0,21041 0,17839 TCP1/PFDN4/TUBB4B 3 
4 PID_REG_GR_PATHWAY 4/91 20/1513 0,02823 0,21566 0,18285 IL6/HSP90AA1/FGG/STAT1 4 
4 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_TH
AT_BIND_AU_RICH_ELEMENTS 4/91 20/1513 0,02823 0,21566 0,18285 PSMC2/PABPC1/PSME1/KHSRP 4 
4 REACTOME_HIV_INFECTION 5/91 30/1513 0,03034 0,21566 0,18285 PSMC2/NPM1/PSME1/SKP1/RAN 5 
4 
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_
PEPTIDE_LOADING_OF_CLASS_I_MHC 3/91 12/1513 0,03116 0,21566 0,18285 PDIA3/CALR/SEC31A 3 
4 
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_E
XON_JUNCTION_COMPLEX 4/91 21/1513 0,03331 0,21566 0,18285 PABPC1/PPP2R2A/RBM8A/RPS3 4 
4 REACTOME_SIGNALING_BY_ILS 4/91 21/1513 0,03331 0,21566 0,18285 IL6/STAT3/STAT1/SKP1 4 
4 PID_INTEGRIN3_PATHWAY 5/91 31/1513 0,03451 0,21566 0,18285 LAMC1/FGB/FGG/SDC4/SPP1 5 
4 REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRAN
SITION_ 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_REC
EPTOR_BCR 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 3/91 13/1513 0,03878 0,21566 0,18285 YWHAG/HSP90AA1/TUBB4B 3 
4 REACTOME_MITOTIC_G2_G2_M_PHASES 3/91 13/1513 0,03878 0,21566 0,18285 YWHAG/HSP90AA1/TUBB4B 3 
4 REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 3/91 13/1513 0,03878 0,21566 0,18285 FGB/F2/FGG 3 
4 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS
_AND_COMPLEXES 3/91 13/1513 0,03878 0,21566 0,18285 YWHAG/HSP90AA1/TUBB4B 3 
4 REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PSME1/SKP1 3 
4 REACTOME_SYNTHESIS_OF_DNA 3/91 13/1513 0,03878 0,21566 0,18285 PSMC2/PCNA/PSME1 3 
4 REACTOME_TRANSLATION 5/91 32/1513 0,03901 0,21566 0,18285 EEF1B2/EIF2S1/PABPC1/EEF1A1/RPS3 5 
4 PID_A6B1_A6B4_INTEGRIN_PATHWAY 4/91 23/1513 0,04497 0,24293 0,20597 LAMC1/YWHAG/LAMB2/CD9 4 
4 
REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIR
ED_FOR_GAG_SYNTHESIS 3/91 14/1513 0,04726 0,24293 0,20597 DCN/BGN/SDC4 3 
4 REACTOME_INTRINSIC_PATHWAY 3/91 14/1513 0,04726 0,24293 0,20597 F9/F2/F10 3 
4 REACTOME_SIGNALING_BY_WNT 3/91 14/1513 0,04726 0,24293 0,20597 PSMC2/PSME1/SKP1 3 
5 PID_ERBB1_DOWNSTREAM_PATHWAY 6/60 30/1513 0,00085 0,20734 0,19939 PPP2R1A/SFN/ARPC5/ARPC1B/YWHAZ/PPP5C 6 
8 REACTOME_GPCR_LIGAND_BINDING 15/219 40/1513 0,00022 0,06851 0,06851 
OXT/NPY/RAMP3/APP/PPBP/INSL5/PENK/GAST/GIP/FZD6/PYY/CG
A/GCG/MLN/C3AR1 15 
8 REACTOME_GPCR_DOWNSTREAM_SIGNALING 14/219 43/1513 0,00186 0,20174 0,20174 
OXT/NPY/RAMP3/APP/PPBP/INSL5/PENK/GAST/GIP/PYY/CGA/GC
G/MLN/C3AR1 14 
8 REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS 11/219 30/1513 0,00197 0,20174 0,20174 OXT/NPY/APP/PPBP/INSL5/PENK/GAST/PYY/CGA/MLN/C3AR1 11 
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10 PID_INSULIN_PATHWAY 4/35 10/1513 0,00005 0,00705 0,00617 CRK/INSR/EIF4EBP1/PTPN11 4 
10 REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 3/35 16/1513 0,00517 0,20565 0,17992 CRK/INSR/EIF4EBP1 3 
10 REACTOME_TRANSLATION 4/35 32/1513 0,00545 0,20565 0,17992 EIF4H/RPL4/EIF4EBP1/EIF3A 4 
10 REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 3/35 17/1513 0,00618 0,20565 0,17992 CRK/INSR/EIF4EBP1 3 
10 
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE
_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING
_TO_43S 3/35 18/1513 0,00730 0,20565 0,17992 EIF4H/EIF4EBP1/EIF3A 3 
10 REACTOME_METABOLISM_OF_PROTEINS 7/35 104/1513 0,00801 0,20565 0,17992 GALNT5/GALNT7/EIF4H/HSPA9/RPL4/EIF4EBP1/EIF3A 7 
10 PID_MET_PATHWAY 3/35 20/1513 0,00988 0,21120 0,18479 CRK/EIF4EBP1/PTPN11 3 
10 PID_CXCR4_PATHWAY 3/35 22/1513 0,01292 0,21120 0,18479 ITGA2/CRK/PTPN11 3 
10 ST_INTEGRIN_SIGNALING_PATHWAY 3/35 22/1513 0,01292 0,21120 0,18479 VASP/ITGA2/CRK 3 
10 REACTOME_AXON_GUIDANCE 6/35 91/1513 0,01578 0,21120 0,18479 VASP/ANK1/MYH10/ITGA2/COL5A2/EVL 6 
13 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_T
O_CCT_TRIC 7/77 11/1513 0,00000 0,00005 0,00005 CCT3/CCT7/CCT6A/CCT5/CCT8/CCT2/CCT4 7 
13 KEGG_ECM_RECEPTOR_INTERACTION 9/77 50/1513 0,00066 0,06183 0,05773 LAMB1/VTN/LAMA4/TNC/GP5/THBS2/COL5A1/LAMA2/COL5A3 9 
13 KEGG_FOCAL_ADHESION 11/77 81/1513 0,00193 0,07516 0,07017 
LAMB1/VTN/LAMA4/TNC/CAPN2/PAK2/TLN1/THBS2/COL5A1/LA
MA2/COL5A3 11 
13 REACTOME_PROTEIN_FOLDING 7/77 15/1513 0,00000 0,00044 0,00041 CCT3/CCT7/CCT6A/CCT5/CCT8/CCT2/CCT4 7 
13 KEGG_OOCYTE_MEIOSIS 5/77 18/1513 0,00152 0,07516 0,07017 YWHAH/YWHAE/PRKACA/CALML3/PPP3CA 5 
13 REACTOME_APOPTOSIS 7/77 37/1513 0,00201 0,07516 0,07017 PSME2/VIM/PSMB1/PAK2/PLEC/HIST1H1B/FAS 7 
13 PID_INTEGRIN1_PATHWAY 8/77 48/1513 0,00225 0,07516 0,07017 LAMB1/VTN/LAMA4/TNC/CSPG4/THBS2/COL5A1/LAMA2 8 
13 KEGG_APOPTOSIS 4/77 13/1513 0,00312 0,07516 0,07017 CAPN2/PRKACA/FAS/PPP3CA 4 
13 REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 4/77 13/1513 0,00312 0,07516 0,07017 YWHAE/PRKACA/TUBB/DYNC1H1 4 
13 REACTOME_MITOTIC_G2_G2_M_PHASES 4/77 13/1513 0,00312 0,07516 0,07017 YWHAE/PRKACA/TUBB/DYNC1H1 4 
13 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS
_AND_COMPLEXES 4/77 13/1513 0,00312 0,07516 0,07017 YWHAE/PRKACA/TUBB/DYNC1H1 4 
13 REACTOME_CELL_CYCLE_MITOTIC 6/77 30/1513 0,00319 0,07516 0,07017 PSME2/PSMB1/YWHAE/PRKACA/TUBB/DYNC1H1 6 
13 BIOCARTA_AGR_PATHWAY 4/77 14/1513 0,00421 0,08503 0,07938 LAMA4/PAK2/UTRN/LAMA2 4 
13 PID_NFAT_3PATHWAY 4/77 14/1513 0,00421 0,08503 0,07938 YWHAH/YWHAE/PRKACA/PPP3CA 4 
13 PID_A6B1_A6B4_INTEGRIN_PATHWAY 5/77 23/1513 0,00490 0,08674 0,08098 LAMB1/LAMA4/YWHAH/YWHAE/LAMA2 5 
13 REACTOME_METABOLISM_OF_PROTEINS 12/77 104/1513 0,00490 0,08674 0,08098 
CCT3/RPS12/CCT7/MAN2A1/CCT6A/CCT5/CCT8/EIF4A1/CCT2/PRO
Z/F7/CCT4 12 
13 REACTOME_CELL_CYCLE 6/77 35/1513 0,00711 0,11828 0,11043 PSME2/PSMB1/YWHAE/PRKACA/TUBB/DYNC1H1 6 
13 PID_TELOMERASE_PATHWAY 3/77 10/1513 0,01174 0,18462 0,17236 YWHAE/XRCC6/XRCC5 3 
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13 REACTOME_APOPTOTIC_EXECUTION_PHASE 4/77 19/1513 0,01341 0,19975 0,18649 VIM/PAK2/PLEC/HIST1H1B 4 
13 BIOCARTA_CHREBP2_PATHWAY 3/77 11/1513 0,01556 0,20178 0,18838 YWHAH/YWHAE/PRKACA 3 
13 SIG_CHEMOTAXIS 3/77 11/1513 0,01556 0,20178 0,18838 ARHGAP1/PAK2/ACTR2 3 
13 REACTOME_HIV_INFECTION 5/77 30/1513 0,01569 0,20178 0,18838 PSME2/PSMB1/PAK2/XRCC6/XRCC5 5 
13 KEGG_ALZHEIMERS_DISEASE 4/77 21/1513 0,01917 0,23583 0,22017 CAPN2/CALML3/FAS/PPP3CA 4 
14 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 13/124 29/1513 0,00000 0,00002 0,00001 
ALDOA/LDHB/TPI1/ENO2/ENO1/GALM/ADH5/AKR1A1/ALDH1A3/
ALDH9A1/PGK1/PGM2/LDHA 13 
14 KEGG_PYRUVATE_METABOLISM 8/124 16/1513 0,00001 0,00073 0,00065 LDHB/HAGH/AKR1B1/GRHPR/ALDH9A1/GLO1/MDH1/LDHA 8 
14 KEGG_GLUTATHIONE_METABOLISM 8/124 21/1513 0,00013 0,00378 0,00337 GSR/GSS/LAP3/GSTT1/GSTM3/IDH1/GSTO1/GSTP1 8 
14 KEGG_DRUG_METABOLISM_CYTOCHROME_P450 7/124 10/1513 0,00000 0,00019 0,00017 GSTT1/GSTM3/ADH5/ALDH1A3/GSTO1/AOX1/GSTP1 7 
14 REACTOME_GLUCOSE_METABOLISM 10/124 27/1513 0,00002 0,00111 0,00099 ALDOA/PYGB/TPI1/ENO2/ENO1/UGP2/GOT1/PGK1/PGM2/MDH1 10 
14 KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 6/124 10/1513 0,00004 0,00158 0,00141 GSTT1/GSTM3/ADH5/ALDH1A3/GSTO1/GSTP1 6 
14 KEGG_CITRATE_CYCLE_TCA_CYCLE 6/124 12/1513 0,00017 0,00378 0,00337 ACO2/IDH1/ACO1/FH/SUCLG2/MDH1 6 
14 
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CY
CLE 6/124 12/1513 0,00017 0,00378 0,00337 LDHB/ACO2/IDH1/FH/SUCLG2/LDHA 6 
14 REACTOME_GLUCONEOGENESIS 7/124 17/1513 0,00020 0,00415 0,00370 ALDOA/TPI1/ENO2/ENO1/GOT1/PGK1/MDH1 7 
14 KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 6/124 13/1513 0,00029 0,00519 0,00462 ALDOA/TPI1/PHPT1/AKR1B1/MPI/TSTA3 6 
14 KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 7/124 18/1513 0,00031 0,00519 0,00462 GNPDA1/MPI/UGDH/UGP2/PGM2/TSTA3/PGM3 7 
14 REACTOME_PHASE_II_CONJUGATION 7/124 19/1513 0,00046 0,00658 0,00586 GSS/AHCY/UGDH/CNDP2/UGP2/GSTO1/GSTP1 7 
14 
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSP
ORT 6/124 14/1513 0,00047 0,00658 0,00586 LDHB/ACO2/IDH1/FH/SUCLG2/LDHA 6 
14 KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 5/124 10/1513 0,00062 0,00805 0,00718 LDHB/AHCY/GOT1/MPST/LDHA 5 
14 REACTOME_GLYCOLYSIS 5/124 12/1513 0,00169 0,01938 0,01728 ALDOA/TPI1/ENO2/ENO1/PGK1 5 
14 REACTOME_BIOLOGICAL_OXIDATIONS 7/124 23/1513 0,00169 0,01938 0,01728 GSS/AHCY/UGDH/CNDP2/UGP2/GSTO1/GSTP1 7 
14 REACTOME_METABOLISM_OF_CARBOHYDRATES 15/124 82/1513 0,00188 0,02027 0,01807 
ALDOA/PYGB/TPI1/ENO2/ENO1/PGLS/GLCE/ARSB/GUSB/UGP2/GO
T1/PGK1/PGM2/TKT/MDH1 15 
14 KEGG_ARGININE_AND_PROLINE_METABOLISM 5/124 13/1513 0,00257 0,02612 0,02329 LAP3/ASS1/CKB/ALDH9A1/GOT1 5 
14 KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 4/124 10/1513 0,00612 0,05334 0,04756 ADSL/ASS1/GOT1/NIT2 4 
14 KEGG_TYROSINE_METABOLISM 4/124 10/1513 0,00612 0,05334 0,04756 ADH5/ALDH1A3/GOT1/AOX1 4 
14 REACTOME_GLUTATHIONE_CONJUGATION 4/124 10/1513 0,00612 0,05334 0,04756 GSS/CNDP2/GSTO1/GSTP1 4 
14 REACTOME_TRNA_AMINOACYLATION 5/124 16/1513 0,00713 0,05933 0,05290 TARS/KARS/PPA2/PPA1/YARS 5 
14 REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS 4/124 11/1513 0,00902 0,07173 0,06395 NAMPT/PDXK/GSTO1/QPRT 4 
14 KEGG_STARCH_AND_SUCROSE_METABOLISM 5/124 17/1513 0,00945 0,07207 0,06426 PYGB/GUSB/UGDH/UGP2/PGM2 5 
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14 KEGG_PENTOSE_PHOSPHATE_PATHWAY 4/124 14/1513 0,02254 0,16501 0,14712 ALDOA/PGLS/PGM2/TKT 4 
14 REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 4/124 15/1513 0,02883 0,20295 0,18094 TARS/KARS/PPA1/YARS 4 
15 KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 25/135 62/1513 0,00000 0,00000 0,00000 
CPB2/SERPIND1/C5/C8G/C4BPB/C3/F12/C9/C6/KLKB1/F13A1/KNG1/
C1S/C8A/C4BPA/F13B/SERPINC1/C8B/CFI/MASP2/F11/C4A/C4B/CF
B/CFH 25 
15 REACTOME_INNATE_IMMUNE_SYSTEM 17/135 61/1513 0,00001 0,00038 0,00037 
LBP/C5/C8G/C4BPB/C3/C9/C6/C1S/PLCG2/C8A/C4BPA/C8B/CFI/MA
SP2/C4A/CFB/CFH 17 
15 REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 8/135 24/1513 0,00070 0,01948 0,01888 F12/KLKB1/F13A1/KNG1/F13B/SERPINC1/F11/GP1BA 8 
15 NABA_ECM_REGULATORS 22/135 124/1513 0,00084 0,02105 0,02040 
SERPINA7/SERPIND1/MMP2/F12/ADAMTS8/SULF1/PZP/F13A1/KNG
1/ITIH4/ITIH1/SERPINA4/CST2/CTSF/CPN2/SERPINA6/ITIH2/F13B/S
ERPINC1/ADAMTS13/SERPINA3/MASP2 22 
15 REACTOME_COMPLEMENT_CASCADE 15/135 28/1513 0,00000 0,00000 0,00000 
C5/C8G/C4BPB/C3/C9/C6/C1S/C8A/C4BPA/C8B/CFI/MASP2/C4A/CFB
/CFH 15 
15 BIOCARTA_COMP_PATHWAY 10/135 19/1513 0,00000 0,00008 0,00008 C5/C3/C9/C6/C1S/C8A/MASP2/C4A/C4B/CFB 10 
15 BIOCARTA_LECTIN_PATHWAY 8/135 12/1513 0,00000 0,00008 0,00008 C5/C3/C9/C6/C8A/MASP2/C4A/C4B 8 
15 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 11/135 25/1513 0,00000 0,00016 0,00015 C5/C8G/C3/C9/C6/C1S/C8A/C8B/HLA-DPA1/C4A/C4B 11 
15 BIOCARTA_CLASSIC_PATHWAY 8/135 14/1513 0,00001 0,00029 0,00028 C5/C3/C9/C6/C1S/C8A/C4A/C4B 8 
15 REACTOME_REGULATION_OF_COMPLEMENT_CASCADE 7/135 12/1513 0,00002 0,00073 0,00070 C4BPB/C3/C4BPA/CFI/C4A/CFB/CFH 7 
15 KEGG_PRION_DISEASES 9/135 23/1513 0,00008 0,00235 0,00228 C5/C8G/C9/C6/SOD1/BAX/NCAM1/C8A/C8B 9 
15 REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT 5/135 13/1513 0,00376 0,08676 0,08407 C3/C1S/MASP2/C4A/CFB 5 
15 KEGG_N_GLYCAN_BIOSYNTHESIS 5/135 14/1513 0,00543 0,10749 0,10416 ST6GAL1/MGAT1/MAN2A2/MAN1C1/B4GALT1 5 
15 REACTOME_INTRINSIC_PATHWAY 5/135 14/1513 0,00543 0,10749 0,10416 F12/KLKB1/KNG1/F11/GP1BA 5 
15 BIOCARTA_LAIR_PATHWAY 4/135 10/1513 0,00832 0,14406 0,13960 C5/C3/C6/KNG1 4 
15 REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY 4/135 10/1513 0,00832 0,14406 0,13960 CSK/ICOSLG/PTPN6/HLA-DPA1 4 
15 KEGG_LEISHMANIA_INFECTION 5/135 16/1513 0,01024 0,16683 0,16166 TGFB1/C3/NCF4/PTPN6/HLA-DPA1 5 
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Table S4- Patient V16-Enriched pathways for each cluster with the respective Gene Ratio, Background ratio (Bg Ratio), p-value, p-adjust, q-value, Gene Id and counts 
(number of genes (proteins) per pathways). The highlighted pathways were the one selected for the bar plots graphs.  
Cluster Description GeneRatio BgRatio pvalue p.adjust qvalue geneID Count 
1 KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION 5/108 11/1659 0,0004 0,0762 0,0712 GNAI2/MAPK3/MAP2K1/HSP90AB1/HSP90AA1 5 
1 REACTOME_SIGNALING_BY_EGFR_IN_CANCER 7/108 24/1659 0,0006 0,0762 0,0712 CLTA/EPS15L1/MAPK3/MAP2K1/AP2B1/HGS/HSP90AA1 7 
1 KEGG_HUNTINGTONS_DISEASE 6/108 19/1659 0,0009 0,0762 0,0712 NDUFAB1/CLTA/BAX/AP2B1/CREB3L2/HIP1 6 
1 PID_CERAMIDE_PATHWAY 5/108 13/1659 0,0009 0,0762 0,0712 MAPK3/BAX/MAP2K1/BID/TRADD 5 
1 PID_VEGFR1_2_PATHWAY 6/108 23/1659 0,0027 0,1816 0,1697 MAPK3/MAP2K1/HSP90AB1/HGS/HSP90AA1/PTPN11 6 
1 PID_VEGFR1_PATHWAY 4/108 11/1659 0,0039 0,1892 0,1768 MAPK3/HSP90AA1/PTPN11/NRP2 4 
1 REACTOME_EGFR_DOWNREGULATION 4/108 11/1659 0,0039 0,1892 0,1768 CLTA/EPS15L1/AP2B1/HGS 4 
1 KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 6/108 26/1659 0,0052 0,1892 0,1768 MAPK3/IFNAR1/MAP2K1/BID/PTPN11/HLA-A 6 
1 KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 4/108 12/1659 0,0056 0,1892 0,1768 CCL2/MAPK3/HSP90AB1/HSP90AA1 4 
1 PID_GMCSF_PATHWAY 4/108 12/1659 0,0056 0,1892 0,1768 CCL2/MAPK3/MAP2K1/PTPN11 4 
1 KEGG_PROSTATE_CANCER 5/108 20/1659 0,0075 0,2165 0,2022 MAPK3/MAP2K1/HSP90AB1/CREB3L2/HSP90AA1 5 
1 BIOCARTA_MET_PATHWAY 4/108 13/1659 0,0077 0,2165 0,2022 MAPK3/MAP2K1/MET/PTPN11 4 
1 KEGG_MELANOGENESIS 4/108 14/1659 0,0102 0,2469 0,2307 GNAI2/MAPK3/MAP2K1/CREB3L2 4 
1 REACTOME_INTRINSIC_PATHWAY 4/108 14/1659 0,0102 0,2469 0,2307 F9/KLKB1/F10/F11 4 
3 REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 11/98 62/1659 0,0007 0,1558 0,1332 
DLD/PSMD5/AHCY/GCLC/PSMA6/FAH/PSMB1/PSPH/NQO1/
HIBCH/SMS 11 
3 
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESEN
TATION 9/98 50/1659 0,0020 0,1558 0,1332 
PSMD5/PSMA6/BLMH/PSMB1/SEC23A/UBE2N/UBA7/UBE2L
3/SEC31A 9 
3 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_D
EGRADATION 7/98 32/1659 0,0020 0,1558 0,1332 PSMD5/PSMA6/BLMH/PSMB1/UBE2N/UBA7/UBE2L3 7 
3 REACTOME_DNA_REPLICATION 6/98 24/1659 0,0021 0,1558 0,1332 PSMD5/PSMA6/PSMB1/PPP2R1A/PCNA/PAFAH1B1 6 
3 REACTOME_GLUCOSE_METABOLISM 6/98 28/1659 0,0047 0,1996 0,1706 PPP2R1A/UGP2/PGK1/GBE1/MDH1/ALDOA 6 
3 REACTOME_CELL_CYCLE_MITOTIC 7/98 37/1659 0,0048 0,1996 0,1706 PSMD5/PSMA6/PSMB1/YWHAE/PPP2R1A/PCNA/PAFAH1B1 7 
3 REACTOME_G1_S_TRANSITION 5/98 20/1659 0,0049 0,1996 0,1706 PSMD5/PSMA6/PSMB1/PPP2R1A/PCNA 5 
3 REACTOME_MITOTIC_G1_G1_S_PHASES 5/98 21/1659 0,0062 0,1996 0,1706 PSMD5/PSMA6/PSMB1/PPP2R1A/PCNA 5 
3 REACTOME_METABOLISM_OF_MRNA 9/98 59/1659 0,0064 0,1996 0,1706 
PSMD5/RPS12/PSMA6/PSMB1/DDX6/PPP2R1A/KHSRP/LSM4/
EIF4A1 9 
3 REACTOME_ADAPTIVE_IMMUNE_SYSTEM 14/98 117/1659 0,0070 0,1996 0,1706 
C3/PSMD5/CSK/VASP/PSMA6/BLMH/PSMB1/SEC23A/UBE2N
/PPP2R1A/UBA7/UBE2L3/SEC31A/PLCG2 14 
3 REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC 4/98 14/1659 0,0072 0,1996 0,1706 PSMD5/PSMA6/PSMB1/NQO1 4 
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3 REACTOME_METABOLISM_OF_RNA 9/98 61/1659 0,0080 0,2027 0,1732 
PSMD5/RPS12/PSMA6/PSMB1/DDX6/PPP2R1A/KHSRP/LSM4/
EIF4A1 9 
3 REACTOME_MITOTIC_M_M_G1_PHASES 5/98 23/1659 0,0093 0,2173 0,1857 PSMD5/PSMA6/PSMB1/PPP2R1A/PAFAH1B1 5 
3 REACTOME_BIOLOGICAL_OXIDATIONS 5/98 24/1659 0,0112 0,2272 0,1942 AHCY/GCLC/ADH1B/UGP2/GSTP1 5 
3 REACTOME_CELL_CYCLE 7/98 43/1659 0,0112 0,2272 0,1942 PSMD5/PSMA6/PSMB1/YWHAE/PPP2R1A/PCNA/PAFAH1B1 7 
3 REACTOME_SIGNALING_BY_WNT 4/98 16/1659 0,0120 0,2277 0,1946 PSMD5/PSMA6/PSMB1/PPP2R1A 4 
3 KEGG_GLUTATHIONE_METABOLISM 5/98 25/1659 0,0134 0,2388 0,2041 GCLC/IDH1/GPX4/GSTP1/SMS 5 
3 PID_ERBB1_DOWNSTREAM_PATHWAY 6/98 35/1659 0,0146 0,2404 0,2054 ARPC3/YWHAE/EGFR/ARPC2/PPP2R1A/ACTR2 6 
3 BIOCARTA_ACTINY_PATHWAY 3/98 10/1659 0,0177 0,2404 0,2054 ARPC3/ARPC2/ACTR2 3 
3 REACTOME_SYNTHESIS_OF_DNA 4/98 18/1659 0,0185 0,2404 0,2054 PSMD5/PSMA6/PSMB1/PCNA 4 
3 REACTOME_IMMUNE_SYSTEM 19/98 199/1659 0,0197 0,2404 0,2054 
C3/PSMD5/CSK/VASP/PSMA6/BLMH/PSMB1/C9/IL18/SEC23A
/UBE2N/PPP2R1A/UBA7/UBE2L3/SEC31A/PLCG2/C8B/CFI/EI
F4A1 19 
3 REACTOME_PHASE_II_CONJUGATION 4/98 19/1659 0,0223 0,2404 0,2054 AHCY/GCLC/UGP2/GSTP1 4 
3 REACTOME_S_PHASE 4/98 19/1659 0,0223 0,2404 0,2054 PSMD5/PSMA6/PSMB1/PCNA 4 
3 REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 3/98 11/1659 0,0233 0,2404 0,2054 DDX6/LSM4/EIF4A1 3 
3 REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING 3/98 11/1659 0,0233 0,2404 0,2054 CSK/FGB/FGG 3 
3 REACTOME_TCR_SIGNALING 3/98 11/1659 0,0233 0,2404 0,2054 CSK/VASP/UBE2N 3 
3 REACTOME_METABOLISM_OF_NUCLEOTIDES 5/98 29/1659 0,0248 0,2404 0,2054 ADK/CMPK1/GART/GMPS/TXNRD1 5 
3 REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 5/98 30/1659 0,0284 0,2404 0,2054 PSMD5/PSMA6/PSMB1/RAN/PPIA 5 
3 BIOCARTA_CDC42RAC_PATHWAY 3/98 12/1659 0,0298 0,2404 0,2054 ARPC3/ARPC2/ACTR2 3 
3 BIOCARTA_FIBRINOLYSIS_PATHWAY 3/98 12/1659 0,0298 0,2404 0,2054 SERPINB2/FGB/FGG 3 
3 BIOCARTA_MPR_PATHWAY 3/98 12/1659 0,0298 0,2404 0,2054 ARPC3/ARPC2/ACTR2 3 
3 KEGG_TYROSINE_METABOLISM 3/98 12/1659 0,0298 0,2404 0,2054 MIF/FAH/ADH1B 3 
3 REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR 4/98 21/1659 0,0315 0,2404 0,2054 PSMD5/PSMA6/PSMB1/PLCG2 4 
3 
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INF
ECTION 4/98 22/1659 0,0368 0,2404 0,2054 CSK/EGFR/PLCG2/ATP6V1G1 4 
3 KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 3/98 13/1659 0,0371 0,2404 0,2054 AHCY/SMS/LDHA 3 
3 REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES 3/98 13/1659 0,0371 0,2404 0,2054 UBE2N/UBA7/EIF4A1 3 
3 REACTOME_GLYCOLYSIS 3/98 13/1659 0,0371 0,2404 0,2054 PPP2R1A/PGK1/ALDOA 3 
3 REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 3/98 13/1659 0,0371 0,2404 0,2054 YWHAE/PPP2R1A/PAFAH1B1 3 
3 PID_PDGFRB_PATHWAY 6/98 43/1659 0,0375 0,2404 0,2054 CSK/ARPC3/YWHAE/ARPC2/PPP2R1A/ACTR2 6 
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3 REACTOME_INNATE_IMMUNE_SYSTEM 8/98 67/1659 0,0400 0,2404 0,2054 C3/C9/UBE2N/PPP2R1A/UBA7/PLCG2/C8B/CFI 8 
3 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 5/98 33/1659 0,0412 0,2404 0,2054 DLD/ADH1B/PGK1/LDHA/ALDOA 5 
3 REACTOME_HIV_INFECTION 5/98 33/1659 0,0412 0,2404 0,2054 PSMD5/PSMA6/PSMB1/RAN/PPIA 5 
3 ST_INTEGRIN_SIGNALING_PATHWAY 4/98 23/1659 0,0426 0,2404 0,2054 VASP/ZYX/PLCG2/ACTR2 4 
3 KEGG_CITRATE_CYCLE_TCA_CYCLE 3/98 14/1659 0,0452 0,2404 0,2054 DLD/IDH1/MDH1 3 
3 
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PR
OTEINS 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_
OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY
_G1 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP
1 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_
CDC6 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMP
LEX 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_ORC1_REMOVAL_FROM_CHROMATIN 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 3/98 14/1659 0,0452 0,2404 0,2054 CSK/FGB/FGG 3 
3 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AN
D_COMPLEXES 3/98 14/1659 0,0452 0,2404 0,2054 YWHAE/PPP2R1A/PAFAH1B1 3 
3 REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G 3/98 14/1659 0,0452 0,2404 0,2054 PSMD5/PSMA6/PSMB1 3 
3 KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 3/98 15/1659 0,0542 0,2450 0,2093 UBE2N/UBA7/UBE2L3 3 
3 REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIG
ENS_ENDOSOMES 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITI
ON_ 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTO
R_BCR 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_MITOTIC_G2_G2_M_PHASES 3/98 15/1659 0,0542 0,2450 0,2093 YWHAE/PPP2R1A/PAFAH1B1 3 
3 REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE 3/98 15/1659 0,0542 0,2450 0,2093 DLD/IDH1/LDHA 3 
3 REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
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3 REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 3/98 15/1659 0,0542 0,2450 0,2093 PSMD5/PSMA6/PSMB1 3 
3 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_
BIND_AU_RICH_ELEMENTS 4/98 25/1659 0,0556 0,2479 0,2118 PSMD5/PSMA6/PSMB1/KHSRP 4 
5 KEGG_ARGININE_AND_PROLINE_METABOLISM 5/101 14/1659 0,0010 0,1739 0,1645 LAP3/ASS1/ALDH2/ACY1/ALDH7A1 5 
5 REACTOME_PHOSPHOLIPID_METABOLISM 6/101 22/1659 0,0015 0,1739 0,1645 ARSA/HEXB/ARSB/PLD3/PLD4/CHKB 6 
6 NABA_CORE_MATRISOME 38/223 145/1659 0,0000 0,0036 0,0035 
IGFBP5/NID2/MXRA5/COL1A1/SPARC/IGFBP2/COL21A1/LA
MA5/EMILIN2/CILP/COL5A3/FRAS1/TNC/SLIT1/IGFBP4/SPO
N2/CILP2/IGFBP7/COL1A2/COL14A1/COL6A2/IGFBP6/LAMB
2/PODN/FBN1/THBS4/PRELP/MFAP5/MEPE/SMOC1/COL6A1/
MMRN2/COL16A1/COL5A2/EMILIN1/IGFBP3/LTBP1/HMCN2 38 
6 NABA_COLLAGENS 9/223 19/1659 0,0003 0,0443 0,0432 
COL1A1/COL21A1/COL5A3/COL1A2/COL14A1/COL6A2/COL
6A1/COL16A1/COL5A2 9 
6 NABA_ECM_GLYCOPROTEINS 27/223 108/1659 0,0006 0,0443 0,0432 
IGFBP5/NID2/MXRA5/SPARC/IGFBP2/LAMA5/EMILIN2/CILP
/FRAS1/TNC/SLIT1/IGFBP4/SPON2/CILP2/IGFBP7/IGFBP6/LA
MB2/FBN1/THBS4/MFAP5/MEPE/SMOC1/MMRN2/EMILIN1/I
GFBP3/LTBP1/HMCN2 27 
6 
REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_A
CTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IG
FBPS 7/223 13/1659 0,0006 0,0443 0,0432 MMP2/IGFBP5/IGFBP2/IGFBP4/IGFBP6/PLG/IGFBP3 7 
6 KEGG_ECM_RECEPTOR_INTERACTION 15/223 47/1659 0,0007 0,0443 0,0432 
COL1A1/LAMA5/SDC1/COL5A3/TNC/COL1A2/COL6A2/SDC2
/LAMB2/DAG1/THBS4/COL6A1/SDC4/COL5A2/CD44 15 
6 PID_SYNDECAN_1_PATHWAY 10/223 26/1659 0,0012 0,0587 0,0572 
TGFB1/COL1A1/LAMA5/SDC1/COL1A2/COL14A1/COL6A2/C
OL6A1/COL16A1/COL5A2 10 
6 PID_INTEGRIN3_PATHWAY 10/223 28/1659 0,0023 0,0971 0,0947 
COL1A1/SDC1/TNC/COL1A2/FBN1/PDGFB/PLAUR/TGFBR2/
VEGFA/SDC4 10 
6 REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 13/223 44/1659 0,0036 0,1363 0,1330 
MMP2/MMP15/COL1A1/COL21A1/TIMP2/COL5A3/COL1A2/C
OL14A1/COL6A2/PLG/COL6A1/COL16A1/COL5A2 13 
6 PID_GLYPICAN_1PATHWAY 5/223 10/1659 0,0060 0,1839 0,1794 TGFB1/APP/TGFBR2/VEGFA/PRNP 5 
6 REACTOME_NCAM1_INTERACTIONS 6/223 14/1659 0,0065 0,1839 0,1794 COL1A1/COL1A2/COL6A2/COL6A1/COL5A2/PRNP 6 
6 PID_AVB3_INTEGRIN_PATHWAY 10/223 32/1659 0,0068 0,1839 0,1794 
COL1A1/SDC1/COL1A2/COL14A1/COL6A2/TGFBR2/COL6A1/
VEGFA/COL16A1/COL5A2 10 
6 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 15/223 58/1659 0,0074 0,1839 0,1794 
RELT/TGFB1/CCL24/TNFRSF13B/CD27/VEGFC/PPBP/TNFRS
F21/PDGFB/PDGFA/TGFBR2/VEGFA/TNFRSF19/CXCL12/TNF
SF12 15 
6 REACTOME_GLYCOSAMINOGLYCAN_METABOLISM 12/223 44/1659 0,0104 0,2285 0,2229 
SDC1/SLC9A1/B3GNT2/SDC2/CSGALNACT1/PRELP/SDC4/C
HST3/EXT1/ST3GAL6/CD44/B3GNT7 12 
6 REACTOME_COLLAGEN_FORMATION 9/223 29/1659 0,0107 0,2285 0,2229 
COL1A1/COL21A1/COL5A3/COL1A2/COL14A1/COL6A2/COL
6A1/COL16A1/COL5A2 9 
7 REACTOME_MUSCLE_CONTRACTION 12/229 29/1659 0,0002 0,0520 0,0509 
MYL2/MYL9/MYL3/MYL1/MYLK/TPM2/CALD1/TPM3/DES/
MYH11/MYH8/TNNT1 12 
7 KEGG_CARDIAC_MUSCLE_CONTRACTION 8/229 15/1659 0,0003 0,0520 0,0509 
MYL2/ATP1B3/MYL3/MYH7/CACNA2D1/TPM2/ATP1B1/TPM
3 8 
7 REACTOME_BASIGIN_INTERACTIONS 6/229 10/1659 0,0008 0,0557 0,0546 ATP1B3/ITGB1/BSG/CAV1/ATP1B1/L1CAM 6 
7 REACTOME_STRIATED_MUSCLE_CONTRACTION 8/229 17/1659 0,0009 0,0557 0,0546 MYL2/MYL3/MYL1/TPM2/TPM3/DES/MYH8/TNNT1 8 
7 KEGG_DILATED_CARDIOMYOPATHY 10/229 25/1659 0,0010 0,0557 0,0546 
MYL2/MYL3/ITGB1/TTN/MYH7/CACNA2D1/TPM2/TPM3/EM
D/DES 10 
Annex I | Supplementary information for Chapter VI 
 
215 
 
7 KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM 10/229 25/1659 0,0010 0,0557 0,0546 
MYL2/MYL3/ITGB1/TTN/MYH7/CACNA2D1/TPM2/TPM3/EM
D/DES 10 
7 
REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_
FOR_GAG_SYNTHESIS 6/229 12/1659 0,0029 0,1361 0,1332 DCN/B3GAT3/CSPG4/BGN/HSPG2/AGRN 6 
7 PID_INTEGRIN_A4B1_PATHWAY 7/229 16/1659 0,0033 0,1361 0,1332 MYH2/VCAM1/CRK/ITGB1/IGSF8/THBS2/JAM2 7 
7 REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 8/229 21/1659 0,0047 0,1631 0,1597 DCN/HS6ST1/B3GAT3/CSPG4/BGN/HSPG2/AGRN/EXT2 8 
7 KEGG_VIRAL_MYOCARDITIS 10/229 30/1659 0,0049 0,1631 0,1597 
MYH1/MYH2/CXADR/CD55/EIF4G1/CAV1/MYH7/MYH11/M
YH8/HLA-B 10 
7 PID_EPHA_FWDPATHWAY 5/229 10/1659 0,0067 0,2013 0,1971 EPHA1/EPHA4/CRK/EPHA7/EPHA6 5 
8 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_C
CT_TRIC 10/293 10/1659 0,0000 0,0000 0,0000 
TUBA4A/CCT7/CCT6A/CCT5/CCT8/CCT3/CCT2/TCP1/ACTB/
CCT4 10 
8 REACTOME_PROTEIN_FOLDING 10/293 13/1659 0,0000 0,0009 0,0008 
TUBA4A/CCT7/CCT6A/CCT5/CCT8/CCT3/CCT2/TCP1/ACTB/
CCT4 10 
8 PID_PDGFRB_PATHWAY 19/293 43/1659 0,0000 0,0052 0,0047 
MAPK1/YWHAQ/YWHAH/ACTN4/ARPC1B/ACTR3/STAT3/IQ
GAP1/ARHGDIA/YWHAB/YWHAG/YWHAZ/GRB2/SFN/ARP
C5/ARPC4/LYN/DNM2/PTPRJ 19 
8 BIOCARTA_RHO_PATHWAY 11/293 19/1659 0,0001 0,0089 0,0080 
VCL/PFN1/ARPC1B/ACTR3/CFL1/ARHGAP1/TLN1/ARHGEF1
/ARPC5/GSN/ARPC4 11 
8 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 13/293 26/1659 0,0001 0,0106 0,0095 
C5/C8G/ACTN4/C6/FCGR3B/C1S/ACTN2/FCGR3A/C1QC/ACT
N1/C4A/C4B/H2AFY 13 
8 PID_RAC1_PATHWAY 10/293 17/1659 0,0002 0,0106 0,0095 
ARPC1B/ACTR3/STAT3/IQGAP1/ARHGDIA/CFL1/PAK2/ARP
C5/NCF2/ARPC4 10 
8 PID_FOXO_PATHWAY 8/293 12/1659 0,0002 0,0131 0,0117 YWHAQ/CAT/YWHAH/YWHAB/YWHAG/YWHAZ/SFN/XPO1 8 
8 PID_BETA_CATENIN_NUC_PATHWAY 9/293 15/1659 0,0003 0,0142 0,0127 
YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/SFN/MMP9/XP
O1/VCAN 9 
8 PID_ERBB1_DOWNSTREAM_PATHWAY 15/293 35/1659 0,0004 0,0179 0,0160 
MAPK1/YWHAQ/YWHAH/ARPC1B/ACTR3/STAT3/IQGAP1/C
APN2/YWHAB/YWHAG/YWHAZ/GRB2/SFN/ARPC5/ARPC4 15 
8 REACTOME_PURINE_METABOLISM 9/293 16/1659 0,0005 0,0200 0,0179 ADSL/ATIC/CAT/HPRT1/IMPDH2/PNP/ADSS/ADA/APRT 9 
8 SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 9/293 16/1659 0,0005 0,0200 0,0179 
MAPK1/YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/GRB2/
SFN/CAP1 9 
8 BIOCARTA_CHREBP2_PATHWAY 7/293 11/1659 0,0009 0,0297 0,0266 
YWHAQ/YWHAH/YWHAB/FASN/YWHAG/YWHAZ/PRKAR1
A 7 
8 SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES 8/293 15/1659 0,0018 0,0485 0,0434 
YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/PAK2/GRB2/SF
N 8 
8 BIOCARTA_MPR_PATHWAY 7/293 12/1659 0,0018 0,0485 0,0434 MAPK1/ARPC1B/ACTR3/PRKAR1A/ARPC5/CAP1/ARPC4 7 
8 ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY 7/293 12/1659 0,0018 0,0485 0,0434 YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/GRB2/SFN 7 
8 KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 10/293 22/1659 0,0022 0,0573 0,0512 
YWHAQ/TUBA4A/ARPC1B/YWHAZ/NCL/HCLS1/TUBB/ACT
B/ARPC5/ARPC4 10 
8 PID_NFAT_3PATHWAY 8/293 16/1659 0,0030 0,0726 0,0649 
YWHAQ/YWHAH/KPNB1/YWHAB/YWHAG/YWHAZ/SFN/XP
O1 8 
8 REACTOME_SIGNALING_BY_SCF_KIT 7/293 13/1659 0,0033 0,0745 0,0666 MAPK1/STAT3/YWHAB/GRB2/MMP9/PTPN6/LYN 7 
8 KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 8/293 17/1659 0,0048 0,1042 0,0932 IARS2/SARS/AARS/KARS/YARS/CARS/LARS/HARS 8 
8 PID_LKB1_PATHWAY 7/293 14/1659 0,0055 0,1082 0,0967 YWHAQ/YWHAH/CAB39/YWHAB/YWHAG/YWHAZ/SFN 7 
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8 PID_CDC42_PATHWAY 9/293 21/1659 0,0060 0,1082 0,0967 
MAPK1/ARPC1B/ACTR3/IQGAP1/ARHGDIA/CFL1/PAK2/ARP
C5/ARPC4 9 
8 KEGG_CELL_CYCLE 6/293 11/1659 0,0060 0,1082 0,0967 YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/SFN 6 
8 PID_INSULIN_GLUCOSE_PATHWAY 6/293 11/1659 0,0060 0,1082 0,0967 YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/SFN 6 
8 REACTOME_METABOLISM_OF_NUCLEOTIDES 11/293 29/1659 0,0073 0,1262 0,1128 
NME1/ADSL/GSR/ATIC/CAT/HPRT1/IMPDH2/PNP/ADSS/AD
A/APRT 11 
8 KEGG_PENTOSE_PHOSPHATE_PATHWAY 7/293 15/1659 0,0088 0,1346 0,1204 ALDOC/PGD/TALDO1/ALDOB/PGM2/G6PD/TKT 7 
8 KEGG_ADHERENS_JUNCTION 10/293 26/1659 0,0094 0,1346 0,1204 
VCL/MAPK1/ACTN4/IQGAP1/ACP1/ACTB/ACTN2/ACTN1/PT
PN6/PTPRJ 10 
8 KEGG_PURINE_METABOLISM 11/293 30/1659 0,0098 0,1346 0,1204 
NME1/ADSL/NME3/ATIC/HPRT1/IMPDH2/PNP/ADSS/ADA/A
PRT/ITPA 11 
8 PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY 6/293 12/1659 0,0103 0,1346 0,1204 MAPK1/STAT3/TLN1/GRB2/GSN/PTPN6 6 
8 SIG_CHEMOTAXIS 6/293 12/1659 0,0103 0,1346 0,1204 ACTR3/CFL1/ARHGAP1/PAK2/GDI2/GDI1 6 
8 BIOCARTA_INTEGRIN_PATHWAY 8/293 19/1659 0,0108 0,1346 0,1204 VCL/MAPK1/CAPNS1/CAPN1/TLN1/GRB2/ACTN2/ACTN1 8 
8 KEGG_LEISHMANIA_INFECTION 8/293 19/1659 0,0108 0,1346 0,1204 MAPK1/FCGR3B/ITGB2/NCF2/FCGR3A/NCF4/PTPN6/ITGAM 8 
8 
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMB
RANE 8/293 19/1659 0,0108 0,1346 0,1204 
MAPK1/DUSP3/STAT3/CLTC/YWHAB/GRB2/PRKAR1A/DNM
2 8 
8 REACTOME_TRNA_AMINOACYLATION 8/293 19/1659 0,0108 0,1346 0,1204 IARS2/SARS/AARS/KARS/YARS/CARS/LARS/HARS 8 
8 REACTOME_INFLUENZA_LIFE_CYCLE 12/293 35/1659 0,0128 0,1517 0,1356 
RPS16/IPO5/CLTC/KPNB1/RPS15A/CALR/RPS2/RPS21/RPSA/
XPO1/RPS18/RPS3 12 
8 REACTOME_SIGNALLING_BY_NGF 11/293 31/1659 0,0129 0,1517 0,1356 
MAPK1/DUSP3/STAT3/CLTC/ARHGDIA/YWHAB/ADAM17/A
RHGEF1/GRB2/PRKAR1A/DNM2 11 
8 
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQU
ENTLY_THE_43S_COMPLEX 7/293 16/1659 0,0134 0,1532 0,1370 RPS16/RPS15A/RPS2/RPS21/RPSA/RPS18/RPS3 7 
8 REACTOME_SIGNALING_BY_ILS 9/293 24/1659 0,0163 0,1728 0,1545 
MAPK1/IL6/STAT3/YWHAB/YWHAZ/GRB2/PTPN6/CASP1/L
YN 9 
8 BIOCARTA_MCALPAIN_PATHWAY 6/293 13/1659 0,0164 0,1728 0,1545 MAPK1/CAPNS1/CAPN1/CAPN2/TLN1/PRKAR1A 6 
8 PID_AR_PATHWAY 6/293 13/1659 0,0164 0,1728 0,1545 APPL1/HNRNPA1/XRCC6/GSN/XRCC5/PA2G4 6 
8 KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 19/293 67/1659 0,0185 0,1816 0,1624 
VCL/MAPK1/PFN1/ACTN4/ARPC1B/IQGAP1/ITGA2/ITGB2/C
FL1/PAK2/ARHGEF1/ACTB/ARPC5/MSN/ACTN2/GSN/ACTN1
/ARPC4/ITGAM 19 
8 BIOCARTA_ACTINY_PATHWAY 5/293 10/1659 0,0194 0,1816 0,1624 ARPC1B/ACTR3/ARPC5/PSMA7/ARPC4 5 
8 PID_TELOMERASE_PATHWAY 5/293 10/1659 0,0194 0,1816 0,1624 MAPK1/NCL/HNRNPC/XRCC6/XRCC5 5 
8 REACTOME_SIGNALING_BY_RHO_GTPASES 5/293 10/1659 0,0194 0,1816 0,1624 ARHGDIB/ARHGDIA/ARHGAP1/GDI2/GDI1 5 
8 REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 7/293 17/1659 0,0194 0,1816 0,1624 SARS/AARS/KARS/YARS/CARS/LARS/HARS 7 
8 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 11/293 33/1659 0,0211 0,1934 0,1729 
ALDOC/GAPDH/LDHB/ENO1/ACSS2/HK3/ADH5/PGAM1/AL
DOB/PGM2/HK1 11 
8 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_
BIND_AU_RICH_ELEMENTS 9/293 25/1659 0,0216 0,1936 0,1731 
PSMA3/PSMD10/HSPA8/YWHAB/YWHAZ/TNPO1/PSMA7/XP
O1/ELAVL1 9 
8 BIOCARTA_CLASSIC_PATHWAY 6/293 14/1659 0,0245 0,2145 0,1918 C5/C6/C1S/C1QC/C4A/C4B 6 
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8 PID_MTOR_4PATHWAY 7/293 18/1659 0,0271 0,2323 0,2077 MAPK1/YWHAQ/YWHAH/YWHAB/YWHAG/YWHAZ/SFN 7 
8 KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 9/293 26/1659 0,0281 0,2361 0,2111 
MAPK1/ARPC1B/CFL1/ARPC5/FCGR3A/GSN/ARPC4/LYN/DN
M2 9 
8 BIOCARTA_LAIR_PATHWAY 5/293 11/1659 0,0305 0,2369 0,2119 C5/IL6/C6/KNG1/ITGB2 5 
8 BIOCARTA_UCALPAIN_PATHWAY 5/293 11/1659 0,0305 0,2369 0,2119 CAPNS1/CAPN1/TLN1/ACTN2/ACTN1 5 
8 REACTOME_DNA_REPAIR 5/293 11/1659 0,0305 0,2369 0,2119 RPA3/DDB1/XRCC6/RPA2/XRCC5 5 
8 REACTOME_IRON_UPTAKE_AND_TRANSPORT 5/293 11/1659 0,0305 0,2369 0,2119 CP/ATP6V1A/ATP6V1B2/ATP6V1C1/FTL 5 
10 KEGG_PYRUVATE_METABOLISM 7/106 18/1659 0,0001 0,0187 0,0185 AKR1B1/GRHPR/MDH2/ALDH9A1/ME1/GLO1/HAGH 7 
10 REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE 5/106 10/1659 0,0002 0,0279 0,0276 ACO2/MDH2/FH/SUCLG1/SUCLG2 5 
10 KEGG_CITRATE_CYCLE_TCA_CYCLE 5/106 14/1659 0,0012 0,0900 0,0890 ACO2/MDH2/FH/SUCLG1/SUCLG2 5 
10 KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 5/106 14/1659 0,0012 0,0900 0,0890 TPI1/SORD/PFKL/AKR1B1/AKR1B10 5 
10 REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE 5/106 15/1659 0,0017 0,1026 0,1014 ACO2/MDH2/FH/SUCLG1/SUCLG2 5 
10 REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 5/106 18/1659 0,0042 0,2089 0,2065 ACO2/MDH2/FH/SUCLG1/SUCLG2 5 
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Table S5- Patient P03-Enriched pathways for each cluster with the respective Gene Ratio, Background ratio (Bg Ratio), p-value, p-adjust, q-value, Gene Id and counts 
(number of genes (proteins) per pathways). The highlighted pathways were the one selected for the bar plots graphs. 
Cluster Description GeneRatio BgRatio pvalue p.adjust qvalue geneID Count 
1 REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING 4/36 11/1407 1,1E-04 1,6E-02 1,5E-02 RAP1B/FGB/FGG/APBB1IP 4 
1 REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 4/36 14/1407 3,0E-04 2,3E-02 2,2E-02 RAP1B/FGB/FGG/APBB1IP 4 
2 REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 5/58 15/1407 2,2E-04 3,3E-02 3,1E-02 CAB39/EIF4B/YWHAB/EIF4G1/CRK 5 
2 REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 5/58 16/1407 3,1E-04 3,3E-02 3,1E-02 CAB39/EIF4B/YWHAB/EIF4G1/CRK 5 
4 PID_CERAMIDE_PATHWAY 4/71 11/1407 1,5E-03 2,4E-01 2,4E-01 MAPK1/IGF1/PAWR/PDGFA 4 
4 KEGG_GLIOMA 4/71 12/1407 2,2E-03 2,4E-01 2,4E-01 MAPK1/IGF1/PDGFA/CALML5 4 
7 REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 15/85 41/1407 2,7E-09 4,1E-07 3,9E-07 
MMP11/TIMP1/MMP2/PCOLCE/COL6A3/PCOLCE2/MMP3/COL3A
1/PLG/COL12A1/COL6A1/COL5A1/KLKB1/COL1A2/PRSS1 15 
7 REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX 7/85 13/1407 2,9E-06 2,2E-04 2,1E-04 MMP11/TIMP1/MMP2/MMP3/PLG/KLKB1/PRSS1 7 
7 NABA_COLLAGENS 7/85 20/1407 9,4E-05 4,7E-03 4,5E-03 COL6A3/COL3A1/COL12A1/COL6A6/COL6A1/COL5A1/COL1A2 7 
7 REACTOME_COLLAGEN_FORMATION 8/85 28/1407 1,5E-04 5,6E-03 5,3E-03 
PCOLCE/COL6A3/PCOLCE2/COL3A1/COL12A1/COL6A1/COL5A1/
COL1A2 8 
7 PID_AVB3_INTEGRIN_PATHWAY 8/85 31/1407 3,2E-04 9,8E-03 9,3E-03 
VCL/COL6A3/COL3A1/COL12A1/COL6A1/ANGPTL3/COL5A1/CO
L1A2 8 
7 REACTOME_NCAM1_INTERACTIONS 5/85 14/1407 9,3E-04 2,4E-02 2,2E-02 COL6A3/COL3A1/COL6A1/COL5A1/COL1A2 5 
7 NABA_CORE_MATRISOME 18/85 141/1407 1,2E-03 2,6E-02 2,4E-02 
PCOLCE/COL6A3/PCOLCE2/COL3A1/PRG2/ADIPOQ/COL12A1/PR
ELP/RSPO1/COL6A6/COL6A1/ECM1/NTNG1/COL5A1/SPARC/FRA
S1/LUM/COL1A2 18 
7 PID_SYNDECAN_1_PATHWAY 6/85 25/1407 2,8E-03 5,4E-02 5,1E-02 COL6A3/COL3A1/COL12A1/COL6A1/COL5A1/COL1A2 6 
7 PID_P75_NTR_PATHWAY 4/85 13/1407 5,8E-03 9,9E-02 9,3E-02 RTN4R/MMP3/PLG/ADAM17 4 
7 REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH 5/85 21/1407 6,7E-03 1,0E-01 9,7E-02 COL6A3/COL3A1/COL6A1/COL5A1/COL1A2 5 
7 REACTOME_SIGNALING_BY_PDGF 6/85 30/1407 7,5E-03 1,0E-01 9,8E-02 COL6A3/COL3A1/PLG/COL6A1/COL5A1/COL1A2 6 
7 NABA_ECM_REGULATORS 14/85 118/1407 8,8E-03 1,1E-01 1,1E-01 
MMP11/TIMP1/MMP2/SERPINF1/SERPINA4/MMP3/PLG/ADAM17/
SERPINA7/SERPINA5/SERPINA6/SERPINA3/MASP2/PRSS1 14 
7 KEGG_TYROSINE_METABOLISM 3/85 10/1407 1,9E-02 2,2E-01 2,1E-01 FAH/HPD/DBH 3 
8 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 13/141 29/1407 1,0E-06 1,9E-04 1,5E-04 
ADH1B/DLD/TPI1/ENO2/ENO1/ADH5/AKR1A1/ALDH1A3/ALDOA
/ALDH9A1/PGAM1/PGK1/PGM2 13 
8 KEGG_DRUG_METABOLISM_CYTOCHROME_P450 7/141 10/1407 8,2E-06 7,6E-04 6,2E-04 ADH1B/GSTT1/GSTM3/ADH5/ALDH1A3/AOX1/GSTP1 7 
8 KEGG_PYRUVATE_METABOLISM 8/141 16/1407 5,4E-05 3,3E-03 2,7E-03 DLD/AKR1B1/GRHPR/MDH2/ALDH9A1/GLO1/HAGH/MDH1 8 
8 REACTOME_GLUCONEOGENESIS 8/141 17/1407 9,3E-05 3,6E-03 3,0E-03 TPI1/ENO2/ENO1/MDH2/ALDOA/PGAM1/PGK1/MDH1 8 
8 REACTOME_GLUCOSE_METABOLISM 10/141 26/1407 9,7E-05 3,6E-03 3,0E-03 
TPI1/ENO2/ENO1/MDH2/ALDOA/UGP2/PGAM1/PGK1/PGM2/MDH
1 10 
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8 KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 6/141 10/1407 1,4E-04 4,2E-03 3,5E-03 ADH1B/GSTT1/GSTM3/ADH5/ALDH1A3/GSTP1 6 
8 PID_FOXO_PATHWAY 6/141 11/1407 2,8E-04 7,3E-03 6,0E-03 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ/SOD2 6 
8 KEGG_CITRATE_CYCLE_TCA_CYCLE 6/141 12/1407 5,1E-04 9,4E-03 7,7E-03 DLD/ACO2/IDH1/ACO1/MDH2/MDH1 6 
8 PID_LKB1_PATHWAY 6/141 12/1407 5,1E-04 9,4E-03 7,7E-03 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ/EZR 6 
8 REACTOME_GLYCOLYSIS 6/141 12/1407 5,1E-04 9,4E-03 7,7E-03 TPI1/ENO2/ENO1/ALDOA/PGAM1/PGK1 6 
8 REACTOME_BIOLOGICAL_OXIDATIONS 8/141 22/1407 7,9E-04 1,3E-02 1,1E-02 ADH1B/MAT2B/GCLC/GSS/AHCY/MAT2A/UGP2/GSTP1 8 
8 PID_MTOR_4PATHWAY 7/141 18/1407 1,1E-03 1,5E-02 1,3E-02 YWHAQ/YWHAH/YWHAE/EIF4A1/YWHAG/CYCS/YWHAZ 7 
8 KEGG_PYRIMIDINE_METABOLISM 6/141 14/1407 1,4E-03 1,5E-02 1,3E-02 DPYD/NME1/NT5C/CMPK1/AK3/TXNRD1 6 
8 PID_NFAT_3PATHWAY 6/141 14/1407 1,4E-03 1,5E-02 1,3E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ/PPP3CA 6 
8 SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 6/141 14/1407 1,4E-03 1,5E-02 1,3E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ/SERPINB6 6 
8 KEGG_CELL_CYCLE 5/141 10/1407 1,6E-03 1,5E-02 1,3E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ 5 
8 KEGG_TYROSINE_METABOLISM 5/141 10/1407 1,6E-03 1,5E-02 1,3E-02 ADH1B/MIF/ADH5/ALDH1A3/AOX1 5 
8 PID_INSULIN_GLUCOSE_PATHWAY 5/141 10/1407 1,6E-03 1,5E-02 1,3E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ 5 
8 REACTOME_PHASE_II_CONJUGATION 7/141 19/1407 1,6E-03 1,5E-02 1,3E-02 MAT2B/GCLC/GSS/AHCY/MAT2A/UGP2/GSTP1 7 
8 BIOCARTA_CHREBP2_PATHWAY 5/141 11/1407 2,6E-03 2,3E-02 1,9E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ 5 
8 ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY 5/141 11/1407 2,6E-03 2,3E-02 1,9E-02 YWHAQ/YWHAH/YWHAE/YWHAG/YWHAZ 5 
8 REACTOME_METABOLISM_OF_NUCLEOTIDES 8/141 26/1407 2,7E-03 2,3E-02 1,9E-02 DPYD/NME1/NT5C/AMPD2/CMPK1/AK1/GART/TXNRD1 8 
10 NABA_ECM_GLYCOPROTEINS 23/147 102/1407 1,6E-04 4,3E-02 4,2E-02 
AGRN/NID2/COCH/LAMA4/IGFBP5/FGL2/PXDN/EMILIN2/LAMC
1/CILP/LTBP2/NID1/MMRN1/SPARCL1/FNDC1/THBS4/MFAP5/ME
PE/SMOC1/SRPX/EMILIN1/FBLN2/LTBP1 23 
10 NABA_CORE_MATRISOME 27/147 141/1407 7,5E-04 1,0E-01 9,9E-02 
AGRN/DCN/NID2/COCH/LAMA4/IGFBP5/FGL2/PXDN/EMILIN2/L
AMC1/CILP/LTBP2/NID1/MMRN1/SPARCL1/FNDC1/THBS4/MFAP
5/COL4A2/MEPE/SMOC1/COL15A1/SRPX/EMILIN1/FBLN2/LTBP1
/PRG4 27 
11 REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION 8/55 52/1407 6,4E-04 8,0E-02 7,7E-02 MUC16/ARSA/RPN2/ARSB/GALNT1/B3GNT8/GALNT6/MAN1B1 8 
11 REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS 4/55 13/1407 1,2E-03 8,0E-02 7,7E-02 MUC16/GALNT1/B3GNT8/GALNT6 4 
12 
REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATIO
N_AND_ARYLSULFATASE_ACTIVATION 6/88 12/1407 3,5E-05 8,5E-03 8,1E-03 F9/PROC/F2/PROZ/F10/F7 6 
12 REACTOME_SEMAPHORIN_INTERACTIONS 7/88 27/1407 9,4E-04 1,1E-01 1,1E-01 PLXND1/SEMA6D/RHOA/PTPRC/CFL1/PAK2/TLN1 7 
12 BIOCARTA_EXTRINSIC_PATHWAY 4/88 10/1407 2,2E-03 1,6E-01 1,6E-01 PROC/F2/F10/F7 4 
12 REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 6/88 24/1407 2,7E-03 1,6E-01 1,6E-01 F9/PROC/F13A1/F2/F10/F7 6 
12 REACTOME_COMMON_PATHWAY 4/88 11/1407 3,4E-03 1,6E-01 1,6E-01 PROC/F13A1/F2/F10 4 
12 BIOCARTA_AMI_PATHWAY 4/88 12/1407 4,8E-03 2,0E-01 1,9E-01 PROC/F2/F10/F7 4 
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13 REACTOME_METABOLISM_OF_PROTEINS 21/101 100/1407 2,5E-06 5,4E-04 4,4E-04 
RPS12/CCT7/UGGT1/CCT6A/CCT5/CCT8/CCT3/HSPA9/EEF2/RPL4
/PABPC1/MPI/EEF1A1/EIF5A/HSPD1/GANAB/CS/RPS21/RPS3A/RP
SA/ACTB 21 
13 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_
CCT_TRIC 6/101 10/1407 2,0E-05 2,2E-03 1,8E-03 CCT7/CCT6A/CCT5/CCT8/CCT3/ACTB 6 
13 BIOCARTA_CDC42RAC_PATHWAY 6/101 11/1407 4,1E-05 2,2E-03 1,8E-03 ARPC5/ARPC1B/ACTR3/ARPC2/ACTR2/ARPC4 6 
13 BIOCARTA_MPR_PATHWAY 6/101 11/1407 4,1E-05 2,2E-03 1,8E-03 ARPC5/ARPC1B/ACTR3/ARPC2/ACTR2/ARPC4 6 
13 
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EX
ON_JUNCTION_COMPLEX 8/101 21/1407 5,0E-05 2,2E-03 1,8E-03 RPS12/RPL4/PABPC1/PPP2R1A/PPP2R2A/RPS21/RPS3A/RPSA 8 
13 REACTOME_PEPTIDE_CHAIN_ELONGATION 7/101 18/1407 1,3E-04 4,7E-03 3,9E-03 RPS12/EEF2/RPL4/EEF1A1/RPS21/RPS3A/RPSA 7 
13 REACTOME_INFLUENZA_LIFE_CYCLE 8/101 24/1407 1,5E-04 4,7E-03 3,9E-03 RPS12/CLTC/KPNB1/RPL4/RPS21/RPS3A/RPSA/RAN 8 
13 REACTOME_PROTEIN_FOLDING 6/101 14/1407 2,2E-04 5,6E-03 4,6E-03 CCT7/CCT6A/CCT5/CCT8/CCT3/ACTB 6 
13 REACTOME_METABOLISM_OF_MRNA 10/101 39/1407 2,6E-04 5,6E-03 4,6E-03 
PSMD5/RPS12/RPL4/PABPC1/PPP2R1A/PPP2R2A/RPS21/RPS3A/RP
SA/KHSRP 10 
13 REACTOME_METABOLISM_OF_RNA 10/101 39/1407 2,6E-04 5,6E-03 4,6E-03 
PSMD5/RPS12/RPL4/PABPC1/PPP2R1A/PPP2R2A/RPS21/RPS3A/RP
SA/KHSRP 10 
13 REACTOME_CELL_CYCLE 8/101 26/1407 2,8E-04 5,6E-03 4,6E-03 
PSMD5/HSPA2/PRKACA/PPP2R1A/PPP2R2A/TUBB/PCNA/PAFAH
1B1 8 
13 PID_RAC1_PATHWAY 6/101 16/1407 5,2E-04 9,4E-03 7,7E-03 ARPC5/ARPC1B/ACTR3/ARPC2/ACTR2/ARPC4 6 
13 REACTOME_CELL_CYCLE_MITOTIC 7/101 22/1407 5,6E-04 9,4E-03 7,7E-03 PSMD5/PRKACA/PPP2R1A/PPP2R2A/TUBB/PCNA/PAFAH1B1 7 
13 BIOCARTA_RHO_PATHWAY 6/101 17/1407 7,6E-04 1,1E-02 9,2E-03 ARPC5/ARPC1B/ACTR3/ARPC2/ACTR2/ARPC4 6 
13 PID_CDC42_PATHWAY 6/101 17/1407 7,6E-04 1,1E-02 9,2E-03 ARPC5/ARPC1B/ACTR3/ARPC2/ACTR2/ARPC4 6 
13 PID_ERBB1_DOWNSTREAM_PATHWAY 8/101 30/1407 8,3E-04 1,1E-02 9,4E-03 
ARPC5/ARPC1B/ACTR3/ARPC2/PPP2R1A/PPP2R2A/ACTR2/ARPC
4 8 
13 
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYC
LE 5/101 12/1407 9,1E-04 1,2E-02 9,7E-03 LDHB/IDH2/CS/FH/LDHA 5 
13 REACTOME_TRANSLATION 8/101 31/1407 1,1E-03 1,3E-02 1,1E-02 RPS12/EEF2/RPL4/PABPC1/EEF1A1/RPS21/RPS3A/RPSA 8 
13 KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 5/101 13/1407 1,4E-03 1,6E-02 1,3E-02 SARS/DARS/TARS/KARS/YARS 5 
13 KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 6/101 19/1407 1,5E-03 1,6E-02 1,3E-02 ARPC5/ARPC1B/ARPC2/TUBB/ACTB/ARPC4 6 
13 KEGG_SPLICEOSOME 6/101 20/1407 2,0E-03 2,0E-02 1,6E-02 HSPA2/HNRNPU/PCBP1/HSPA6/HNRNPC/HNRNPK 6 
13 REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 5/101 14/1407 2,1E-03 2,0E-02 1,6E-02 SARS/DARS/TARS/KARS/YARS 5 
13 
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPOR
T 5/101 14/1407 2,1E-03 2,0E-02 1,6E-02 LDHB/IDH2/CS/FH/LDHA 5 
13 REACTOME_MRNA_SPLICING 6/101 21/1407 2,6E-03 2,4E-02 2,0E-02 HNRNPA2B1/HNRNPU/PCBP1/HNRNPC/DHX9/HNRNPK 6 
13 REACTOME_TRNA_AMINOACYLATION 5/101 15/1407 2,9E-03 2,5E-02 2,1E-02 SARS/DARS/TARS/KARS/YARS 5 
13 REACTOME_MRNA_PROCESSING 6/101 22/1407 3,4E-03 2,8E-02 2,3E-02 HNRNPA2B1/HNRNPU/PCBP1/HNRNPC/DHX9/HNRNPK 6 
13 
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_M
RNA 6/101 22/1407 3,4E-03 2,8E-02 2,3E-02 HNRNPA2B1/HNRNPU/PCBP1/HNRNPC/DHX9/HNRNPK 6 
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13 KEGG_RIBOSOME 5/101 16/1407 4,0E-03 3,1E-02 2,6E-02 RPS12/RPL4/RPS21/RPS3A/RPSA 5 
13 REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 6/101 24/1407 5,5E-03 3,5E-02 2,9E-02 RPS12/RPL4/PABPC1/RPS21/RPS3A/RPSA 6 
13 BIOCARTA_CHREBP2_PATHWAY 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 FASN/PRKACA/PPP2R1A/PPP2R2A 4 
13 
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSE
QUENTLY_THE_43S_COMPLEX 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 RPS12/RPS21/RPS3A/RPSA 4 
13 REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 PRKACA/PPP2R1A/TUBB/PAFAH1B1 4 
13 REACTOME_MITOTIC_G1_G1_S_PHASES 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 PSMD5/PPP2R1A/PPP2R2A/PCNA 4 
13 REACTOME_MITOTIC_G2_G2_M_PHASES 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 PRKACA/PPP2R1A/TUBB/PAFAH1B1 4 
13 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_A
ND_COMPLEXES 4/101 11/1407 5,6E-03 3,5E-02 2,9E-02 PRKACA/PPP2R1A/TUBB/PAFAH1B1 4 
13 
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_C
AP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_
43S 5/101 18/1407 7,0E-03 4,0E-02 3,3E-02 RPS12/PABPC1/RPS21/RPS3A/RPSA 5 
13 
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLIC
ATION 5/101 18/1407 7,0E-03 4,0E-02 3,3E-02 RPS12/RPL4/RPS21/RPS3A/RPSA 5 
13 
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGE
TING_TO_MEMBRANE 5/101 18/1407 7,0E-03 4,0E-02 3,3E-02 RPS12/RPL4/RPS21/RPS3A/RPSA 5 
13 KEGG_CITRATE_CYCLE_TCA_CYCLE 4/101 12/1407 7,9E-03 4,3E-02 3,6E-02 ACLY/IDH2/CS/FH 4 
13 REACTOME_DNA_REPLICATION 4/101 12/1407 7,9E-03 4,3E-02 3,6E-02 PSMD5/PPP2R1A/PCNA/PAFAH1B1 4 
13 PID_PDGFRB_PATHWAY 7/101 37/1407 1,4E-02 7,3E-02 6,0E-02 ARPC5/ARPC1B/ACTR3/ARPC2/PPP2R1A/ACTR2/ARPC4 7 
13 PID_NFAT_3PATHWAY 4/101 14/1407 1,4E-02 7,5E-02 6,1E-02 KPNB1/PRKACA/CASP3/RAN 4 
13 KEGG_STARCH_AND_SUCROSE_METABOLISM 4/101 16/1407 2,3E-02 1,2E-01 9,7E-02 GBE1/PYGB/UGDH/HK1 4 
13 
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULE
S 5/101 24/1407 2,4E-02 1,2E-01 1,0E-01 ATP6V1A/PRKACA/FTL/HK1/TF 5 
13 REACTOME_INTEGRATION_OF_ENERGY_METABOLISM 4/101 17/1407 2,9E-02 1,4E-01 1,2E-01 ACLY/FASN/PRKACA/PPP2R1A 4 
13 REACTOME_G1_S_TRANSITION 3/101 10/1407 3,0E-02 1,4E-01 1,2E-01 PSMD5/PPP2R1A/PCNA 3 
13 REACTOME_MITOTIC_M_M_G1_PHASES 3/101 11/1407 3,9E-02 1,8E-01 1,5E-01 PSMD5/PPP2R1A/PAFAH1B1 3 
13 KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 4/101 20/1407 5,0E-02 2,3E-01 1,9E-01 ARPC5/ARPC1B/ARPC2/ARPC4 4 
13 
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_
METABOLISM 3/101 13/1407 6,1E-02 2,7E-01 2,2E-01 ACLY/FASN/ME1 3 
13 REACTOME_BIOLOGICAL_OXIDATIONS 4/101 22/1407 6,7E-02 2,9E-01 2,4E-01 ALDH1A1/UGDH/CNDP2/GCLM 4 
13 REACTOME_SIGNALLING_BY_NGF 4/101 22/1407 6,7E-02 2,9E-01 2,4E-01 CLTC/PRKACA/CASP3/PPP2R1A 4 
13 KEGG_ENDOCYTOSIS 5/101 32/1407 7,4E-02 3,1E-01 2,5E-01 CHMP4B/HSPA2/CLTC/HSPA6/RAB11B 5 
13 KEGG_INSULIN_SIGNALING_PATHWAY 4/101 23/1407 7,7E-02 3,2E-01 2,6E-01 PYGB/FASN/PRKACA/HK1 4 
13 
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEM
BRANE 3/101 15/1407 8,7E-02 3,5E-01 2,8E-01 CLTC/PRKACA/PPP2R1A 3 
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13 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THA
T_BIND_AU_RICH_ELEMENTS 3/101 15/1407 8,7E-02 3,5E-01 2,8E-01 PSMD5/PABPC1/KHSRP 3 
13 KEGG_PYRUVATE_METABOLISM 3/101 16/1407 1,0E-01 4,0E-01 3,3E-01 LDHB/ME1/LDHA 3 
13 REACTOME_GLUCOSE_METABOLISM 4/101 26/1407 1,1E-01 4,2E-01 3,5E-01 GBE1/PYGB/PRKACA/PPP2R1A 4 
13 KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 3/101 17/1407 1,2E-01 4,4E-01 3,6E-01 MPI/UGDH/HK1 3 
13 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME
_DEGRADATION 3/101 18/1407 1,3E-01 5,0E-01 4,1E-01 PSMD5/UBE2N/TPP2 3 
13 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 4/101 29/1407 1,5E-01 5,0E-01 4,1E-01 LDHB/GALM/HK1/LDHA 4 
13 REACTOME_PHASE_II_CONJUGATION 3/101 19/1407 1,5E-01 5,0E-01 4,1E-01 UGDH/CNDP2/GCLM 3 
13 ST_INTEGRIN_SIGNALING_PATHWAY 3/101 19/1407 1,5E-01 5,0E-01 4,1E-01 CSE1L/ACTR3/ACTR2 3 
13 KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 LDHB/LDHA 2 
13 KEGG_WNT_SIGNALING_PATHWAY 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 PRKACA/PPP2R1A 2 
13 REACTOME_GLUTATHIONE_CONJUGATION 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 CNDP2/GCLM 2 
13 
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMB
RANE 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 UBE2N/PPP2R1A 2 
13 REACTOME_REGULATION_OF_APOPTOSIS 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 PSMD5/CASP3 2 
13 REACTOME_SULFUR_AMINO_ACID_METABOLISM 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 CNDP2/GCLM 2 
13 
REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KIN
ASES_UPON_TLR7_8_OR_9_ACTIVATION 2/101 10/1407 1,6E-01 5,0E-01 4,1E-01 UBE2N/PPP2R1A 2 
13 PID_HIF1_TFPATHWAY 3/101 20/1407 1,7E-01 5,2E-01 4,3E-01 HK1/TF/LDHA 3 
13 REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 3/101 20/1407 1,7E-01 5,2E-01 4,3E-01 PSMD5/KPNB1/RAN 3 
13 REACTOME_ACTIVATED_TLR4_SIGNALLING 2/101 11/1407 1,8E-01 5,4E-01 4,5E-01 UBE2N/PPP2R1A 2 
13 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPM
ENT_AND_PLATELET_PRODUCTION 2/101 11/1407 1,8E-01 5,4E-01 4,5E-01 CAPZA1/PRKACA 2 
13 SIG_CHEMOTAXIS 2/101 11/1407 1,8E-01 5,4E-01 4,5E-01 ACTR3/ACTR2 2 
13 KEGG_GLUTATHIONE_METABOLISM 3/101 21/1407 1,9E-01 5,5E-01 4,5E-01 IDH2/GCLM/G6PD 3 
13 REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 5/101 44/1407 2,0E-01 5,8E-01 4,8E-01 PSMD5/GLUD1/CNDP2/PHGDH/GCLM 5 
13 KEGG_PURINE_METABOLISM 3/101 22/1407 2,1E-01 5,8E-01 4,8E-01 AK2/ATIC/ADSS 3 
13 KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION 2/101 12/1407 2,1E-01 5,8E-01 4,8E-01 PRKACA/RAB11B 2 
13 REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 2/101 12/1407 2,1E-01 5,8E-01 4,8E-01 PSMD5/PABPC1 2 
13 REACTOME_HIV_INFECTION 3/101 23/1407 2,3E-01 6,2E-01 5,1E-01 PSMD5/KPNB1/RAN 3 
13 KEGG_APOPTOSIS 2/101 13/1407 2,4E-01 6,2E-01 5,1E-01 PRKACA/CASP3 2 
13 KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 2/101 13/1407 2,4E-01 6,2E-01 5,1E-01 MPI/HK1 2 
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13 REACTOME_PURINE_METABOLISM 2/101 13/1407 2,4E-01 6,2E-01 5,1E-01 ATIC/ADSS 2 
13 REACTOME_SIGNALING_BY_FGFR 2/101 13/1407 2,4E-01 6,2E-01 5,1E-01 PRKACA/PPP2R1A 2 
13 REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS 6/101 59/1407 2,4E-01 6,3E-01 5,2E-01 APOC3/ACLY/FASN/PRKACA/PITPNB/ME1 6 
14 KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 17/99 59/1407 1,6E-07 3,1E-05 2,9E-05 
C4A/SERPING1/CPB2/SERPIND1/C5/C8G/F12/C6/KNG1/SERPINF2/
C8A/CFH/SERPINC1/C8B/PLAU/C4B/CFB 17 
14 NABA_ECM_REGULATORS 21/99 118/1407 2,9E-05 2,8E-03 2,6E-03 
HRG/SERPING1/SERPIND1/F12/PZP/KNG1/ITIH4/ITIH1/CTSF/CPN
2/SERPINF2/SERPINA11/ADAMTSL2/ITIH2/AGT/SERPINC1/HTRA
1/ADAMTS13/PLAU/ITIH3/MMP19 21 
14 REACTOME_COMPLEMENT_CASCADE 8/99 26/1407 2,5E-04 1,6E-02 1,5E-02 C4A/C5/C8G/C6/C8A/CFH/C8B/CFB 8 
14 BIOCARTA_LECTIN_PATHWAY 5/99 12/1407 8,3E-04 3,7E-02 3,4E-02 C4A/C5/C6/C8A/C4B 5 
14 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 10/99 47/1407 1,1E-03 3,7E-02 3,4E-02 TGFB1/GHR/EGFR/CSF1R/PRL/INHBC/LEP/MET/IL6ST/FAS 10 
14 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 7/99 25/1407 1,2E-03 3,7E-02 3,4E-02 C4A/C5/C8G/C6/C8A/C8B/C4B 7 
14 BIOCARTA_COMP_PATHWAY 6/99 19/1407 1,3E-03 3,7E-02 3,4E-02 C4A/C5/C6/C8A/C4B/CFB 6 
14 BIOCARTA_CLASSIC_PATHWAY 5/99 14/1407 1,9E-03 4,6E-02 4,2E-02 C4A/C5/C6/C8A/C4B 5 
14 PID_UPA_UPAR_PATHWAY 6/99 23/1407 3,9E-03 8,5E-02 7,9E-02 GPLD1/TGFB1/LRP1/EGFR/ITGB1/PLAU 6 
14 REACTOME_HEMOSTASIS 15/99 116/1407 1,2E-02 2,4E-01 2,2E-01 
HRG/SERPING1/TGFB1/APOB/F12/THBS1/KNG1/MERTK/ITGB1/C
LU/SERPINF2/SERPINC1/L1CAM/PLAU/SLC3A2 15 
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